<?xml version="1.0" encoding="UTF-8" ?>
<rss version="2.0"
	xmlns:excerpt="http://wordpress.org/export/1.2/excerpt/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:wp="http://wordpress.org/export/1.2/"
>

<channel> 
	<title>Compass</title>
	<link>http://localhost/wordpress</link>
	<description>Blah blah</description>
	<pubDate>Sun, 07 Feb 2016 14:06:19 +0000</pubDate>
	<language>en-US</language>
	<wp:wxr_version>1.2</wp:wxr_version>
	<wp:base_site_url>http://localhost/wordpress</wp:base_site_url>
	<wp:base_blog_url>http://localhost/wordpress</wp:base_blog_url>

	<wp:author>
		<wp:author_id>5</wp:author_id>
		<wp:author_login><![CDATA[spoon]]></wp:author_login>
		<wp:author_email><![CDATA[georges.guigui@spoonconsulting.com]]></wp:author_email>
		<wp:author_display_name><![CDATA[spoon]]></wp:author_display_name>
		<wp:author_first_name><![CDATA[]]></wp:author_first_name>
		<wp:author_last_name><![CDATA[]]></wp:author_last_name>
	</wp:author>

	
			<item>

	<title>Positive Top-Line Data from a 424-Patients Ph2b Trial of Plecanatide for IBS-C</title>
	<pubDate>2014-04-30T16:33:09+02:00</pubDate>
	<wp:post_id>4902</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Following the positive results, Synergy Pharm.<wbr> management plans to move forward with the 3.<wbr>0mg dose, and expects to initiate Ph3 trials in the second half of 2014.<wbr> It is reported that Synergy may need additional capital or a partner to fund all of its envisaged clinical development programs through to completion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Synergy has successfully completed a Ph2b trial of plecanatide with chronic idiopathic constipation (CIC), and is currently enrolling patients into its pivotal Ph3 CIC program.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>- Synergy expects to finish a Ph3 trial of Plecanatide in CIC by early 2015 and started its second Ph3 study this week (data expected 2H:15).<wbr></P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Synergy initiated a Ph2b study of plecanatide for the treatment of IBS-C in December 2012 (<A href="http://clinicaltrials.gov/ct2/show/NCT01722318?term=plecanatide&amp;rank=5">NCT01722318</A>).<wbr> </div><div style="margin-bottom: 10px;">Preliminary analysis of the data indicates that the trial has met PE (to determine an effective, safe and well tolerated dose for plecanatide phase 3 trials with IBS-C patients).<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>- Patients taking the plecanatide 3.<wbr>0mg dose experienced statistically significant improvement in change from baseline versus placebo in worst abdominal pain and met the FDA overall responder endpoint for IBS-C over the 12-week treatment.<wbr></P>
<P>- Plecanatide was safe and well tolerated with no treatment-related serious adverse events.<wbr> The most common event was diarrhea, which occurred in 9.<wbr>3% of the 3.<wbr>0mg plecanatide-treated patients.<wbr></P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Reported diarrhea rates for Plecanatide were lower than that seen for Forest Lab/<wbr>Almirall/<wbr>Astellas' Linzess in early trials (9.<wbr>3% vs.<wbr> 12.<wbr>2%-16.<wbr>5%) which generates a tolerability benefit that could be used to commercially differentiate this drug from Linzess.<wbr> </div><div style="margin-bottom: 10px;">Analysts think Plecanatide may be positioned for patients who cannot tolerate Linzess and therefore expect that ~30-50% of Linzess patients could be potential candidates (<EM>Cantor April 30 2014 report</EM>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Plecanatide is a proprietary analog of the body's naturally occurring gastrointestinal hormone, uroguanylin.<wbr> It represents a novel approach to the treatment of GI diseases and disorders.<wbr> </div><div><EM>Source: Synergy Pharm</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1972">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-30T16:33:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-30T16:33:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Second Ex-Takeda to Join Acino</title>
	<pubDate>2014-04-30T15:49:22+02:00</pubDate>
	<wp:post_id>4903</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: After the recent appointment of J Davidsen as CEO, Ernesto Alegria is the second ex-Takeda executive to join the company (as CFO).<wbr> This second announcement may be considered either as a potential signal of Takeda interest in the company or a new organization being implemented within Takeda since the arrival of Ch Weber as new COO.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">J Davidsen announcement (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9474" class="defaultlink">Oncology9474: Ex-Takeda to Join Acino as New CEO</a>).<wbr> </div><div style="margin-bottom: 10px;">E Alegira announcement (see <A href="http://www.acino-pharma.com/html/index.php?id=715&amp;L=1">http:/<wbr>/<wbr>www.<wbr>acino-pharma.<wbr>com/<wbr>html/<wbr>index.<wbr>php?id=715&amp;L=1</A>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Acino presented its latest financial results for the first half-year 2013 in July 2013.<wbr> </div><div style="margin-bottom: 10px;">The company was delisted from the SIX Swiss Exchange, following its full takeover by Pharma Strategy Partners GmbH (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140431&edate=20140101&rec=234" class="defaultlink">DKPHybrids234: Acino to be Acquired for $439M</a>).<wbr> </div><div><EM>Source: Acino</EM> </div><!-- Comment details --><a name="dkphybrids237attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_237_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_237_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(32,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_dkphybrids_237_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(41,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140431&edate=20140101&rec=237">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-30T15:49:22+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-30T15:49:22+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category dkphybrids > <![CDATA[dkphybrids]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Announces New Phase IV Study With Enzalutamide & Abiraterone</title>
	<pubDate>2014-04-30T15:02:54+02:00</pubDate>
	<wp:post_id>4904</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">CommentL Following the recmet initiation of the phase IV PLATO study 
evaluating the addition of abiraterone in patients who have progressed on 
enzalutamide, Astellas is now starting a smilar study where enzalutamide is 
added upon progression with abiraterone NCT02116582.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design/<wbr>Endpoints</STRONG> </div><div style="margin-bottom: 10px;">The new study will be slightly smaller in size 200 vs.<wbr> 500 in PLATO and will 
be a multi-centre single arm study.<wbr> </div><div style="margin-bottom: 10px;">Primary Outcome - radiographic PFS </div><div style="margin-bottom: 10px;">Secondary Outcomes OC, PSA response time to PSA progression and safety.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines &amp; Location</STRONG> </div><div style="margin-bottom: 10px;">The study is due to start this month and complete in  terms of primary 
endpoint in May 2016 </div><div style="margin-bottom: 10px;">It will be undertaken in Belguim, France, Germany, Netherlands, Spain  
&amp; the UK </div><div>Source: ClinicalTrials.<wbr>gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9669">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-30T15:02:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-30T15:02:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New J&J Sponsored Study With ARN-509</title>
	<pubDate>2014-04-30T14:50:28+02:00</pubDate>
	<wp:post_id>4905</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: J&amp;J have initiated an important new study evaluating the 
combination of ARN-509 (JNJ-56021927) with abiraterone from a safety dosing 
and preliminary efficacy perspective The study is seen as potentially providing 
dosing recommendations for future studies of abiraterone combined with 
JNJ-56021927.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Potential Design</STRONG> </div><div style="margin-bottom: 10px;">This is a multicenter, open-label study in participants with mCRPC.<wbr> The 
study will be a single sequence design (ie, all participants will take 
abiraterone acetate + prednisone [AAP] once daily on Days 1-7 of Treatment Cycle 
1 and then proceed with combined daily intake of AAP+JNJ-56021927 from Treatment 
Cycle 1, Day 8 through to the end of treatment (ie, for up to an expected 
duration of approximately 18 months).<wbr> </div><div style="margin-bottom: 10px;">The study will consist of a 28-day screening phase to determine eligibility, 
an open-label treatment phase consisting of 28-day treatment cycles, and a 
30-day follow-up phase for collection of adverse events (AE) after last dose of 
study drug.<wbr> </div><div style="margin-bottom: 10px;">Participants will have blood samples collected during the study to evaluate 
pharmacokinetics, safety, and antitumor activity (PSA).<wbr> Participant safety will 
also be monitored by the collection of adverse events.<wbr> </div><div style="margin-bottom: 10px;">Imaging assessments for disease evaluation will be planned at discretion of 
the Investigator.<wbr> </div><div style="margin-bottom: 10px;">Once all participants have completed study treatment up to Cycle 3 Day 1, a 
data cutoff is planned to evaluate the short term safety profile of the 
combination and to complete the PK analysis up to the cutoff date.<wbr> All 
participants will  thereafter continue on study (ie, to receive treatment) 
until disease progression, withdrawal of consent, lost to follow-up, or the 
occurrence of unacceptable toxicity.<wbr> The end of the study is defined when all 
participants have completed treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG> Study Timelines/<wbr>Numbers</STRONG> </div><div style="margin-bottom: 10px;">N=26 </div><div style="margin-bottom: 10px;">Study start date June 2014 </div><div style="margin-bottom: 10px;">Study primary completion date November 2016 </div><div style="margin-bottom: 10px;"><DIV class="info-title"><STRONG>ClinicalTrials.<wbr>gov Identifier:</STRONG></DIV> </div><div><DIV class="identifier">NCT02123758</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9668">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-30T14:50:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-30T14:50:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas' Xtandi Gains Reimbursement in Austria</title>
	<pubDate>2014-04-30T13:21:46+02:00</pubDate>
	<wp:post_id>4906</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Main Association of Austrian Social Security Institutions has announced the addition to the reimbursement list of Xtandi (enzalutamide) in the treatment of mCRPC, which has progressed during or after docetaxel-based chemotherapy, from 1 May.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">An appropriate specialist department or centre must make the diagnosis and initial prescription.<wbr> Furthermore, it is required that regular monitoring be provided by an appropriate specialist or technical department.<wbr> </div><div style="margin-bottom: 10px;">The drug has recently been recommended highly by Germany's Institute for Quality and Efficiency in Healthcare (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9491" class="defaultlink">Oncology9491: IQWiG Decides Xtandi Deserves First Highest AMNOG Innovation Score After Re-assessment</a>) and endorsed by the United Kingdom's National Institute for Health and Care Excellence (NICE), which recommended an extended funding status in January (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9430" class="defaultlink">Oncology9430: UK NICE Issued Second Draft Guidance on Xtandi</a>.<wbr> </div><div><EM>Source: GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9667">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-30T13:21:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-30T13:21:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on Medy-Tox' Innotox (Liquid Toxin) for Glabellar Lines</title>
	<pubDate>2014-04-30T10:29:35+02:00</pubDate>
	<wp:post_id>4907</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Y-E Lee (Dysport PM, Korea) we have got recent update on Medy-Tox's liquid toxin (recommended dose, launch date and expected price) as well as the company's key claims @ the Association of Korean Dermatologists Spring Symposium this month.<wbr> Please see below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_9_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_5_ScreenCapture5.jpg"> </div><div>Full Presentation Attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140431&edate=20140101&rs=/link%20Neurology7543%407" class="defaultlink">@7</a> </div><!-- Comment details --><a name="neurology7539attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(13,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(31 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(167,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(90,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(122,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(61,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_7_Innotox%20materials.zip">Innotox materials.zip</a>&nbsp;&nbsp;(3,3 MB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_8_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(115,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7539_9_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(99,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7539">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-30T10:29:35+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-30T10:29:35+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Speculation Intensifies That Allergan Will Bid For Shire</title>
	<pubDate>2014-04-29T18:15:33+02:00</pubDate>
	<wp:post_id>4908</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Speculation Intensifies That Allergan Will Bid For Shire</span>&nbsp;<br><span style="font-size: 12px;">Comment: They are known to have talked earlier in the year and speculation is mounting that Allergan will make a bid for Shire of the order of $33bn within days.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7533">...</a><br></div><div><EM>Bloomberg</EM> just reported that Allergan contacted Sanofi and J&amp;J to see if either is inclined to make a bid.<wbr> The news service's sources said the two are considering their options in early-satge discussions.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7538">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7533">View thread  Neurology7533: Speculation Intensifies That Allergan Will Bid For Shire</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-29T18:15:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-29T18:15:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Daewoong Launches Nabota/Evosyal for Glabellar Lines</title>
	<pubDate>2014-04-29T18:06:12+02:00</pubDate>
	<wp:post_id>4909</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to Dr.<wbr> Kim Bum-joon, who supervised the clinical trials, Nabota was effective with moderate to severe glabellar lines and showed no significant difference in terms of safety and efficacy when compared with its competitors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Daewoong said Nabota is already scheduled to be exported to the U.<wbr>S.<wbr>, Europe, the Middle East and South America (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7296" class="defaultlink">Neurology7296: Daewoong's Botulinum Toxin NABOTA Gains Ground in Latin America</a>).<wbr> <BR> </div><div>Source: <A href="http://nwww.koreaherald.com/view.php?ud=20140429001497">The Korea Herald<BR></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7537">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-29T18:06:12+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-29T18:06:12+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer's Proposal To Acquire AstraZeneca</title>
	<pubDate>2014-04-29T13:35:09+02:00</pubDate>
	<wp:post_id>4910</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pfizer hosted a "Business Update Call" yesterday to comment further on its proposed bid for AZ and its continuing interest in a possible transaction.<wbr> Its remarks underscore the serious nature of its intent and provide a rational for the combined business.<wbr> Key sldies are highlighted below.<wbr> </div><div style="margin-bottom: 10px;">When questioned as to "Why go public with a call like this" Ian Read CEO responded.<wbr> </div><div style="margin-bottom: 10px;">"Well, we tried, we attempted to have private conversations with AZ.<wbr> We are governed by some very rigid panel rules, competition panel rules.<wbr> We would prefer to have been in negotiations and discussions with AstraZeneca's management on the best way to do this.<wbr> But we are, by the rules, forced to make an announcement this Monday that we have been in discussions with them.<wbr> We had conversations with them and I tried to get a mutually &ndash; a mutual announcement, we could say that we were in preliminary discussions, looking for ways to combining the companies.<wbr> AZ rebuffed that attempt, so therefore we were forced to go public with the release we made today.<wbr> So that's the reason .<wbr>.<wbr>, We're not doing this because we don't have good businesses and innovation, and we don't have good business of vaccine, we don't have good businesses in established.<wbr>" </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_11_ScreenCapture11.jpg"> </div><!-- Comment details --><a name="pharmaworld10832attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(190,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(138,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(98,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(204,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(131,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(118,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(136,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(141,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(145,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(159,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10832_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(108,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10832">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-29T13:35:09+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-29T13:35:09+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Speculation Intensifies That Allergan Will Bid For Shire</title>
	<pubDate>2014-04-29T11:06:59+02:00</pubDate>
	<wp:post_id>4911</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: They are known to have talked earlier in the year and speculation is mounting that Allergan will make a bid for Shire of the order of $33bn within days.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Bid Rational</STRONG> </div><div style="margin-bottom: 10px;"><OL><LI>A strong defensive move against the unwelcome Valeant bid
</LI>
<LI>An inversion deal such as, where US drugmakers seek to relocate their headquarters to countries with a lower tax rate, could also be part of the attraction
</LI>
<LI>Shire's strong sales of high margin drugs for treating orphan diseases.<wbr>
</LI>
</OL> </div><div style="margin-bottom: 10px;"><STRONG>Valeant's Attempts To Win Over Sale-Side Analysts Raise Many Questions About Its Strategy</STRONG> </div><div style="margin-bottom: 10px;">A luncheon held by Valeant &amp; Ackmann for sell-side analysts last Friday does not seem to have been well received.<wbr> Analysts at BMO are certainly questioning the lack of sound bid rational and ability of Valeant to cut costs in what  is generally considered a well-run business.<wbr> BMO rates Valeant's chance of success as 50%.<wbr> </div><div>Source: Reuters &amp; BMO Analyst report </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7538c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div><EM>Bloomberg</EM> just reported that Allergan contacted Sanofi and J&amp;J to see if either is inclined to make a bid.<wbr> The news service's sources said the two are considering their options in early-satge discussions.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7533">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-29T11:06:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-29T11:06:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Chi-Med/AstraZeneca's Volitinib to Enter Ph2 Trial</title>
	<pubDate>2014-04-29T10:19:38+02:00</pubDate>
	<wp:post_id>4912</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In December 2011 AstraZeneca and Hutchison MediPharma (HMP) enter into a global licensing, co-development, and commercialisation agreement.<wbr> Volitinib (HMPL-504/<wbr>AZD6094), discovered and developed in China by HMP, is a potent and highly selective small molecule inhibitor of the c-Met receptor with opportunities in lung, gastric, renal and other cancers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Territories</U>: The development costs for Volitinib in China will be shared between HMP and AstraZeneca, with HMP continuing to lead the development in China.<wbr> AstraZeneca will lead and pay for the development of Volitinib for the rest of the world.<wbr> </div><div style="margin-bottom: 10px;"><U>Financials</U>: An initial cash payment of US$20 million was payable by AstraZeneca to HMP upon the signing of the agreement.<wbr> In addition, HMP will receive up to US$120 million contingent upon the successful achievement of clinical development and first sale milestones.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Data presented @ AACR 2013 support the potential clinical utility of volitinib as a selective agent for the therapeutic treatment of gastric cancers harboring dysregulated cMET signaling.<wbr> (<A href="http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/73/8_MeetingAbstracts/928">http:/<wbr>/<wbr>cancerres.<wbr>aacrjournals.<wbr>org/<wbr>cgi/<wbr>content/<wbr>meeting_abstract/<wbr>73/<wbr>8_MeetingAbstracts/<wbr>928</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><EM><STRONG>Discovery, preclinical and early clinical evaluation of volitinib: A potent and selective c-Met kinase inhibitor</STRONG></EM> </div><div style="margin-bottom: 10px;">Aberrant activation of c-Met signalling pathway has been identified to drive tumor growth/<wbr>invasion and be involved in drug resistance.<wbr> Targeting c-Met pathway represents a compelling opportunity to new anti-cancer therapies.<wbr> Volitinib (HMPL-504/<wbr>AZD6094) is a potent small molecule c-Met kinase inhibitor with IC<SUB>50</SUB>s in low nanomolar range at enzyme and cell levels.<wbr> It was found to be highly selective in a screen against a broad panel of kinases.<wbr> Volitinib has favourable pharmacokinetic properties and demonstrated strong anti-tumor activity in various human xenograft models harbouring c-Met gene amplification and/<wbr>or protein over-expression.<wbr> Strong pharmacokinetic/<wbr>pharmacodynamic and target/<wbr>tumor growth inhibition relationship was observed in the anti-tumor efficacy studies.<wbr> In preclinical safety evaluation, volitinib was found to have favourable safety profile with large predicted safety margins.<wbr> Volitinib is currently in Phase I clinical development.<wbr> Detailed results on chemistry structure-activity relationship, including the chemical structure of volitinib and the strategy to address renal toxicity seen with other c-Met inhibitors, <I>in vitro</I> and <I>in vivo</I> evaluation including pharmacokinetic/<wbr>pharmacodynamic correlation, pharmacokinetic and drug metabolism characterisation, and non-clinical safety evaluation will be presented.<wbr> </div><div style="margin-bottom: 10px;"><EM><STRONG>Targeting MET in preclinical models to support the clinical development of volitinib in NSCLC</STRONG></EM><BR>MET is a transmembrane tyrosine kinase receptor that is deregulated (gene amplification, mutation and over-expression) across multiple cancer types.<wbr> Signalling through MET is normally activated through interactions with its specific ligand, hepatocyte growth factor (“HGF”).<wbr> Aberrant MET/<wbr>HGF activation can stimulate tumor growth, promote angiogenesis, induce metastasis and may contribute to resistance mechanisms in several tumor types.<wbr> Several non-selective MET inhibitors have entered clinical development; results have been mixed based on potency, selectivity, and/<wbr>or patient selection.<wbr> Volitinib is a potent (IC<SUB>50</SUB> 4 nM) and selective (&gt;650 fold selectivity over 265 kinases), small molecule inhibitor of MET.<wbr> Recent evaluation of volitinib across a panel of cancer cell lines demonstrated selectivity for MET-driven disease, with MET amplified cell lines being most sensitive (IC50s of 1nM) and also suggesting limited off target activity.<wbr> Volitinib resistant cell lines with MET amplification were identified and used to better understand the relationship of concurrent mutations with response.<wbr> In addition to cancer cell line selectivity, we are analysing preclinical models of NSCLC that are representative of key patient segments, namely MET amplification and over-expression.<wbr> In newly diagnosed NSCLC adenocarcinomas, focal MET amplification events represent ~3% of the population while over-expression of MET (without gene amplification) is observed in the majority of patients.<wbr> In preclinical models, focal Met amplification in EBC-1 and NCI-H1993 caused significant tumor growth inhibition, confirming sensitivity to volitinib.<wbr> Given the prevalence of over-expression in NSCLC, however, we sought to build a platform of evidence for the therapeutic use of volitinib in preclinical models lacking amplification of the MET gene.<wbr> Using a patient-derived xenograft model (PDX) of EGFR wild-type (“WT”), KRAS WT and metastatic NSCLC disease (HLXF-036LN), we demonstrate that volitinib induces tumor regression as monotherapy and has added therapeutic benefit when used in combination with taxotere.<wbr> In addition, we show robust efficacy effects for additional preclinical models, LG0567, LG0645 and Calu-3, for either volitinib alone or in combination with taxotere.<wbr> In parallel pharmacodynamic studies, we demonstrate that volitinib inhibits p-MET and downstream signalling in each model.<wbr> Together, using an integrated platform of molecular characterization and MET FISH and IHC scores, corresponding anti-tumor responses to volitinib are being evaluated for several patient segments.<wbr> We are using these studies to inform the design of patient selection criteria for upcoming clinical trials in NSCLC.<wbr> </div><div><EM>Source: AstraZeneca; AACR</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9661">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-29T10:19:38+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-29T10:19:38+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer's Nexavar (sorafenib) Recommended for EU Approval for Thyroid Cancer</title>
	<pubDate>2014-04-29T09:52:45+02:00</pubDate>
	<wp:post_id>4913</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The EU CHMP has recommended the drug for approval for the treatment of patients with progressive, localy advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine.<wbr> Final decision is expected by mid-2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The CHMP recommendation is based on data from the Ph3 DECISION (stu<B>D</B>y of soraf<B>E</B>nib in lo<B>C</B>ally advanced or metastat<B>I</B>c patient<B>S</B> with radioactive <B>I</B>odine refractory thyr<B>O</B>id ca<B>N</B>cer) trial.<wbr> </div><div style="margin-bottom: 10px;">In the study, sorafenib significantly extended progression-free survival (PFS), the primary endpoint of the study, compared to placebo (HR=0.<wbr>59 [95% CI, 0.<wbr>46-0.<wbr>76]; p&lt;0.<wbr>001), which represents a 41% reduction in the risk of disease progression or death for patients who received sorafenib compared to placebo-treated patients.<wbr> </div><div style="margin-bottom: 10px;">The median PFS was 10.<wbr>8 months in patients treated with sorafenib, compared to 5.<wbr>8 months in patients receiving placebo.<wbr> </div><div style="margin-bottom: 10px;">The safety and tolerability profile of sorafenib in patients in the trial was generally consistent with the known profile of sorafenib.<wbr> The most common treatment-emergent adverse events in the sorafenib arm were hand-foot skin reaction, diarrhea, alopecia, weight loss, fatigue, hypertension and rash.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Nexavar is already approved for patients with hepatocellular carcinoma and advanced renal cell carcinoma.<wbr> </div><div><EM>Source: Bayer</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9659">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-29T09:52:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-29T09:52:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bavarian Nordic Evaluates its Immunotherapy (CV-301) in Bladder Cancer</title>
	<pubDate>2014-04-29T09:38:38+02:00</pubDate>
	<wp:post_id>4914</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The first patient has entered in a randomized prospective Ph2 trial, sponsored by the NCI.<wbr> PE is to assess if there is a improvement in disease-free survival for patients receiving BCG treatment and CV-301 immunotherapy compared to those receiving BCG treatment alone.<wbr> Beginning of the year, the company prioritized the colorectal indication based on the promising clinical Ph2 study results.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Source:<A href="http://clinicaltrials.gov/ct2/show/NCT02015104?recr=Open&amp;no_unk=Y&amp;cond=bladder&amp;spons=nci&amp;rank=5"> NCT02015104</A> </div><div style="margin-bottom: 10px;">In the study, sponsored by the National Cancer Institute, 54 patients with high grade non-muscle invasive bladder cancer whose cancer has progressed after initial BCG (Bacillus Calmette-Guerin) treatment will be treated with BCG alone or in combination with CV-301.<wbr> </div><div style="margin-bottom: 10px;"><U>Lead investigator</U> for the study is Piyush K.<wbr> Agarwal, M.<wbr>D.<wbr>, Head, Bladder Cancer Section, National Cancer Institute, NIH.<wbr> </div><div style="margin-bottom: 10px;"><U>Timelines</U>: completion date is due in November 2017 </div><div style="margin-bottom: 10px;"><U>Locations</U> USA (2 sites) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">CV-301 (formerly developed as PANVAC) is an immunotherapy product candidate for the treatment of multiple cancers.<wbr> It originates from the same poxvirus technology platform as PROSTVAC.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9657_1_ScreenCapture1.jpg"><EM>Source: Bavarian Nordic</EM> </div><!-- Comment details --><a name="oncology9657attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9657_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(68,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9657">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-29T09:38:38+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-29T09:38:38+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Capsugel to Scale-Up Manufacturing for Oral Octreotide</title>
	<pubDate>2014-04-28T17:44:39+02:00</pubDate>
	<wp:post_id>4915</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Capsugel today announced an agreement with Chiasma, Inc.<wbr>, wherein Capsugel’s Dosage Form Solutions (DFS) business unit is scaling up manufacturing for the oral form of octreotide in clinical development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Underway at Capsugel’s FDA- and MHRA-accredited site in Livingston, Scotland, which became part of Capsugel’s DFS network when it acquired Encap Drug Delivery in March 2013.<wbr> </div><div style="margin-bottom: 10px;">Capsugel DFS has already manufactured several clinical batches of the compound, including those needed for the new drug application (NDA) registration.<wbr> </div><div style="margin-bottom: 10px;">Commercial scale batches are expected to be validated during the fourth quarter 2014 or first quarter 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Capsugel has invested heavily in its capability to optimize and accelerate formulation scale up at the Livingston site.<wbr> </div><div style="margin-bottom: 10px;">The company recently installed commercial scale milling equipment (U20 Comil) and associated containment equipment, in-house printing facilities, and large-scale capsule coating equipment (up to 160L capacity).<wbr> </div><div style="margin-bottom: 10px;">The facility modifications and equipment installations were successfully completed at the end of the first quarter 2014, with initial commercial scale manufactures now in progress.<wbr> </div><div>Full PR @ <A href="http://capsugel.com/en/news-events/news/capsugel-enters-agreement-with-chiasma-for-scale-up-manufacture-of-oral-octreotide-acetate/">http:/<wbr>/<wbr>capsugel.<wbr>com/<wbr>en/<wbr>news-events/<wbr>news/<wbr>capsugel-enters-agreement-with-chiasma-for-scale-up-manufacture-of-oral-octreotide-acetate/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9654">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T17:44:39+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T17:44:39+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Critical Pharmaceuticals Commences Intranasal Development of Teriparatide</title>
	<pubDate>2014-04-28T17:20:19+02:00</pubDate>
	<wp:post_id>4916</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Critical Pharmaceuticals in combination with the University of 
Nottingham and Nottingham University Hospitals NHS Trust have started a phI 
trial of a nano-enable intranasal terparaitide for the treatment 
of osteoporosis.<wbr> </div><div style="margin-bottom: 10px;">The trial is being undertaken in healthy post-menopausal women.<wbr> </div><div style="margin-bottom: 10px;">Teriparatide is a highly effective existing treatment for osteoporosis but it 
currently has to be injected on a daily basis.<wbr> It has been reformulated 
utilising Critical's CriticalSorb™ technology.<wbr> </div><div style="margin-bottom: 10px;">Professor Tahir Masud, Consultant in Geriatric Medicine at Nottingham 
University Hospitals NHS Trust and Chief Investigator for the clinical trial, 
said: "I look forward to progressing this exciting new therapy for a very 
debilitating disease into the clinic.<wbr> A nasal teriparatide product has the 
potential to significantly benefit patients, their families, carers and 
clinicians with improved clinical outcomes and greatly enhanced ease of 
use.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>PhI Trial Design</STRONG> </div><div>The clinical trial is a five-way cross-over study design in healthy 
post-menopausal women representative of the target patient population.<wbr> The 
objectives of the study are to understand the levels of the drug in the body 
(pharmacokinetics) after intranasal administration of three doses of the 
teriparatide product versus subcutaneous injection of marketed product 
(ClinicalTrials.<wbr>gov Identifier NCT01913834).<wbr> The study will also test the 
performance of two different nasal delivery devices and use scintigraphic 
imaging to better understand how deposition can influence the levels of drug in 
the body over time.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7655">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T17:20:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T17:20:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Celgene Enters $2.5bln Deal for Late-Stage Crohn's Disease Drug Candidate</title>
	<pubDate>2014-04-28T17:13:54+02:00</pubDate>
	<wp:post_id>4917</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Celgene has announced a global licensing deal to develop and market Nogra Pharma's GED-0301, reported to be a potentially transformative therapy that demonstrated striking clincical activity in a Ph2 for CD.<wbr> Celgene plans to start Ph3 by year-end 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<P>A double-blind, placebo-controlled, multicenter phase II trial of three doses of GED-0301 in 166 patients with active Crohn's disease has been completed.<wbr> </P>
<P>The data have been submitted to a major medical journal and will be presented at an upcoming medical congress.<wbr> </P>
<P>Based upon these results, Celgene plans to initiate a Ph3 registration program by year-end 2014.<wbr> </P></DIV> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>$710M upfront payment</LI>
<LI>Potential $815M aggregate regulatory and development milestones for multiple indications</LI>
<LI>Potential $1,050M aggregate tiered sales milestones if annual net sales reach $4,000M</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1971_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="gastroenterology1971attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1971_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1971">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T17:13:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T17:13:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Forest to Acquire Furiex for Up to $1.46bln</title>
	<pubDate>2014-04-28T16:49:57+02:00</pubDate>
	<wp:post_id>4918</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Forest would buy Furiex to access eluxadoline, a oral locally-acting mu opioid receptor agonist and delta opioid receptor antagonist, for IBS-d reported as a "very complementary" drug candidate to its own bowel drug Linzess.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Forest said it expected the Furiex deal to close in the second or third quarter of 2014 and said it would not affect the timing of the Forest-Actavis acquisition.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1970_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1970_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><BR><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Furiex is on track to submit a marketing application for eluxadoline by the end of the third quarter of 2014.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1970_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1970_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">At the beginning of February, Furiex updated timelines of eluxadoline citing it was considering alternatives to partner the drug.<wbr> (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1938" class="defaultlink">GastroEnterology1938: Furiex Provides Update on its IBS-d Drug</a>).<wbr> </div><div><EM>Source: Furiex; Forest</EM> </div><!-- Comment details --><a name="gastroenterology1970attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1970_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(20,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1970_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(51,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1970_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(56,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1970_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(54,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1970">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T16:49:57+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T16:49:57+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OncoGenex/Teva Prostate Cancer Drug Misses PhIII Endpoint</title>
	<pubDate>2014-04-28T14:40:10+02:00</pubDate>
	<wp:post_id>4919</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: OncoGenex and Teva have announced that their PhIII SYNERGY trial with custirsen in mCRPC has failed to demonstrate an improvement over standard chemotherapy in terms of overall survival.<wbr> </div><div style="margin-bottom: 10px;">Custirsen was evaluated in combination with docetaxel and prednisone vs docetaxel prednisone alone.<wbr> Median survival was 23.<wbr>4 months vs 22.<wbr>2 months, respectively; hazard ratio 0.<wbr>93 and one-sided p value 0.<wbr>207.<wbr> The adverse events observed were similar to custirsen's known adverse event profile.<wbr> </div><div style="margin-bottom: 10px;">Commenting of the results of the Synergy trial Scott Cormack President &amp; CEO of OncoGenex stated: </div><div style="margin-bottom: 10px;">"The results of SYNERGY are unexpected, particularly given the wealth of scientific evidence supporting the targeting of clusterin to combat treatment resistance in first-line prostate cancer.<wbr> A thorough analysis of the data is underway to understand the potential factors that may have contributed to the results.<wbr> Importantly, we remain strong in our belief that targeting mechanisms of treatment resistance is a critical path forward in the fight against cancer and we continue to actively pursue this approach through the two ongoing Phase 3 trials of custirsen and the seven Phase 2 trials of apatorsen in four tumor types.<wbr>" </div><div>source: <A href="http://www.ongcogenex.com/">www.<wbr>ongcogenex.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9651">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T14:40:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T14:40:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer AG Reports Successful Start to 2014</title>
	<pubDate>2014-04-28T13:44:03+02:00</pubDate>
	<wp:post_id>4920</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Pharma segment achieved strong growth driven by Xarelto, Eylea, Stivarga and Xofigo and Adempas which posted combined sales of €598M (among which €36M for Xofigo).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10829_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Sales increased in all regions on an Fx-adjusted basis, with particularly strong growth in Japan, China and France.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10829_3_ScreenCapture3.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10829_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="pharmaworld10829attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10829_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(85 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10829_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(46,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10829_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(46,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10829">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T13:44:03+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T13:44:03+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sativex(R) Cancer Pain Indication Receives Fast Track Designation from FDA</title>
	<pubDate>2014-04-28T13:15:26+02:00</pubDate>
	<wp:post_id>4921</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The US Agency has granted Fast Track designation to Sativex(R) for the treatment of pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy.<wbr> Sativex is currently in Ph3 for this indication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>US</STRONG> - GW is developing Sativex(R) in the US in collaboration with Otsuka Pharm.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ex-US</STRONG> - Sativex is approved for MS spasticity in ~25 ex-US countries so far.<wbr> GW and their partners are in the process of an ongoing, stepwise launch with timelines likely driven by the often-long ex-US drug pricing process as well as any additional complexities for a cannabis derived product.<wbr> </div><div><EM>Source: GW Pharm; Morgan Stanley</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7532">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T13:15:26+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T13:15:26+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Study Evaluates Evolution of Facial Aesthetic with Botox in Real-World</title>
	<pubDate>2014-04-28T12:03:28+02:00</pubDate>
	<wp:post_id>4922</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: F.<wbr> Truong (Medical Director, Neurology Franchise), picked up interesting data from Allergan's poster presentation at Anti-Aging Medicine World Congress (AMWC April 3-5 2014).<wbr> The objective of this first long-term study was to assess  the evolution of facial aesthetic treatment in patients receving long-term, continuous treatment with Botox at 11 sites in the US, Canada, France, Brazil and Australia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">International, multicenter, retrospective chart review with cross sectional analysis </div><div style="margin-bottom: 10px;">Patients charts from 1992-2012 were reviewed for eligibility.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7530_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Self-Perception of Age (SPA) was used to assess how facial line (GL, CF and FHL) affected each patient's perceived age relative to their chronologic age.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7530_2_ScreenCapture2.jpg"> </div><div>Poster attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140431&edate=20140101&rs=/link%20Neurology7531%403" class="defaultlink">@3</a> </div><!-- Comment details --><a name="neurology7530attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7530_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(49 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7530_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(136 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7530_3_Allergan%255fAMC2014%20poster.pdf">Allergan_AMC2014 poster.pdf</a>&nbsp;&nbsp;(119,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7530">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T12:03:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T12:03:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Bayer's Strategy is to Become N°1 OTC Company</title>
	<pubDate>2014-04-28T11:27:14+02:00</pubDate>
	<wp:post_id>4923</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Bayer's Strategy is to Become N°1 OTC Company</span>&nbsp;<br><span style="font-size: 12px;">Comment: Bayer is to buy privately held Dihon Pharmaceutical Group Co, a maker of traditional herbal Chinese medicines (TCM).<wbr> Dihon has about 2,400 employees and generated sales of 123 million euros ($168 million) in 2013.<wbr> A spokeswoman closed to Bayer said it was too early to say whether Dihon's products would be exported to Germany or Europe.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10758">...</a><br></div><div style="margin-bottom: 10px;"><SPAN style="background-color: #888888;"><SPAN style="background-color: #ffffff;"><SPAN style="background-color: #ffffff;">Bayer</SPAN> Healthcare China President Alok Kanti has stated that the acquisition of <SPAN style="background-color: #ffffff;">Kunming Dihon Pharmaceutical</SPAN> Group Co.<wbr>, Ltd.<wbr>, targets the OTC segment and Dihon's sales channels in small and medium-sized cities, but that its Traditional Chinese Medicine (TCM) and other businesses were not central to the transaction.<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #888888;"><SPAN style="background-color: #ffffff;">Kanti underlined that greater OTC strength will boost overall portfolio sales in grassroots markets.<wbr> </SPAN></SPAN> </div><div><SPAN style="background-color: #888888;"><SPAN style="background-color: #ffffff;">He noted that <SPAN style="background-color: #ffffff;">Bayer</SPAN> is also interested in Dihon's GMP-certified factory in mid-tier Kunming, whose municipal infrastructure is particularly compelling.<wbr></SPAN></SPAN> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10828">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10758">View thread  PharmaWorld10758: Bayer's Strategy is to Become N°1 OTC Company</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T11:27:14+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T11:27:14+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AbbVie Management Expects FY14 Lupron Sales to be Down Modestly from 2013</title>
	<pubDate>2014-04-28T11:22:13+02:00</pubDate>
	<wp:post_id>4924</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AbbVie's Q1 14 performance was led by Humira, which delivered &gt;18% global operational growth.<wbr> Global Lupron sales were $189M, up to 5.<wbr>6% on an operational basis.<wbr> Management highlighted it is developing veliparib (its PARP inhibitor) in areas that no other PARP has explored.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9650_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>ELAGOLIX</STRONG> - Management reported initial data from the 1st of 2 pivotal studies in endometriosis in H2 14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">AbbVie has got a very competitive profile in the large HCV market.<wbr> The company outlined it has made good progress in building the appropriate infrastructure for the commercialization (late 2014 in US) of its inteferon-free combination.<wbr> </div><div style="margin-bottom: 10px;">When it comes to other important drug candidates in oncology, management highlighted its late-stage assets: </div><div style="margin-bottom: 10px;"><UL><LI>ABT-199 (Bcl2-inhibitor) for hematological malignancies, and CLL</LI>
<LI>ABT-888 Veliparib (PARP inhibitor) for a dozen different cancer types (in non-small cell lung cancer, which is an area that no other PARP inhibitor has explored, the company found a way to successfully combine with carboplatin-based chemotherapy)</LI>
<LI>elotuzuman in Ph3 for MM</LI>
</UL> </div><div><EM>Source: AbbVie transcript</EM> </div><!-- Comment details --><a name="oncology9650attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9650_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9650">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T11:22:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T11:22:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Reckitt To Beef Up Its OTC Consumer Health Business</title>
	<pubDate>2014-04-28T09:54:27+02:00</pubDate>
	<wp:post_id>4925</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Following last week's transaction between GSK &amp; Novartis in the 
Consumer Healthcare space, Reckitt is reportedly about to make an $8bn purchase 
of US Merck's consumer OTC business.<wbr> </div><div style="margin-bottom: 10px;">Reckitt is believed to be the front-runner in the auction, with Bayer 
seemingly the other bidder.<wbr> </div><div style="margin-bottom: 10px;">Merck's OTC business is best known for its Claritin anti-allergy medicine.<wbr> 
Reckitt's current business is largely focused around the gastrointestinal 
treatment Gaviscon and the pain-killer Nurofen.<wbr> </div><div style="margin-bottom: 10px;">If successful this will be Reckitt's largest takeover since it was formed in 
1999.<wbr> Consumer healthcare products currently account for about one quarter of 
its revenue but that could rise to around 35% if it successfully secures Merck's 
business.<wbr> </div><div>Source: Sunday Times April 27th </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1969">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T09:54:27+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T09:54:27+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lilly's Ramucirumab (Cyramza) Approved by FDA for Gastric Cancer</title>
	<pubDate>2014-04-28T09:45:53+02:00</pubDate>
	<wp:post_id>4926</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The US Agency approved Lilly's fully monoclonal antibody of the IgG1 class as a single-agent treatment for patients with advanced or metastatic gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=8528" class="defaultlink">Oncology8528: Lilly Announces Positive Results For Ramucirumab in Phase III Gastric Cancer Trial</a> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">7 trials are ongoing : <A href="http://clinicaltrials.gov/ct2/results?term=ramucirumab&amp;recr=Open&amp;submit_fld_opt">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>results?term=ramucirumab&amp;recr=Open&amp;submit_fld_opt</A>= </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
Feb 2014 Ph3 for Lung cancer met PE of OS</LI>
<LI>
Sept 2013 Ph3 TRIO breast cancer trial missed PE</LI>
</UL> </div><div><EM>Source: Lilly; clinicaltrials.<wbr>gov</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9648">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-28T09:45:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-28T09:45:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medivation Signs Deal to Expand Footprint in Next Generation Cancer Treatment</title>
	<pubDate>2014-04-25T16:43:06+02:00</pubDate>
	<wp:post_id>4927</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The agreement signed with OncoFusion pertains to certain compounds targeting Bromodomain and Extra-Terminal (BET) proteins for potential use in oncology and other disease areas.<wbr> Bromodomain (BRD) target represents the most advanced drug development program of OncoFusion.<wbr> The bromodomain and extra-terminal family BRD proteins have been implicated in gene fusions associated with NUT midline carcinoma and have been shown to activate the Myc oncogene.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<P>Medivation has exclusive WW rights for the development and commercialization of these compounds.<wbr></P>
<P>Medivation can also access OncoFusion's library of small molecule BET bromodomain inhibitor compounds and thereafter select compounds for further development.<wbr></P>
<DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">OncoFusion will receive upfront payments along with potential milestone payments.<wbr> OncoFusion is also entitled to royalties on the commercial sale of approved products as defined in the agreement.<wbr></DIV>
<DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">Financial terms: not disclosed.<wbr></DIV>


<DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none"><STRONG></STRONG></DIV>
<DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<P>- oncology discovery and development company targeting gene fusions that are thought to drive many common cancers.<wbr></P>
<P>- the technology is based on discoveries from the laboratories of the companies’ co-founders, Dr.<wbr> Arul Chinnaiyan and Dr.<wbr> Shaomeng Wang, at the U.<wbr> of Michigan.<wbr></P>
<H1></H1>
<P>This Bromodomain (BRD) target represents the most advanced drug development program of OncoFusion.<wbr> The bromodomain and extra-terminal family BRD proteins have been implicated in gene fusions associated with NUT midline carcinoma and have been shown to activate the Myc oncogene.<wbr></P>
<P>OncoFusion’s current lead compounds exhibit low nanomolar affinities for BRD2-4 and on-target nanomolar activities against tumor cells (manuscript in preparation).<wbr> Furthermore, the compound has good drug-like properties such as low molecular weight and high solubility.<wbr> Extensive optimization of the leads and animal studies are currently being performed.<wbr></P>
<P><EM>Source: </EM><A href="http://oncofusion.com/"><EM>http:/<wbr>/<wbr>oncofusion.<wbr>com/<wbr></EM></A></P></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9645">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-25T16:43:06+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-25T16:43:06+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: TEOXANE Expands EVOSYAL Partnership with ALPHAEON</title>
	<pubDate>2014-04-25T11:47:02+02:00</pubDate>
	<wp:post_id>4928</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">What is the registration status of EVOSYAL, if any, in the markets where Azzaluere is sold?</span>&nbsp;<br></div><div>Evosyal is not launched yet in the US or in Europe.<wbr> Daewoong has just launched Nabota (the name in Korea) in South Korea.<wbr> They will need clinical development to register in US and in EU and it might take several years but they can start to register in some IC countries (Latin America, Russia, Asia, MEast) with the Korean dossier.<wbr> We haven't seen any plan to immediate launch in IC countries yet and I guess it will come along the year and in 2015.<wbr> We will obviously monitor the moves from Teoxan and Evosyal.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7529">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7524">View thread  Neurology7524: TEOXANE Expands EVOSYAL Partnership with ALPHAEON</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-25T11:47:02+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-25T11:47:02+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Progenics Pharmaceuticals Announces the Completion of Enrolment of Chemotherapy Naive Cohort in Phase II Trial of PSMA Antibody Drug Conjugate</title>
	<pubDate>2014-04-25T11:19:33+02:00</pubDate>
	<wp:post_id>4929</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During ASCO GU in January 2014, Progenics presented positive data from their Phase 2 trial of Prostate Specific Membrane Antigen antibody Drug Conjugate (PSMA ADC) in post-docetaxel metastatic castration resistant prostate cancer (mCRPC).<wbr> Yesterday, Progenics announced the completion of enrolment for a total of 36 patients in the chemotherapy naïve cohort of their Phase II trial (<A href="http://clinicaltrials.gov/show/NCT01695044">NCT01695044</A>).<wbr> </div><div style="margin-bottom: 10px;">PSMA ADC uses technology licensed from Seattle Genetics.<wbr> It <SPAN style="TEXT-ALIGN: justify; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/19px Helvetica; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: #403838; WORD-SPACING: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px">consists of a fully human anti-PSMA monoclonal antibody conjugated to monomethylauristatin E through a valine-citrulline linker.<wbr></SPAN> This antibody specifically binds to antigen (Prostate Specific Membrane Antigen) that is expressed only on prostate cell membrane and blood vessels that are supplying "nutrition" to cancer cells.<wbr> Once bound, the conjugate is internalised into the prostate cancer cell and monomethyl auristatin E is released within the cell to disrupt microtubule that is normally required for cell replication.<wbr> This disruption causes instability of the cancer cell and hence cell death.<wbr> Unlike traditional chemotherapy, PSMA ADC is able to deliver the drug selectively to targeted cancer cells and hence minimising treatment related toxicity.<wbr> </div><div>Source: <A href="http://www.progenics.com/">www.<wbr>progenics.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9641">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-25T11:19:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-25T11:19:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: TEOXANE Expands EVOSYAL Partnership with ALPHAEON</title>
	<pubDate>2014-04-25T10:39:43+02:00</pubDate>
	<wp:post_id>4930</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">TEOXANE Expands EVOSYAL Partnership with ALPHAEON</span>&nbsp;<br><span style="font-size: 12px;">Comment: Terms of the agreement outlines that TEOXANE will become the exclusive licensor and distributor of ALPHAEON's EVOSYAL (Botulinum toxin Type A developed by Daewoong Pharm.<wbr>), across the EU, Central Europe, Russia and South Africa.<wbr> The expanded partnership also provides TEOXANE with a right of first refusal to distribute all other ALPHAEON products and services that are brought to the EU market.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7524">...</a><br></div><div style="margin-bottom: 10px;">What is the registration status of EVOSYAL, if any, in the markets where Azzaluere is sold? <a name="Neurology7529c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Evosyal is not launched yet in the US or in Europe.<wbr> Daewoong has just launched Nabota (the name in Korea) in South Korea.<wbr> They will need clinical development to register in US and in EU and it might take several years but they can start to register in some IC countries (Latin America, Russia, Asia, MEast) with the Korean dossier.<wbr> We haven't seen any plan to immediate launch in IC countries yet and I guess it will come along the year and in 2015.<wbr> We will obviously monitor the moves from Teoxan and Evosyal.<wbr> </div></div></div><div>Amedeo </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7528">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7524">View thread  Neurology7524: TEOXANE Expands EVOSYAL Partnership with ALPHAEON</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-25T10:39:43+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-25T10:39:43+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Weaker Q1 Sales From Novartis Including Those Of Sandostatin LAR</title>
	<pubDate>2014-04-24T19:36:48+02:00</pubDate>
	<wp:post_id>4931</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:Novartis results were slightly weaker than anticipated, including a 1% decline in pharmaceutical sales attributed to generic competition to Zometa as well as a slowdown in sales of its leukaemia drug Glivec and cancer drug Afinitor.<wbr> Forecasts for the latter have been downgraded for reasons shown below, whilst Sandostatin sales progression was also considered weak by one analyst most notably because US sales declined 1% in CER.<wbr> </div><div style="margin-bottom: 10px;">One of the analysts on the earnings call picked up on the low Sandostatin growth rate and questioned whether competitive pressures following their (Ipsen's) positive data in neuroendocrine tumours at the end of last year was having an impact.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><P style="margin: 0cm 0cm 0pt;">"Keep in mind there are still multiple new indications ahead for this product in carcinoid and the lymphoma and other indications.<wbr> Some people have written that they &ndash; they fear that the downgrade in Afinitor will have a negative impact on the outlook for the oncology business and while this is a little bit negative, you also have to remember and I will show you some data in a while that we have other oncology products coming that are not yet in most people&rsquo;s forecast models.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P style="margin: 0cm 0cm 0pt;">We believe more about these products and perhaps more on intentions regarding Camurus's fluid crystal technology will be revealed in June when the company is hosting an investor R&amp;D day.<wbr></P> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_1_ScreenCapture1.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_6_ScreenCapture6.jpg"> </div><div>On the development front little has changed froma filing perspective with Afinitor still scheduled to be filed for non-functioning GI and Lung NET in 2015 and Signifor approvals in acromegaly expected in the second half of the year.<wbr>.<wbr> There is no greater specificty in terms of filing date for LC1699 for Cushing's and news that the phII trial that is ongoing with that product has been changed into a randomised double-blind trial.<wbr> </div><!-- Comment details --><a name="endocrinology7653attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(108,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(112,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(144,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(220 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(172,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7653_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(278,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7653">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-24T19:36:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-24T19:36:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sun Pharma's US Baclofen Filing Slated For 2018</title>
	<pubDate>2014-04-24T17:24:59+02:00</pubDate>
	<wp:post_id>4932</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: SPARC's recent update on its R&amp;D pipeline highlights 
the progress it is continuing to make with its baclofen programme for 
MS spasticity, a programme which it appears it intends to out-license.<wbr> 
Meaanwhile, nothing meaningful appears to have happened in terms of progress 
with the octreotide long-acting programme.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7527_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7527_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7527_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><P align="left"></P> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7527_4_ScreenCapture5.jpg">
 </div><div style="margin-bottom: 10px;"><P align="left">When questioned about the status of the Octreotide programme and 
progress since the last update <B></B></P> </div><div><P align="left"></P> </div><!-- Comment details --><a name="neurology7527attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7527_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(118,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7527_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(146,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7527_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(86,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7527_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(109,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7527_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(119,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7527">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-24T17:24:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-24T17:24:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>TEOXANE Expands EVOSYAL Partnership with ALPHAEON</title>
	<pubDate>2014-04-24T17:06:24+02:00</pubDate>
	<wp:post_id>4933</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Terms of the agreement outlines that TEOXANE will become the exclusive licensor and distributor of ALPHAEON's EVOSYAL (Botulinum toxin Type A developed by Daewoong Pharm.<wbr>), across the EU, Central Europe, Russia and South Africa.<wbr> The expanded partnership also provides TEOXANE with a right of first refusal to distribute all other ALPHAEON products and services that are brought to the EU market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ALPHAEON and TEOXANE began their partnership in August 2013, when ALPHAEON acquired an exclusive U.<wbr>S.<wbr> license to market the full line of TEOXANE's products that include cosmeceuticals and hyaluronic acid-based wrinkle-fillers.<wbr> </div><div style="margin-bottom: 10px;"><U>TEOXANE products</U> contain 100 percent non-animal origin, resorbable hyaluronic acid.<wbr> Hyaluronic acid dermal fillers are the most widely used aesthetic fillers worldwide.<wbr> The company also has an extensive line of creams and other cosmeceuticals.<wbr> </div><div>see <A href="http://alphaeon.com/healthcare-specialist/products/list">http:/<wbr>/<wbr>alphaeon.<wbr>com/<wbr>healthcare-specialist/<wbr>products/<wbr>list</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7528c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">What is the registration status of EVOSYAL, if any, in the markets where Azzaluere is sold? <a name="Neurology7529c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Evosyal is not launched yet in the US or in Europe.<wbr> Daewoong has just launched Nabota (the name in Korea) in South Korea.<wbr> They will need clinical development to register in US and in EU and it might take several years but they can start to register in some IC countries (Latin America, Russia, Asia, MEast) with the Korean dossier.<wbr> We haven't seen any plan to immediate launch in IC countries yet and I guess it will come along the year and in 2015.<wbr> We will obviously monitor the moves from Teoxan and Evosyal.<wbr> </div></div></div><div>Amedeo </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7524">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-24T17:06:24+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-24T17:06:24+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New Ph2 Trial With Teva's Huntexil for Huntington</title>
	<pubDate>2014-04-24T16:58:11+02:00</pubDate>
	<wp:post_id>4934</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New Ph2 Trial With Teva's Huntexil for Huntington</span>&nbsp;<br><span style="font-size: 12px;">Comment: Pridopidine 45mg, 67.<wbr>5mg, 90mg, and 112.<wbr>5mg will be assessed twice-daily vs placebo for the symptomatic treatment of Huntington's Disease.<wbr> PE will determine change from baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at week 26.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7306">...</a><br></div><div style="margin-bottom: 10px;">On April 24h Teva announced the enrollment of the first patient in the Pride-HD study.<wbr> To be noted, the completion date has been delayed to March 2015, and locations expanded to global from EU/<wbr>US.<wbr> </div><div style="margin-bottom: 10px;">Professor G.<wbr> Bernhard Landwehrmeyer, M.<wbr>D.<wbr>, Ph.<wbr>D, FRCP, and professor of neurology, Ulm University Hospital, Germany will be the lead study investigator.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Drug</STRONG> </div><div style="margin-bottom: 10px;">Pridopidine is an investigational, oral, small molecule being developed for the symptomatic treatment of Huntington&rsquo;s disease (HD).<wbr> Teva intends to design and complete new clinical studies of pridopidine to assess its potential for symptomatic relief of HD.<wbr> Earlier clinical studies of pridopidine conducted in the U.<wbr>S.<wbr>, EU and Canada in patients with HD indicate a significant treatment effect on an important secondary endpoint, Total Motor Score (TMS).<wbr> </div><div>In previous studies, where doses up to 45 mg bid were tested, pridopidine was well tolerated with an adverse event profile similar to placebo, and treatment with pridopidine was not associated with worsening of disease signs and symptoms.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7523">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7306">View thread  Neurology7306: New Ph2 Trial With Teva's Huntexil for Huntington</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-24T16:58:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-24T16:58:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The First Approval OF PARP Inhibitor Is Underway</title>
	<pubDate>2014-04-24T13:35:23+02:00</pubDate>
	<wp:post_id>4935</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Today FDA Oncologic Drugs Advisory Committee announced that the committee is planning to discuss application submitted by AstraZeneca for olaparib on 25 June.<wbr> Olaparib is the most advanced PARP inhibitors in development, followed by rucaparib by Clovis Oncology and Niraparib by TesaroBio.<wbr> </div><div style="margin-bottom: 10px;">The proposed indication (use) for olaparib is as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed ovarian cancer (including fallopian tube or primary peritoneal) with germline BRCA mutation as detected by an FDA-approved test, who are in response (complete response or partial response) to platinum-based chemotherapy.<wbr> Discovery of PARP inhibitors has come a long way (<a href="http://ci.beaufour-ipsen.com/traction#/single&amp;amp;proj=Oncology&amp;amp;rec=9400" class="defaultlink">Oncology9400:PARP Inhibitors Are Bouncing Back in Oncology),</a> and olaparib is likely to be the first PARP inhibitor available by Q3 2014 (also see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9634" class="defaultlink">Oncology9634: AstraZeneca Reports Flat Q1:14 Results and Flags Dynamic Pipeline</a>).<wbr> </div><div>Source: <A href="http://www.fda.gov/">www.<wbr>fda.<wbr>gov</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9805c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: Yesterday FDA held the Oncologic Drugs Advisory Committee and agency advisors voted 11-2 for AstraZeneca should complete a study to confirm olaparib's benefit before an approval decision can be made.<wbr> If the FDA requires AstraZeneca to complete a confirmatory study before deciding on approval, the company is estimated to lose $150 million in sales through 2016, Bloomberg Industries said.<wbr> Most importantly, A delay also would raise questions about AstraZeneca&rsquo;s view that its experimental medicines were undervalued by Pfizer in the proposed acquisition, according to Bloomberg Industries.<wbr>.<wbr> </div><div style="margin-bottom: 10px;">After the committee meeting, Brent Logan (panel member and biostatistics professor at the medical college of Wisconsin) commented after the vote &ldquo;there are a number of issues that raise concern about the benefit of olaparib helping patients to survive without their disease progression.<wbr> That produces a magnitude of uncertainty.<wbr>&rdquo; AstraZeneca&rsquo;s reanalysis of the drug, known as Study 19, found ovarian cancer patients with the BRCA mutation who took olaparib lived 11.<wbr>2 months without their disease progressing compared with 4.<wbr>1 months for those on a placebo.<wbr> FDA staff members questioned whether the reanalysis skewed the results.<wbr> If the difference in progression-free survival isn&rsquo;t as pronounced, the risks associated with olaparib may outweigh the benefit.<wbr> Safety concerns include bone marrow suppression, fatigue, nausea and abdominal pain as well as a &ldquo;small but concern risk&rdquo; of developing a certain kind of leukemia, according to the report.<wbr> </div><div>AstraZeneca is attempting to gain accelerated approval of olaparib based on a Phase II clinical trial, the middle of three stages of trials usually required for approval.<wbr> Early FDA clearance would require the drugmaker to complete a final-phase study, called SOLO-2, to stay on the market.<wbr> Results from that study are expected to be available at the end of 2015.<wbr>The FDA is expected to decide whether to grant olaparib accelerated approval by Oct.<wbr> 3.<wbr> AstraZeneca also is studying the drug in lung and breast cancers.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9637">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-24T13:35:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-24T13:35:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca Reports Flat Q1:14 Results and Flags Dynamic Pipeline</title>
	<pubDate>2014-04-24T11:00:55+02:00</pubDate>
	<wp:post_id>4936</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AZ has highlighted progress with new cancer drugs, including MEDI4736 (anti-PD-L1), the first of its immuno-onco drug candidate (moving into Ph3 for lung cancer).<wbr> The diabetes platform, recently boosted by an alliance with BMS, contributed 2 percentage points of revenue growth.<wbr> Sales in Japan, outlined as one of the company's key priorities, increased by 13% (CER) to $537M.<wbr> Management made no reference to a reported £60bn bid approach from Pfizer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Q1 14 revenue was $6,416M, up to 3% (CER).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Q1 14 sales decreased 2% to $221M (vs $240M in Q1 13) </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>China</U> now represents approximately 40% of the total Emerging Markets business, with growth driven by Pulmicort, Crestor, Nexium and Symbicort.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9634_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9634_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9634_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9634_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Management announced Ph3 initiations for: </div><div style="margin-bottom: 10px;"><UL><LI>MEDI4736 (PD-L1, PACIFIC trial), as a sequential therapy following chemoradiation in patients with locally advanced, unresectable NSCLC.<wbr></LI>
<LI>AZD9291 (EGFR, also granted breakthrough therapy designation) in NSCLC,</LI>
<LI>olaparib (PARPi) in breast cancer (also granted US priority review in 2d line BRCAm ovarian cancer with potential approval on 3 Oct), &gt; see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9637" class="defaultlink">Oncology9637: The First Approval OF PARP Inhibitor Is Underway</a></LI>
<LI>selumetinib (MEKi) in uveal melanoma.<wbr> </LI>
<LI>brodalumab (psoriatic arthritis) and tralokinumab (severe asthma)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9634_6_ScreenCapture6.jpg"> </div><div><EM>Source: AstraZeneca</EM> </div><!-- Comment details --><a name="oncology9634attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9634_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9634_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(28,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9634_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(53,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9634_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(35,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9634_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(49,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9634_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(27,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9634">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-24T11:00:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-24T11:00:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan's First Response To The Valeant Bid</title>
	<pubDate>2014-04-23T19:01:05+02:00</pubDate>
	<wp:post_id>4937</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has today adopted a "poison pill" strategy to try and counter any further advance by Valeant.<wbr> Its Board has unanimously adopted a one-year stockholder rights plan effective April 22nd 2014 and declared a dividend distribution on each outstanding preferred share purchase right on each outstanding share of the company's common stock.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What are the implications of this move?</STRONG> </div><div style="margin-bottom: 10px;">This "poison pill strategy" essentially stops Bill Ackman acquiring more that his current 9.<wbr>8% stake.<wbr> As he is working with Valeant in partnership to buy Allergan were he to increase his shareholding he could be in a position as an activist shareholder to have more of an influence over a potential takeover.<wbr> </div><div style="margin-bottom: 10px;">The shareholder rights plan that's been implemented means that should Ackman increase his holding above 10% then all existing shareholder (ex Ackman) will receive a 1:1 share split, which would dilute Ackman's holding.<wbr> Essentially, this move is a stall tactic to give Allergan time to consider other offers or reject/<wbr>negotiated the Ackman-Valeant bid.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Analyst Opinion On What Happens Next</STRONG> </div><div style="margin-bottom: 10px;">Aron Gal from Bernstein Research has noted the following </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt;">* $150/<wbr>share will not do it.<wbr> Allergan closed couple of weeks ago at $131/<wbr>share.<wbr> Most investors we talk to look at Allergan as a long term holding, capable of generating 15%/<wbr>year in returns.<wbr> We would argue they would be looking for at least 2-years return to sell their shares - so $170-$180 sounds like a much more reasonable range than $150.<wbr> Another complication is the 66% share of VRX paper.<wbr> Investors would want some further discount to take Valeant shares.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt;">* Another bidder may jump in.<wbr> Several companies have been reported interested in AGN in the past, but the company was expensive and there was no urgency to the deal.<wbr> If AGN is on the block, there may be others who will step in - JNJ, GSK and Nestle come to mind.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt;">* Allergan will fight it.<wbr> AGN CEO Pyott argued in the past against a takeout by Valeant.<wbr> He will almost certainly resist it now (the public offer also indicates that).<wbr> There will be public debate on this but we would also expect several near-term value enhancing steps from Allergan.<wbr> Few thoughts would be (i) increase the range of target EPS growth from 15% to 20%; (ii) announce further cost cuts, (iii) potentially putting in debt structure and using the cash to either buy a large asset or return money to shareholders.<wbr> (iv) provide better disclosures of pipeline and growth sources.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt;">Sources: <A href="http://www.allergan.com">www.<wbr>allergan.<wbr>com</A></SPAN> </div><div><SPAN style="font-size: 11pt;">Bernstein Research note April 22nd</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7521">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-23T19:01:05+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-23T19:01:05+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OncoGenex received Their Third FDA Fast Track Designation for Custirsen</title>
	<pubDate>2014-04-23T18:53:10+02:00</pubDate>
	<wp:post_id>4938</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div><DIV class="article_body">Comment : Following receiving fast track designation for SYNERGY trial (<a href="http://ci.beaufour-ipsen.com/traction#/single&proj=Oncology&rec=9457" class="defaultlink">Oncology9457: OncoGenex Completes PhIII mCPRC Trial),</a> OncoGenex announced today that FDA has granted Fast Track designation to investigation of custirsen when administered in combination with cabazitaxel/<wbr>prednisone for the treatment of men with metastatic castrate-resistant prostate cancer (CRPC) following prior treatment with a docetaxel-containing regimen.<wbr> <BR><BR>This is the third OncoGenex's trial receiving fast track designation.<wbr> AFFINITY is the international, randomized, open-label Phase 3 trial to evaluate if custirsen, when combined with second-line chemotherapy cabazitaxel and prednisone, has the potential to improve survival outcomes for prostate cancer patients compared to second-line chemotherapy alone.<wbr> A total of 630 patients is expected to enrol by Q3-Q4 2014.<wbr></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9632">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-23T18:53:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-23T18:53:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Improving Transurethral Resection of the Bladder Tumor Using a Front-Firing Green Light Laser</title>
	<pubDate>2014-04-23T16:21:53+02:00</pubDate>
	<wp:post_id>4939</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The publication concludes that the modified technique using a front-firing green-light laser to en bloc enucleate bladder tumors is effective and safe for treatment of NMIBC.<wbr> Moreover, it may improve the accurate valuation of tumor stage and prediction of postoperative prognosis, although long-term outcomes and prospective clinical trials are needed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><DIV class="_rp_Q3 rpHighlightAllClass rpHighlightBodyClass" id="Item.MessageUniqueBody" tabindex="0">
<DIV>
<DIV dir="ltr">
<DIV id="OWAFontStyleDivID" style="BACKGROUND-COLOR: white">
<DIV>
<DIV>
<DIV>
<DIV id="OWAFontStyleDivID">
<DIV>
<DIV>
<DIV style="MARGIN: 0px"><SPAN style="FONT-WEIGHT: normal"></SPAN></DIV>
<DIV>
<DIV style="MARGIN: 0px"></DIV></DIV>
<DIV>
<DIV style="MARGIN: 0px"></DIV></DIV>
<DIV>
<DIV>
<DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"></DIV>
<DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"></DIV>
<DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"></DIV>
<DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"></DIV>
<DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9628">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-23T16:21:53+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-23T16:21:53+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: MDV3100 in Patients With Hormone-naïve Prostate Cancer</title>
	<pubDate>2014-04-23T14:39:47+02:00</pubDate>
	<wp:post_id>4940</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">MDV3100 in Patients With Hormone-naïve Prostate Cancer</span>&nbsp;<br><span style="font-size: 12px;">Comment: <EM>Clinicaltrials.<wbr>gov</EM> is listing a new Ph2, sponsored by Astellas Pharma Europe, which will determine the proportion of subjects with a PSA response as a primary outcome measures.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=7191">...</a><br></div><div>Primary analysis of enzalutamide Ph2 trial was published by Professor Tombal in Lancet Oncology on 11th April (<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=24739897" class="defaultlink">PMID:24739897</a>).<wbr> This trial is an open-label, single arm, Phase 2 study to assess the activity and safety of enzalutamide as monotherapy in homone naïve prostate cancer patients who had non-castration levels of testosterone, PSA ≥ 2 ng/<wbr>mL at screening with ECOG=0.<wbr> The PE was the proportion of patients with an ≥ 80% decline in PSA at week 25.<wbr> Enzalutamide monotherapy demonstrated activity of disease suppression (62/<wbr>67 patients had a decline in PSA of 80% or greater at week 25) and was well tolerated (9/<wbr>67 patients had grade 3+ treatment emergent adverse events at week 25).<wbr> These results warrant a rationale for further investigation in this setting.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9627">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology7191">View thread  Oncology7191: MDV3100 in Patients With Hormone-naïve Prostate Cancer</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-23T14:39:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-23T14:39:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sentinel Oncology Announced Alliance Agreement with Oncothyreon To Develop And Commercialise Small Moleucule Chk1 Inhibitors</title>
	<pubDate>2014-04-23T13:09:48+02:00</pubDate>
	<wp:post_id>4941</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Oncothyreon (Seattle, USA) forms alliance with Sentinel Oncology (Cambridge, UK) to develop and commercialise any resulting compounds from Sentinel's Checkpoint Kinase 1 (Chk1) Programme.<wbr> Oncothyreon agrees to a total payments of $174 million for pre-clinical, clinical and commercial milestone and plus a royalty on any net sales under the terms of the alliance.<wbr> Sentinel has been developing Chk1 inhibitors to selectively sensitise tumour cells to DNA damaging agents, enabling effective lower doses of chemo and radiotherapy and reduction in associated side-effects.<wbr> </div><div>Chk1 programmes is to screen for ChK1 inhibitor that acts to prevent intra S and G2/<wbr>M checkpoint cell cycle arrest.<wbr> Without the presence of ChK1 inhibitor, cancer cells are able to activate checkpoint arrest to allow initiation of repairing mechanism.<wbr> As a results, cancer cells are able to evade programmed death and proliferate.<wbr>This is a strategic fit to complement Oncothyreon's current small molecule pipeline programmes including PIX866 (PI-3K inhibitor) that is currently in Ph2 mCRPC patients <a href="http://ci.beaufour-ipsen.com/traction#/single&proj=Oncology&rec=8457&brief=n" class="defaultlink">(Oncology8457 re: First Patient Enters in Ph2 of Oncothyreon's PI-3K for Prostate Cancer)</a> and recurrent glioblastoma patients.<wbr> Some scientific evidences suggesting combination approach of PIK -3 and DNA damage checkpoint dual inhibition may be able to overcome chemo resistance in some tumour cells (Skladanowski et al.<wbr> 2007; Kurosu et al.<wbr> 2013).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9625">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-23T13:09:48+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-23T13:09:48+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>LG Household & HealthCare Considers Buying Elizabeth Arden</title>
	<pubDate>2014-04-23T11:26:45+02:00</pubDate>
	<wp:post_id>4942</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: LG H&amp;H, #2 in the South Korean market, has confirmed that Elizabeth Arden is one of 3 major M&amp;As it is currently reviewing.<wbr> However, the company said that nothing has been finalized.<wbr> Management is looking at cosmetics and personal care companies that have a solid brand and distribution network globally so that it can accelerate its global expansion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The acquisition could help the company become a global luxury cosmetics player, with the expansion of its Korean cosmetic brand portfolio.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7517_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7517_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7517_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="neurology7517attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7517_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(42,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7517_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(33,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7517_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(182,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7517">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-23T11:26:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-23T11:26:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant Proposes Merger With Allergan for $48.30 in cash & 0.83 Valeant Shares/ Allergan share</title>
	<pubDate>2014-04-22T15:29:46+02:00</pubDate>
	<wp:post_id>4943</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Valeant offer of $47bn which is made in conjunction with William Ackman's Hedge Fund, Pershing Square,represents a substantial premium to Allergan's stock price of $116.<wbr>63 on April 10, 2014, the day before Pershing Square crossed the 5% schedule 13D ownership level and commenced its rapid accumulation program of Allergan shares.<wbr> </div><div style="margin-bottom: 10px;">Based on the deal terms Allergan shareholders will own 43% of the combined company.<wbr> Pershing Square.<wbr> Allergan's largest shareholder with a 9.<wbr>7% stake in Allergan, has agreed to elect only stock consideration in the transaction and intends to remain a significant long-term shareholder of the combined company.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Proposed Benefits Of The Combined Valeant/<wbr>Allergan Platform</STRONG> </div><div><DIV class="xn-content">
<P>Valeant and Pershing Square believe that the combination of the two companies is extremely compelling for both Allergan and Valeant shareholders and will create an unrivaled platform for growth and value creation in healthcare.<wbr> The benefits of the combination it is suggested will include:</P>
<UL type="disc"><LI>Unrivaled portfolio in Ophthalmology, Dermatology, and Aesthetics
<UL type="circle"><LI>Provides significant benefits to patients and physicians around the world
</LI>
<LI>High single-digit organic growth rate for foreseeable future
</LI>
</UL>

</LI>
<LI>More than$2.<wbr>7 billionin annual operating cost synergies, not including significant revenue synergies
<UL type="circle"><LI>80% achieved in first six months with the remaining 20% in the following 12 months
</LI>
</UL>

</LI>
<LI>High single-digit tax rate for combined company in addition to cost synergies
</LI>
<LI>25-30% pro forma 2014 Cash EPS accretion assuming the transaction closed and full synergies realized on January 1, 2014; year 2 and beyond Cash EPS expected to grow 15-20%+ depending on deployment of free cash flow
</LI>
<LI>At least $300 million in annual R&amp;D spend to complete future high-probability and late-stage projects
</LI>
<LI>Strong balance sheet, approximately 3 times net debt /<wbr> adjusted EBITDA, and significant operating cash flow to accelerate business development
</LI>
<LI>No antitrust uncertainty
</LI>
<LI>Financing commitments for $15.<wbr>5 billion from Barclays and RBC Capital Markets
</LI>
<LI>Expect to initiate $0.<wbr>20 per share annual dividend at close, in line with current Allergan dividend
</LI>
<LI>Flexible with any and all social issues
</LI>
</UL>
<P>Commenting on the proposal Michael Peason Chariman &amp; CEO of Valeant has stated, "This proposal represents an undeniable opportunity to create extraordinary value for both Allergan and Valeant shareholders by establishing an unrivaled platform with leading positions in ophthalmology, dermatology, aesthetics, dental and the emerging markets.<wbr> Together, we can capitalize on the inherent strengths and complementary portfolios of our two companies, while achieving significant synergies by applying Valeant's unique operating model to a combined set of assets.<wbr></P>
<P>He also noted that while the Allergan CEO and Board of Directors made it clear, both privately and publicly, that they were unwilling to enter discussions with Valeant, it is hopeful that its extremely compelling proposal for the combination will enable further productive discussions to take place.<wbr></P>
<P>Source: <A href="http://www.valeant.com">www.<wbr>valeant.<wbr>com</A></P>
</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10825">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-22T15:29:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-22T15:29:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Valeant Teams Up With Hedge Fund Activist To Try & Acquire Allergan</title>
	<pubDate>2014-04-22T14:47:07+02:00</pubDate>
	<wp:post_id>4944</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Valeant Teams Up With Hedge Fund Activist To Try & Acquire Allergan</span>&nbsp;<br><span style="font-size: 12px;">Comment: Valeant &amp; Hedge Fund activist William Ackman appear poised to make a bid for Allergan.<wbr> A recent security filing notes the intent and the accumulated shareholding of Ackman of 9.<wbr>7% in Allergan.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10821">...</a><br></div><div>Valeant has this afternoon formalised its offer for Allergan bidding $47bn to acquire the company in order to expand its skin and eyecare business.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10824">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10821">View thread  PharmaWorld10821: Valeant Teams Up With Hedge Fund Activist To Try & Acquire Allergan</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-22T14:47:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-22T14:47:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Positive Results from Revance's Injectable Botulinum Toxin Ph1/2 Study in GL</title>
	<pubDate>2014-04-22T13:13:49+02:00</pubDate>
	<wp:post_id>4945</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: RT002 is Revance's proprietary, injectable botulinum toxin investigational product that incorporates the patented TransMTS® technology and is designed to provide a longer lasting duration of effect.<wbr> In the study, RT002 met its primary efficacy and safety endpoints.<wbr> The company plans to continue studying RT002 in a Ph2 active comparator study.<wbr> Data from the study is anticipated in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> RT002 was easy to administer and very well received by patients," said Enrique Garcia-Murray, MD lead investigator for the RT002 study.<wbr> "As the study progressed, we were most impressed by the duration of effect.<wbr> Patients typically see 3 to 4 months of benefit from current botulinum toxin treatments, but we saw an effect that was significantly longer than that.<wbr> My patients were extremely happy about this increased duration.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Design</U> </div><div style="margin-bottom: 10px;">The open-label, dose escalating, Phase 1/<wbr>2 study enrolled 48 adults in four cohorts.<wbr> All subjects had Severe or Moderate wrinkles at baseline, measured using the 4-point Global Line Severity Scale (GLSS).<wbr> </div><div style="margin-bottom: 10px;"><U>Results</U> </div><div style="margin-bottom: 10px;"><UL><LI>94% of subjects were rated with None or Mild wrinkle severity at maximum frown 4 weeks post-treatment using the GLSS as assessed by the clinical investigator.<wbr> 83% of subjects assessed themselves as achieving None or Mild wrinkles at maximum frown at the same time point.<wbr> </LI>
<LI>In the final cohort, the only one where duration of effect was measured, RT002 achieved a median duration of 29.<wbr>4 weeks or 7.<wbr>3 months based on both investigator and subject assessments.<wbr> </LI>
<LI>RT002 was well tolerated, and there was no evidence of spread beyond the treatment site at any dose.<wbr></LI>
</UL> </div><div><EM>Source: Revance</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7515">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-22T13:13:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-22T13:13:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Results Show Superiority in the Side Effect Profile of Aspireo's Somatoprim over Octreotide</title>
	<pubDate>2014-04-22T12:18:04+02:00</pubDate>
	<wp:post_id>4946</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has reported data from a further Ph1b study.<wbr> The final results demonstrate that octreotide significantly inhibits the secretion of insulin and glucagon in humans, and show a significant and sustained increase of plasma glucose levels.<wbr> In contrast, somatoprim has much less of an effect on insulin and glucagon release compared to octreotide, as well as the normalization of glucose control.<wbr> This improved profile was observed even at high doses of somatoprim.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Single-dose, randomized, 5-way cross-over study </div><div style="margin-bottom: 10px;">Healthy volunteers were treated with the highest approved dose of octreotide, 3 different doses of Somatoprim (DG3173) and placebo control.<wbr> </div><div style="margin-bottom: 10px;">The main purpose of the study was to investigate the effects of each treatment on the control of plasma glucose as well as the secretion of insulin and glucagon following a standard meal.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Somatoprim is the company's sole compound in development.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7652_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Q4 2012,</U> the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) issued a positive opinion on an application for orphan medicinal product status for acromegaly.<wbr> </div><div style="margin-bottom: 10px;"><U>Q2 2013,</U> Ph2a results show shows that Somatoprim demonstrated a dose-dependent effect on lowering excess growth hormone (hGH) on treatment-naïve patients suffering from acromegaly.<wbr> No serious adverse events were reported and the reported adverse events were mild to moderate and of transient nature.<wbr> </div><div><U>Q3 2013</U>, Office of Orphan Products Development of the US' FDA granted Aspireo's request for orphan-drug designation for Somatoprim for acromegaly </div><!-- Comment details --><a name="endocrinology7652attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7652_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(43,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7652">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-22T12:18:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-22T12:18:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant Teams Up With Hedge Fund Activist To Try & Acquire Allergan</title>
	<pubDate>2014-04-22T11:04:18+02:00</pubDate>
	<wp:post_id>4947</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Valeant &amp; Hedge Fund activist William Ackman appear poised to make a bid for Allergan.<wbr> A recent security filing notes the intent and the accumulated shareholding of Ackman of 9.<wbr>7% in Allergan.<wbr> </div><div style="margin-bottom: 10px;">The following are specific quotes from a 13D filing with the SEC that highlight this intent.<wbr> </div><div style="margin-bottom: 10px;">"As of April 21, 2014, the Reporting Persons (Pershing Square Capital Management) beneficially owned an aggregate of 28,878,538 shares of Common Stock (which include 24,831,107 shares of Common Stock underlying American-style call options and 3,450,000 shares of Common Stock underlying forward purchase contracts), representing approximately 9.<wbr>7% of the issued and outstanding shares of Common Stock of the Issuer.<wbr>" </div><div style="margin-bottom: 10px;">"Valeant Pharmaceuticals International, Inc.<wbr>, a corporation continued under the laws of British Columbia, Canada (&ldquo;<U>Valeant</U>&rdquo;), and Valeant Pharmaceuticals International, a Delaware corporation and a wholly owned subsidiary of Valeant (&ldquo;<U>Valeant USA</U>&rdquo;), are jointly filing a separate Schedule 13D reporting beneficial ownership of shares of Common Stock.<wbr> The Reporting Persons may be deemed members of a &ldquo;group&rdquo; (within the meaning of Rule 13d-5 under the Exchange Act of 1934, as amended (the &ldquo;<U>Exchange Act</U>&rdquo;)) with Valeant and Valeant USA.<wbr>" </div><div style="margin-bottom: 10px;">"Valeant currently intends to propose a merger in which the Issuer&rsquo;s shareholders (Allergan) will receive a combination of cash and Valeant common shares.<wbr> Valeant has not yet determined the amount of cash and number of Valeant common shares it will offer, but it currently expects the cash component will total around $15 billion.<wbr> Barclays and Royal Bank of Canada have indicated that they are prepared to deliver financing commitments covering the cash portion of the transaction at the time Valeant makes an offer.<wbr>" </div><div style="margin-bottom: 10px;">It also notes that although Valeant currently expects to make an offer, it is under no obligation and provides no assurance it will do so.<wbr> </div><div><STRONG><A href="http://www.sec.gov/Archives/edgar/data/850693/000119312514150906/d711603dsc13d.htm">http:/<wbr>/<wbr>www.<wbr>sec.<wbr>gov/<wbr>Archives/<wbr>edgar/<wbr>data/<wbr>850693/<wbr>000119312514150906/<wbr>d711603dsc13d.<wbr>htm</A></STRONG> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10824c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Valeant has this afternoon formalised its offer for Allergan bidding $47bn to acquire the company in order to expand its skin and eyecare business.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10821">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-22T11:04:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-22T11:04:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer Weighs Up £60bn Bid For AstraZeneca</title>
	<pubDate>2014-04-22T10:28:36+02:00</pubDate>
	<wp:post_id>4948</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The UK Sunday Times headline in the Business Section, suggests that Pfizer has made a tentative approach to acquire AstraZeneca for a sum that could value the business for more than &pound;60bn.<wbr> </div><div style="margin-bottom: 10px;">The article referes to informal discussions that have taken place in recent weeks with sources cited as senior investment bankers and industry sources.<wbr> </div><div style="margin-bottom: 10px;">Astra is believed to have rejected Pfizer's advances but the article does not rule out Pfizer taking an alternative approach.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rational Behind This Development</STRONG> </div><div style="margin-bottom: 10px;">Pfizer is reportedly keen to deploy a $70bn cashpile it has accumulated in overseas subsidiaries.<wbr> Repatriating the cash would result ina colossal tax bill, so it is looking at alternatives in terms of M&amp;A.<wbr> </div><div style="margin-bottom: 10px;">The company has a history of doing big deals to boost its sales.<wbr> Its last purchase beign Wyeth for $68bn in 2009 and before that Warner-Lambert in 2000 for $93bn.<wbr> </div><div style="margin-bottom: 10px;">Astra faces some issues of its own with a number of its big selling drugs loosing patent protection.<wbr> Whilst the new Cheif Executive Pascal Soriot has instilled a new culture and started to revamp the pipeline, he has acknolwedege that the company will not get back onto a growth trajectory until 2017.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, Pfizer and Astra have been working together on a joint approach towards a new lung cancer treatment.<wbr> Potential synergy can also be foreseen in the breast cancer field where AZ has an established presence and Pfizer and promising new treatment.<wbr> </div><div>Source: SundayTimes 20.<wbr>04.<wbr>14 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10818">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-22T10:28:36+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-22T10:28:36+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis to Revamp its Portfolio Via Deals with GSK and Lilly</title>
	<pubDate>2014-04-22T09:39:47+02:00</pubDate>
	<wp:post_id>4949</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis will acquire GSK's cancer drugs business for $16bn (£9.<wbr>5bn) and sell its vaccines division, excluding the flu unit, to GSK for $7.<wbr>1bn.<wbr> Both companies will combine Novartis OTC with GSK's consumer business in a joint venture, creating a world-leading consumer healthcare business and maintaining Novartis' presence in this sector.<wbr> In a separate deal, Novartis has agreed to sell its animal health division to Lilly for nearly $5.<wbr>4bn.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In an interview with Thomson Reuters, the CEO of Novartis clarified some aspects of the transaction in oncology </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> what the GSK products do for us from an oncology standpoint is they make us very strong in two very important areas.<wbr> Renal cell carcinoma because we'll be acquiring Votrient, a new agent; as well as two very important new agents in Metastatic melanoma.<wbr> Now the good thing about this GSK portfolio is it's essentially de-risked that we have just acquired these newly approved agents.<wbr> And if you put those agents in the hand of our tremendous power house in oncology from a commercial standpoint, we believe that we will be able to drive them and maximize value".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG class="hugin">Acquisition of GSK oncology products</STRONG><BR>Novartis has agreed to acquire GSK oncology products for a USD 14.<wbr>5 billion payment and up to USD 1.<wbr>5 billion contingent on a development milestone.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="hugin">Under the terms of the transaction, Novartis would have opt-in rights to GSK's current and future oncology R&amp;D pipeline.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG class="hugin">Combination of Novartis OTC with GSK Consumer Healthcare in a joint venture</STRONG><BR>Novartis and GSK have agreed to create a world-leading consumer healthcare business through a joint venture between Novartis OTC and GSK Consumer Healthcare.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="hugin">Upon completion, Novartis will own a 36.<wbr>5% share of the joint venture and will have four of eleven seats on the joint venture's Board.<wbr> Furthermore, Novartis will have customary minority rights and exit rights at a pre-defined, market-based pricing mechanism.<wbr></P> </div><div><P class="hugin">The geographic footprint would span all regions, with scale and commercial presence in the developed world as well as in key emerging markets, such as Brazil, China, Mexico and Russia.<wbr></P> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10123c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">GSK has asked its shareholders to vote at a meeting on Dec.<wbr> 18 on its proposed major deal with Novartis, which will see the two pharmaceutical group trade more than $20 billion of assets.<wbr> </div><div>In a letter to shareholders endorsing the deal, GSK's chairman Christopher Gent said approval would strengthen its franchises in vaccines and consumer healthcare to complement its leading position in respiratory and HIV.<wbr><BR><BR>"This is the most significant transaction for the Company since the creation of GlaxoSmithKline in 2000," he said.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9617">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-22T09:39:47+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-22T09:39:47+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Acquiers Novel Next Generation Product for Dermal Filler</title>
	<pubDate>2014-04-17T17:48:51+02:00</pubDate>
	<wp:post_id>4950</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Aline Aesthetics, a wholly-owned subsidiary of the TauTona Group, has completed the sale of its Aline Hyaluronic acid (HA) thread technology, under development for use as a dermal filler, to Allergan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Aline HA is comprised of a solid state, cross-linked HA in thread form that is attached to a needle.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Part venture capital fund, part R&amp;D incubator, TauTona Group is a medical device firm committed to the development of disruptive technologies in key therapeutic areas.<wbr> </div><div><EM>Source: TauTona</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7513">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-17T17:48:51+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-17T17:48:51+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Report From The IMS Institute Reports A More Positive Picture Of Healthcare Growth In The US</title>
	<pubDate>2014-04-17T16:45:21+02:00</pubDate>
	<wp:post_id>4951</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:: IMS has this week issued a press release relating to the results of 
a new study which notes that overall healthcare usage is up for the first time 
in three years.<wbr> The impact of patent expiries on drug costs is falling and 
a record number of transformative medicines were launched in 2013.<wbr> </div><div style="margin-bottom: 10px;">The study – <STRONG>Medicine Use and Shifting Costs of Healthcare: A Review 
of the Use of Medicines in the United States in 2013</STRONG> – found that total 
dollars spent on medications in the U.<wbr>S.<wbr> reached $329.<wbr>2 billion last year, up 
3.<wbr>2 percent on a nominal basis and a rebound from the 1.<wbr>0 percent decline in 
2012.<wbr> </div><div style="margin-bottom: 10px;">Primary drivers include the reduced impact of patent expiries, price 
increases, higher spending on innovative new medicines, and greater use by 
patients of the healthcare system.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Patent expiries in 2013 contributed $19 billion to lower medicine 
  spending, compared with $29 billion the previous year.<wbr> </LI>
<LI>At the same time, 36 New Molecular Entities launched in 2013, the largest 
  number in a decade, focused on specific disease areas that include oncology, 
  hepatitis C and HIV.<wbr> </LI>
<LI>Overall utilization of healthcare services grew slightly as consumers 
  returned to the healthcare system – primarily through more office visits to 
  specialist physicians as well as outpatient treatments – following several 
  years of self-rationing.<wbr></LI>
<LI>In addition, patients with insurance paid higher out-of-pocket expenses in 
  the form of deductibles and co-insurance last year, even as prescription 
  co-payments declined and are now less than $5 for more than half of all 
  prescriptions filled.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">“Following several years of decline, 2013 was striking for the increased use 
by patients of all parts of the U.<wbr>S.<wbr> healthcare system – even in advance of full 
implementation of the Affordable Care Act,” said Murray Aitken, executive 
director of the IMS Institute for Healthcare Informatics.<wbr> “Growth in medicine 
spending remains at historically low levels despite a significant uptick last 
year, and continues to contribute to the bending of the healthcare cost 
curve.<wbr>” </div><div style="margin-bottom: 10px;">The report’s key findings include the following: </div><div style="margin-bottom: 10px;"><UL><LI><B>Increase in the utilization of healthcare services and medicines.<wbr></B> 
  The number of physician office visits, hospitalizations and prescriptions 
  filled all increased in 2013.<wbr> The number of patient office visits to primary 
  care physicians fell by 0.<wbr>7 percent in 2013, while visits to specialists 
  increased by 4.<wbr>9 percent overall and by 9.<wbr>5 percent for seniors.<wbr> The number of 
  hospital visits increased last year, most notably by patients who were 
  commercially insured and received outpatient treatments.<wbr> Patients filled an 
  average of more than 12 retail prescriptions last year, up nearly 2 percent 
  year over year.<wbr> Those aged 65 and over filled an average of 28 prescriptions 
  annually, down slightly from 2012.<wbr></LI>
<LI><B>Spending on medicines.<wbr> </B>While drug spending levels have contributed 
  to slower growth in healthcare costs since 2007, nominal spending rose sharply 
  last year.<wbr> The largest single driver of the 4.<wbr>2 percentage point shift in 
  spending growth in 2013 was the $10 billion lower impact of patent expiries.<wbr> 
  Price increases for branded products added $4 billion more in spending growth 
  last year compared to 2012; however, net price growth was essentially flat 
  year over year, reflecting off-invoice discounts and rebates.<wbr> Overall spending 
  on medicines remained concentrated in traditional small-molecule pills 
  dispensed through retail pharmacies, even as higher growth was seen in 
  biologics and specialty drugs – particularly in retail and mail-order 
  settings.<wbr></LI>
<LI><B>Transformations in disease treatment.<wbr> </B>Patients gained access to 36 
  New Molecular Entities (NMEs) in 2013, including ten new notable cancer 
  treatments – the most in more than a decade.<wbr>  A total of 27 new oncology 
  drugs have launched in the past three years.<wbr> Additionally, clusters of 
  innovation are transforming patient care in hepatitis C, multiple sclerosis 
  and diabetes, as well as stroke and acute coronary syndrome.<wbr> In addition to 
  improved patient outcomes, these and other transformational treatments bring 
  with them a shift in where costs are being incurred in the healthcare system – 
  yielding the promise of fewer doctor office visits, less hospitalizations and 
  reduced use of long-term care facilities.<wbr> Seventeen orphan drugs – developed 
  for patient populations of fewer than 200,000 individuals – launched in 2013, 
  the most in any year since the passage of the Orphan Drug Act in 1983.<wbr> The 
  next decade promises a much faster approval process for drugs gaining the Food 
  and Drug Administration’s new <I>Breakthrough Therapy Designation</I>.<wbr> 
   </LI>
<LI><B>Patient payment for healthcare and medicines.<wbr> </B>Patients with 
  insurance are incurring higher out-of-pocket costs for healthcare services 
  despite lower co-pays for many prescriptions and additional discounts for 
  preventive medicines.<wbr> Prescription drug costs paid by most patients are 
  declining, with average out-of-pocket costs falling below $5 for 57 percent of 
  all retail prescriptions filled.<wbr> At the same time, 30 percent of total patient 
  out-of-pocket costs relate to just 2.<wbr>3 percent of prescriptions, often 
  high-cost specialty medicines.<wbr> Twenty-three percent of prescriptions now carry 
  no out-of-pocket costs, a dramatic rise in 2013 driven by common preventive 
  medicines that include oral contraceptives.<wbr></LI>
</UL> </div><div>The full version of the report, including a detailed description of the 
methodology, is available at <A href="http://www.theimsinstitute.org/">www.<wbr>theimsinstitute.<wbr>org</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10815">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-17T16:45:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-17T16:45:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AAA's Expansion Plans For The US</title>
	<pubDate>2014-04-17T16:24:46+02:00</pubDate>
	<wp:post_id>4952</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AAA has announced that it has officially opened a new office in the US situated in the heart of Manhattan where its CEO will be based.<wbr> </div><div style="margin-bottom: 10px;">Commenting on this development, AAA noted that:-<BR>"This is an important step for AAA as the US is a key market for molecular nuclear medicine with nearly half of all nuclear medicine procedures worldwide taking place in the US.<wbr> The aim is to accelerate the company&rsquo;s international growth and further expand its presence and activities in the US as it is advancing in its phase III clinical trial for its lead product Lu-DOTATATE for the treatment of Gastro-Entero-Pancreatic Neuro Endocrine Tumors (GEP-NETs).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Growth Plans</STRONG> </div><div style="margin-bottom: 10px;">AAA&rsquo;s New York office located in the Empire State Building will initially host a few employees, but aims to grow to a team of thirty people in the next 2 years to support its clinical studies for Ga68-DOTATATE (Somakit) and Annexin.<wbr> </div><div style="margin-bottom: 10px;">AAA&rsquo;s New York office will also be heading all developments linked to the setting up of a new manufacturing facility in the US and the launch of AAA&rsquo;s commercial activity in the US.<wbr> </div><div>source:www.<wbr>adacap.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7649">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-17T16:24:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-17T16:24:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Multi-Drug Trial to Speed Development of Cancer Drugs</title>
	<pubDate>2014-04-17T10:26:22+02:00</pubDate>
	<wp:post_id>4953</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A novel lung cancer study will allow British scientists from Cancer Research UK to test &gt;14 drugs from AstraZeneca <AZN.L>and Pfizer <PFE.N>at the same time within one trial.<wbr> A successful programme in lung cancer could also lead to the concept being rolled out into testing drugs for other tumour types.<wbr> This new approach marks a radical break with traditional trial design.<wbr></PFE.N></AZN.L> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- cut time and cost bringing drugs to market </div><div style="margin-bottom: 10px;">- to shift the emphasis from designing a trial around a specific drug to designing it around selecting from a range of drugs for a specific patient.<wbr> </div><div style="margin-bottom: 10px;">- to create a protocol under which scientists can test patients' tumour samples for multiple gene faults and then assign them to an appropriate drug from among those in the trial for testing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The new trial in non-small cell lung cancer will use up to 12 experimental drugs from AstraZeneca, including two compounds designed to boost the immune system that will be given to patients who do not show one of 21 sets of gene faults.<wbr> </div><div style="margin-bottom: 10px;">Pfizer is supplying Xalkori, which is approved for certain rare lung cancers and may also work in some even more unusual types, as well as the experimental drug palbociclib, which has shown promise in breast cancer.<wbr> </div><div style="margin-bottom: 10px;">Approx.<wbr> 15 to 20 patients will be given each drug initially and promising medicines could be fast-tracked into larger-scale testing.<wbr> Those that show no benefit will quickly be dropped.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The U.<wbr>S.<wbr> group Friends of Cancer Research said in November it was backing a similar multi-drug, multi-arm clinical trial to evaluate five experimental lung cancer drugs.<wbr> </div><div>Source: ThomsonOne </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9615">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-17T10:26:22+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-17T10:26:22+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ph2 with BOTOX® for Major Depressive Disorders in Adult Females</title>
	<pubDate>2014-04-16T17:06:11+02:00</pubDate>
	<wp:post_id>4954</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This recently listed trial started this month to assess the safety and efficacy of BOTOX® compared with placebo as treatment for major depressive disorder (MDD) in approx.<wbr> 140 adult females.<wbr> PE will measure change from baseline in the clinic 10-item Montgmery-Asberg Depression Rating Scale (MADRS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Timelines</U> </div><div style="margin-bottom: 10px;">Completion expected: July 2015 /<wbr> November 2015 </div><div style="margin-bottom: 10px;"><STRONG>Criteria of Inclusion /<wbr> Exclusion</STRONG> </div><div><DIV class="indent1" style="BORDER-BOTTOM: white 1px solid; BORDER-LEFT: white 1px solid; MARGIN-TOP: 3ex; BORDER-TOP: white 1px solid; BORDER-RIGHT: white 1px solid">
<P class="indent2" style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><U>Inclusion Criteria:</U></P>
<DIV class="indent2">
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Moderate to severe major depressive disorder</LI>
</UL></DIV>
<P class="indent2" style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><U>Exclusion Criteria:</U></P>
<DIV class="indent2">
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Prior treatment with botulinum toxin of any serotype for any reason</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Use of antidepressant medication for depression within 2 weeks of study</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Diagnosis of Myasthenia gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis</LI>
</UL></DIV>

<P class="color-bullet" style="MARGIN-TOP: 0.7ex">Location: USA (1 site)</P>
<P class="color-bullet" style="MARGIN-TOP: 0.7ex">Source: <A href="http://www.clinicaltrials.gov/ct2/show/NCT02116361?term=PROSTATE+OR+SPASTICITY+OR+BOTULINUM+OR+ACROMEGALY+OR+NSCLC&amp;recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=03%2F16%2F2014&amp;rank=25">NCT02116361</A></P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7512">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-16T17:06:11+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-16T17:06:11+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Investigators to Initiate Ph2 of Everolimus in Poorly Differentiated Neuroendocrine Carcinoma</title>
	<pubDate>2014-04-15T18:09:49+02:00</pubDate>
	<wp:post_id>4955</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The aim of this study, designed to start end of Q3 2014, is to provide a second line therapy to patients with any type of platinum based first line chemotherapy, to gather data on disease control rate and progression free survival.<wbr> The data of this study should be the basis to generate another study to further explore everolimus as maintenance therapy in NEC G3/<wbr> NET G3.<wbr> To be noted, Marianne Pavel (Charité-Universitätsmedizin) will be the principal investigator.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Sponsors and Collaborators</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
AIO-Studien-gGmbH</LI>
<LI>
Assign data management and biostatistics Gmbh</LI>
<LI>
Novartis</LI>
</UL> </div><div style="margin-bottom: 10px;"><DIV class="indent2" style="MARGIN-TOP: 1ex"><STRONG>Recruitment</STRONG></DIV> </div><div style="margin-bottom: 10px;">n=40 </div><div style="margin-bottom: 10px;"><UL><LI>
Male or female ≥18 years of age</LI>
<LI>
Patients with poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC - G3 according to WHO 2010) or well or moderately differentiated neuroendocrine carcinoma (NET - G1/<wbr> G2) that switched to G3 (confirmed by histology) or neuroendocrine tumor G3 (NET G3) and disease progression as measured by RECIST</LI>
<LI>
Treatment during first-line therapy with platin-based chemotherapy</LI>
<LI>
Measurable disease according to RECIST 1.<wbr>1</LI>
<LI>
ECOG status 0-2 (Karnofsky Performance status &gt;= 80%)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: Sept 2014 </div><div style="margin-bottom: 10px;">Estimated Completion dates: May 2016 /<wbr> Aug 2016 </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02113800?term=PROSTATE+OR+BOTULINUM+OR+SPASTICITY+OR+ACROMEGALY+OR+NEUROENDOCRINE&amp;fund=2&amp;rcv_s=03%2F15%2F2014&amp;rank=8">NCT02113800</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7648">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-15T18:09:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-15T18:09:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Former Oncology Head for Takeda Appointed Head of R&D at Tokai Pharm.</title>
	<pubDate>2014-04-15T17:48:13+02:00</pubDate>
	<wp:post_id>4956</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Karen J.<wbr> Ferrante, M.<wbr>D.<wbr> joins Tokai Pharm.<wbr> at a pivotal time as galeterone prepares to enter Ph3 development in CRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Prior to joining Tokai, Dr.<wbr> Ferrante held senior positions at Millennium Pharmaceuticals and its parent company, Takeda Pharmaceuticals, including her role as chief medical officer and a head of R&amp;D for Millennium, The Takeda Oncology Company.<wbr> </div><div style="margin-bottom: 10px;">From 1999 to 2007, she held positions of increasing responsibility at Pfizer Global Research &amp; Development, culminating as vice president and therapeutic area clinical leader in oncology development.<wbr> She began her career in the pharmaceutical industry as associate director of clinical oncology at BMS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Beginning of January 2014, Tokai reported that the results from the ongoing ARMOR2 Ph2 trial will be used to define the Phase 3 trials planned for initiation in the second half of 2014.<wbr><WBR></WBR> </div><div style="margin-bottom: 10px;">New data from this Ph2 trial were presented by the co-investigator at the 2014 ASCO GU in San Francisco.<wbr> </div><div><EM>Source: Tokai Pharm.<wbr></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9609">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-15T17:48:13+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-15T17:48:13+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi Korea to Launch Probi Digestis® for IBS</title>
	<pubDate>2014-04-15T17:16:21+02:00</pubDate>
	<wp:post_id>4957</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Probi Digestis®, indicated for reduction or elimination of signs and symptoms of Irritable Bowel Syndrome in adults, contains <EM>Lactobacillus plantarum</EM> 299v (DSM 9843), also called LP299V®, a single species of <EM>Lactobacillus</EM> that was found by Swedish researchers to have a direct effect on human gastro-intestinal health.<wbr> </div><div><DIV class="text-wrapper">
<DIV class="post-124 page type-page status-publish hentry"><STRONG></STRONG></DIV>
<DIV class="post-124 page type-page status-publish hentry">Probi Digestis® will be launched in all channels Sanofi Korea is currently operating in, mass retail, department stores, drugstore/<wbr>pharmacy, internet and TV home shopping.<wbr> </DIV>
<DIV class="post-124 page type-page status-publish hentry">The product will be sold with Probi Digestis® predominantly displayed on front of the pack and Sanofi will make substantial consumer marketing investment during the launch.<wbr></DIV>

<DIV class="post-124 page type-page status-publish hentry"><STRONG></STRONG></DIV>
<DIV class="post-124 page type-page status-publish hentry">This is the second Probi's deal signed for the Korean market in less than two months (please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1956" class="defaultlink">GastroEnterology1956: DongKook to Distribute Probi's Gut Health Product in Korea</a>).<wbr></DIV>

<DIV class="post-124 page type-page status-publish hentry"><EM>Source: Probi; Sanofi</EM></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1966">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-15T17:16:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-15T17:16:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Q1 Results and Key Takeaways</title>
	<pubDate>2014-04-15T16:48:08+02:00</pubDate>
	<wp:post_id>4958</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: J&amp;J continues to register worldwide pharmaceutical revenue growth with sales in the first quarter up 10.<wbr><WBR>8% (+12.<wbr>2% operational growth vs.<wbr></WBR><WBR> the same period last year), with Stelara, Prezista and Zytiga as key boosters of performance.<wbr> Country wise, management reported that China and Brazil drive the majority of the company growth and the majority of its business in the BRIC markets.<wbr> No information was provided on the dropping of the Mentor's PurTox program.<wbr></WBR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<P>J&amp;J completed its last Ph3 study on PurTox back in 2011, according to <EM>clinicalTrials.<wbr>gov</EM>.<wbr> </P>
<P>Two earlier studies had wrapped before J&amp;J bought Mentor in 2009.<wbr> </P>
<P>Since 2011, though, there hasn't been much said about the treatment until the burial announcement came out.<wbr></P>
<P><STRONG></STRONG></P></DIV> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9607_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9607_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Tahoma','sans-serif'; COLOR: black; FONT-SIZE: 11pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Tahoma','sans-serif'; COLOR: black; FONT-SIZE: 11pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN><SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Tahoma','sans-serif'; COLOR: black; FONT-SIZE: 11pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Tahoma','sans-serif'; COLOR: black; FONT-SIZE: 11pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><div><SPAN style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Tahoma','sans-serif'; COLOR: black; FONT-SIZE: 11pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9607">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-15T16:48:08+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-15T16:48:08+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Highlights from Roche's Q1 2014 Results</title>
	<pubDate>2014-04-15T14:01:55+02:00</pubDate>
	<wp:post_id>4959</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside financial results for the quarter, management has reported that data available from oral octreotide (Ph3 in acromegaly) will be presented at ENDO (June 21-24 in Chicago).<wbr> It was highlighted that the submission is planned in 2015.<wbr> Pipeline wise, Ph3 data of depot octreotide + interferon alpha or depot octreotide + avastin in advanced, poor prognosis carcinoid patients are expected in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG>USD, JPY and Latin America currencies </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>&gt; </STRONG>Negative 6%p impact on Q1 2014 sales growth </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Pharma sales up 4% with continued growth of </div><div style="margin-bottom: 10px;"><STRONG>&gt;</STRONG> Avastin, MabThera/<wbr>Rituxan, Actemra/<wbr>RoActemra and Herceptin compensating for expected decline in Xeloda sales.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Pharma division grew +19% in Japan; 5% in EU and 3% in US (all growh rate at CER).<wbr><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT00569127?term=NCT00569127&amp;rank=1">NCT00569127</A> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_5_ScreenCapture5.jpg"> </div><div>Full Presentation (151 slides) attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140431&edate=20140101&rs=/link%20Endocrinology7647%407" class="defaultlink">@7</a> </div><!-- Comment details --><a name="endocrinology7645attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(17,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(24,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(25,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(24,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(30 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(32,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7645_7_Roche%255fQ1%202014%20Results.pdf">Roche_Q1 2014 Results.pdf</a>&nbsp;&nbsp;(1,9 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7645">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-15T14:01:55+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-15T14:01:55+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: UK's NICE Backs Ferring's Firmagon for PCa Subgroup</title>
	<pubDate>2014-04-15T13:25:22+02:00</pubDate>
	<wp:post_id>4960</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">UK's NICE Backs Ferring's Firmagon for PCa Subgroup</span>&nbsp;<br><span style="font-size: 12px;">Comment: </span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9390">...</a><br></div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"></DIV> </div><div><DIV style="MARGIN: 0px"></DIV> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9605">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9390">View thread  Oncology9390: UK's NICE Backs Ferring's Firmagon for PCa Subgroup</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-15T13:25:22+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-15T13:25:22+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche to Initiate Ph2 with Immuno-Oncology Agent for Bladder Cancer</title>
	<pubDate>2014-04-15T11:30:59+02:00</pubDate>
	<wp:post_id>4961</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Roche's 330-patient trial includes two cohorts -- one looking at treatment-naive/<wbr>cisplatin-ineligible patients and the second including progressors on chemotherapy.<wbr> FPI is expected Q2:14.<wbr> Primary endpoint will measure ORR (up to 3 years).<wbr> A filing based on such a study in bladder cancer, particularly given the non-randomized, non-comparator design is unsure.<wbr> Nonetheless, the study makes Roche the first to further pursue IO in this tumor type.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Age &gt;/<wbr>= 18 years</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Histologically or cytologically documented locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, urethra)</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Representative tumor specimens as specified by the protocol</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Life expectancy &gt;/<wbr>= 12 weeks</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Measurable disease, as defined by RECIST v1.<wbr>1</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Adequate hematologic and end organ function</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: May 2014 - Completion dates: Nov 2015/<wbr>June 2016 </div><div style="margin-bottom: 10px;"><STRONG>Sites</STRONG>: 73 study location (US; EU) </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9601_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9601_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9601_3_ScreenCapture3.jpg"> </div><div><EM>Source: Roche (April 15 2014 - Q1 14 results)</EM> </div><!-- Comment details --><a name="oncology9601attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9601_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(69,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9601_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(71,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9601_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(51,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9601">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-15T11:30:59+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-15T11:30:59+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>pNET Indication Added to the Development Program of Novartis' Dovitinib</title>
	<pubDate>2014-04-15T09:48:46+02:00</pubDate>
	<wp:post_id>4962</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This is an ESS Ph2 trial evaluating dovitinib (TKI) in patients with pancreatic neuroendocrine tumors (with and without prior VEGF-inhibitor therapy, such as sunitinib, bevacizumab, sorafenib or other dedicated VEGF inhibitor).<wbr> PE will meaure PFS at 6 months, calculated using the method of Duffy and Santner.<wbr> The relationship between biomarkers and clinical outcome in the patient population will be explored.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Patients receive dovitinib lactate orally (PO) on days 1-5, 8-12, 15-19, and 22-26.<wbr> Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.<wbr></P>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">After completion of study treatment, patients are followed up every 2 months for 6 months, every 3 months for 6 months, and then periodically for 2 years.<wbr></P></DIV></DIV></DIV></DIV> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n= 63 </div><div style="margin-bottom: 10px;"><UL><LI>Disease Progression,ECOG (Eastern Cooperative Oncology Group) Performance Status 0,ECOG (Eastern Cooperative Oncology Group) Performance Status 1,Intermediate,Low Grade,Measurable,Moderate,Non Measurable.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: April 2014 - Completion date: December 2016 </div><div style="margin-bottom: 10px;">Site: US (4 sites) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7643_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Contacts</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7643_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Source:<A href="http://clinicaltrials.gov/ct2/show/NCT02108782?recr=Open&amp;no_unk=Y&amp;intr=Dovitinib&amp;rank=17"> NCT02108782</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Indications</STRONG>: Dovitinib is under clinical investigation for the treatment of various types of solid tumors including multiple myeloma, prostate, breast, renal, melanoma, urothelial cancer, and gastrointestinal stromal tumors.<wbr> It was also investigated for the treatment of acute myeloid leukemia.<wbr> </div><div><STRONG>MOA</STRONG>: Dovitinib is an oral, anti-angiogenic, anti-neoplastic and potent inhibitor of fibroblast growth factor receptors (FGFR), vascular endothelial growth factor (VEGFR), KIT, Fms-like tyrosine kinase 3 (FLT-3) and platelet-derived growth factors (PDGFR).<wbr> The inhibition of tyrosine kinase results in the induction of endothelial cell apoptosis, a reduction in tumor vasculature, anti-angiogenesis and the inhibition of tumor cell proliferation and migration.<wbr> </div><!-- Comment details --><a name="endocrinology7643attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7643_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(71,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7643_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(55,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7643_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(38,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7643">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-15T09:48:46+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-15T09:48:46+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Wins Court Order Blocking U.K. Animal-Rights Protests</title>
	<pubDate>2014-04-15T09:12:33+02:00</pubDate>
	<wp:post_id>4963</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novartis won a court order restricting animal-rights demonstrations at its U.<wbr>K.<wbr> facilities or against any of its employees after lawyers for the company reported they feared it may be targeted.<wbr> 
A unit of the drugmaker, which already has an injunction against members of Stop Huntingdon Animal Cruelty, a U.<wbr>K.<wbr> activist group, won the extension today of restrictions to cover anyone protesting animal research.<wbr> </div><div style="margin-bottom: 10px;">The pharmaceutical company needed protection following the conviction of a SHAC activist for blackmail last month, one of its lawyers told the court.<wbr> Novartis “may be at risk for any backlash that occurs after the sentence,” he said.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The order bars harassment or intimidation of Novartis employees, including abusive or threatening posts on websites or social media.<wbr> </div><div style="margin-bottom: 10px;">The order also restricts demonstrations to 6 people or fewer, in designated protest zones, with no amplified sounds, and forbids costumes, face-coverings or “blood-splattered costumes.<wbr>” Anyone breaching the injunction can be arrested.<wbr> </div><div style="margin-bottom: 10px;"><U>Source</U>: Novartis Pharmaceuticals U.<wbr>K.<wbr> Ltd &amp; Anr v.<wbr> Stop Huntington Animal Cruelty, High Court of Justice, Queen’s Bench Division, HQ14X01341 </div><div><U>Full article</U>: <A href="http://www.businessweek.com/news/2014-04-14/novartis-wins-court-order-blocking-u-dot-k-dot-animal-rights-protests">http:/<wbr>/<wbr>www.<wbr>businessweek.<wbr>com/<wbr>news/<wbr>2014-04-14/<wbr>novartis-wins-court-order-blocking-u-dot-k-dot-animal-rights-protests</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7642">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-15T09:12:33+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-15T09:12:33+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis to Explore Options for its Horsham Site</title>
	<pubDate>2014-04-14T18:36:06+02:00</pubDate>
	<wp:post_id>4964</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According the company, options could include reusing part of the site for a science or business park.<wbr> In the meantime, part of the site, which is used as the current car park, has been sold to the developer Linden Homes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">Novartis will continue to employ &gt;2,500 people and be "a major inward investor to the UK".<wbr> </DIV> </div><div style="margin-bottom: 10px;"><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">It will retain "an extensive footprint in the UK" with manufacturing sites at Grimsby (chem operations), Liverpool (vaccines) and Dundee (animal health), plus commercial offices in Surrey, and a team at Sittingbourne, Kent, developing patient diagnostic testing products.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none"><EM>Source: Pharmatimes</EM></DIV> </div><div><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none"><STRONG>Recent Background in Traction CI</STRONG></DIV>

<DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10762" class="defaultlink">PharmaWorld10762: Novartis Has Been Discreetly Downsizing</a>.<wbr></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10808">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-14T18:36:06+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-14T18:36:06+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Almirall Withdraws its IBS-c Drug from German Market</title>
	<pubDate>2014-04-14T16:48:49+02:00</pubDate>
	<wp:post_id>4965</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Almirall will cease the distribution of its drug Constella (linaclotide), approved for the symptomatic treatment of moderate-to-severe irritable bowel syndrome with constipation, in Germany, in May, because of its inability to reach a satisfactory conclusion in price negotiations with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband), reports <I>Deutsche Apotheker Zeitung.<wbr> </I> </div><div style="margin-bottom: 10px;">The Federal Joint Committee (G-BA) decided in October last year that no additional benefit had been proven from the manufacturer's submitted dossier, and, as the source reports, the producer had been invited to submit additional data in order to support its application, but it failed to do so.<wbr> </div><div style="margin-bottom: 10px;">Reportedly, for patients in Germany, the drug will continue to be available until current stocks have been used up, and then it will be possible to obtain from international pharmacies.<wbr><BR> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">It is to be assumed that since the G-BA was unequivocal in its resolution of no additional benefit for Constella, the drug was qualified for price negotiations because it could not be placed in an existing reference group; a reference group cannot be formed if there are fewer than three available alternatives.<wbr> </div><div style="margin-bottom: 10px;">Although it is a major step for Almirall to withdraw its drug from what is Europe's largest pharmaceutical market, it should be emphasised that most producers that have withdrawn – or threatened to withdraw – products from Germany over disagreements on price with the GKV-Spitzenverband in the past have eventually reached an agreement and reinstated supply.<wbr> </div><div><EM>Source: IHS GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1965">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-14T16:48:49+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-14T16:48:49+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Halts All Further Development of Its Botulinum Toxin</title>
	<pubDate>2014-04-13T20:56:32+02:00</pubDate>
	<wp:post_id>4966</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Late Friday, a J&amp;J spokesman, announced that its Mentor subsidiary had taken the decision to discontinue all further development of its botulinum toxin , commonly known as PurTox, and focus its activities on its core surgery businesss and the opportunities within the breast implant business.<wbr> </div><div style="margin-bottom: 10px;">J&amp;J acquired Mentor in 2009 and at that time had every intention of launching its puriifed botulinum toxin product on the global aesthetic market based on a number of completed phIII trials.<wbr> </div><div style="margin-bottom: 10px;">Just over four years later it has reversed that decision, with no real disclosure regarding what the issues have been only rumours/<wbr>soft intelligence suggesting regulatory delays and perhaps problems with the commercial manufacture of the product.<wbr> </div><div style="margin-bottom: 10px;">We may hear more on Tuesday, when the group releases its first quarter figures but somehow we suspect the group will gloss over the real issues behind this decision.<wbr> In the context, of the growing number of emerging aesthetic entrants, some of which have ambitions in tems of the US market, the difficulties faced by J&amp;J could begin to question the reality of their product entry strategies.<wbr> </div><div style="margin-bottom: 10px;">Source Reuters &amp; Wall St Journal </div><div>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7509">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-13T20:56:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-13T20:56:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas' Betmiga (mirabegron) Launched in Spain for OAB</title>
	<pubDate>2014-04-11T15:37:23+02:00</pubDate>
	<wp:post_id>4967</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As reported by El Global, the Spanish unit of Japanese drug company Astellas has announced that it has launched the overactive bladder (OAB) treatment Betmiga (mirabegron) in Spain.<wbr> The drug is indicated for adult patients who have not received prior treatment for the condition, as well as for those who have had their treatment with a muscarinic antagonist suspended `due to intolerance or lack of response.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to Astellas, Betmiga was approved at a price that is 10% less than OAB drugs that have been on the market for almost 10 years.<wbr><BR> </div><div style="margin-bottom: 10px;">Betmiga was approved by the European Commission in January 2013, which means that it has taken well over a year to reach the Spanish market </div><div style="margin-bottom: 10px;">Its comparatively low price represents something of a compromise by Astellas, and is a reflection of Spain's increasingly stringent pricing environment.<wbr> Betmiga is likely to be of benefit to approximately 50% of patients who suffer from OAB.<wbr> </div><div><EM>From IHS GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7507">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-11T15:37:23+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-11T15:37:23+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Approves Guerbet's Lipiodol® for the Imaging Tumours in Adults with HCC</title>
	<pubDate>2014-04-11T15:31:34+02:00</pubDate>
	<wp:post_id>4968</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: After having received from the FDA, orphan-drug designation for management of patients with known Hepatocellular carcinoma (HCC) in October 2013, this is a major milestone on the ambitious approach taken by the company to keep the product accessible for US patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>around 35,000 US patients affected in 2013 </LI>
<LI>third-leading cause of cancer-related death in the world</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7641_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7634" class="defaultlink">Endocrinology7634: Sirtex & Guerbet To Co-Develop Their Interventional Radiology Products For Metastatic Liver Cancer</a> </div><!-- Comment details --><a name="endocrinology7641attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7641_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(18,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7641">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-11T15:31:34+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-11T15:31:34+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: NCPE Ireland Has Completed Pharmacoeconomic Evaluation of Xtandi®)</title>
	<pubDate>2014-04-11T09:52:12+02:00</pubDate>
	<wp:post_id>4969</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">NCPE Ireland Has Completed Pharmacoeconomic Evaluation of Xtandi®</span>&nbsp;<br><span style="font-size: 12px;">Comment: The evaluation completed on April 10th.<wbr> The National Centre for Pharmacoeconomics (NCPE) believes that, at the submitted price, enzalutamide is not cost effective for the treatment of adults with metastatic castration-resistant cancer whose disease has progressed on or after docetaxel.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9598">...</a><br></div><div>I guess they are waiting for a patient access scheme i.<wbr>e.<wbr> discount to the price proposed by Enza.<wbr>.<wbr>.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9600">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9598">View thread  Oncology9598: NCPE Ireland Has Completed Pharmacoeconomic Evaluation of Xtandi®</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-11T09:52:12+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-11T09:52:12+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Merz Extends Belotero® Range of HA Fillers</title>
	<pubDate>2014-04-11T09:26:28+02:00</pubDate>
	<wp:post_id>4970</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Merz Extends Belotero® Range of HA Fillers</span>&nbsp;<br><span style="font-size: 12px;"><DIV class="i" id="neurology7502.01i">
<DIV class="ii" id="neurology7502.01ii">Comment: Until now the Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> range was comprised of 3 hyaluronic acid fillers.<wbr><WBR> The extension comprises Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Hydro, Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Soft, Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Balance, Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Intense and Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Volume.<wbr></WBR><WBR></WBR></DIV></DIV></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7502">...</a><br></div><div>At the AMWC (Anti-Aging Medicine World Congress) last week in Monaco, the booth of Merz was mainly branded Belotero &amp; Its new campaign with a very small corner for Bocouture (Merz's Toxin).<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7505">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7502">View thread  Neurology7502: Merz Extends Belotero® Range of HA Fillers</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-11T09:26:28+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-11T09:26:28+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NCPE Ireland Has Completed Pharmacoeconomic Evaluation of Xtandi®</title>
	<pubDate>2014-04-10T17:51:19+02:00</pubDate>
	<wp:post_id>4971</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The evaluation completed on April 10th.<wbr> The National Centre for Pharmacoeconomics (NCPE) believes that, at the submitted price, enzalutamide is not cost effective for the treatment of adults with metastatic castration-resistant cancer whose disease has progressed on or after docetaxel.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In October 2013, Astellas Pharma Co Ltd submitted an economic evaluation to the NCPE on the cost effectiveness of enzalutamide for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) whose disease has progressed on or after docetaxel therapy.<wbr> </div><div style="margin-bottom: 10px;">Updates to the dossier were submitted in December 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Three comparators were considered: best supportive care (BSC), abiraterone acetate (with prednisolone + BSC) and cabazitaxel (with prednisolone + BSC).<wbr> </div><div>More details @ <A href="http://www.ncpe.ie/wp-content/uploads/2014/04/Enzalutamide.-April-14.pdf">http:/<wbr>/<wbr>www.<wbr>ncpe.<wbr>ie/<wbr>wp-content/<wbr>uploads/<wbr>2014/<wbr>04/<wbr>Enzalutamide.<wbr>-April-14.<wbr>pdf</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9600c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><span style="font-weight: bold;">re: NCPE Ireland Has Completed Pharmacoeconomic Evaluation of Xtandi®)</span> </div><div>I guess they are waiting for a patient access scheme i.<wbr>e.<wbr> discount to the price proposed by Enza.<wbr>.<wbr>.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9598">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-10T17:51:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-10T17:51:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Extends Belotero® Range of HA Fillers</title>
	<pubDate>2014-04-10T16:03:07+02:00</pubDate>
	<wp:post_id>4972</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV class="i" id="neurology7502.01i">
<DIV class="ii" id="neurology7502.01ii">Comment: Until now the Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> range was comprised of 3 hyaluronic acid fillers.<wbr><WBR> The extension comprises Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Hydro, Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Soft, Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Balance, Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Intense and Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Volume.<wbr></WBR><WBR></WBR></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="neurology7502.02i">


<DIV class="ii"><STRONG></STRONG></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="neurology7502.03i">

<DIV class="ii" id="neurology7502.03ii">Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Soft, Balance and Intense will be available in key markets as of April 2014.<wbr><WBR></WBR></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="neurology7502.04i">

<DIV class="ii" id="neurology7502.04ii">Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Hydro and Volume will be launched at a later timepoint in 2014.<wbr><WBR></WBR></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="neurology7502.05i">

<DIV class="ii" id="neurology7502.05ii">The entire Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> range will become available worldwide</DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="neurology7502.06i">


<DIV class="ii"><STRONG></STRONG></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="neurology7502.07i">

<DIV class="ii" id="neurology7502.07ii">
<UL><LI>to deliver optimal results for deep skin rehydration, the smoothing and filling of wrinkles or the restoring of facial volume.<wbr><WBR></WBR></LI>
<LI>for additional comfort, the Belotero fillers are now available with lidocaine</LI>
</UL></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="neurology7502.08i">

<DIV class="ii" id="neurology7502.08ii"><STRONG></STRONG></DIV></DIV> </div><div style="margin-bottom: 10px;"><DIV class="i" id="neurology7502.09i">

<DIV class="ii" id="neurology7502.09ii">
<UL><LI>Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Hydro is an entry-level product that combines non-crosslinked HA with Glycerol and is designed for targeted rehydration whilst restoring radiance and elasticity.<wbr><WBR> </WBR></LI>
<LI>Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Soft ensures the optimal correction and smoothening of fine lines due to its excellent cohesivity.<wbr><WBR> </WBR></LI>
<LI>Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Balance integrates seamless into the skin and is designed for the correction of moderate lines and wrinkles</LI>
<LI>Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Intense fills deep lines and is optimal for lip augmentation treatments due to a balanced elasticity that safely provides excellent skin support</LI>
<LI>Belotero<SUP><SPAN style="FONT-SIZE: 90%">®</SPAN></SUP> Volume models and restores facial volumes through its outstanding malleability and powerful volumising capacity.<wbr><WBR></WBR></LI>
</UL></DIV></DIV> </div><div><DIV class="i hovered" id="neurology7502.010i">

<DIV class="ii" id="neurology7502.010ii"><EM>Source: Merz</EM></DIV></DIV> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7505c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>At the AMWC (Anti-Aging Medicine World Congress) last week in Monaco, the booth of Merz was mainly branded Belotero &amp; Its new campaign with a very small corner for Bocouture (Merz's Toxin).<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7502">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-10T16:03:07+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-10T16:03:07+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Potential Biomarker of Enzalutamide Presented at AACR</title>
	<pubDate>2014-04-10T13:26:40+02:00</pubDate>
	<wp:post_id>4973</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Men with metastatic, castration-resistant prostate cancer who started treatment with the drug enzalutamide (Xtandi) and had a molecule called AR-V7 present in circulating tumor cells (CTCs) obtained prior to treatment had a worse response to enzalutamide compared with those who had no detectable AR-V7, according to results presented at the AACR Annual Meeting 2014, April 5-9.<wbr> A small study is ongoing to see whether AR-V7 might predict resistance to abiraterone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9596_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Bio and Expertise</U> at <A href="http://www.hopkinsmedicine.org/profiles/results/directory/profile/9451649/emmanuel-antonarakis?cp_doc=yes&amp;CLEARPAGECACHE=false&amp;vip_doc=false&amp;lastName=antonarakis&amp;hch_doc=no&amp;gs_doc=yes&amp;jh_doc=yes&amp;directRef=%2Fdoctors%2Fresults%2Fdirectory%2Fprofile%2F9451649%2Femmanuel-antonarakis">http:/<wbr>/<wbr>www.<wbr>hopkinsmedicine.<wbr>org/<wbr>profiles/<wbr>results/<wbr>directory/<wbr>profile/<wbr>9451649/<wbr>emmanuel-antonarakis?cp_doc=yes&amp;CLEARPAGECACHE=false&amp;vip_doc=false&amp;lastName=antonarakis&amp;hch_doc=no&amp;gs_doc=yes&amp;jh_doc=yes&amp;directRef=%2Fdoctors%2Fresults%2Fdirectory%2Fprofile%2F9451649%2Femmanuel-antonarakis</A> </div><div style="margin-bottom: 10px;">Emmanuel Antonarakis, M.<wbr>D.<wbr>, an assistant professor of oncology at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, and lead investigator of the study reported that he is also conducting a small study to see whether AR-V7 might predict resistance to abiraterone.<wbr> "We hope to be able to present the results from that study later this year.<wbr>"<BR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>recruitment: n=31 men with mCRPC</LI>
<LI>protocol: before the patients were treated with enzalutamide, blood samples were obtained for later analysis of CTCs.<wbr> Blood samples also were obtained, both when the patients responded to the therapy and at disease progression.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><U>Results Presented</U></STRONG> </div><div style="margin-bottom: 10px;">When the blood samples were analysed, the researchers detected AR-V7 mRNA in the pre-treatment blood samples of 12 (38.<wbr>7%) of the 31 patients.<wbr> These 12 patients had poorer prostate-specific antigen (PSA) response rates to the drug (0% [0/<wbr>12] when compared with the 19 patients who were negative for AR-V7 (52.<wbr>6% [10/<wbr>19], <I>P</I> = .<wbr>004).<wbr> </div><div style="margin-bottom: 10px;">The researchers determined the association between AR-V7 status and PSA response rates, which was the primary clinical endpoint.<wbr> None of the patients who were positive for AR-V7 achieved a PSA response.<wbr> </div><div style="margin-bottom: 10px;">The patients who were positive for AR-V7 also had shorter PSA-progression free survival (PFS) (median: 1.<wbr>4 vs 5.<wbr>9 months, hazard ratio [HR] 7.<wbr>4, 95% confidence interval [CI] 2.<wbr>7 to 20.<wbr>6, log-rank <I>P </I>&lt; .<wbr>001), and shorter PFS (median: 2.<wbr>1 vs 6.<wbr>1 months, HR 8.<wbr>5, 95% CI 2.<wbr>8 to 25.<wbr>4, log-rank <I>P</I>&lt; .<wbr>001) than AR-V7-negative patients.<wbr> </div><div style="margin-bottom: 10px;">Independently predictive of PSA-PFS were the presence of AR-V7 (HR 3.<wbr>5, 95% CI 1.<wbr>2 to 10.<wbr>5, <I>P</I> = .<wbr>027), baseline PSA level (HR 1.<wbr>01, 95% CI 1.<wbr>00 to 1.<wbr>01, <I>P</I> = .<wbr>042), and prior abiraterone treatment (HR 5.<wbr>4, 95% CI 1.<wbr>1 to 26.<wbr>5, <I>P </I>= .<wbr>039) </div><div style="margin-bottom: 10px;">Similarly, presence of AR-V7 (HR 3.<wbr>7, 95% CI 1.<wbr>2 to 11.<wbr>9, <I>P</I> = .<wbr>026) and prior abiraterone use (HR 8.<wbr>7, 95% CI 1.<wbr>0 to 75.<wbr>6, <I>P</I> = .<wbr>049) were both independently predictive of PFS in multivariable analysis.<wbr> </div><div style="margin-bottom: 10px;"><EM>Source: "Androgen Receptor Splice Variant-7 Predicts Resistance to Enzalutamide in Patients With Castration-Resistant Prostate Cancer".<wbr> Abstract 2910</EM> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Unpublished data exist on ~100 patients confirming these results.<wbr> However, we believe these results are unlikely to significantly restrict market potential for XTANDI™.<wbr> In fact, since the v7 splice variant is strongly correlated with emergence of castration-resistant disease, we believe that these findings actually support the hypothesis that XTANDI™ is likely to grow in efficacy the earlier it is deployed </div><div><EM>Source: Aegis Capital Corp April 9 2014</EM> </div><!-- Comment details --><a name="oncology9596attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9596_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(6,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9596">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-10T13:26:40+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-10T13:26:40+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>POC Trial for Pancreatic Cancer Put on Hold by FDA</title>
	<pubDate>2014-04-09T17:31:50+02:00</pubDate>
	<wp:post_id>4974</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The US agency has informed Halozyme Therapeutics that a clinical hold has been placed on patient enrollment and dosing of PEGPH20 in an ongoing Ph2 trial (Study 202) evaluating the drug candidate in patients with pancreatic cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to the FDA, this action was being taken in view of the company's recent decision to temporarily halt enrollment and dosing of PEGPH20 in the Ph2 trial.<wbr> </div><div style="margin-bottom: 10px;">The company is gathering information relevant to evaluating the possible difference in the thromboembolic event rate between the patients treated with PEGPH20 vs the patients treated without the drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9594_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology9594attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9594_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(46,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9594">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-09T17:31:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-09T17:31:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Spain's Oryzon Epigenetics Program for Neurodegenerative Diseases</title>
	<pubDate>2014-04-09T12:09:41+02:00</pubDate>
	<wp:post_id>4975</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Yesterday Roche linked up with Oryzon Genomics to develop epigenetics-based medicines, with a focus on cancer (lead molecule in Ph1/<wbr>2a for AML).<wbr> The Spanish company has a second programme in Lysine demethylase-1 (LSD1) inhibition for Alzheimer's and Huntington's disease expected to enter in clinical trials in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7499_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7499_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Founded in 2000 in Barcelona, Spain </div><div style="margin-bottom: 10px;">Privately held, clinical stage biotechnology company considered as the European champion in Epigenetics with a strong portfolio in the field.<wbr> </div><div style="margin-bottom: 10px;">Its LSD program is currently covered by 18 patent families.<wbr> </div><div style="margin-bottom: 10px;">The company has a strong technological platform for biomarker identification.<wbr> </div><div><EM>Source: Oryzon</EM> </div><!-- Comment details --><a name="neurology7499attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7499_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(11,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7499_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(4,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7499">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-09T12:09:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-09T12:09:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Positive OAB Results With Topical Toxin</title>
	<pubDate>2014-04-09T12:03:19+02:00</pubDate>
	<wp:post_id>4976</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A physician-initiated study with Lipella's topical botulinum formulation LP-09 has demonstrated positive efficacy and safety findings in a small study involving 24 subjects with overactive bladder (OAB).<wbr>The results, published in European Urology, indicate the potential for reducing the need for cystoscopic needle injections when using botulinum toxin for treating OAB patients that are refractory to anti-muscarinic therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design &amp; Key Findings</STRONG> </div><div style="margin-bottom: 10px;">The double-blind, randomized, placebo-controlled clinical trial compared the intravesical instillation of a topical botulinum toxin type A formulation to placebo in 24 subjects diagnosed with OAB </div><div style="margin-bottom: 10px;">Significant reductions in both urinary urgency and urinary frequency were observed.<wbr>.<wbr> </div><div style="margin-bottom: 10px;">The trial was conducted at Tzu Chi University, in Hualien, Taiwan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Safety Advantage vs.<wbr> Injectable Administration</STRONG> </div><div style="margin-bottom: 10px;">Iimportantly the study showed no treatment-associated urinary retention or increase in the patients&rsquo; post-void residual volume, a more common adverse effect observed when using cystoscopic needle injection.<wbr> </div><div style="margin-bottom: 10px;">In an accompanying editorial, Professor Martin Michel from Johannes Gutenberg University, Mainz, Germany, who was not part of the study, noted that the possibility that botulinum toxin exerts its beneficial effects, at least in part, at the levels of the urothelium and/<wbr>or afferent nerves raises the possibility that more direct targeting of these sites may maintain efficacy but have improved tolerability.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Manufacturer of LP-09</STRONG> </div><div style="margin-bottom: 10px;">Lipella Pharmaceuticals Inc.<wbr>, the developer of LP-09, is a specialty biopharmaceutical company focused on the development of topical liposomal formulations for multiple therapeutic applications, including Interstitial Cystitis, Hemorrhagic Cystitis, and Overactive Bladder.<wbr> </div><div style="margin-bottom: 10px;">Lipella&rsquo;s initial pre-clinical development of LP-09 in the United States received funding from the National Institutes of Health Small Business Innovation and Research program.<wbr> </div><div><TABLE style="width: 100%;"><TBODY><TR><TD class="bb">Source:www.<wbr>lipella.<wbr>com</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7496">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-09T12:03:19+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-09T12:03:19+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Tests a New Indication for Xeomin®</title>
	<pubDate>2014-04-08T18:01:16+02:00</pubDate>
	<wp:post_id>4977</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Xeomin® will be tested in approx.<wbr> 20 participants with focal task-specific dystonia of one or both hands, selectively triggered by performance on a musical instrument.<wbr> The principal outcome measure of this POC trial will be improvement in musical performance, measured by self-rated questionnaire, quantitative MIDI analysis and blinded high speed video analysis post treatment compared to at 4 weeks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: March 2014 </div><div style="margin-bottom: 10px;">Completion dates: Dec 2016 /<wbr> Dec 2017 </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG> </div><div style="margin-bottom: 10px;">Icahn School of Medicine at Mount Sinai </div><div style="margin-bottom: 10px;"><STRONG>Principal Investigators</STRONG> </div><div style="margin-bottom: 10px;">Steven Frucht, MD </div><div style="margin-bottom: 10px;">David M Simpson, MD </div><div><EM>Source: </EM><A href="http://clinicaltrials.gov/ct2/show/NCT02107261?term=PROSTATE+OR+SPASTICITY+OR+BOTULINUM+OR+ACROMEGALY+OR+NSCLC&amp;recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=03%2F08%2F2014&amp;rank=15"><EM>NCT02107261</EM></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7494">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-08T18:01:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-08T18:01:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Combination of Androgen Receptor Antagonist Plus Everolimus Evaluated for Prostate Cancer</title>
	<pubDate>2014-04-08T17:49:01+02:00</pubDate>
	<wp:post_id>4978</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The purpose of the Ph1b study is to test the safety (primary outcome) of the combination of J&amp;J's ARN-509 (an androgen receptor antagonist similar to enzalutamide) plus everolimus in men with progressive mCRPC after treatment with abiraterone.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=58 </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: April 2014 - Completion date: April 2016 </div><div style="margin-bottom: 10px;"><STRONG>Principal Investigator</STRONG> </div><div style="margin-bottom: 10px;">Dana Rathkopf, MD (Memorial Sloan-Kettering Cancer Center) </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02106507?term=PROSTATE+OR+SPASTICITY+OR+BOTULINUM+OR+ACROMEGALY+OR+NSCLC&amp;recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=03%2F08%2F2014&amp;rank=11">NCT02106507</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9593">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-08T17:49:01+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-08T17:49:01+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lilly CEO Lechleiter Underscores Local Regulatory Challenges</title>
	<pubDate>2014-04-08T16:47:22+02:00</pubDate>
	<wp:post_id>4979</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment : Eli Lilly Chairman &amp; CEO John Lechleiter has publicly stated that his company's biggest current challenge is efficiently navigating regulatory processes to deliver new products to patients as quickly as possible.<wbr> </div><div style="margin-bottom: 10px;">He specifically cited one innovative drug that will not be launched in China for eight more years, despite already being available in the U.<wbr>S.<wbr> and Europe.<wbr> </div><div style="margin-bottom: 10px;">He also listed intellectual property protection as a major concern, with the birth of every new product requiring massive investment and significant risk.<wbr> </div><div style="margin-bottom: 10px;">He praised the Chinese authorities for progress made in this regard, but called nonetheless for stricter law enforcement.<wbr> Lechleiter also voiced his hope that Reimbursement Drug List (RDL) revisions would match the quadrennial international standard.<wbr> He confirmed that Lilly has a vested interest in Chinese medical reform, particularly in hospitals and reimbursements, underscoring that China is not immune to slowing emerging market growth, despite its torrid pace of development.<wbr> </div><div><EM>Source : Fierce Pharma</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10800">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-08T16:47:22+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-08T16:47:22+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Critical Pharm.'s CriticalSorb Technology Granted Patent by USPTO</title>
	<pubDate>2014-04-08T15:35:58+02:00</pubDate>
	<wp:post_id>4980</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The patent application allowed by the USPTO (application number 13/<wbr>063,411) relates to pharmaceutical compositions of growth hormone or parathyroid hormone and the CriticalSorb™ absorption enhancer in a form suitable for administration to the nasal, buccal and /<wbr> or respiratory tract.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The allowance of a US patent will provide important protection to future license partners for the future development and commercialisation of CP024 (nasal spray formulation of somatropin (recombinant human growth hormone) and CP046 (intranasal teriparatide).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Similar patent protection has already been obtained in Russia, Singapore and New Zealand.<wbr> </div><div style="margin-bottom: 10px;">Patents are pending in EU and Japan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The drug candidate has completed two Ph1 clinical studies.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>
CP024 was shown to be well tolerated and able to induce insulin-like growth factor I (IGF-I) to the same levels as a subcutaneous injection of the marketed product.<wbr></LI>
</UL> </div><div><EM>Source: Critical Pharm.<wbr></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7639">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-08T15:35:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-08T15:35:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Poster Data At The Upcoming AAN Meeting</title>
	<pubDate>2014-04-08T15:14:44+02:00</pubDate>
	<wp:post_id>4981</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The upcoming AAN Meeting in Philadelphia (April 26th-May 3rd) is highlighting a number of studies sponsored by Allergan and Merz, including a new Allergan sponsored rating scale for CD and a post-stroke spasticity study undertaken by Merz which suggests that "many patients would prefer shorter injection intervals".<wbr> Additionally, there are two UK posters featuring Dysport- Xeomin switch data, one highlighting the cost benefit and the other an appropriate dose ratio based on a clinical audit.<wbr> Finally, two interesting new applications for toxin are noted that of radiation induced cancer pain and muscle cramps associated with diabetic neuropathy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Allergan Posters</STRONG> </div><div style="margin-bottom: 10px;">Allergan has 17 posters at the meeting with the majority focused on migraine and chronic headache (10), four on CD and two on spasticity.<wbr> </div><div style="margin-bottom: 10px;"><EM><STRONG>Spasticity</STRONG></EM> </div><div style="margin-bottom: 10px;">One of the two spasticity studies, interestingly focuses on the breadth of studies undertaken with Botox in this area, the other the impact of spasticity on healthcare utilisation among MS patients </div><div style="margin-bottom: 10px;"><STRONG>[P3.<wbr>042] A Compilation of Spasticity Studies Evaluating Onabotulinumtoxin A</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>OBJECTIVE:</STRONG> OnabotulinumtoxinA (BOTOX&reg;, Allergan, Irvine CA USA) has been studied as treatment for adult and pediatric spasticity for over 20 years.<wbr><BR><STRONG>BACKGROUND:</STRONG> To develop a comprehensive inventory of Allergan-sponsored spasticity studies examining onabotulinumtoxinA to provide guidance on future studies.<wbr><BR><STRONG>DESIGN/<wbr>METHODS:</STRONG> Spasticity studies meeting predetermined criteria were identified for data extraction using Allergan study databases.<wbr> Studies were assessed according to 30 parameters, including but not limited to interventional vs.<wbr> non-interventional design, duration, number of sites, patient type, spasticity presentation, treatment paradigm, and outcomes measures.<wbr><BR><STRONG>RESULTS:</STRONG> This project yielded 47 Phase 1-4 studies (40 interventional, 7 non-interventional) performed between 1996-2013 and with 12-120 weeks duration.<wbr> Interventional studies evaluated post-stroke or cerebral palsy patients.<wbr> Most were double-blind-placebo-controlled (n=13), open label (n=12), or both (n=6).<wbr> The largest study contained 58 sites.<wbr> Thirty studies were conducted in US and/<wbr>or Europe, 3 in Australia, 4 in Asia.<wbr> The developmental interventional studies (n=36) contained over 5172 patients.<wbr> Treatment data emerged for 39 unique muscles [(21 lower limb (LL), 18 upper limb (UL)].<wbr> Wrist, hand, and gastrocnemius muscles were most commonly treated.<wbr> OnabotulinumtoxinA maximum doses were 400 U (fixed) and 6.<wbr>3 U/<wbr>kg (weight-based) in the UL and 360 U and 8 U/<wbr>kg in LL.<wbr> Patient follow-up approached 30 months.<wbr> There were 73 physician-reported and 25 patient/<wbr>caregiver-reported outcomes and all studies collected safety data.<wbr> Non-interventional studies covered multiple etiologies related to upper motor neuron syndrome (e.<wbr>g.<wbr> stroke, MS), and were more recent (2009-2013).<wbr> Most studies (n=6) were in US and/<wbr>or Europe.<wbr> The largest study had 127 sites.<wbr> Seven physician-reported, 12 patient/<wbr>caregiver-reported, and 28 utilization outcomes (e.<wbr>g.<wbr> patient/<wbr>prescriber/<wbr>disease characteristics) were measured.<wbr><BR><STRONG>CONCLUSIONS:</STRONG> OnabotulinumtoxinA has been extensively studied for treatment of spasticity against a variety of rating scales/<wbr>assessments and outcomes measures </div><div style="margin-bottom: 10px;"><STRONG>[P4.<wbr>150] The Impact of Spasticity Severity on Healthcare Utilization Among MS Patients: A Large-Scale Six-Year Follow-Up Study Tuula Tyry et al<BR><BR></STRONG><STRONG>OBJECTIVE: </STRONG><BR>To assess the association of spasticity and healthcare utilization (HCU) among North American Research Committee on Multiple Sclerosis (NARCOMS) registry participants.<wbr><BR><STRONG>BACKGROUND:</STRONG><BR>Over 80% of multiple sclerosis (MS) patients ultimately experience spasticity.<wbr> Spasticity is associated with fatigue, pain, impaired mobility and lower quality of life.<wbr> The impact of spasticity on HCU is poorly understood.<wbr><BR><STRONG>DESIGN/<wbr>METHODS:</STRONG><BR>NARCOMS maintains a self-report database of MS patients who volunteer health-related information through online or paper questionnaires at enrollment and semi-annually thereafter.<wbr> Among 5172 individuals who completed surveys in 2005 and 2011, we evaluated the association of HCU with spasticity reported using the 5-point Performance Scales spasticity subscale (PSss).<wbr><BR><STRONG>RESULTS:</STRONG><BR>Responders were predominantly female (76.<wbr>2%) and white (96.<wbr>2%).<wbr> In 2005 their mean (SD) age was 52 (9.<wbr>8) years, disease duration 13.<wbr>7 (9.<wbr>1) years, and 50.<wbr>8% were able to walk unassisted.<wbr> 18.<wbr>8% reported no spasticity, 36.<wbr>2% minimal, 17.<wbr>5% mild, 15.<wbr>7% moderate, 9.<wbr>9% severe and 1.<wbr>9% total spasticity.<wbr> In the prior 6 months, 653 (13.<wbr>2%) reported an ER visit while 358 (7.<wbr>1%) reported a hospitalization.<wbr> Frequencies for both increased with spasticity severity (p&lt;0.<wbr>001 for linear trend).<wbr> Over 6 years, PSss improved or remained stable in 74.<wbr>9% and worsened in 25.<wbr>9%.<wbr> As compared to participants whose PSss score worsened, those with improved spasticity were less likely to report an ER visit (OR 0.<wbr>83; 95%CI: 0.<wbr>67-1.<wbr>03) or a hospitalization (OR 0.<wbr>76; 95%CI: 0.<wbr>59-0.<wbr>99) even after accounting for disability and sociodemographic factors.<wbr><BR><STRONG>CONCLUSIONS:</STRONG><BR>More severeand worseningspasticity is associated with greater HCU, emphasizing the adverse impact of spasticity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><EM>Cervival Dystonia</EM></STRONG> </div><div style="margin-bottom: 10px;">The four CD posters include 2 based upon the outcome of the CD PROBE study, one a pilot study evaluating dose comparisons between Xeomin and Botox and the fourth a clinimetic test of the modules in a new CCDRS scale.<wbr> </div><div style="margin-bottom: 10px;"><BR>Extracts from each of the CD studies is highlighted below: </div><div style="margin-bottom: 10px;"><STRONG>[P7.<wbr>069] Treatment Outcomes in Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE) Jankovic et al</STRONG> </div><div style="margin-bottom: 10px;">METHODS: CD PROBE subjects were na&iuml;ve to botulinum toxin, new to practice, or had &ge;16 weeks since last treatment if in a previous clinical trial.<wbr> Effectiveness assessments included Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), Clinician Global Impression of Change (CGIC), Patient Global Impression of Change (PGIC), and Pain Numeric Rating Scale (PNRS).<wbr> Dosages and inter-dose intervals varied due to the real-world nature of the design.<wbr> Descriptive and inferential statistics were utilized to evaluate changes in outcomes over 3 treatments.<wbr><BR>RESULTS: In the 1046 enrolled subjects (74.<wbr>4% female; 63.<wbr>5% toxin na&iuml;ve), mean age was 58.<wbr>0&plusmn;14.<wbr>7y, mean time from onset to diagnosis was 5.<wbr>0&plusmn;8.<wbr>1y, mean time from diagnosis to first treatment was 1.<wbr>1&plusmn;4.<wbr>5y.<wbr> Mean dose was 189.<wbr>8&plusmn;87.<wbr>1U, with an average of 14.<wbr>6 and 15.<wbr>1 weeks between treatments.<wbr> Mean TWSTRS total score in subjects who completed all TWSTRS assessments (n=479) decreased from 39.<wbr>2 at baseline to 27.<wbr>1 at final visit (P&lt;0.<wbr>0001).<wbr> Furthermore, a significantly higher percentage of physicians reported improvement in CGIC from initial to final assessment (n=479, 91.<wbr>2% vs 95.<wbr>0%; P&lt;0.<wbr>0001), and significantly higher percentages of subjects reported improvement in PGIC (n=470; 83.<wbr>0% vs 91.<wbr>7%; P&lt;0.<wbr>0001).<wbr> Mean PNRS scores significantly improved from 6.<wbr>2&plusmn;2.<wbr>2 to 4.<wbr>2&plusmn;2.<wbr>5 (n=286; P&lt;0.<wbr>0001).<wbr> Regarding safety, 17.<wbr>8% (n=185) subjects reported &ge;1 treatment-related adverse event (AE) and 3.<wbr>2% (n=33) reported a serious AE.<wbr> The most common AEs were muscular weakness (7.<wbr>0%), dysphagia (6.<wbr>4%), and neck pain (2.<wbr>7%).<wbr><BR>CONCLUSIONS: Results from CD PROBE, the largest registry for CD, support the conclusion that onabotulinumtoxinA is an effective and safe treatment for patients with focal dystonia involving neck muscles.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>[P7.<wbr>062] Cervical Dystonia Patient Registry for Observation of OnabotulinumtoxinA Efficacy (CD PROBE): Treatment Patterns and Subject Disposition P Charles et al<BR><BR></STRONG><STRONG>OBJECTIVE:</STRONG><BR>To report the treatment patterns and disposition for subjects participating in CD PROBE.<wbr><BR><STRONG>BACKGROUND:</STRONG><BR>CD PROBE is the largest observational registry ever conducted of subjects with cervical dystonia (CD), the most common focal dystonia.<wbr><BR><STRONG>DESIGN/<wbr>METHODS:</STRONG><BR>Prospective, multicenter, observational subject registry of three treatments for adult CD subjects na&iuml;ve to botulinum toxin (BoNT), previous treatment &ge;16 weeks if in another clinical trial, or new to the physician's practice (ClinicalTrials.<wbr>gov NCT00836017; Jankovic et al.<wbr> BMC Neurol 2011;11:140).<wbr><BR><STRONG>RESULTS:</STRONG><BR>Over 44 months, 1046 CD subjects were enrolled and 1041 subjects (age 58.<wbr>0&plusmn;14.<wbr>7y, 25.<wbr>6% male, 63.<wbr>5% toxin na&iuml;ve) completed first treatment and consist of the analysis population.<wbr> Age at symptom onset averaged 49.<wbr>0&plusmn;16.<wbr>7y, time to diagnosis 5.<wbr>0&plusmn;8.<wbr>1y, followed by an additional 1.<wbr>1&plusmn;4.<wbr>5y until treatment.<wbr> The most common forms of CD were torticollis in 47.<wbr>5%, and laterocollis in 38.<wbr>9%.<wbr> A total of 2481 treatment sessions were administered.<wbr> The mean onabotulinumtoxinA dose for treatment 1 was 171.<wbr>6&plusmn;78.<wbr>9U, treatment 2 199.<wbr>6&plusmn;88.<wbr>3U, treatment 3, 207.<wbr>2&plusmn;93.<wbr>0U.<wbr> An average of 14.<wbr>6 weeks separated treatments 1 and 2, 15.<wbr>1 weeks for 2 and 3, and most subjects (78.<wbr>0%) exceeded 13 weeks between treatments.<wbr> Electromyography (EMG) guided most injections (73.<wbr>3%), and most commonly injected muscles were splenius capitis (81.<wbr>6%), sternocleidomastoid (76.<wbr>9%), levator scapulae (67.<wbr>3%), and trapezius (63.<wbr>6%).<wbr> 636 (60.<wbr>8%) completed all 3 treatment sessions, but only 48.<wbr>0% subjects completed the study, with approximately 20% of remaining subjects discontinuing participation after each treatment.<wbr> The most common reason for discontinuation was loss to follow-up.<wbr><BR><STRONG>CONCLUSIONS:</STRONG><BR>CD PROBE is the largest registry of CD treatment experience, and defined subject demographics, CD characteristics, and treatment paradigms.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>S27.<wbr>004] Clinimetric Testing of the Modules for the Comprehensive Cervical Dystonia Rating Scale (CCDRS) Cynthia Comella et al</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>OBJECTIVE:<BR></STRONG>To test the clinimetrics of the modular comprehensive cervical dystonia (CD) rating scale (CCDRS), that evaluates severity of motor and non-motor features<BR><STRONG>BACKGROUND:<BR></STRONG>The CCDRS is a modular, comprehensive scale that rates the multiple features of CD not currently captured by other scales.<wbr><BR><STRONG>DESIGN/<wbr>METHODS:</STRONG><BR>Patients with CD were evaluated with the CCDRS developed using a modified Delphi methodology.<wbr> The CCDRS includes 3 modules: revised Toronto Western Spasmodic Torticollis Rating scale (TWSTRS-2); TWSTRS-PSYCH (a psychiatric screen); and the Cervical Dystonia Impact Profile-58 (CDIP-58).<wbr> With classical clinimetric techniques we analyzed the modules of the CCDRS for reliability, item correlations, and factor structure.<wbr><BR><STRONG>RESULTS:</STRONG><BR>209 CD patients (73% women, age 59<U>+</U>10 years, CD duration 15<U>+</U>12 years) were included from 10 sites.<wbr> Internal consistency of the TWSTRS-2 severity had an acceptable Cronbach's alpha of 0.<wbr>60.<wbr> Item to total correlations showed that elimination of selected items with low correlations (&lt;0.<wbr>20) (anterocollis, retrocollis, lateral and sagittal shift, dystonic neck tremor and effect of sensory tricks) increased alpha to 0.<wbr>71.<wbr> Construct validity of the total TWSTRS-2 using an exploratory factor analysis showed three factors: Motor severity, disability and pain.<wbr> Items with low item to total correlations above did not have sufficient factor loadings to be included.<wbr> The TWSTRS-PSYCH had a Cronbach's alpha of 0.<wbr>84.<wbr> All item to total correlations were satisfactory, and factor analysis results revealed one factor.<wbr> When TWSTRS-2 and TWSTRS-PSYCH were combined, alpha increased to 0.<wbr>88 with four factors (motor, disability, pain and psychiatric issues).<wbr> The CDIP-58 had an alpha (0.<wbr>98) with 8 factors.<wbr> However, several items loaded on multiple factors.<wbr><BR><STRONG>CONCLUSIONS:</STRONG><BR>The modules of the CCDRS are reliable with a logical factor structure.<wbr> Together these modules incorporate objective and patient perceptions to provide within a single scale a method for assessing the neurological burden of cervical dystonia </div><div style="margin-bottom: 10px;"><STRONG>[P7.<wbr>065] The Retrospective Evaluation of the Dose of IncobotulinumtoxinA and OnabotulinumtoxinA for the Clinical Management of Cervical Dystonia and Blepharospasm: TRUDOSE Pilot Study Charlampos Tzoulis et al</STRONG> </div><div style="margin-bottom: 10px;">Objective: To evaluate dose utilization and injection intervals of onabotulinumtoxinA and incobotulinumtoxinA for treatment of CD and blepharospasm in clinical practice.<wbr><BR>Background: Limited data exists on the comparative real-world doses of onabotulinumtoxinA and incobotulinumtoxinA in cervical dystonia (CD) and blepharospasm.<wbr><BR>Methods: Retrospective medical records review in Norway and UK for patients with a primary diagnosis of idiopathic CD or blepharospasm.<wbr> Patients received onabotulinumtoxinA for at least 2 years prior to switching to incobotulinumtoxinA and received treatment for at least 2 years post switch.<wbr> Abstracted data included dose, reason for switching, injection visit date and adverse events.<wbr> Paired t-test was used to test for within subject differences in total annual dose and average inter-injection interval.<wbr><BR>Results: Thirty-nine patients (25 CD; 14 Blepharospasm) qualified and collectively received 530 injections over the 4-year observation period.<wbr> Reasons for switching were tender/<wbr>financial.<wbr> Average number of injections per patient was 5.<wbr>97 (onabotulinumtoxinA) and 7.<wbr>61 (incobotulinumtoxinA) over identical time periods pre and post switch.<wbr> CD average annual dose per patient year for onabotulinumtoxinA and incobotulinumtoxinA was 444.<wbr>7U (SD=236.<wbr>3U) and 536.<wbr>3U (SD=306.<wbr>9U) (p =.<wbr>007), respectively and 50.<wbr>4U (SD=50.<wbr>6U) and 64U(SD=53.<wbr>2U) (p =.<wbr>002) for blepharospasm, respectively.<wbr> Average total dose ratios of incobotulinumtoxinA:onabotulinumtoxinA were 1.<wbr>21 for CD and 1.<wbr>27 for blepharospasm.<wbr> Inter-injection intervals for all patients were 15.<wbr>8 weeks (onabotulinumtoxinA) and 14.<wbr>4 weeks (incobotulinumtoxinA weeks)(p=.<wbr>005).<wbr> Inter-injection intervals for CD were 15.<wbr>6 weeks (onabotulinumtoxinA) and 14.<wbr>5 weeks (incobotulinumtoxinA) (p=.<wbr>062); for blepharospasm, inter-injection intervals were 16.<wbr>3 weeks (onabotulinumtoxinA) and 14.<wbr>2 weeks (incobotulinumtoxinA)(p=.<wbr>041).<wbr> No SAE's reported.<wbr><BR>Conclusions: Results suggest that the utilization of onabotulinumtoxinA and incobotulinumtoxinA for CD and blepharospasm are not equivalent.<wbr> Data show a trend for increased dose utilization with incobotulinumtoxinA post-switch, suggesting the incobotulinumtoxinA: onabotulinumtoxinA ratio may be &gt;1 after switching and dosing should be based on individual patient needs and not a specific dose ratio.<wbr> Although some of our results did not reach statistical significance, this is likely due to the small sample size.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Merz Posters</STRONG> </div><div style="margin-bottom: 10px;">The main Merz poster highlights the results from two cross-sectional patient and physician surveys it has undertaken.<wbr> However, there is also a non company sponsored poster indicating how Xeomin could be used as effectively as Botox for the prevention of chronic migraine headache.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>[P1.<wbr>143] Satisfaction With Botulinum Toxin Treatment In Post-Stroke Spasticity: Results From Two Cross-Sectional Surveys Of Patients And Physicians Djamel Bensmail et al<BR><BR></STRONG><STRONG>OBJECTIVE:</STRONG> To evaluate patient and physician satisfaction with botulinum toxin treatment for post-stroke spasticity<BR><STRONG>BACKGROUND:</STRONG> Botulinum toxin injections are the first-line treatment for patients with post-stroke spasticity.<wbr> However, for some patients, treatment at the standard-of-care 12‑week interval may result in re-emergence of symptoms before re-injection.<wbr><BR><STRONG>DESIGN/<wbr>METHODS:</STRONG> Structured patient and physician surveys in Canada, France, Germany, and the USA.<wbr> Eligible patients had received &ge;2 abobotulinumtoxinA, incobotulinumtoxinA, or onabotulinumtoxinA treatments for post-stroke spasticity.<wbr> Information regarding current and prior botulinum toxin treatments and treatment satisfaction was collected.<wbr> Physicians were experienced in treating post-stroke spasticity, with &ge;3 years' experience of injecting botulinum toxin; information regarding satisfaction with botulinum toxin treatment was collected.<wbr> Data were summarized using descriptive statistics.<wbr><BR><STRONG>RESULTS:</STRONG> Seventy-nine patients with post-stroke spasticity participated; 61 patients (77%) currently received treatment with onabotulinumtoxinA, 15 (19%) with abobotulinumtoxinA and three (4%) with incobotulinumtoxinA.<wbr> Most patients were overall very (40.<wbr>5%) or somewhat (48.<wbr>1%) satisfied with their current treatment.<wbr> Satisfaction was highest at the time of peak effect and lowest just before re-injection.<wbr> While 78.<wbr>9% of patients preferred injection intervals &le;12 weeks, only 45.<wbr>6% received such intervals.<wbr> Intervals &le;10 weeks were preferred by 43.<wbr>4% of patients but received by just 6.<wbr>3%.<wbr> The mean (standard deviation) interval was 13.<wbr>7 (3.<wbr>5) weeks.<wbr> Most physicians questioned (n=105) were moderately (57.<wbr>7%) or very satisfied (36.<wbr>5%) with botulinum<BR>toxins, but felt that on average 16.<wbr>2% of patients would benefit from shorter injection intervals and 24.<wbr>6% would benefit from higher doses than those permitted.<wbr><BR><STRONG>CONCLUSIONS:</STRONG> Overall, patient satisfaction with botulinum toxin treatment for post-stroke spasticity is high, but declines toward the end of each injection cycle.<wbr> Hence, many patients would prefer shorter injection intervals than the standard 12 weeks.<wbr> While most physicians are satisfied with botulinum toxin injections for post-stroke spasticity, many feel that a proportion of patients might gain additional benefit from shorter intervals and higher doses than those currently permitted.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>[P7.<wbr>188] Incobotulinumtoxin A for the Preventive Treatment Of Chronic Migraine Headaches Patrick Grogan et al</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>OBJECTIVE:</STRONG> To report clinical experience using incobotulinumtoxin A (ibtxA) in the treatment of chronic migraine headache prevention.<wbr><BR><STRONG>BACKGROUND:</STRONG> Of the four botulinum toxin formulations available, onabotulinumtoxin A (obtxA) is FDA-approved for chronic migraine headache prevention.<wbr> While effective, studies recommend 155 units of obtxA administered over 31 sites per injection cycle<SUP>1,2</SUP>.<wbr> IbtxA was added to the formulary for San Antonio military treatment facilities in late 2011 based on cost advantage ($100 less per 100-unit vial), ease of storage(refrigeration not required pre-reconstitution), and a convenient 50-unit vial option, compared to 100- and 200-unit vial options with obtxA.<wbr> Several patients with chronic migraine headaches have been initiated on ibtxA, or converted from obtxA to ibtxA, in our clinic.<wbr><BR><STRONG>DESIGN/<wbr>METHODS:</STRONG> Case series; retrospective record review of patients receiving ibtxA for migraine prophylaxis.<wbr><BR><STRONG>RESULTS:</STRONG> 64 patients were identified who had received ibtxA injections for at least 2 injection cycles, administered every 10-12 weeks.<wbr> Total ibtxA dosage per cycle ranged from 40-250units, average 125 units.<wbr> Injections were distributed over a maximum of 30 sites (average 20); none utilized the injection pattern delineated in the PREEMPT studies<SUP>1,2</SUP>.<wbr> Overall, 48 (75%) noted improvement, with a greater than 50% reduction in monthly migraine frequency and/<wbr>or 50% reduction in migraine severity.<wbr> Among responders, 44 (92%) received ibtxA dosages of 150units or less per cycle, and 24 (50%) received 100units or less.<wbr><BR><STRONG>CONCLUSIONS: </STRONG>This study supports ibtxA, similar to obtxA, as an effective option for chronic migraine prophylaxis.<wbr> Additionally, by showing effectiveness utilizing relatively lower dosage and fewer injection sites, this supports potential added benefits in financial costs and patient comfort.<wbr> To our knowledge, this is the largest case series on use of ibtxA in migraine prevention.<wbr> Further research will be needed to clarify ibtxA as a viable option for migraine prophylaxis </div><div style="margin-bottom: 10px;"><STRONG><EM>Dysport - Xeomin Switch Data (Non company sponsored data)</EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>S27.<wbr>003] Conversion From AbobotulinumtoxinA to IncobotulinumtoxinA Formulation Of Botulinum Toxin: Clinic Experience In 257 Cases<BR><BR></STRONG><STRONG><EM><STRONG>Donald G.<wbr> Grosset</STRONG>, Elaine G.<wbr> Tyrrell, Katherine A.<wbr> Grosset<BR>Glasgow, United Kingdom </EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>OBJECTIVE:</STRONG> To explore the dose equivalence ratio and treatment costs for abobotulinumtoxinA and incobotulinumtoxinA for patients with focal dystonias<BR><STRONG>BACKGROUND:</STRONG> The availability of several botulinum toxin products provides the opportunity to explore switching between formulations.<wbr> Dose equivalence ratios between formulations are the subject of much debate.<wbr><BR><STRONG>DESIGN/<wbr>METHODS:</STRONG> Patients in our dystonia clinic were switched from established abobotulinumtoxinA therapy to incobotulinumtoxinA to assess dose requirements, injection intervals and potential advantages of incobotulinumtoxinA, including cost.<wbr> Switching was generally initiated at a 4:1 ratio of botulinum toxin units.<wbr> Follow-up examined dose requirements and inter-dose intervals for a period of &ge;1 year.<wbr> Efficacy and adverse events were captured at clinic review according to a standardised proforma, and doses and injection sites adjusted according to clinical need.<wbr> Data shown are mean (standard deviation).<wbr><BR><STRONG>RESULTS:</STRONG> We switched 257 patients (72.<wbr>0% female) with a mean age of 60.<wbr>8 (13.<wbr>3) years.<wbr> Data were available for 251 patients with cervical dystonia (n=122, 48.<wbr>6%), hemifacial spasm (n=91, 36.<wbr>3%), blepharospasm (n=19, 7.<wbr>6%), or segmental or generalised dystonia (n=19, 7.<wbr>6%).<wbr> Patients were switched from abobotulinumtoxinA to incobotulinumtoxinA with a mean dose ratio of 4.<wbr>07 (0.<wbr>50).<wbr> After switching, incobotulinumtoxinA dose requirements remained stable; the mean dose ratio at the end of the review period (52-219 weeks after switching) was 3.<wbr>89 (0.<wbr>58).<wbr> The mean inter-dose interval at the end of the review period was 12.<wbr>9 (3.<wbr>3) weeks and unchanged compared to before switching (12.<wbr>9 (3.<wbr>0) weeks).<wbr> Five patients (2.<wbr>0%) discontinued incobotulinumtoxinA; one reverted to abobotulinumtoxinA; the remaining four stopped botulinum injections.<wbr> Overall, switching from abobotulinumtoxinA to incobotulinumtoxinA reduced expenditure to 76.<wbr>7% (14.<wbr>8%) of the pre-switch cost of botulinum toxin, saving &gt;23%.<wbr><BR><STRONG>CONCLUSIONS: </STRONG>For patients with conditions commonly treated in dystonia clinics, switching from abobotulinumtoxinA to incobotulinumtoxinA, given at equivalent doses (~4:1 unit ratio) and at similar intervals, achieved significant cost savings while maintaining therapy benefit.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>[P7.<wbr>064] Clinical Audit of the Efficacy of Xeomin Against Dysport for the Treatment of Dystonia<BR><BR></STRONG><STRONG><EM><STRONG>Daveena Meeks</STRONG>,<SUP>1</SUP>Christopher Clough<SUP>2</SUP><BR><SUP>1</SUP><SUP>2</SUP>London, United Kingdom </EM></STRONG> </div><div style="margin-bottom: 10px;">OBJECTIVE:<BR>To monitor whether or not the optimal therapeutic outcome was maintained for the clinical management of adults affected by Dystonia based on the exchange of Dysport and Xeomin using a conversion ratio of 4:1.<wbr><BR>BACKGROUND:<BR>Botox, Dysport and Xeomin are commercial Botulinum Toxin Type A (BoTN-A) formulations commonly used for the management of Dystonia in the UK.<wbr> BoTN-A are not generic; each formulation has a distinct degree of biological activity per unit.<wbr> Conversion ratios must therefore be applied when switching between BoTN-A formulations, in order to preserve equivalent therapeutic outcomes.<wbr> The conversion ratios of BoTN-A formulations, however, are highly disputed.<wbr> In July 2012, our outpatient clinic changed the management of adults affected by Dystonia from Dysport to Xeomin, based on a conversion ratio of 4:1.<wbr><BR>DESIGN/<wbr>METHODS:<BR>We performed a retrospective audit, using electronic patient records from 133 adult patients, to examine the therapeutic dose administered and individual clinical outcomes.<wbr><BR>RESULTS:<BR>127 patients (aged 27-88 years) were included in the audit (Cervical Dystonia, n=70; Blepharospasm, n=41; Oromandibular n=1; limb dystonia, n=10; other (includes tics and tremor), n=5).<wbr> The conversion ratio of 4:1 (Dysport:Xeomin) was adequate for 63.<wbr>0% (n=80) of patients; 37.<wbr>0% of patients (n=47) required a Xeomin dosage equivalent to more than 25% of their prior Dysport therapy.<wbr><BR>CONCLUSION:<BR>The findings from this audit suggest that the conversion ratio to use to sustain optimal symptomatic relief when exchanging from Dysport to Xeomin is 3.<wbr>64:1.<wbr> We recommend that the protocol for the treatment of dystonia should be adjusted accordingly and that clinicians should consider titrating upwards to maintain optimal patient care.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Two New Indications Of Possible Application Of Toxin Treatment</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>[P3.<wbr>315] Focal Injection of Incobotulinum Toxin A Improves Refractory Local Cancer Pain at the Site of Radiation/<wbr>Surgery<BR><BR></STRONG><STRONG><EM><STRONG>Rezvan Rostami</STRONG>,<SUP>1</SUP>Duarte Machado,<SUP>2</SUP>Diana Richardson,<SUP>3</SUP>Bahman Jabbari<SUP>1</SUP><BR><SUP>1</SUP>New Haven, CT, USA, <SUP>2</SUP>Hamden, CT, USA, <SUP>3</SUP>West Haven, CT, USA </EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>OBJECTIVE:</STRONG><BR>To report the relief from refractory focal post-radiation or post-surgical cancer pain after local treatment with IncobotulinumtoxinA.<wbr><BR><STRONG>BACKGROUND:</STRONG> Cancer patients who undergo surgery or radiation develop focal pain at the site of radiation or surgery.<wbr> In some patient the pain is severe and responds poorly to conventional analgesic agents.<wbr> Onabotulinum A has shown analgesic effects in chronic migraine, diabetic allodynia and post herpetic neuralgia.<wbr> Incobotulinum toxin A relieves the pain of cervical dystonia but has not been studies in post radiation/<wbr>surgical focal pain of cancer patients.<wbr> .<wbr><BR><STRONG>DESIGN/<wbr>METHODS:</STRONG><BR>We have prospectively studied the effect of incobotulinum toxinA (inco-A)under an institutional approved protocol in12 patients with moderate to severe focal pain (VAS&gt;5) associated with cancer resection or radiation.<wbr> Efficacy was measured by VAS, Patient Global Impression of change (PGIC), and Quality of life Scale for Pain at 4, 6, 8.<wbr>10.<wbr>12 weeks.<wbr> Primary outcome measure was two grades or more improvement in VAS at 4 weeks with patient satisfaction in PGIC.<wbr> Secondary outcome was improvement of quality of life scale for pain (at 4 weeks)<BR><STRONG>RESULTS:</STRONG><BR>Two patients passed away early during the study and one dropped out due to a skin reaction few days after IncoA administration.<wbr> Of the remaining 9 paitents, 8 reported significant improvement of VAS scale and quality of life as well as satisfaction with treatment in PGIC(P&lt;0.<wbr>05).<wbr> None of the 9 patients reported any side effects.<wbr><BR><STRONG>CONCLUSIONS:</STRONG><BR>Local injection of Inobotulinum toxin A can significantly reduce refractory focal post resection and post radiation pain in cancer patients.<wbr> This observation warrants further investigation of the role of botulinum toxin therapy in this important pain disorder.<wbr><BR><STRONG>Study Supported by:</STRONG> Merz harmaceuticals </div><div style="margin-bottom: 10px;"><STRONG>[S20.<wbr>006] Botulinum Toxin For Muscle Cramps Associated With Diabetic Neuropathy: A Double-Blind, Placebo-Controlled Study<BR><BR></STRONG><STRONG><EM><STRONG>Domenico Antonio Restivo</STRONG>,<SUP>1</SUP>Antonio Pavone, <SUP>1</SUP>Damiano Gullo,<SUP>1</SUP>Stefano Jann,<SUP>2</SUP>Riccardo Vigneri<SUP>1</SUP><BR><SUP>1</SUP>Catania, Italy, <SUP>2</SUP>Milan, Italy </EM></STRONG> </div><div>OBJECTIVE: The aim of the present study was to evalute the effect of BoNT/<wbr>A in reducing the severity and the frequency of occurrences of cramps in patients with diabetic neuropathy.<wbr> BACKGROUND: muscle cramp is a painful, involuntary, paroxysmal muscle contraction observed in several neurological and metabolic diseases other than in a number of physiological conditions including muscle fatigue, pregnancy, and in elderly.<wbr> The association of muscle cramps with diabetes mellitus (DM), as well as with diabetic peripheral neuropathy, has been known for several years.<wbr><BR>No pharmacological treatment has shown to provide adequate relief in reducing cramp-associated pain.<wbr> Botulinum toxin type A (BoNT/<wbr>A) has demonstrated to be effective in reducing cramp frequency and severity in patients with benign cramp-fasciculations syndrome.<wbr><BR>DESIGN/<wbr>METHODS: In this double-blind, randomized trial, thirty patients with diabetic neuropathy and frequent leg cramps underwent BoNT/<wbr>A injections (N=15) or normal saline (N=15).<wbr><BR>Primary outcome: variation in the mean intensity of cramping pain (on a scale from 0 to 10).<wbr> Secondary outcomes: variations in the number of occurrences; variations in the electrophysiologically measured Cramp Threshold Frequency (CTF); variations in the Cramp Severity Scale (CSS).<wbr> Patients were evaluated before, and at week 1, 4, 8, 12, 16, 20 after injections.<wbr> RESULTS: all the outcome measures showed significant changes in the treated group as compared with placebo.<wbr> The effect appeared at week 1, and persisted untill week 16, disappearing at week 20.<wbr> CONCLUSIONS: BoNT/<wbr>A can be a safe and promising treatment for painful cramps associated with diabetic neuropathy.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology8287c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Merz study in collaboration wtih Yale University NCT01931865 <EM>IncobotulinumtoxinA for Treatment of Focal Cancer Pain After Surgery and/<wbr>or Radiation</EM> has been recently updated on clinicaltrials.<wbr>gov as terminated 'lost the recruiting source- no recruitment for the past 18months, PI moving'.<wbr>  It was expected to complete in July 2015 </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7491">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-08T15:14:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-08T15:14:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Partners with CMA to Support Chinese Clinical development</title>
	<pubDate>2014-04-08T12:27:50+02:00</pubDate>
	<wp:post_id>4982</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Chinese Medical Association (CMA) and Takeda have signed a memorandum of understanding for a 5-year bilateral partnership to build a long-term and efficient Sino-Japanese medical/<wbr>academic platform.<wbr> Details of the protocol are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- host of regular forums, starting this year in Beijing, Guangzhou and Shanghai, with 1,500 experts invited to discuss diabetes, digestive diseases, prostate cancer and endometriosis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.cma.org.cn/ensite/">http:/<wbr>/<wbr>www.<wbr>cma.<wbr>org.<wbr>cn/<wbr>ensite/<wbr></A> </div><div style="margin-bottom: 10px;">The Chinese Medical Association (CMA) is a non-profit registered academic and commonweal corporate body voluntarily formed by Chinese medical science and technology professionals, and an important social force in the development of medical science and technology in China.<wbr> </div><div style="margin-bottom: 10px;">The CMA, established in 1915, now has 84 specialty societies under its umbrella, covering all medical fields.<wbr> </div><div>Missions of the CMA include uniting and organizing medical professionals, abiding by the National Constitution, laws and regulations of the State, and implementing the principle of science and technology work and healthcare work of the State.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9590">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-08T12:27:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-08T12:27:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on Arno's Trial with Onapristone for Advanced CRPC</title>
	<pubDate>2014-04-08T12:13:10+02:00</pubDate>
	<wp:post_id>4983</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: After approval of an Invstigational Medicinal Product Dossier from the UK Health Authority, Medicines and Healthcare products Regulatory Agency, the company yesterday announced the enrollment of the first patient in a Ph1/<wbr>2 trial.<wbr> A CRO has been engaged, and additional UK sites planned.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">(Trial # <A href="http://clinicaltrials.gov/ct2/show/NCT02049190?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=01%2F20%2F2014&amp;rank=312">NCT02049190</A>) </div><div style="margin-bottom: 10px;"><STRONG>- Location</STRONG> </div><div style="margin-bottom: 10px;">The single-site trial is taking place at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust in the UK.<wbr> </div><div style="margin-bottom: 10px;">Additional UK sites are planned.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>- CRO</STRONG> </div><div style="margin-bottom: 10px;">Arno has engaged Biotrial, a drug evaluation and pharmacology research company.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>- Investigator of the trial</STRONG> </div><div style="margin-bottom: 10px;">Professor Johann de Bono, MD, PhD, MSc, FRCP, Professor of Experimental Cancer Medicine at The Institute of Cancer Research (ICR) and Honorary Consultant in Medical Oncology at The Royal Marsden.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Original Article in Traction</STRONG> See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9470" class="defaultlink">Oncology9470: Arno's Onapristone to Enter Ph1/<wbr>2 in Patients With Advanced CRPC</a> </div><div><EM>Source: Arno Therapeutics</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10069c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: Arno Therapeutics, Inc.<wbr>, presented data from its ongoing Phase I/<wbr>II clinical trial (NCT02049190) evaluating investigational lead compound onapristone in men with advanced castration-resistant prostate cancer (CRPC) after failure of abiraterone or enzalutamide at the 21st Annual Prostate Cancer Foundation (PCF) Scientific Retreat, being held October 23-25, 2014 at the La Costa Hotel in Carlsbad, California.<wbr> The randomized, open-label Phase I/<wbr>II trial is evaluating onapristone in extended-release tablet formulations in up to five dose levels (10-50 mg BID) in patients with advanced CRPC.<wbr> </div><div style="margin-bottom: 10px;">The study is being conducted in two stages, with an expansion component; the first stage evaluates dose selection and the second will expand the number of patients at the determined recommended Phase II dose (RP2D) to confirm the safety profile and provide a preliminary assessment of anti-tumour activity.<wbr> The DRC has approved the study to proceed to the escalation portion of stage 1 and has opened the next three dosing levels, evaluating onapristone at 30, 40 or 50 mg BID with six randomized patients per cohort.<wbr> In addition, the APR diagnostic method is being refined and will be used for selective biomarker-driven patient enrichment by way of a design that guarantees greater than 75% of patients at the RP2D are biomarker-positive.<wbr> </div><div style="margin-bottom: 10px;">In stage 1, researchers randomized patients at two dose levels at either 10 or 20 mg onapristone twice a day (BID) with three to six patients per cohort.<wbr> At baseline, researchers evaluated tumour biopsies of hormone-naive and castration-resistant study subjects for PR expression, which will support the companion diagnostic being developed to identify patients who are more likely to respond to onapristone.<wbr> As progesterone expression in prostate cancer has been reported to increase in CRPC specimens, the transcriptionally activated PR (APR) offers a potential biomarker target in advanced CRPC.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Updated Data:</STRONG></SPAN> </div><div style="margin-bottom: 10px;">Of the CRPC specimens tested at baseline, 13 of 45 (28.<wbr>9%) demonstrated PR expression (measured as greater than 1% of cells tested expressing PR) and two of 45 (4.<wbr>4%) had strong PR expression (measured as greater than 50% of cells tested).<wbr> To date, 14 patients have been screened, of whom 11 have been enrolled and are being treated.<wbr> All patients are white males with a median age of 72 years (54--89), an ECOG score of 1, and a baseline prostate-specific antigen (PSA) showing high values (median of 141 ng/<wbr>dl).<wbr> No dose-limiting toxicities (DLTs) were identified at the first two dose-levels and no significant liver function test abnormalities were observed.<wbr> </div><div>Treatment-emergent adverse events (AEs) of greater than or equal to Grade 2 included fatigue (2 patients), constipation (2 patients), hyponatremia (low sodium level) and aggressive behaviour (1 patient), and Grade 4 central retinal artery occlusion, which occurred 14 days after treatment discontinuation (1 patient), but were all considered unrelated to onapristone.<wbr> Two serious adverse events were reported, but were both also considered unrelated to onapristone.<wbr> Six of 11 (55%) patients reported drug-related AEs, all Grade 1, with no discontinuations secondary to onapristone-related adverse events.<wbr> Pharmacokinetics (PK) of the drug also appeared dose proportional.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9589">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-08T12:13:10+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-08T12:13:10+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca Signs New Deal to Use Starpharma's Dendrimer Drug Delivery Technology</title>
	<pubDate>2014-04-08T11:43:18+02:00</pubDate>
	<wp:post_id>4984</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This new agreement follows on Astrazeneca's evaluation of Starpharma's technology a couple of years ago.<wbr> Under the new deal, AZ will use Starpharm's technology to improve cancer drugs from its own preclinical stage cancer research program.<wbr> Starpharma's DEP™ dendrimer drug delivery technology improves the performance of pharmaceuticals.<wbr> More details below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The agreement follows on from an evaluation by AstraZeneca which began in September 2012 (AZ obtained the right to test certain proprietary Starpharma oncololy molecules based on Starpharma's dendrimer technoloy).<wbr> </div><div style="margin-bottom: 10px;">The new agreement will see the application of Starpharma’s technology to a cancer drug, from AstraZeneca’s pipeline (compounds undisclosed at the time of the announcement).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">There are two other companies actively working on polymer-based system for the delivery of docetaxel.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>The most advanced is <U>BIND Therapeutics</U> which is currently in Ph2 clinical trials.<wbr> While its drug looks effective, its side effect profile appears no better than standard docetaxel with a large number of patients suffering from neutropenia (background in Traction see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9353" class="defaultlink">Oncology9353: Nanomedicine Platform Takes A Leap Forward</a> - <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9118" class="defaultlink">Oncology9118: First Clinical Accurin Targets Prostate Cancer</a>).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>The private company <U>Cerulean</U> has made little progress with its docetaxel in the last 3 years.<wbr> As it has recently suffered a failed clinical trial with its main lead program, it is believed this program is likely to remain low priority in the future.<wbr> (for a Cerulean's platform overview please clik here <A href="http://ceruleanrx.com/nanopharmaceuticals/platform-overview/">http:/<wbr>/<wbr>ceruleanrx.<wbr>com/<wbr>nanopharmaceuticals/<wbr>platform-overview/<wbr></A> ).<wbr> Cerulean’s nanopharmaceuticals dynamically target tumors by entering through the large pores associated with blood vessels leading to tumors and releasing their drug inside the tumor over time.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- HQ: Melbourne (Australia) </div><div style="margin-bottom: 10px;">- Lead product: Vivagel in Ph3 for the treatment/<wbr>prevention of bacterial vaginosis </div><div style="margin-bottom: 10px;">- Drug Delivery partners: GSK; Lilly; AZ </div><div style="margin-bottom: 10px;">- Pipeline: A number of dendrimer-enhanced, or DEP™ versions of existing drugs are under development.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>The most advanced of these is DEP™-Docetaxel, a dendrimer-enhanced version of docetaxel (Taxotere<SUP>®</SUP>) which is in Ph1, with preliminary results likely within a year.<wbr> </LI>
<LI>A similar dendrimer version of oxiliplatin (Eloxatin) is undergoing preclinical testing.<wbr></LI>
</UL> </div><div>- Technology: The dendrimer technology is based around a synthetic polymer, made mainly from the amino acid lysine.<wbr> Bespoke dendrimers are constructed by adding successive layers to a core construct, with each new layer called a generation.<wbr> It is the wide flexibility in choosing the core, branching elements, and the surface molecules on the final generation, that give the dendrimer the desired characteristics for pharmaceutical, life science, chemical, electronic and materials applications (for more details please click here <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140431&edate=20140101&rs=/link%20Oncology9633%401" class="defaultlink">@1</a>).<wbr> </div><!-- Comment details --><a name="oncology9586attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9586_1_SPL%255fdendrimer%255ffact%255fsheet.pdf">SPL_dendrimer_fact_sheet.pdf</a>&nbsp;&nbsp;(468,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9586_2_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(84,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9586">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-08T11:43:18+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-08T11:43:18+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GTx Announces Departure Of CEO & Confirms Pathway Forward</title>
	<pubDate>2014-04-07T12:45:20+02:00</pubDate>
	<wp:post_id>4985</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Mitch Steiner Vice Chairman, CEO and co-founder of GTx is leaving the company to pursue other business interests.<wbr> Marc Hanover, also a co-founder of GTx has been named interim CEO until the AGM in 2015.<wbr> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" style="width: 100%;"><TBODY><TR><TD>
<TABLE style="width: 100%;"><TBODY><TR align="left"><TD valign="top">&nbsp;</TD>
</TR>
</TBODY>
</TABLE>
Marc S Hanover has served as president and chief operating officer of GTx since the company's inception in Sept 1997</TD>
</TR>
<TR><TD>
<TABLE style="width: 100%;"><TBODY><TR align="left"><TD valign="top">
<DIV class="article_body"><BR>In spite of Mitch Steiner's departure, the company claims to be committed to the implementation of GTx&rsquo;s strategy, which includes pursuing a marketing application in Europe for enobosarm 3mg for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer.<wbr> <BR><BR>Additionally, GTx remains focused on the following: <BR><BR>&bull; Completing the required Phase I studies and gaining regulatory approval of the company&rsquo;s pediatric investigation plan (PIP) from the European Medicines Agency (EMA) Pediatric Committee in order to submit by the first quarter of 2015 a marketing authorization application (MAA) in the European Union (EU) for enobosarm 3mg for the prevention and treatment of muscle wasting in patients with advanced non-small cell lung cancer (NSCLC) <BR>&bull; Completing in the 3rd quarter of this year, the company&rsquo;s ongoing Phase 2 clinical study of enobosarm 9mg to treat androgen receptor and estrogen receptor positive advanced breast cancer <BR>&bull; Meeting with the United States Food and Drug Administration (FDA) to determine an appropriate regulatory path forward in the U.<wbr>S.<wbr> for enobosarm 3 mg for the prevention and treatment of cancer cachexia in NSCLC, and <BR>&bull; Completing the company&rsquo;s ongoing Phase 2 clinical study of GTx-758 as a secondary hormonal treatment for men with castration-resistant prostate cancer.<wbr></DIV>
<DIV class="article_body">Source:www.<wbr>gtxinc.<wbr>com</DIV>

</TD>
</TR>
</TBODY>
</TABLE>
<TABLE style="width: 100%;"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE>
</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9583">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-07T12:45:20+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-07T12:45:20+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Aesthetics Has Launched a New Physician Loyalty Program</title>
	<pubDate>2014-04-07T11:00:58+02:00</pubDate>
	<wp:post_id>4986</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: "My Merz Select" program went live on April 1st.<wbr> The platform is a simple, transparent program where physicians are able to select the benefits, determine the details and craft customized solutions for their practices.<wbr> </div><div style="margin-bottom: 10px;">"My Merz Select" is one of several programs that Merz Aesthetics expects to launch in 2014 in order to demonstrate their commitment to providing high-quality aesthetic products supported by a superior customer experience.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">internet website: <A href="http://www.mymerzselect.com/">http:/<wbr>/<wbr>www.<wbr>mymerzselect.<wbr>com/<wbr></A> </div><div style="margin-bottom: 10px;">- the platform allows physicians to purchase products that meet the specific needs of their practices </div><div style="margin-bottom: 10px;">- the entire premise of the platform is based on feedback from physicians customers.<wbr> </div><div style="margin-bottom: 10px;">- the platform offers a range of ways for aesthetic proactices to receive discounts and rebates, from up-front off-invoice discounts to account credit and free product.<wbr> </div><div><EM>Source Merz Aesthetics</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7489">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-07T11:00:58+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-07T11:00:58+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Enters Distribution & Supply Agreement for Cuvposa in Canada</title>
	<pubDate>2014-04-07T10:23:45+02:00</pubDate>
	<wp:post_id>4987</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Cuvoposa is the first and only FDA approved treatment for pediatric 
chronic drooling associated with neurologic conditions.<wbr> As of last 
Friday Merz agreed a transaction with Pediapharm to distribute this product 
in Canada, reinforcing Pediapharm's position as a supplier of pediatric 
specialty products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is CUVPOSA™ ?</STRONG> </div><div style="margin-bottom: 10px;">CUVPOSA™ (glycopyrrolate) is an oral solution intended for pediatric chronic 
severe drooling (sialorrhea) associated with conditions such as cerebral palsy.<wbr> 
Chronic severe drooling, according to experts in the field, is a poorly 
managed condition in up to 30% of children with CP.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>US Situation</STRONG> </div><div style="margin-bottom: 10px;">CUVPOSA™ was approved by the FDA in July 2010 and has been commercially 
available in the U.<wbr>S.<wbr> since April 2011.<wbr> It is the only FDA-approved treatment to 
reduce chronic severe drooling in pediatric patients (aged 3-16) with neurologic 
conditions associated with problem drooling.<wbr> </div><div>Source: <a href="http://www.merzusa.com" class="defaultlink" title="www.merzusa.com">merzusa.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7488">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-07T10:23:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-07T10:23:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>NCCN Awarded Grant to Facilitate Research of Enzalutamide in Six Cancer Types</title>
	<pubDate>2014-04-04T11:43:04+02:00</pubDate>
	<wp:post_id>4988</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) has been awarded a $2.<wbr>2-million grant from Astellas and Medivation to develop a program to scientifically assess and define the clinical effectiveness of enzalutamide in six cancer type (bladder, breast, endometrial, HCC, ovarian and prostate cancers).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The NCCN ORP will utilize the grant from Astellas Pharma, Inc.<wbr> and Medivation, Inc.<wbr> to support investigator-initiated clinical and correlative studies at NCCN Member Institutions and their affiliate community hospitals for enzalutamide.<wbr> </div><div style="margin-bottom: 10px;"><U>First Phase</U> </div><div style="margin-bottom: 10px;">- to involve the establishement of an NCCN Enzalutamide Request for Proposals Development Team to evaluate existing data and to discuss and define the data and type of studies necessary to further characterize the clinical effectiveness of the drug in the six cancer types.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.nccn.org/clinical_trials/clinicians.aspx">http:/<wbr>/<wbr>www.<wbr>nccn.<wbr>org/<wbr>clinical_trials/<wbr>clinicians.<wbr>aspx</A> </div><div style="margin-bottom: 10px;">The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 25 of the world's leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives.<wbr> </div><div style="margin-bottom: 10px;">Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system.<wbr> </div><div style="margin-bottom: 10px;">As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.<wbr> </div><div><EM>Source: NCCN</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9578">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-04T11:43:04+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-04T11:43:04+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dr Falk Pharma Targets Orphan GI Indication</title>
	<pubDate>2014-04-03T17:14:50+02:00</pubDate>
	<wp:post_id>4989</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the European Crohn's and Colitis Organisation (ECCO) Congress (Feb 20-22, Copenhagen) patients and orphan indications were at the heart of the IBD pipelines.<wbr> Dr.<wbr> Falk Pharma presented results of low dose budesonide in maintaining clinical remission and QoL in collagenous colitis (CC), and organised an educational satellite symposium on microscopic colitis.<wbr> With most of the company’s products having generic counterparts at the moment, Dr.<wbr> Falk Pharma is turning its focus toward orphan GI indications, in order to expand its product offering.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Dr.<wbr> Andreas Münch</U> of University Hospital in Linköping, Sweden, presented these data on February 21, 2014, suggesting that Budenofalk sustained year-long treatment of remittent CC patients, since it was found to be safe and effective in maintaining remission.<wbr> </div><div style="margin-bottom: 10px;"><U>Title</U>: Low-dose budesonide maintains clinical remission and quality of life in collagenous colitis over a one year period: Results from the randomised, placebo-controlled BUC-63/<wbr>COC-trial.<wbr> </div><div style="margin-bottom: 10px;"><U>Design of the Ph3 Trial</U> <A href="http://clinicaltrials.gov/ct2/show/NCT01278082?lead=dr+falk&amp;rank=21">NCT01278082</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1962_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1962_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Microscopic colitis is inflammation of the bowel that is only visible using a microscope.<wbr> Microscopic colitis is a type of IBD, which refers to a group of conditions that causes inflammation in the bowel due to an excessive build-up of white blood cells in the bowel lining.<wbr> </div><div style="margin-bottom: 10px;">Microscopic colitis is less severe than other types of IBD because it does not lead to cancer and rarely requires surgery.<wbr> However, microscopic colitis can cause considerable pain and discomfort.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is Collagenous Colitis (CC) ?</STRONG> </div><div style="margin-bottom: 10px;">Microscopic colitis has two main forms: collagenous colitis and lymphocytic colitis.<wbr> </div><div style="margin-bottom: 10px;">The symptoms of and treatment for both are identical.<wbr> Some scientists believe the two forms may be different presentations of the same disease.<wbr> Slight differences in the way intestinal tissues appear when seen with a microscope set them apart.<wbr> In both forms, an increase in white blood cells can be seen within the intestinal epithelium—the layer of cells that lines the intestine.<wbr> Increased white blood cells are a sign of inflammation.<wbr> But with collagenous colitis, the layer of collagen beneath the epithelium appears thicker than normal.<wbr> Collagen is a structural protein in bones and cartilage.<wbr> In the intestines, collagen anchors the intestinal epithelium to underlying layers of tissue.<wbr> The thicker collagen layer seen with collagenous colitis may result from inflammation.<wbr> </div><div><EM>Source: ECCO; NDDIC</EM> </div><!-- Comment details --><a name="gastroenterology1962attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1962_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(72,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1962_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(27,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1962">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-03T17:14:50+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-03T17:14:50+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MAA Submitted for XTANDI (Chemo-Naïve mCRPC)</title>
	<pubDate>2014-04-03T13:19:37+02:00</pubDate>
	<wp:post_id>4990</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Approval is expected around late Q3:14.<wbr> Xtandi in Europe is an important growth driver for Astellas.<wbr> The company is the sole distributor of Xtandi in Europe and pays double-digit royalties to Medivation ($15M).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">J&amp;J has established a strong footprint as treatment in Europe tends to be concentrated in large centers where oncologists play a much bigger role in managing patients.<wbr> </div><div style="margin-bottom: 10px;">The company will report 1Q14 earnings on April 15th and will provide a first glimpse into the dynamics of the prostate cancer market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In March 2014, Astellas and Medivation submitted a supplemental NDA for chemotherapy-naïve advanced prostate cancer </div><div style="margin-bottom: 10px;"><UL><LI>Analysts with MorganStanley expect the end-Sep or so the pre-chemo approval in the US.<wbr></LI>
</UL> </div><div><EM>Source: Astellas; MorganStanley Report March 31 2014</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9575">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-03T13:19:37+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-03T13:19:37+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Study Shows BioGaia's Probiotics Prevent Common Infections in Children</title>
	<pubDate>2014-04-03T12:47:21+02:00</pubDate>
	<wp:post_id>4991</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The study confirms earlier published data in proving that preventive use of <EM>L.<wbr> reuteri</EM> Protectis in healthy children reduces diarrhoeic episodes, and respiratory tract infections in supplemented children.<wbr> This is yet another study that shows that BioGaia's Protectis (<EM>L.<wbr> reuteri</EM> Protecti)s has preventive effects in common infections.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><EM>Source: EuroMonitor International 2013</EM> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1961_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- H/<wbr>C company founded in 1990, working with probiotics.<wbr> </div><div style="margin-bottom: 10px;">- Partners: pharma and health food companies </div><div style="margin-bottom: 10px;">- Main Competitors </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1961_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">- Distribution partner network </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1961_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">- Products </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1961_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">Article published in <EM>Pediatrics</EM> on March 17 2014 <A href="http://pediatrics.aappublications.org/content/early/2014/03/11/peds.2013-0652.abstract">http:/<wbr>/<wbr>pediatrics.<wbr>aappublications.<wbr>org/<wbr>content/<wbr>early/<wbr>2014/<wbr>03/<wbr>11/<wbr>peds.<wbr>2013-0652.<wbr>abstract</A>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><P style="FONT-FAMILY: arial, helvetica, sans-serif; FONT-SIZE: 12pt"><SPAN style="FONT-SIZE: 12pt"></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="FONT-FAMILY: arial, helvetica, sans-serif; FONT-SIZE: 12pt"><SPAN style="FONT-SIZE: 12pt"></SPAN></P> </div><div><P style="FONT-FAMILY: arial, helvetica, sans-serif; FONT-SIZE: 12pt"><SPAN style="FONT-SIZE: 12pt"></SPAN></P> </div><!-- Comment details --><a name="gastroenterology1961attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1961_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(35,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1961_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(52,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1961_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(38,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1961_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(39,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1961">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-03T12:47:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-03T12:47:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>CROMA-PHARMA Adds Hugel's Botulax to its Range of Fillers</title>
	<pubDate>2014-04-02T22:15:45+02:00</pubDate>
	<wp:post_id>4992</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: CROMA-PHARMA will become the exclusive distribution partner and will be responsible for conducting the required clinical trials and studies.<wbr> CROMA-PHARMA  expects to invest an estimated two-digit million Euro amount for conducting these studies.<wbr>  Following the final approval of FDA, EMA and other authorities, CROMA-PHARMA will then market the new products in EU, North America and Oceania markets.<wbr> </div><div style="margin-bottom: 10px;"><H3>Marketing &amp; Distribution</H3> </div><div style="margin-bottom: 10px;">Duration: 10 years </div><div style="margin-bottom: 10px;">CROMA-PHARMA will promote the new products under their own label/<wbr>brand (not yet disclosed).<wbr> </div><div style="margin-bottom: 10px;">Products shall enter the markets in 2018.<wbr> </div><div style="margin-bottom: 10px;">Forecast of sales until 2021 estimate returns of more than 100 milion Euro.<wbr> </div><div style="margin-bottom: 10px;"><H3>About CROMA-PHARMA</H3> </div><div style="margin-bottom: 10px;">Private global specialty pharmaceutical and surgical company dedicated to development and commercialization of innovative products in the ophthalmology, osteoarthritis and aesthetic dermatology fields.<wbr> </div><div style="margin-bottom: 10px;">Founded in 1976, the company is headquartered in Austria and employs approximately 470 individuals at its headquarters and subsidiaries in Austria, Belgium, Canada, Denmark, Finland, France, Germany, the Netherlands, Norway, Poland, Romania, Spain, Sweden and the USA.<wbr> </div><div style="margin-bottom: 10px;">Today as a global player CROMA distributes its products in 102 countries via its own commercial sales organization(s), strategic partnerships and distributors.<wbr> </div><div style="margin-bottom: 10px;">Products: 'Princess' range of fillers <A href="http://www.croma.at/en/cromaproducts/aesthetics/product-range">http:/<wbr>/<wbr>www.<wbr>croma.<wbr>at/<wbr>en/<wbr>cromaproducts/<wbr>aesthetics/<wbr>product-range</A> </div><div style="margin-bottom: 10px;"><H3>About Botulax</H3> </div><div style="margin-bottom: 10px;"><A href="http://www.hugel.co.kr/hugel/html_e/02_products&amp;technology/01_botulinumtoxintypea.html">http:/<wbr>/<wbr>www.<wbr>hugel.<wbr>co.<wbr>kr/<wbr>hugel/<wbr>html_e/<wbr>02_products&amp;technology/<wbr>01_botulinumtoxintypea.<wbr>html</A> </div><div><EM>Source: CHROMA-PHARMA</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7486">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-02T22:15:45+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-02T22:15:45+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Real Life Assessment of QoL in Patients Switched to Vesicare (solifenacin) for OAB</title>
	<pubDate>2014-04-02T17:58:21+02:00</pubDate>
	<wp:post_id>4993</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This is a 12 month non-interventional study, sponsored by Astellas, to evaluate the effects of solifenacin on QoL of patients previously treated with antimuscarinics.<wbr> PE will measure change from baseline.<wbr> Currently, this is only a single-centre Czech Rep.<wbr> trial, and no evidences suggesting ongoing development plan in other countries.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: n=2000 </div><div style="margin-bottom: 10px;"><DIV class="indent2">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">_ Patients with OAB symptoms being treated by urologists in Czech Republic</P>
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">
Previous unsuccessful OAB medication (antimuscarinic treatment for at least 1 month) less than 4 weeks ago defined by:
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">number of micturitions &gt; 8/<wbr>24 h or</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">decrease in urgency urinary incontinence (UUI) or incontinence episodes /<wbr> 24 h less than 50% or</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">decrease in urgency episodes /<wbr> 24 h less than 50% or</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">decrease in number of micturitions /<wbr> 24 h less than 20% or</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">not acceptible tolerability</LI>
</UL></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Eligible to start Vesicare™ 5 or 10 mg according to Summary of Product Characteristics (SmPC).<wbr></LI>
</UL>
<P><U>Timelines</U>
</P><P>Start date: March 2014</P></DIV> </div><div style="margin-bottom: 10px;">Completion date: Feb.<wbr> 2016 </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02087098?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=03%2F02%2F2014&amp;rank=339">NCT02087098</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9574">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-02T17:58:21+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-02T17:58:21+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Plans To Initiate Various pNET Projects In 2014</title>
	<pubDate>2014-04-02T17:08:52+02:00</pubDate>
	<wp:post_id>4994</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Christine Massien (VP Medical Endocrinology Franchise), we have learnt that Novartis is inviting pNET patients already receiving Afinitor to participate in various paid projects it plans to start in 2014.<wbr> The nature of these projects is not specified but one could speculate whether positive results from COOPERATE-2 pNET trial might be paving the way for a phIII study evaluating combination therapy with pasireotide? There has been much speculation about a new PhIII pasireotide NET study of some description.<wbr> Please advise the CI Dept or Christine Massien if you here anything to support this conclusion.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7638_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Details of the PhII COOPERATE-II Trial (n=150)</STRONG> </div><div style="margin-bottom: 10px;">The goal of this randomised open study is to learn if and how long everolimus alone or in combination with pasireotide LAR can help to control advanced pancreatic neuroendocrine tumors and prolong PFS.<wbr> The safety of the combined treatments will also be studied.<wbr> </div><div style="margin-bottom: 10px;">The Principal Investigator for this study is James Yao and he confirmed at ENETS that the study had completed accrual and was due to report later this year (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7617" class="defaultlink">Endocrinology7617: ENETS Intelligence Part1- NET Competitor Intelligence & Novartis Symposium</a>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7638_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">Phase I data supporting the safety profile of the combination was reported back in 2012 (see Endorinology7011)</DIV> </div><div><DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7638_3_ScreenCapture3.jpg"></DIV> </div><!-- Comment details --><a name="endocrinology7638attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7638_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(142,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7638_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(40,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7638_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(38,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7638">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-02T17:08:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-02T17:08:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Prana's PBT2 Failed in a Mid-stage Alzheimer Study</title>
	<pubDate>2014-04-01T15:57:16+02:00</pubDate>
	<wp:post_id>4995</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Prana reported PBT2 did not show a statistically significant reduction in the levels of beta-amyloid plaques in the brain when compared with a placebo in patients with a mild form of the condition.<wbr> Prana also said the drug did not improve brain metabolic activity, cognition and function in the study.<wbr> The setback in Alzheimer's study raised concerns as the company plans to advance the drug into a confirmatory Ph3 for Huntington's disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7482_1_ScreenCapture1.jpg"> </div><div><EM>Source: Prana; company PRs/<wbr>presentation/<wbr>results; CI</EM> </div><!-- Comment details --><a name="neurology7482attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7482_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(106,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7482">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-01T15:57:16+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-01T15:57:16+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Urine Test Has The Ability To Predict Bladder Cancer Recurrence</title>
	<pubDate>2014-04-01T15:13:41+02:00</pubDate>
	<wp:post_id>4996</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Researchers publishing in the journal of Clinical Cancer Research highlight a new simple DNA methylation marker test utilising urine that can predict non-muscle invasive bladder cancer recurrence with a higher degree of sensitivity and specificity than current diagnostics.<wbr> </div><div style="margin-bottom: 10px;">The researchers were led by Gangning Liang, PhD, an associate professor in the Department of Urology at the University of Southern California Norris Comprehensive Cancer Center in Los Angeles.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nature Of The Test</STRONG> </div><div style="margin-bottom: 10px;">The team focused on DNA methylation, which is the process by which genes can be activated or silenced.<wbr> To study the effectiveness of the test, the team collected 368 urine samples over 7 years from 90 NMIBC patients who were being watched for tumor recurrence.<wbr> After isolating DNA from the samples, they performed DNA methylation analyses and identified six markers.<wbr> </div><div style="margin-bottom: 10px;">From this, they shortlisted a three-marker combination - SOX1, IRAK3 and L1-MET - that resulted in the highest specificity, with an area under the curve (AUC) score of 0.<wbr>95.<wbr> </div><div style="margin-bottom: 10px;">The researchers explain that an AUC score of 1 means the test is perfect in anticipating the outcome and scores near 0.<wbr>5 mean the test is inaccurate.<wbr> </div><div style="margin-bottom: 10px;">A study  has shown that the urine test is able to detect tumour recurrence with 80% sensitivity and 97% specificity in NMIBC patients.<wbr> Figures which the researchers suggest are higher than current standards of monitoring such as cytology and cytoscopy.<wbr> </div><div style="margin-bottom: 10px;">Laing notes that the test does need to undergo larger clinical trials before it can be routinely used in the clinic.<wbr> </div><div>Source: <ABBR class="site-title" title="Clinical Cancer Research">Clin Cancer Res</ABBR> April 1, 2014 20:7 1978-1989; doi:10.<wbr>1158/<wbr>1078-0432.<wbr>CCR-13-2637 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9570">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-01T15:13:41+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-01T15:13:41+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Almirall Has In-Licensed InDex Pharm's Kappaproct® (Personalized Treatment for UC)</title>
	<pubDate>2014-04-01T15:08:29+02:00</pubDate>
	<wp:post_id>4997</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Companies have signed an agreement for Almirall to market the drug in Europe.<wbr> Deal value could exceed $100M (upfront payment + milestones).<wbr> Kappaproct®, currently in Ph3, is being developed with a companion diagnostic to allow pre-selection of patients who are most likely to benefit from treatment with the drug.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>MOA</U>: DNA-based immunomodulatory sequence that targets the toll-like receptor 9.<wbr> </div><div style="margin-bottom: 10px;"><U>Indication</U>: Has potential for the treatment of severe UC.<wbr> </div><div style="margin-bottom: 10px;"><U>Status</U>: Results from the ongoing European Ph3 COLLECT are expected mid-2014.<wbr> </div><div style="margin-bottom: 10px;"><U>Regulatory</U>: Orphan Drug Designation from the European Medicines Agency for “active Ulcerative Colitis”, and can expect a fast track process.<wbr> </div><div style="margin-bottom: 10px;"><U>Patent protection</U>: EU, US and Japan &gt;2020.<wbr> </div><div style="margin-bottom: 10px;"><U>Companion Diagnostic</U>: The CDx is under development and is being pre-validated in the ongoing clinical study.<wbr> </div><div><EM>Source: InDex Pharm</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1958">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-01T15:08:29+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-01T15:08:29+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SOBI To Assume Direct Marketing Responsibility For Orfadin in the US</title>
	<pubDate>2014-04-01T14:52:52+02:00</pubDate>
	<wp:post_id>4998</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: SOBI established its US affiliate in the US in 2012 to increase its 
focus on the North American Market.<wbr> As part of this it is now assuming direct 
responsibility for the marketing of Orfadin an orphan drug for heriditary 
tyrosinaemia and re-launching the drug under the SOBI company name.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Comprehensive Support Program Launched Alongside</STRONG> </div><div style="margin-bottom: 10px;">As part of the relaunch the company is introducing Orfadin4U - a support 
program offering pharmacy services, adherence support, reimbursement and 
financial expertise, and experienced and knowledgeable staff to increase support 
for patients, caregivers and healthcare providers.<wbr> Orfadin4U will become the 
exclusive pharmacy services provider for the distribution of Orfadin in the US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Clinician's Viewpoint</STRONG> </div><div style="margin-bottom: 10px;">"For patients with hereditary 
tyrosinaemia type 1, early diagnosis and adherence are critical in allowing for 
optimal outcomes.<wbr> A comprehensive patient support program addressing the many 
unmet needs of these patients will clearly help them in effectively managing 
this serious but treatable disease", says Dr Harvey Levy, Professor of 
Paediatrics, Harvard Medical School.<wbr> </div><div>Source: <A href="http://www.sobi.com">www.<wbr>sobi.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10791">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-01T14:52:52+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-01T14:52:52+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Rise of the 'Patient Affairs Officer' Position</title>
	<pubDate>2014-04-01T14:32:05+02:00</pubDate>
	<wp:post_id>4999</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">  </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 12pt"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 12pt"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 12pt"></SPAN> </div><div><SPAN style="FONT-SIZE: 12pt"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10790">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-01T14:32:05+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-01T14:32:05+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Head to Head Comparison Trial of Xeomin vs "Toxin II" for Glabellar Frown Lines</title>
	<pubDate>2014-04-01T14:07:25+02:00</pubDate>
	<wp:post_id>5000</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The purpose of this Ph4 study is to show that two FDA-approved Botulinum toxin drugs called Xeomin® and Toxin II can reduce glabellar frown lines.<wbr> Given the doses used, AG Benoit considers the undisclosed toxin most probably be Botox.<wbr> PE will assess primary efficacy at 1 month from baseline.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: 250 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Outpatient females 18 to 50 years of age</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Moderate to severe glabellar frown lines</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Start date: Feb 2014</P> </div><div style="margin-bottom: 10px;">Completion dates: June 2014 /<wbr> September 2014 </div><div><A href="http://clinicaltrials.gov/ct2/show/NCT02096081?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F26%2F2014&amp;rank=259">Source: NCT02096081</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7479">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-01T14:07:25+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-01T14:07:25+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>DongKook to Distribute Probi's Gut Health Product in Korea</title>
	<pubDate>2014-04-01T10:44:32+02:00</pubDate>
	<wp:post_id>5001</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Probi Mageformation and pain, common symptoms that are sometimes mild or temporary but often more severe and diagnosed as IBS.<wbr> Launch is planned this quarter.<wbr> </div><div style="margin-bottom: 10px;"><H3><STRONG>About</STRONG> Probi Mage</H3> </div><div style="margin-bottom: 10px;">In two independent studies, <EM>Lactobacillus plantarum 299v (LP299V<SUP>&reg;</SUP>)</EM>, was proven to have a positive effect on the intestinal health of people with irritable bowel syndrome (IBS).<wbr>  The symptoms for irritable bowel syndrome are alternating diarrhoea and constipation, the formation of gas and pain.<wbr> Approximately 10-20% of the population periodically suffer from such problems.<wbr> </div><div style="margin-bottom: 10px;">The studies were double blind and placebo controlled and were conducted in Sweden (Nobaek et al.<wbr> 2000) and in Poland (Niedzielin et al.<wbr> 2001).<wbr> In the studies, the test subjects with IBS were given a fruit drink with or without <EM>Lactobacillus plantarum 299v </EM>(400 ml/<wbr>day) and the IBS symptoms were monitored over a period of four weeks.<wbr> </div><div style="margin-bottom: 10px;">The formation of gas in the intestines decreased rapidly and significantly in the group that ingested <EM>Lactobacillus plantarum 299v,</EM> compared with the placebo group in the Nobaek et al.<wbr> (2000) study, (see graph).<wbr> At a follow-up examination 12 months later, the test subjects who had ingested <EM>Lactobacillus plantarum 299v </EM>were deemed to have better gastrointestinal function, compared with the placebo group.<wbr> </div><div style="margin-bottom: 10px;">In the Niedzielin et al.<wbr> (2001) study, there was an improvement in the IBS symptoms in 95% of the test subjects in the <EM>Lactobacillus plantarum 299v</EM> group, compared with 15% in the placebo group.<wbr> </div><div style="margin-bottom: 10px;"><H3><STRONG>Marketing and Distribution</STRONG></H3> </div><div style="margin-bottom: 10px;"><P align="left">Dongkook will launch Probi Magedepartment stores and TV/<wbr>Internet home shopping, one of the largest distribution channels for dietary supplement products in Korea.<wbr></P> </div><div style="margin-bottom: 10px;"><H3><STRONG>Korean Context for Probiotics Supplement</STRONG></H3> </div><div style="margin-bottom: 10px;">South Korea is the third largest probiotic supplement market in Asia.<wbr> </div><div style="margin-bottom: 10px;"><P align="left">The South Korean market for probiotic supplements is estimated to have a value of USD 54 million, and its annual growth rate over the past five years has been on avarage 15%.<wbr></P> </div><div style="margin-bottom: 10px;"><H3><STRONG>Probiotic market</STRONG></H3> </div><div style="margin-bottom: 10px;">In 2012, the global market for probiotics/<wbr>probiotic food amounted to SEK 172 billion, and is expected to be worth SEK 228 billion by 2017<SUP>1</SUP>.<wbr> Europe and parts of Asia are considered the mature markets and are also the regions that have shown greatest demand during recent years.<wbr> Due to a rising population and greater prosperity, Asia is the region where demand is expected to grow most in coming years.<wbr> </div><div style="margin-bottom: 10px;">Positive growth is also expected in less developed markets, such as Brazil and North America, in the future.<wbr> Food products in the form of yoghurt and drinks dominate the global probiotics market, and dairy products continue to hold the strongest position.<wbr> Surveys show that probiotic juices remain an underdeveloped market with strong growth expectations.<wbr> The dietary supplement market represents about one-tenth of the food market, but stronger growth is expected in coming years.<wbr> </div><div style="margin-bottom: 10px;"><EM>1) Euromonitor 2013</EM> </div><div style="margin-bottom: 10px;"><H3 align="left"><STRONG>Probi AB SnapShot</STRONG></H3> </div><div style="margin-bottom: 10px;"><UL><LI>
Swedish publicly traded biotechnology company that develops effective and well-documented probiotics.<wbr>

</LI>
<LI>
Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas.<wbr> The products are available to consumers in more than 30 countries worldwide.<wbr> The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments.<wbr>

</LI>
<LI>
Probi had sales of MSEK 102 in 2013.<wbr>

</LI>
<LI>The Probi share is listed on NASDAQ OMX Stockholm, Small-cap.<wbr>
</LI>
<LI>Probi has approximately 4,000 shareholders.<wbr>
</LI>
</UL> </div><div><EM>Source: ProBi</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1956">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-04-01T10:44:32+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-04-01T10:44:32+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer to Increase Production Capacity in China</title>
	<pubDate>2014-03-31T15:04:31+02:00</pubDate>
	<wp:post_id>5002</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On the occasion of the visit of the President of the People's Republic of China in Germany, an agreement was signed by CEO of Bayer to invest around &euro;100M to ensure a reliable supply to meet the domestic demand for Bayer's H/<wbr>C products.<wbr> In China, strategy of the company is to expand sales force and increase commercial power of its brands.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Plans &amp; Progress of Bayer in China</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Plans</SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>1/<wbr> Expand sales force from 30 cities to &gt;130 cities, covering 75% of OTC market
</LI>
<LI>2/<wbr> Extend geo footprint launching global brands in China
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">2013 Progress</SPAN> </div><div style="margin-bottom: 10px;"><UL><LI>Sales growth: +14%
</LI>
<LI>Successful geo expansion achieving target of 75% of OTC market
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Competitive Context</SPAN> </div><div style="margin-bottom: 10px;">Recently, Bayer acquired privately held Dihon Pharm, a maker of Traditional Chinese Medicine (TCM) and Chinese OTC brands.<wbr> Significant synergies are expected from their complementary OTC business.<wbr> </div><div style="margin-bottom: 10px;">- Of note, a couple of years ago, Boehringher Ingelheim as well as GSK reported a strong interest in this area (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10469" class="defaultlink">PharmaWorld10469: Boehringer Ingelheim Reports Stong 2012 Performance and Strategy in China</a>; <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10045" class="defaultlink">PharmaWorld10045: GSK Announces New Business in China</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Bayer is #2 in a Highly Fragmented OTC Market</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">OTC market grew ~5% versus 2012</P> </div><div style="margin-bottom: 10px;"><P align="left">Top10 players have got ~30% share of the OTC market</P> </div><div><P align="left">Bayer ranks #2 with 4.<wbr>4% share of the OTC market behind J&amp;J</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10789">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-31T15:04:31+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-31T15:04:31+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Class of Drug Enters Clinical Development for NET</title>
	<pubDate>2014-03-31T14:48:44+02:00</pubDate>
	<wp:post_id>5003</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Esanex Inc an Indianapolis -based pharmaceutical company spun out of Lilly Ventures is listing a new trial in ClinicalTrials.<wbr>gov evaluating its lead drug SNX-5422 in combination with everolimus for the treatment of metastatic GEPNET or bronchial NET </div><div style="margin-bottom: 10px;"><STRONG>What is SNX-5422?</STRONG> </div><div style="margin-bottom: 10px;">SNX-5422 is a pro-drug of SNX-2112, a potent, highly selective, small-molecule inhibitor of the molecular chaperone heat shock protein 90 (Hsp90).<wbr> Hsp90 has been found to be expressed in 95% of subjects with pancreatic neuroendocrine tumors.<wbr> </div><div style="margin-bottom: 10px;"><P style="margin-bottom: 1ex; margin-top: 0ex;"><STRONG>The Current Study Design</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="margin-bottom: 1ex; margin-top: 0ex;">Will determine the MTD of SNX-5422 when given in combination with everolimus in patients with neuroendocrine tumors.<wbr>The clinical starting dose of 50 mg/<wbr>m2 qod for SNX-5422 in combination with daily everolimus is 50% of the SNX-5422 qod mono-therapy MTD.<wbr> The choice to continue once every other day SNX-5422 dosing is based on the safety and efficacy profiles from prior studies, so that drug holidays are interspersed into weekly dosing.<wbr> The planned subsequent dose levels are 75% and 100% of the SNX-5422 qod mono-therapy MTD.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin-bottom: 1ex; margin-top: 0ex;">SNX-5422 capsules will be dosed in the morning once every other day (qod) for 21 days (11 doses), followed by a 7 day drug free period.<wbr> Dose escalation will be based on safety defined as 1 or less dose limiting toxicities during the first 28 day cycle at any dose level.<wbr> Dose escalation will not exceed a dose of 100 mg/<wbr>m2 SNX-5422 qod even if the MTD has not been identified.<wbr> Subjects will receive daily oral everolimus in the PM about the same time every day for 28 days.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin-bottom: 1ex; margin-top: 0ex;"><STRONG>Timelines for NCT02063958</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="margin-bottom: 1ex; margin-top: 0ex;">Fifteen patients will be enrolled in the study which is being undertaken at two US centres Georgetown University Medical Centre Washington &amp; Hackensack University Medical Centre New Jersey and due to complete in February 2015</P> </div><div style="margin-bottom: 10px;"><P style="margin-bottom: 1ex; margin-top: 0ex;"><STRONG>Esanix's Profile &amp; SNX-5422's History</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="margin-bottom: 1ex; margin-top: 0ex;">Lilly Ventures partner Steven Hall is listed in the filing as the president and CEO of Esanex, and Lilly Ventures Managing Director Ed Torres is listed as an executive officer and director.<wbr> Other investors include: Intersouth Partners, Esanex Holdings LTD, and the Indiana Seed Fund.<wbr> Total money raised so far is $15.<wbr>5m.<wbr> The company currently has only once drug in clinical development.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin-bottom: 1ex; margin-top: 0ex;">The company appears to be a resurrection of Serenex, a North Carolina-based cancer drug company that was acquied by Pfizer in 2008.<wbr> Several former Serenex executives appear to be involved in Esanex and in regulatory filings, Esanex lists its business address as the office of Lilly Ventures, a former Serenex investor.<wbr> Life sciences investor Intersouth Partners, another Serenex investor, also lists Esanex as a portfolio company.<wbr><BR><BR>Apparently, Pfizer shelved Serence's drug due to ocular toxicity in canine studies.<wbr> Similarly, AstraZeneca returned the rights of two Hsp90 inhibitors it was developing to their original owner, Infinity Pharmaceuticals, in 2008, and Bristol-Myers Squibb halted development on tanespimycin in 2010.<wbr></P> </div><div>But the climate for Hsp90 inhibitors today may be more amenable than it was just a few years ago.<wbr> Last year, Novartis presented results from phI/<wbr>II studies with its candidate AUY922, demonstrating that the drug had an acceptable safety profile and produced &ldquo;manageable&rdquo; side effects.<wbr> Swiss company Debiopharm is also developing an Hsp90 inhibitor, Debio 0932, and delivered positive safety results in a study last year.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7636">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-31T14:48:44+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-31T14:48:44+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pfizer and GSK Expand Consumer H/C Business</title>
	<pubDate>2014-03-31T13:49:54+02:00</pubDate>
	<wp:post_id>5004</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Last week, GSK announced a two-stage transaction for the acquisition of the full ownership of its Indonesian Consumer HC business, wherease Pfizer purchased Ferrosan's dietary supplements and lifestyle products.<wbr> Thanks to L-X Nguyen-Lairaud, an analysis of the rationale for each company is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale and Analysis for Pfizer and GSK</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>GSK</STRONG> has acquired full ownership of its Indonesian Consumer HC business in a transaction in two stages, which also includes the company divesting : </div><div style="margin-bottom: 10px;">- a non-core brand for eyecare and </div><div style="margin-bottom: 10px;">- a manufacturing facility in the country.<wbr> </div><div style="margin-bottom: 10px;">An example of GSK focusing its business in growth markets &amp; consumer care.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Context</SPAN> : GSK&rsquo;s Indonesian Consumer Healthcare business sells brands such as Panadol&trade;, Sensodyne&trade; and Scotts&trade;, and is an important emerging markets for GSK.<wbr> </div><div style="margin-bottom: 10px;">It has seen significant growth over the last five years, with net sales reaching close to &pound;50 million in 2013 in comparison to around &pound;16 million in 2008.<wbr> With increased geographical coverage and by using targeted product innovation serving a fast-expanding middle class, the future prospects for the consumer care business are strong.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PFIZER</STRONG> has entered into a definitive agreement to purchase Ferrosan&rsquo;s consumer healthcare business, which includes dietary supplements and lifestyle products.<wbr> </div><div style="margin-bottom: 10px;">Based in Copenhagen, Ferrosan is an innovative and long-established Consumer HC company in the Nordic region with a portfolio of leading brands in as many countries as Russia, Ukraine, Poland, Turkey and many countries throughout Central and Eastern Europe.<wbr> </div><div style="margin-bottom: 10px;">Ferrosan&rsquo;s portfolio includes Multi-tabs&reg;, a popular multivitamin brand, <STRONG>Bifiform</STRONG>&reg;, a leading probiotic, Fri Flyt/<wbr>Active Omega, an Omega 3 product, and IMEDEEN&reg; premium oral skincare brands.<wbr> </div><div style="margin-bottom: 10px;">* <STRONG>Bifiform </STRONG>is Top 3rd player on anti-diarrhoeal market in Russia (after Linex and Smecta) with huge media investments.<wbr> </div><div>Full stories : <A href="http://www.firstwordpharma.com/node/1199226#axzz2xWhZy1vW" target="_blank">http:/<wbr>/<wbr>www.<wbr>firstwordpharma.<wbr>com/<wbr>node/<wbr>1199226#axzz2xWhZy1vW</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1953">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-31T13:49:54+02:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-31T13:49:54+02:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sirtex & Guerbet To Co-Develop Their Interventional Radiology Products For Metastatic Liver Cancer</title>
	<pubDate>2014-03-28T18:54:45+01:00</pubDate>
	<wp:post_id>5005</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Highlighted by the "Caring For Carinoid Patients" website is the news that Sirtex Medical and Guerbet SA have initiated a collaboration in clinical studies of primary and secondary metastatic liver cancer to address the unmet clinical need in patients with HCC, metastatic CRC, metastic NET and different types of primary and secondary liver cancers.<wbr> The goal of the collaboration is to examine how the SIR-Spheres microspheres of Sirtex and Lipiodol Guerbet can be combined or sequenced optimally.<wbr> </div><div style="margin-bottom: 10px;">Commenting on this agreement Sirtex CEO Gilman Wong said: "The shared vision of Sirtex and Guerbet is that one day, instead of terminally ill patients liver cancer can be considered a chronic disease with which patients can live well.<wbr> Since being at Sirtex I have been fortunate to meet a number of patients who have survived liver cancer for many years following treatment with SIR-Spheres microspheres.<wbr> I hope that through this collaboration we achieve clinical studies improvements for the benefit of patients with liver cancer.<wbr> If the initial collaboration proves fruitful future collaborations in R&amp;D and marketing between our companies could be considered.<wbr> " </div><div style="margin-bottom: 10px;"><STRONG>Development Status Of SIR-Spheres</STRONG><BR><BR>SIR-Spheres microspheres are currently being evaluated in six international multicentre RCT in metastatic colorectal cancer (mCRC) and hepatocellular carcinoma (HCC), which cumulatively recruit more than 2,100 patients.<wbr> The first of these RCT, the SIRFLOX study completed enrolling patients in April 2013 and is expected to report its findings in early 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nature of Guerbet's Product</STRONG><BR><BR>Guerbet's Lipiodol Ultra Fluid is used in transarterial chemoembolisation (cTACE) for the treatment of patients with inoperable liver tumours.<wbr> Over 100 clinical studies have been published on the cTACE, of which 12 were international RCT, with a total of more than 10,000 patients with intermediate stage HCC have been reported in peer-reviewed scientific literature.<wbr> Recently, cTACE has been established as the standard treatment for patients with intermediate stage HCC in three international clinical consensus guidelines in Japan, Europe and the United States.<wbr> These consensus guidelines recommend unanimously cTACE as the standard treatment for patients with intermediate stage HCC These recommendations were made with a Level of Evidence grade 1iiA and 1A Recommendation in European guidelines <BR><BR>The chief executive officer ,Guerbet, Dr.<wbr> Yves L'Epine, said.<wbr> "We are thrilled about the potential of combining or sequencing products to enhance the effectiveness of interventional radiology procedures in patients with unresectable liver tumours In fact, the Lipiodol and SIR-Spheres are individually proven and widely used therapies, have never been examined together or sequentially.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms &amp; Next Steps</STRONG> </div><div>He noted that a Master Clinical Research Collaboration Agreement is to be executed between the two companies which will provide the framework from which to launch a series of clinical projects investigating innovative ways of using Lipiodol and SIR-Spheres in patients with inoperable liver tumours.<wbr> <BR><BR>The first project under the Agreement consists in a series of clinical studies designed to evaluate the potential for synergy between the two therapies and whether therapies can be combined or sequenced in a way that provides an optimised tumour control.<wbr><BR><BR>Source:www.<wbr>sirtex.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7634">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-28T18:54:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-28T18:54:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Phase 1 Study to Evaluate Immune Response and Tolerability Of Combination of Two Immunotherapies (Ipilimumab And Sipuleucel-T) for CRPC</title>
	<pubDate>2014-03-28T18:00:26+01:00</pubDate>
	<wp:post_id>5006</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: From ECCO-ITOC congress in Munich in March, combination of immunotherapies has been repeatedly communicated by various keynote speakers as the future solution.<wbr> This is the first immunotherapies combination trial in development for prostate cancer.<wbr> Although it is a likely to be a POC trial and not sponsored by neither BMS nor Dendreon, the data could have a significant impact on the role of immunotherapy in mCRPC setting.<wbr> Currently, this is only a single-centre US trial and no evidences suggesting ongoing development plan outside of US.<wbr> </div><div style="margin-bottom: 10px;">This is a Prostate Oncology Specialists Inc (NCI) sponsored (investigator led) trial.<wbr> A total of 9 patients is expected to enrol.<wbr> Study is expected to start in April 2013 and primary completion date is in Dec 2015.<wbr> </div><div style="margin-bottom: 10px;">Below is the details of the trial: </div><div style="margin-bottom: 10px;">ClinicalTrials.<wbr>gov Identifier: NCT01832870 </div><div style="margin-bottom: 10px;">Current Status: enrolment completed, ongoing active </div><div style="margin-bottom: 10px;">Patient Inclusion Criteria: subjects who are eligible to receive sipuleucel-T in accordance with FDA approved labelling of sipuleucel-T </div><div style="margin-bottom: 10px;">Study Design: open-label, single group assignment </div><div style="margin-bottom: 10px;">Primary outcome: Efficacy in terms of immune response (antigen specific memory T cell response, antigen specific T cell proliferation) </div><div style="margin-bottom: 10px;">Secondary outcome: PSA doubling time, Time to PSA progression, Time to salvage therapy, % of PSA decline </div><div style="margin-bottom: 10px;">Time frame: expected 18 months </div><div>Source: <A href="http://www.clinicaltrial.gov">www.<wbr>clinicaltrial.<wbr>gov</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9567">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-28T18:00:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-28T18:00:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Auspex Provides Progress with Huntington Drug and Deuterium Platform</title>
	<pubDate>2014-03-28T16:42:46+01:00</pubDate>
	<wp:post_id>5007</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Update on ongoing programs is provided below, as well as the outcomes of a recent market research done by Auspex, which demonstrates strong interest from neurologists in using SD-809.<wbr> Of note, the company ended Q4:13 with $36.<wbr>7M in cash, and raised an additional $87.<wbr>1M in net proceeds in an IPO last month.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7476_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">It is worth noting that the design of the First-HD study has significant similarity to a phase 3 study that supported XENAZINE&rsquo;s FDA approval in 2008.<wbr> The two studies share the same endpoint and the same duration of treatment with a similar up-titration period </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7476_1_ScreenCapture1.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>for Chorea Associated with HD</STRONG> </div><div style="margin-bottom: 10px;">- currently in a Ph3 registration trial (First-HD) in the US </div><div style="margin-bottom: 10px;">- open-label (ARC-HD) in progress to evaluate long-term safety as well as provide guidance on how to swith patients who are currently on tetrabenazine to SD-809 (ARC-HD Switch).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Top-line data from the First-HD and ARC-HD expected to be available Q4:14 (management originally anticipated a potential interim ARC-HD SWITCH read sometime in 1H14)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Path to Market</STRONG> </div><div style="margin-bottom: 10px;">Auspex expects to file a NDA for SD-809 for the treatment of chorea associated with HD in 4Q14.<wbr> </div><div style="margin-bottom: 10px;">Auspex plans to pursue the Section 505(b)(2) regulatory path, which will allow Auspex to rely on certain prior nonclinical and clinical safety findings made by the FDA in the approval of XENAZINE.<wbr> </div><div style="margin-bottom: 10px;">Based on its interactions with FDA, Auspex believes that with the completion of First-HD, it will have completed all the preclinical and clinical studies necessary for a Section 505(b)(2) NDA filing.<wbr> </div><div style="margin-bottom: 10px;">Auspex plans to include data from the ARC-HD Switch study in the NDA filing, which will allow information in product labeling that help guide physicians to switch XENAZINE patients to SD-809.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>for Tardive Dyskinesia</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Top-line results expected to be available mid-2015.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>for Tourette Syndrome</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Top-line date expected Q4:14.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Other deuterium-containing compounds in Auspex&rsquo;s pipeline include SD-254 (EFFEXOR analog for neuropathic pain), which has completed two phase 1 trials, as well as three preclinical stage assets: </div><div><UL><LI>SD-560 (pirfenidone analog for idiopathic pulmonary fibrosis),
</LI>
<LI>SD-970 (BRILINTA analog for acute coronary syndrome), and
</LI>
<LI>SD-900 (XELJANZ analog for rheumatoid arthritis)
</LI>
</UL> </div><!-- Comment details --><a name="neurology7476attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7476_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(82,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7476_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(132,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7476">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-28T16:42:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-28T16:42:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Generic Copaxone for RRMS May Enter the EU Market Next Year</title>
	<pubDate>2014-03-27T14:37:46+01:00</pubDate>
	<wp:post_id>5008</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: On EMA requirement, privately held Synthon ran a Ph3 GATE comparative clinical trial in order to submit a Copaxone generic application.<wbr> The trial success brings into focus its potential EU entry in May 2015.<wbr> The company expects its g-Copaxone to be the sole generic on the market for a number of years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Synthon has already submitted an ANDA for glatiramer acetate, 20 mg/<wbr>ml solution for injection in pre-filled syringes to the FDA in November 2011.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Ph3 trial for glatiramer acetate “demonstrated an equivalent efficacy and safety profile” compared to Teva’s Copaxone in patients with relapsing remitting multiple sclerosis (RRMS).<wbr> </div><div style="margin-bottom: 10px;">GATE was set up following Scientific Advice received from the European Medicines Agency (EMA) with the aim to show equivalence of Synthon’s glatiramer acetate (Synthon GTR) with Teva’s Copaxone<SUP>®</SUP> in a well-controlled 3-arm double-blind study that was also designed to show superiority of the two active treatment groups over placebo.<wbr> </div><div style="margin-bottom: 10px;">The large-scale, multicenter study consists of a nine-month double-blind efficacy comparison followed by a currently ongoing 15-month open-label extension and runs in Europe (including Russia, Ukraine and Belarus), Mexico, South Africa and the United States.<wbr> </div><div style="margin-bottom: 10px;">Data gathered during the double-blind part of the study “present a solid basis for the regulatory submission in Europe in order to make an equivalent alternative to Copaxone": Synthon CEO Jacques Lemmens.<wbr> </div><div>Source: <A href="http://www.synthon.com/Corporate/News/PressReleases/Synthon-announces-successful-outcome-of-the-PhaseIII-GATE-study-with-its-generic-glatiramer-acetate">http:/<wbr>/<wbr>www.<wbr>synthon.<wbr>com/<wbr>Corporate/<wbr>News/<wbr>PressReleases/<wbr>Synthon-announces-successful-outcome-of-the-PhaseIII-GATE-study-with-its-generic-glatiramer-acetate</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7473">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-27T14:37:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-27T14:37:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Allergan Plans Registration Trial with BOTOX® for UI Due to OAB in Ped Patients</title>
	<pubDate>2014-03-27T11:21:13+01:00</pubDate>
	<wp:post_id>5009</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan Plans Registration Trial with BOTOX® for UI Due to OAB in Ped Patients</span>&nbsp;<br><span style="font-size: 12px;">Comment: The Ph3 study will evaluate the safety and efficacy of BOTOX® in pediatric patients between the ages of 12 to 17 years who have not been adequately managed with anticholinergics.<wbr> PE will measure Change from Baseline in Number of Daily Episodes of Urinary Incontinence.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7470">...</a><br></div><div>It appears this study maybe the Post Marketing Commitment study which Botox received after approval of the adult OAB indication in the US H2 2012.<wbr> The details of the Paediatric study Botox committed to (which can be found in the Adult OAB FDA approval letter) seem to match the info above, the letter also references an extension study of 48 weeks for subjects completing this study.<wbr> The number of patients in this study would very low to consider registration.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7472">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7470">View thread  Neurology7470: Allergan Plans Registration Trial with BOTOX® for UI Due to OAB in Ped Patients</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-27T11:21:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-27T11:21:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cosmo Provides FY13 Results and Key Strategic Events</title>
	<pubDate>2014-03-27T11:05:07+01:00</pubDate>
	<wp:post_id>5010</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside financial results for FY13 management highlighted the excellent market performance of Lialda in the US (fatest growing UC tablet, 29% MS in the 5-ASA market).<wbr> For Uceris (launched mid February 2013, and commercialized by Salix and Ferring) sales reached $66M.<wbr> When it comes to the pipeline, we have detailed below the Methylene Blue MMX, chromoendoscopy for colon cancer screening and surveillance undergoing Ph3 development with leading endoscopists KOLs in EU, USA and Canada, as well as rifamycin SV MMX which Ph3 (for traveller's diarrhea) and Ph2 (for diverticulitis) are run by Dr Falk Pharma in Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1951_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Separation of duties of Chairman and CEO </div><div style="margin-bottom: 10px;">• Mauro Ajani – Full time Chairman with focus on strategic projects </div><div style="margin-bottom: 10px;">• Alessandro Della Chà – New CEO and executive member of the board </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>MoA</STRONG> non invasive staining of cellular structures in the colon through methylene blue delivered by tablet (MMX technology).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Ph3 trial protocol</STRONG> safety and efficacy of Methylene Blue MMX® modified release tablets administered to subjects undergoing screening or surveillance colonoscopy </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1951_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1951_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Primary endpoint</STRONG> Proportion of patients with at least 1 adenoma proven by histology </div><div style="margin-bottom: 10px;"><STRONG>Secondary end points</STRONG> Number of polyps; Number of adenomas; False positive rate in patient.<wbr> </div><div style="margin-bottom: 10px;"><U>USA and Canada</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1951_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Europe</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1951_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="gastroenterology1951attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1951_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(74,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1951_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(89 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1951_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(10,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1951_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(35,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1951_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(37,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1951">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-27T11:05:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-27T11:05:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Shares of Exelixis Declined 35% After Disappointment Over Cabozantinib Study</title>
	<pubDate>2014-03-27T10:01:14+01:00</pubDate>
	<wp:post_id>5011</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: IDM determined that the COMET-1 Ph3 (n=960= study of the drug should continue until the final analysis later this year.<wbr> Late-stage of J&amp;J's Zytiga and Astellas/<wbr>Medivation's Xtandi were halted early due to positive efficacy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Indication: 3rd-line mCRPC </div><div style="margin-bottom: 10px;">COMET-1 is a randomized, double-blind, controlled trial designed to enroll 960 patients with mCRPC who have progressed after treatment with docetaxel, abiraterone and/<wbr>or enzalutamide.<wbr> </div><div style="margin-bottom: 10px;">All patients in the trial have bone metastases and there is no limit to the number or type of prior treatments.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9566_1_ScreenCapture1.jpg"> </div><div><EM>Source: Exelixis</EM> </div><!-- Comment details --><a name="oncology9566attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9566_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9566">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-27T10:01:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-27T10:01:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Plans Registration Trial with BOTOX® for UI Due to OAB in Ped Patients</title>
	<pubDate>2014-03-26T17:43:55+01:00</pubDate>
	<wp:post_id>5012</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph3 study will evaluate the safety and efficacy of BOTOX® in pediatric patients between the ages of 12 to 17 years who have not been adequately managed with anticholinergics.<wbr> PE will measure Change from Baseline in Number of Daily Episodes of Urinary Incontinence.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=108 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Symptoms of overactive bladder (OAB) (frequency/<wbr>urgency) with urinary incontinence for at least 6 months</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">OAB symptoms not adequately managed by 1 or more anticholinergic agents</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: March 2014 </div><div style="margin-bottom: 10px;">Completion date: March 2017 /<wbr> Dec 2018 </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG> </div><div style="margin-bottom: 10px;">USA (1 site) </div><div><A href="http://clinicaltrials.gov/ct2/show/NCT02097121?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F26%2F2014&amp;rank=81">Source: NCT02097121</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7472c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>It appears this study maybe the Post Marketing Commitment study which Botox received after approval of the adult OAB indication in the US H2 2012.<wbr> The details of the Paediatric study Botox committed to (which can be found in the Adult OAB FDA approval letter) seem to match the info above, the letter also references an extension study of 48 weeks for subjects completing this study.<wbr> The number of patients in this study would very low to consider registration.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7470">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-26T17:43:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-26T17:43:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AZ Reinforces its Focus on Japan</title>
	<pubDate>2014-03-26T13:13:40+01:00</pubDate>
	<wp:post_id>5013</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the beginning of this year, management highlighted Japan as one of the company's key priorities for a faster return to growth.<wbr> In line with this strategy, the company completed yesterday the purchase of Sumitomo's 20% remaining shares in AstraZeneca K.<wbr>K to gain full control of its Japanese unit.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Valued at approx.<wbr> JPY10 billion ($102M), the purchase will give AZ a control of the entire shareholding of AstraZeneca K.<wbr>K.<wbr> </div><div><EM>Source: AstraZeneca</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9564">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-26T13:13:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-26T13:13:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AllaChem LLC Plans For A Phase 1/2 Study of An Anti-Androgen (ONC1-13B) In mCRPC Patients</title>
	<pubDate>2014-03-26T11:40:32+01:00</pubDate>
	<wp:post_id>5014</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AllaChem has two leading compounds from their Cancer Platform - ONC1-13B and ONC2-13B.<wbr> ONC1-13B is now in clinical development for mCRPC.<wbr> It is a small molecule, next-in-class, anti-androgen and binds to AR and inhibits AR nuclear translocation.<wbr> It also inhibits the formation of transcription complex with AR.<wbr> The inhibition of AR activity through mechanisms in addition to androgen ablation, such as modulation of signal transduction pathways, may delay prostate cancer progression.<wbr> The clinical development plan for ONC1-13B is in Russia only and there is no sufficient evidence suggesting future trials are planned in Asia, USA or EU.<wbr> </div><div style="margin-bottom: 10px;">The phase I /<wbr> II clinical studies evaluate the efficacy, safety, tolerability and pharmacokinetics of single and multiple doses of ONC1-13B in the treatment of subjects with progressive metastatic castration-resistant prostate cancer.<wbr> A total of12-24 mCRPC patients are expected to be enrolled from 4-6 clinical sites in the Russian Federation .<wbr> The studies will evaluate ONC1-13B efficacy, safety, tolerability and pharmacokinetics upon single and repeated oral administration of 40, 80, 160, and 320 mg doses.<wbr> Currently the status of the trial is 'planned' as of July 2013, submission package for the phase I/<wbr>II clinical studies is under review by the Russian Regulatory Agencies.<wbr> </div><div style="margin-bottom: 10px;">Key Milestones: </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>July 2011:</STRONG> ONC1-13B and ONC2-13B patented (WO 2012/<wbr>011840: CYCLIC N,N&rsquo;-DIARYLTHIOUREAS AND N,N&rsquo;-DIARYLUREAS AS ANDROGEN RECEPTOR ANTAGONISTS, ANTI-CANCER AGENT, METHOD FOR PRODUCING AND USING SAME)
</LI>
<LI><STRONG>July 2013: t</STRONG>he company reported the completion of preclinical studies of ONC1-13B, a small molecule androgen receptor (AR) inhibitor for the treatment of prostate and breast cancers - anti-tumour activity was confirmed in xenograft tumour models with Prostate cancer and MCF7 (Breast Cancer cell line).<wbr> AllaChem then filed for the submission package for the Phase I/<wbr>III studies to Russian Regulatory agencies based on promising preclinical evidences supporting rationale for clinical development.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">Company Profile: </div><div style="margin-bottom: 10px;">AllaChem is an independent company based in Florida and evidences suggesting it may have a strong affiliation with Russia.<wbr>  AllaChem has four platform focusing on development of small molecule in HCV, Cancer, Flu (partnered with ASAVI), and CNS (partnered with Avineuro).<wbr> </div><div>Source: <A href="http://allachem.com/pipeline/cancer-platform/">http:/<wbr>/<wbr>allachem.<wbr>com/<wbr>pipeline/<wbr>cancer-platform/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9563">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-26T11:40:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-26T11:40:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ferring to Test Bowel Preparation in Children</title>
	<pubDate>2014-03-25T18:26:15+01:00</pubDate>
	<wp:post_id>5015</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><DIV class="identifier"></DIV> </div><div style="margin-bottom: 10px;"><P class="identifier"> </P> </div><div style="margin-bottom: 10px;"><P class="identifier"> </P> </div><div style="margin-bottom: 10px;"><P class="identifier"> </P> </div><div style="margin-bottom: 10px;"><P class="identifier"> </P> </div><div style="margin-bottom: 10px;"><P class="identifier"></P> </div><div style="margin-bottom: 10px;"><P class="identifier"></P> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>The U.<wbr> S.<wbr> FDA approved Prepopik on July 17, 2012</LI>
<LI>Approved in 1980, for use outside the U.<wbr>S.<wbr>, Prepopik has been used for colon prep by approximately 28.<wbr>8 million people globally.<wbr> </LI>
<LI>In Canada, Prepopik is marketed as Pico-Salax, and in the U.<wbr>K.<wbr> as Picolax</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Dosage and Administration</STRONG> - PREPOPIK, supplied as a powder, must be reconstituted with cold water right before its use </div><div style="margin-bottom: 10px;">Two dosing regimens, each requires two separate dosing times </div><div style="margin-bottom: 10px;"> “Split Dose” method is preferred method o First dose: during evening before the colonoscopy o Second dose: next day, during the morning prior to the colonoscopy </div><div> “Day Before” method is alternative method if “Split Dose” is not appropriate o First dose: during afternoon or early evening before the colonoscopy o Second dose: 6 hours later during evening before colonoscopy </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1949">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-25T18:26:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-25T18:26:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways from D Pyott Interview with Analysts</title>
	<pubDate>2014-03-25T17:52:24+01:00</pubDate>
	<wp:post_id>5016</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Analysts with BMO Capital markets recently met CEO of Allergan at its offices in Irvine, CA.<wbr> Pyott discussed his perspective of a growth vs consolidation, as well as Botox potential "blue ocean" indications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">D Pyott reported that within the context of strategy, Allergan is focused on growth and in-licensing within its core areas and would even look beyond its current therapeutic areas if something were compelling enough and met the “accretive to growth” focus.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;">Mr.<wbr> Pyott described the foundation work that Allergan is laying in Japan and China, saying Allergan is “spending a fortune” to set the groundwork, but that it is well worth it as it is doing so to secure longer-term growth.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Depression and premature ejaculation represent potential “blue ocean” indications, or indications that Allergan sees as redefining the potential treatment options and competitive spaces Allergan will have to itself for some time, if successful in gaining an approval.<wbr> </div><div><EM>Source: BMO Capital Markets March 25 2014</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7468">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-25T17:52:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-25T17:52:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EU Approved Cometriq® (cabozantinib) for Medullary Thyroid Cancer</title>
	<pubDate>2014-03-25T17:32:44+01:00</pubDate>
	<wp:post_id>5017</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Pursuant to the terms of a commercialization and distribution agreement between Exelixis and Sobi signed in February 2013, Sobi will support the commercialisation of Cometriq in the EU for the approved indication through the end of 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Additionally, the Committee for Orphan Medicinal Products (COMP) during its January 2014 meeting reviewed the designation for COMETRIQ (cabozantinib) as an orphan medicinal product for the treatment of medullary thyroid carcinoma and recommended maintenance of orphan drug designation at the time of marketing authorization.<wbr> </div><div><EM>Source: Exelixis</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7632">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-25T17:32:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-25T17:32:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Phase 2 US Study Of MLN-0128 (Dual mTOR Inhibitor) In mCRPC Patients</title>
	<pubDate>2014-03-25T13:06:39+01:00</pubDate>
	<wp:post_id>5018</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Millennium collaborated with Memorial Sloan Kettering Cancer Centre to evaluate efficacy and safety of MLN-0128 in mCRPC setting.<wbr> It is a US only, phase 2, uncontrolled, single group assignment, open label study.<wbr> A total of 21 patients are planned to be enrolled in the study.<wbr> Patients receive MLN0128 at a dose of 5mg daily continuously for 1 cycle (4 weeks) for assessment of sensitivity and resistance prior taxane-based chemotherapy.<wbr> This appears to be academia initiated POC study in mCRPC as other evidences suggesting Millennium's focus for MLN-0128 remain in haematological cancers and in combination with aromatase inhibitors in ER/<wbr>PR+ metastatic breast cancer.<wbr> </div><div style="margin-bottom: 10px;">Clinical Trial ID: NCT02091531 </div><div style="margin-bottom: 10px;">Start Date: 1st March 2014 </div><div style="margin-bottom: 10px;">Expected Completion Date: March 2017 (Duration 3 years) </div><div style="margin-bottom: 10px;">MOA: inhibits both TORC1 and TORC2 complexes of mTOR and results in tumour apoptosis and suppress tumour proliferation via PI3K/<wbr>Akt/<wbr>mTOR signalling pathway.<wbr> </div><div style="margin-bottom: 10px;">MLN-0128 was initially developed by Intellikine Inc.<wbr> who was acquired by Millennium (Takeda Group) in Dec 2011.<wbr> In the consideration, Takeda will pay $190m in upfront and up to $120m in additional potential clinical development milestones.<wbr> Takeda has the responsibility for global strategy and development plan for MLN-0128.<wbr> MLN-0128 is currently under development programmes in ER/<wbr>PR+ metastatic breast cancer, bladder cancer and haematological cancers (Trial details shown in table below).<wbr> Preclinical data suggests efficacy of MLN-0128 in breast cancer models driven by HER2-PI3K-AKT-mTOR pathway.<wbr> This implicates the role of PI3K-AKT-mTOR signalling pathway in abrogating resistance to trastuzumab therapy and therefore an attractive strategy to enhance the clinical activity of trastuzumab therapy, as well as to prevent or delay the development of resistance.<wbr> Similarly, the study results presented at 2012 American Society of Heamatology (ASH) Annual Meeting and Exposition concluded that oral MLN0128 has been observed as generally well tolerated, with a limited incidence of hyperglycemia, a toxicity associated with PI3k/<wbr>Akt/<wbr>mTOR pathway inhibition.<wbr> The preliminary study results support the rationale for development in haematological cancers.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9562_1_Table.png"> </div><div>Source: <A href="http://www.clinicaltrial.gov/">www.<wbr>clinicaltrial.<wbr>gov</A> , <A href="http://www.millennium.com/">www.<wbr>millennium.<wbr>com</A> </div><!-- Comment details --><a name="oncology9562attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9562_1_Table.png">Table.png</a>&nbsp;&nbsp;(62,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9562">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-25T13:06:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-25T13:06:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Gene Therapy Strategy for Huntington's Disease</title>
	<pubDate>2014-03-25T12:03:20+01:00</pubDate>
	<wp:post_id>5019</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Last month, CHDI Foundation and Genzyme, a Sanofi company, entered into a collaboration to develop adeno-associated virus delivery of a novel gene silencing therapeutic approach for Huntington’s disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>to develop a therapeutic clinical candidate that will aim to lower huntingtin protein expression, as well as the preparation and filing of an investigational new drug application with one or more regulatory authorities for an initial clinical appraisal.<wbr></LI>
</UL> </div><div>Source: CHDI; Genzyme </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7466">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-25T12:03:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-25T12:03:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UK's NICE Rejects Bayer's Xofigo</title>
	<pubDate>2014-03-24T14:36:47+01:00</pubDate>
	<wp:post_id>5020</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Draft guidance issued regarding the use of Bayer's radiopharmaceutical Xofigo for the treatment of mCRPC rejects the use of the drug within the NHS because the company has provided no comparison on how well it works versus other treatments.<wbr> There is scope for consultation on this guidance.<wbr> </div><div style="margin-bottom: 10px;">The proposed price of £24,240 for a course of treatment is considered high in the context of no comparative data.<wbr> </div><div>Bayer is already trying to address this through a comparative trial it will initiate this year comparing Xofigo plus abiraterone and prednisolone versus abiraterone, placebo and prednisolone in 800 patients with cancer that has spread to the bone but where it is causing nor or only mild symptoms (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9207" class="defaultlink">Oncology9207: Bayer Highlights 5 New NMEs and Life-Cycle Intention Plans for Radium-223 In CRPC</a>).<wbr> The trial is supposed to start before mid-year and complete in 2017.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9558">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-24T14:36:47+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-24T14:36:47+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>World’s First Drug Therapy Approved in Japan for ADPKD</title>
	<pubDate>2014-03-24T13:35:33+01:00</pubDate>
	<wp:post_id>5021</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Discovered and developed by Otsuka, Samsca (tolvaptan) has been approved in Japan as the first drug treatment in the world to slow the progression of autosomal dominant polycystic kidney disease (ADPKD).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In EU, as of December, 2013, an application for regulatory approval of tolvaptan in ADPKD had been received and is under review (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7557" class="defaultlink">Endocrinology7557: EMA Accepts Otsuka's MAA for Polycystic Kidney Disease Drug</a>).<wbr> </div><div style="margin-bottom: 10px;">In the US, based on a review issued by the FDA, discussions are ongoing regarding supplementary data and the path forward for resubmission (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7421" class="defaultlink">Endocrinology7421: New Drug To Treat Polycystic Kidney Disease May Not Gain US Approval</a>).<wbr> </div><div><EM>Source: Otsuka</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7631">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-24T13:35:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-24T13:35:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>XTANDI® Approved in Japan for CRPC</title>
	<pubDate>2014-03-24T09:52:45+01:00</pubDate>
	<wp:post_id>5022</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Morgan Stanley</STRONG> &gt; " .<wbr>.<wbr>.<wbr> The timing is as expected, but at the final stage usage was limited to post-chemo, which leaves a slightly negative impression.<wbr> Regulatory review so far has focused on castration-resistant prostate cancer (CRPC), but Astellas’ announcement today carried an additional information on label that “efficacy and safety.<wbr>.<wbr>.<wbr> have not been established in patients… who have not received chemotherapy.<wbr>” We think approval may be granted for use in pre-chemo patients also if Astellas submits data from the PREVAIL trial to Japanese regulators (US filing for pre-chemo completed in March).<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Barclays</STRONG> &gt; " .<wbr>.<wbr>.<wbr> The first-to-market advantage for Xtandi may not be as substantial as we had expected.<wbr> Astellas will have to limit sales promotion to the post-chemotherapy indication and, given the conservative nature of Japanese physicians, off-label use will likely be relatively minimal.<wbr> .<wbr>.<wbr>.<wbr> Astellas provided no comments on its strategy for obtaining expanded approval for pre-chemo therapy but we see two possible options: 1) a formal amended NDA application could be submitted based on data from the PREVAIL study once it has been completed or 2) Astellas could petition the regulatory authorities to amend the product label based on data from the interim analysis of the PREVAIL study.<wbr> Obviously, the latter option could result in a faster possible approval".<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div><EM>Source: Astellas</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9556">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-24T09:52:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-24T09:52:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Findings from Botox Asthma Study in Australia</title>
	<pubDate>2014-03-24T09:41:06+01:00</pubDate>
	<wp:post_id>5023</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Andrew Stork (Scientific Mnager) we have information on the findings of the world-first trial with Botox in patients with severe asthma who experience spasms in their vocal cords as well as their lungs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">Monash Health director of respiratory and sleep medicine Phil Bardin used a device called a bronchoscope to see inside the airways and guide the injections to a specific area of vocal cord tissue where they injected a small amount of botulinum toxin.<wbr> 

<DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">The botox partially paralysed the muscles, causing the voicebox to relax and allow air through to the lungs, in findings published on Monday in the journal <EM>Respirology</EM> - "Abnormal vocal cord movement treated with botulinum toxin in patients with asthma resistant to optimised management" (see below)</DIV>
<DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none"><A href="http://onlinelibrary.wiley.com/doi/10.1111/resp.12271/abstract">http:/<wbr>/<wbr>onlinelibrary.<wbr>wiley.<wbr>com/<wbr>doi/<wbr>10.<wbr>1111/<wbr>resp.<wbr>12271/<wbr>abstract</A>.<wbr></DIV>
<P style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none"><STRONG></STRONG></P>
<DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<DIV>
<DIV id="abstract">
<DIV class="section" id="resp12271-sec-0002">
<DIV class="para">
<P>In an observational study, we evaluated the benefits of unilateral vocal cord injection with botulinum toxin in 11 patients (total 24 injections).<wbr> Subjects had asthma resistant to optimised treatment and abnormal vocal cord movement.<wbr> Responses after botulinum toxin treatment were assessed using asthma control test (ACT) scores, vocal cord narrowing quantified by computerised tomography (CT) of the larynx and spirometry.<wbr> Side-effects were recorded.<wbr></P></DIV></DIV>
<DIV class="section" id="resp12271-sec-0003">
<H4>Results</H4>
<DIV class="para">
<P>ACT scores improved overall (9.<wbr>1 ± 2.<wbr>4 before and 13.<wbr>5 ± 4.<wbr>5 after treatment; difference 4.<wbr>4 ± 4.<wbr>2; P &lt; 0.<wbr>001).<wbr> There was also an improvement in airway size on CT larynx (time below lower limit of normal at baseline 39.<wbr>4 ± 37.<wbr>63% and improved to 17.<wbr>6 ± 25.<wbr>6% after injection; P = 0.<wbr>032).<wbr> Spirometry was not altered.<wbr> One patient experienced an asthma exacerbation but overall side-effects were moderate, chiefly dysphonia and dysphagia.<wbr></P></DIV></DIV>
<DIV class="section" id="resp12271-sec-0004">
<H4>Conclusions</H4>
<DIV class="para">
<P>Although a placebo effect cannot be ruled out, local injection of botulinum toxin may be an effective treatment for intractable asthma associated with abnormal vocal cord movement.<wbr> </P>
<P>Further mechanistic studies and a double-blind randomised controlled trial of botulinum toxin treatment are merited.<wbr> </P></DIV></DIV></DIV></DIV></DIV></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7462">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-24T09:41:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-24T09:41:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Antisense Has Reached a Major Milestone with the Recruitment of ATL1103 for Acromegaly</title>
	<pubDate>2014-03-21T16:52:56+01:00</pubDate>
	<wp:post_id>5024</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Antisense has reported that 24 acromegalic patients have been successfully enrolled and randomized to one of the two treatment regimens of dosing in the Ph2.<wbr> With patient enrollment now complete, the company anticipates reporting the results of the statistical analysis from all patients by mid 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ATL1103 Ph2 trial is a randomised, open-label, parallel group study of the safety, tolerability, pharmacokinetics and efficacy of two subcutaneous dosing regimens of ATL1103 in 24 adult patients with acromegaly dosed with ATL1103 for 13 weeks (3 months) with two months of follow up.<wbr> </div><div style="margin-bottom: 10px;">Two ATL1103 dosing regimens are being tested (a) 200 mg 3 times in the first week then once weekly thereafter (200 mg/<wbr>week) or (b) 200 mg 3 times in the first week then twice weekly thereafter (400 mg/<wbr>week).<wbr> </div><div style="margin-bottom: 10px;">The primary endpoints or main purposes of the trial as listed on the trial protocol are (i) to evaluate the safety and tolerability of ATL1103 in patients with acromegaly, and (ii) to evaluate the single dose and multiple dose pharmacokinetic profiles of ATL1103 via the subcutaneous route in patients with acromegaly.<wbr> </div><div style="margin-bottom: 10px;">A secondary, but important endpoint that is also on the trial protocol is the evaluation of ATL1103’s effect on serum insulin like growth factor I (IGF-I) levels in patients.<wbr> The secondary endpoint is the average percentage reduction in serum IGF-I levels at the end of treatment compared to baseline levels for each of the two dosing regimens used in the Ph2 study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7552" class="defaultlink">Endocrinology7552: Positive Results from the Interim Analysis of Antisense's ATL1103 for Acromegaly</a>.<wbr> </div><div>Source: Antisense </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7629">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-21T16:52:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-21T16:52:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz to Test Xeomin for Sialorrhea Resulting from Neurological Conditions</title>
	<pubDate>2014-03-21T16:29:08+01:00</pubDate>
	<wp:post_id>5025</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The objective of this Ph3 is to investigate the efficacy and safety of 2 different dose levels of the drug (75 U or 100 U per cycle), compared with placebo.<wbr> PE will assess unstimulated salivary flow rate (uSFR).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">n=180 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">
Chronic troublesome sialorrhea (for at least 3 months) at screening, defined as the presence of all of the following, at screening and at baseline and for at least the 3 months before screening (where retrospective response to questionnaires is impossible, a statement of equivalent severity will suffice):
<OL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">A Drooling Severity and Frequency Scale [DSFS] sum score of at least 6 points and</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">A score of at least 2 points for each item of the DSFS and</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">A score of at least 3 points on the modified Radboud Oral Motor Inventory for Parkinson's Disease [mROMP], Section 'III Drooling', Item A).<wbr></LI>
</OL></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">A score of at most 2 points on the mROMP Section 'II Swallowing Symptoms' Item A) and a score of at most 3 points on Item C), at screening and at baseline.<wbr>.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Start date: March 2014</LI>
<LI>Completion date: April 2015 /<wbr> July 2016</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Locations</STRONG> </div><div style="margin-bottom: 10px;">USA; Germany; Poland </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02091739?term=botulinum+OR+SPASTICITY+OR+ULCERATIVE+OR+CROHN+OR+ACROMEGALY+OR+PORSTATE&amp;recr=Open&amp;no_unk=Y&amp;phase=01234&amp;fund=2&amp;rcv_s=02%2F21%2F2014&amp;rank=6">NCT02091739</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7461">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-21T16:29:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-21T16:29:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EU Positive Opinion on Takeda's Entyvio® (vedolizumab) in UC and CD</title>
	<pubDate>2014-03-21T15:34:59+01:00</pubDate>
	<wp:post_id>5026</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The CHMP Opinion for vedolizumab will now be reviewed by the European Commission EC.<wbr> The U.<wbr>S FDA is currently reviewing the BLA for the drug.<wbr> The drug is part of Takeda's EU strategy for accelerating its presence in Specialty Care.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1946_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Takeda submitted a MAA to the EMA in March 2013 for vedolizumab for the treatment of adults with moderately to severely active UC or CD.<wbr> </div><div style="margin-bottom: 10px;">If the CHMP recommendation is formally adopted by the EC, vedolizumab would be approved for marketing in the 28 member states of the EU as well as Norway, Iceland and Liechtenstein.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1946_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Vedolizumab, developed for the treatment of UC and CD, is a humanized monoclonal antibody that is designed to specifically antagonize the alpha4beta7 integrin, inhibiting the binding of alpha4beta7 to intestinal mucosal addressin cell adhesion molecule 1 (MAdCAM-1) and fibronectin, but not vascular cell adhesion molecule 1 (VCAM 1).<wbr> </div><div><EM>Source: Takeda</EM> </div><!-- Comment details --><a name="gastroenterology1946attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1946_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(73,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1946_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(78,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1946">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-21T15:34:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-21T15:34:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Biogen Idec to Spread Out to Other Neurodegenerative Disorders</title>
	<pubDate>2014-03-21T14:12:21+01:00</pubDate>
	<wp:post_id>5027</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Biogen Idec is putting up part of a $17M investment in a Cambridge biotech startup, working on a drug to treat ataxia, and will have the option to acquire the company during early-stage development (Ph1).<wbr> The drug candidates may also be able to treat other forms of genetic disorder, such as those associated with<A href="http:///search?q=Multiple+Sclerosis" style="FONT-WEIGHT: bold; TEXT-DECORATION: none"> </A>MS and Huuntington's disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Ataxion has just 2 FTEs— Joshua Resnick (CEO) and CSO Martin Jefson, former head of Neuroscience Research at Pfizer.<wbr> </div><div style="margin-bottom: 10px;">Holtzman and Kevin Koch, Biogen’s senior vice president of research and development, joined the board this month.<wbr> </div><div style="margin-bottom: 10px;">Resnick, Jean-Francois Formela and David Grayzel of Atlas, and Claus Braestrup, former CEO of Lundbeck Pharmaceuticals and Chairman of Saniona, are also on Ataxion’s board of directors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Late Stage Programs</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7460_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Late Stage Pipeline Events</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7460_2_ScreenCapture2.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7460_3_ScreenCapture3.jpg"> </div><!-- Comment details --><a name="neurology7460attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7460_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(174,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7460_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(8,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7460_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(55,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7460">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-21T14:12:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-21T14:12:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ENETS Intelligence Part 2- New Imaging Techniques For NET Diagnosis & Treatment Prognosis</title>
	<pubDate>2014-03-20T18:16:16+01:00</pubDate>
	<wp:post_id>5028</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lisa Bodei, Consultant Nuclear Medicine Physician, European Institute of Oncology, Milan, gave an interesting lecture at ENETS on the future of functional and anatomical imaging.<wbr> She emphsised how it is becoming increasingly integrated into the personalised daignostic/<wbr>treatment paradigm in NET.<wbr> New and emerging strategies based around SSR-antagonists and GLP1-R peptides were reviewed.<wbr> Therapeutic lablelling of the SSR-antagonist JR11 creates a theranostic that can double the dose of radiation absorbed by a tumour compared to the agonsit 177 Lu DOTA-TATE (e.<wbr>g.<wbr> AAA's Lutathera).<wbr> The topic will be further reviewed at the upcoming meeting at the Royal Society of Medicine on the 10th April "Current &amp; future developments in therapy using radionuclides" (see programme below).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_8_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_9_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_10_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_11_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_12_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_13_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;">As therapeutics labelled with Lutiteum it has been shown that the dose absorbed is double that of the agonist.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_14_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_16_ScreenCapture18.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_15_ScreenCapture17.jpg"> </div><!-- Comment details --><a name="endocrinology7625attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(163 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(102,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(143,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(175,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(174,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(130,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(208,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_8_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(204,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_9_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(154,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_10_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(164,2 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_11_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(141,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_12_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(160,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_13_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(200,6 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_14_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(188,3 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_15_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(127,1 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7625_16_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(105,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7625">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-20T18:16:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-20T18:16:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Soft Intelligence From ENETS on Nurse Funding</title>
	<pubDate>2014-03-20T16:57:38+01:00</pubDate>
	<wp:post_id>5029</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Nigel Homer (UK BU Head Endocrinology) has validated with a Novartis product manager at ENETS, rumours that Novartis are looking to copy our nurse service in the UK and considering offering this service in other markets.<wbr> </div><div style="margin-bottom: 10px;">He confirmed that currently Novartis is funding nurses at select centres in the UK but that it is looking to extend this service to other centres which are prepared to put patients on Sandostatin LAR.<wbr> </div><div>If you come across this offering in other countries, please make the Franchise or the CI team aware.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7622">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-20T16:57:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-20T16:57:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Agrees nmCPRC Trial As A Potential Path Forward For GTx-750</title>
	<pubDate>2014-03-20T14:52:17+01:00</pubDate>
	<wp:post_id>5030</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: GTx met with the FDA Q4 2013 to get more regulatory clarity for the development of GTx-758 an estrogen receptor alpha agonist.<wbr> It claimes that the FDA agreed a potential regulatory path forward for GTx-758 may be in men with high risk non-metastatic castrate-resistant prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>GTx-758 Current Status Phase II Trial</STRONG> </div><div style="margin-bottom: 10px;">GTx is enrolling an open label Phase 2 clinical study to evaluate the safety and effectiveness at two doses of GTx-758 125 milligrams and 250 milligram oral daily dose in men with metastatic and nmCRPC.<wbr> The primary endpoint of study is the apportion of patients with a greater or equal than 50% reduction from baseline in serum PSA by day 90.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Other key endpoints include, free testosterone levels, sex hormone-binding globulin levels, and total testosterone levels as well as the effects on tumor progression in the study subjects.<wbr> In addition the study evaluating the ability of GTx-758 to treat certain estrogen deficiency side effects associated with androgen deprivation therapy such as hot flashes, bone loss, and insulin resistance.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">The clinical study will enroll a total of 76 patients with the first cohort of 38 patients with mCRPC receiving a 125-milligram daily dose of GTx-758.<wbr> Having completed enrollment of the first cohort of patients and following a planned safety review by an independent Data Safety Monitoring Board, the trial is now enrolling an additional 38 patients in the 250-milligram oral daily dose arm.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">The first 10 patients to receive the 250-milligram dose will be men with mCRPC and thereafter enrollment will be open to men with either metastatic or non-metastatic CRPC assuming GTx-758 continues to have an acceptable safety profile.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Last month, preliminary efficacy and safety data for the 125-milligram cohort was presented at the GU ASCO meeting.<wbr> Of the 36 patients for whom GTx had available laboratory values, 83% had levels of SHBG that more than doubled from baseline and free testosterone was reduced in 92% of these patients with 81% of the patients having at least a 50% reduction in free testosterone.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Of the 22 patients that completed 90 days on the trial, 91% experienced decreases in PSA levels, with 36% exhibiting decreases greater than 30%.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG>Safety Profile</STRONG> </div><div style="margin-bottom: 10px;">Preliminary data also showed that a majority of subjects who were experiencing hot flashes prior to taking GTx-758 reported an improvement in and/<wbr>or stabilization of their hot flashes.<wbr> Moreover,bone turnover markers decreased in the majority of these patients as well.<wbr> Overall it iss claimed that GTx-758 continues to be well tolerated with no reported venous thromboembolic events or deaths.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">We're continuing to enroll patients in the 250-milligram cohort.<wbr> And so far, the drug appears to be well tolerated at this dose as well.<wbr> We expect the study to be completed and data available later in the second half of this year.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Result of FDA Meeting</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">The FDA apparently suggested to GTx a trial design that maybe acceptable could be to randomize men who have high risk nmCRPC to either GTx-758 or placebo and the primary endpoint of the study could be metastasis-free survival.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Additionally, this study could use free testosterone levels to identify men who have sub-optimal castration, which should allow us to correlate free testosterone levels with metastasis-free survival.<wbr> FDA it suggests may be open to discussing the way to validate free testosterone as a surrogate endpoint in the future.<wbr></P> </div><div><P class="pwrapper">Source: <A href="http://www.GTX.com">www.<wbr>gtxinc.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9554">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-20T14:52:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-20T14:52:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Spectrum at the Roth Capital Meeting - NDA Submission Plans For Bladder Cancer</title>
	<pubDate>2014-03-20T14:35:03+01:00</pubDate>
	<wp:post_id>5031</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During the Roth Capital H/<wbr>C Conference, Spectrum expanded on its intentions with regard to a filing for Apaziquone for non-muscle invasive bladder cancer (NMIBC) and its hopes that it will be the first drug approved for the treatment of NMIBC in the US.<wbr> Apaziquone is one of three near-term NDA candidates.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9552_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Kurt Gustafson CFO made the following comments in relation to the drug "We ran two Phase III studies with apaziquone, both of which were favorable but neither of which individually was statistically significant.<wbr> However, when we take a look at the pooled dataset of these two Phase III studies, it was statistically significant and so our plan here is to go file with the FDA with that pooled dataset and start a Phase III study later this year to try to get approval for the drug in this indication.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Alongside its comments about apaziquone, the group also provided an update on its other activities (see below).<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9552_2_ScreenCapture2.jpg"></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9552_3_ScreenCapture3.jpg"></P> </div><div><P class="pwrapper">Spectrum Overview<img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9552_4_ScreenCapture4.jpg"></P> </div><!-- Comment details --><a name="oncology9552attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9552_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(143,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9552_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(108,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9552_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(121,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9552_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(113 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9552">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-20T14:35:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-20T14:35:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Anterios Reports Development Of Next Generation Injectable Botulinum Toxin</title>
	<pubDate>2014-03-20T12:08:16+01:00</pubDate>
	<wp:post_id>5032</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to the company, AI-09 utilizes neither lyophilization nor albumin, and will be packaged as a ready-to-use injectable liquid in bottles or pre-filled syringes.<wbr> Timothy C.<wbr> Flynn, MD, independent clinical investigator, will be presenting "Differentiating Botulinum Toxin Type A Preparations: Basic and Clinical Science" at the annual meeting of The American Academy of Dermatology in Denver on March 24<SUP>th</SUP>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">AI-09 has demonstrated therapeutic equivalence to the current generation of reconstituted commercialized products in a standard pre-clinical model as well as excellent long-term stability.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">AI-09 is a complementary product to the company's topical botulinum prescription Ph2b product ANT-1207, which is being developed for wrinkles, hyperhidrosis, and acne.<wbr> </div><div><EM>Source: Anterios</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7454">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-20T12:08:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-20T12:08:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz Collaborates on a POC Trial with Xeomin® for Trigeminal Neuralgia</title>
	<pubDate>2014-03-19T17:30:15+01:00</pubDate>
	<wp:post_id>5033</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sponsored by the Thomas Jefferson U.<wbr>, the study will assess if Xeomin® is superior to placebo in the treatment of medically refractory trigeminal neuralgia (TN).<wbr> PE will measure the difference in mean number of attacks between active and placebo groups.<wbr> </div><div><DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><STRONG>Protocol</STRONG></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Subjects will be asked to maintain an attack diary throughout the study.<wbr> They will also be asked to attend 4 office visits; Visit 1- Screening Visit, Visit 2- Injection Visit, Visit 3- Follow-Up Visit and Visit 4- Final Visit.<wbr> </P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">At the end of the study the active (Xeomin®) and placebo groups will be compared to see if one group had better relief than the other.<wbr></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><STRONG>Recruitment</STRONG></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">n=40 (Subjects must have a mean attack frequency of at least 3 episodes/<wbr>day of 4/<wbr>10 pain).<wbr></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><STRONG>Timelines</STRONG></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Start date: March 2014</P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Completion date: May 2015 /<wbr> Sept 2015</P>
<P>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02088632?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=02%2F19%2F2014&amp;rank=239">NCT02088632</A></P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7452">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-19T17:30:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-19T17:30:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cologuard® Test Under Review for Detecting Colorectal Cancer</title>
	<pubDate>2014-03-19T16:59:26+01:00</pubDate>
	<wp:post_id>5034</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The test from Exact Sciences Corp.<wbr> and the Mayo Clinic detects more tumors than methods using blood in the stool, revealed the study.<wbr> Lead author Thomas Imperiale from Indiana U.<wbr> Medical Center in Indianapolis said the test has been to be having about as much potential as colonoscopy has for detecting colon cancer.<wbr> The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to review Exact Science’s PMA application for Cologuard on March 27, 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Results from the <A href="http://clinicaltrials.gov/ct2/show/NCT01397747?term=deep-c&amp;rank=1">DeeP-C</A> pivotal clinical study have been published online in the <EM>New England Journal of Medicine</EM>.<wbr> The peer-reviewed study, “Multi-target Stool DNA Testing for Colorectal-Cancer Screening” will also appear in the journal’s April 3, 2014 print issue.<wbr> </div><div style="margin-bottom: 10px;">The 12,776-patient DeeP-C study was designed to determine the performance characteristics of Exact Sciences’ multi-target stool DNA-based screening test, Cologuard®, for colorectal cancer and to compare that performance to the fecal immunochemical test (FIT), a commonly used non-invasive colorectal cancer screening test.<wbr> </div><div style="margin-bottom: 10px;">The DeeP-C study took place at 90 centers throughout the U.<wbr>S.<wbr> and Canada.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1945_1_ScreenCapture1.jpg"> </div><div>Cologuard® is designed to have patients collect a stool sample at home and send it to a lab where the sample will be processed through a series of sophisticated laboratory procedures to isolate specific DNA targets.<wbr> The targeted DNA is then amplified and analyzed for molecular alterations associated with cancerous and pre-cancerous conditions of the colon and rectum.<wbr> Doctors will discuss results with their patients.<wbr> If the Cologuard® result is positive, patients should be referred for a diagnostic colonoscopy.<wbr> While the science behind stool-based DNA screening is complex, the specimen collection process is easy, requiring no bowel preparation and no dietary restrictions.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2013c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Mayo officials announced yesterday they will be the first in the US to offer patients the Cologuard test, by which patients collect their stool samples and mail them in sealed containers for DNA analysis of their colon cancer risks.<wbr> </div><div style="margin-bottom: 10px;"><P class="Text_Body"><STRONG>Cologuard Prescription &amp; Usage</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="Text_Body">Cologuard is intended for adults 50 and older who are only at average risk for colon cancer based on their health and family history.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="Text_Body">After mailing in stool samples in secure packaging provided by the company, patients will learn of their results from their doctors in as little as two weeks.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="Text_Body"><STRONG>Medical Publication</STRONG></P> </div><div><P class="Text_Body">Clinical trial results published this March in the <EM>New England Journal of Medicine</EM> showed the test was 92% accurate at identifying patients with colon cancer and 69% accurate at identifying patients with the kinds of bowel lesions or polyps that indicate a high risk for cancer.<wbr></P> </div></div><a name="GastroEnterology2065c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The Centers for Medicare and Medicaid Services (CMS) has issued a final National Coverage Determination for US company Exact Sciences' Cologuard, which will come into effect immediately.<wbr> Furthermore, based on a preliminary payment report, the CMS is considering reimbursement of the diagnostic test for the full amount of USD502 requested by Exact Sciences.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Significance</STRONG> </div><div>The CMS's reimbursement decision is positive news for Exact Sciences, as it markets the first US FDA-approved non-invasive colorectal cancer DNA test covered by Medicare.<wbr> Although the payment amount is still preliminary, it is probable that the firm will have the diagnostic test reimbursement for the full amount requested.<wbr> With more than 50 million Medicare patients, many of whom will require regular screenings, the firm is anticipated to generate significant revenues in the future.<wbr> </div></div><a name="gastroenterology1945attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1945_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(20,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1945">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-19T16:59:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-19T16:59:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bavarian Nordic Reports 2013 Results and Highlights Key Drug Milestones</title>
	<pubDate>2014-03-19T14:21:02+01:00</pubDate>
	<wp:post_id>5035</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management anticipates the PROSPECT study (cancer immunotherapy for CRPC Prostvac) to be fully enrolled by year-end 2014, and expects filing for approval sooner than anticipated.<wbr> For the second immunotherapy candidate, CV-301, colorectal cancer was prioritized, with additional new indications such as bladder cancer entering POC trials.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9551_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>ProstVac</STRONG> </div><div style="margin-bottom: 10px;">- PROSPECT trial: Regulatory delays in EU continue to impact site initiation, particularly in Germany and the Netherlands.<wbr> As a consequence, the study is now expected to be fully enrolled in H2 2014.<wbr> </div><div style="margin-bottom: 10px;">- Management is to continue to research the potential of PROSTVAC in combination with checkpoint inhibitors, ADT and radiotherapy.<wbr> </div><div style="margin-bottom: 10px;">- As part of the pre-launch planning for PROSTVAC, the company began expansion of our manufacturing facility in Kvistgaard, Denmark to accommodate the future commercial production of PROSTVAC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Bladder Cancer</U> </div><div style="margin-bottom: 10px;">NCI plans to initiate a Phase 2 study of CV-301 in patients with bladder cancer whose cancer has progressed after BCG treatment (H1 2014) </div><div style="margin-bottom: 10px;">This tumor is well known to respond to immunotherapy, and BCG (Bacillus Calmette–Guerin) for use in bladder cancer was the first modern immunotherapy to be approved in many countries to prevent the recurrence of superficial bladder tumors </div><div style="margin-bottom: 10px;"><U>Colorectal Cancer</U> </div><div style="margin-bottom: 10px;">Obtain regulatory feedback from the FDA on the development plan(H2, 2014), followed by initiation of a randomized, controlled trial depending on availability of funds.<wbr> </div><div><EM>Source: Bavarian Nordic</EM> </div><!-- Comment details --><a name="oncology9551attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9551_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(35,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9551_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(16,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9551">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-19T14:21:02+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-19T14:21:02+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo Acquiers Caisson Biotech's Heparosan-Based Drug Delivery for >$100M</title>
	<pubDate>2014-03-18T17:18:45+01:00</pubDate>
	<wp:post_id>5036</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: HEPtune, which conjugates the polymer heparosan to a drug to prolong its half-life, will be licensed to Novo Nordisk exclusively for insulin products, and non-exclusively for delivery of human growth hormones, and treatments for obesity and inflammatory diseases.<wbr> Heparosan is a stealthy molecule well suited for use as a drug delivery vehicle due to its natural origin and properties in the body.<wbr> Therefore, heparosan-modified therapeutics may offer improved pharmacokinetics, drug performance properties, as well as new options for treatment and hope for patients, especially those undergoing life-long treatments.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- the heparosan aids the drug to circulate in the blood stream </div><div style="margin-bottom: 10px;">- opportunity for patients that no longer can take drugs such as PEG due to the occurrence of PEG antibodies </div><div style="margin-bottom: 10px;"><UL><LI>heparosan is a naturally occurring polymer in the body, and get degraded.<wbr> It is not recognised as a foreign substance when injected, thus it is not expected the body to generate antibodies to the heparosan</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Caisson uses novel, heparosan-based conjugates to enhance the therapeutic properties of pharmaceuticals by increasing product half-life, reducing immunogenicity, and increasing stability.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7621">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-18T17:18:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-18T17:18:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>sNDA of Astellas/Medivation's XTANDI™ in Pre-Chemo Filed</title>
	<pubDate>2014-03-18T15:58:40+01:00</pubDate>
	<wp:post_id>5037</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Based on positive results from the PREVAIL Ph3 study (announced in late 2013), a filing in the U.<wbr>S.<wbr> by the end of 1Q 2014 was largely expected.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to analysts at Barclays, approval could come as early as late September if priority review is granted by FDA.<wbr> A supplemental application filing in the EU is expected later this year.<wbr> </div><div style="margin-bottom: 10px;">Analysts at Aegis forecast sales of XTANDI™ in the U.<wbr>S.<wbr> chemotherapy-naïve patient population alone could exceed $2bn by the 2021 /<wbr> 2022 time frame.<wbr> Zytiga™, has only convinced about 7% of urologists who treat chemotherapy-naïve HRPC to prescribe Zytiga™.<wbr> Thus, a timely U.<wbr>S.<wbr> approval of XTANDI™ in chemonaïve HRPC setting should permit rapid market penetration.<wbr> </div><div><EM>Source: Medivation; Barclays; Aegis Capital</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9548">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-18T15:58:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-18T15:58:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Intercept To File For US & European Approval of New Biliary Cirrhosis Agent</title>
	<pubDate>2014-03-18T15:46:58+01:00</pubDate>
	<wp:post_id>5038</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment Intercept has announced that its PhIII POISE trial with obeticholid 
acid for the treatment of primary biliary cirrhosis has met its primary 
endpoint.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Top-Line Results</STRONG> </div><div style="margin-bottom: 10px;">OCA, at both a 10 mg dose and a 5 mg dose titrated to 10 mg, met the trial's 
primary endpoint of achieving a reduction in serum alkaline phosphatase (ALP) to 
&lt; 1.<wbr>67x ULN with a = 15% reduction from baseline and a normal bilirubin level 
after 12 months of therapy.<wbr> The proportion of patients meeting the POISE primary 
endpoint was: 10% in the placebo group, 47% in the 10 mg OCA group and 46% in 
the 5-10 mg OCA group (both dose groups p &lt; 0.<wbr>0001 vs placebo) in an 
intention to treat analysis.<wbr> </div><div style="margin-bottom: 10px;">The placebo group experienced a mean decrease in ALP from baseline of 5%, 
compared to a significant mean decrease of 39% in the 10 mg OCA dose group and 
33% in the 5-10 mg OCA titration group (both dose groups p &lt; 0.<wbr>0001 vs 
placebo).<wbr> In addition, both OCA dose groups met pre-specified secondary 
endpoints of improvements in other liver function parameters, including GGT, 
ALT, AST and total bilirubin (both dose groups p &lt; 0.<wbr>0005 vs placebo).<wbr> </div><div style="margin-bottom: 10px;">OCA, Intercept's lead product candidate, is a bile acid analog and 
first-in-class agonist of the farnesoid X receptor (FXR) in development for PBC, 
nonalcoholic steatohepatitis (NASH) and other liver and intestinal diseases.<wbr> </div><div style="margin-bottom: 10px;">"These POISE trial results indicate that OCA clearly produced clinically 
meaningful improvements, not only in the primary endpoint but also across a 
broad range of biochemical liver function parameters," said Professor Frederik 
Nevens, M.<wbr>D.<wbr> Ph.<wbr>D.<wbr>, Chairman of the Department of Hepatology at the University 
of Leuven, Belgium and the lead investigator in POISE.<wbr> "While ursodiol has been 
the mainstay of PBC therapy for the past 20 years, a significant proportion of 
patients fail to get an adequate response with this drug and we need new 
therapies to prevent their disease progressing to cirrhosis and liver failure.<wbr> I 
believe that the POISE data indicate OCA will provide a meaningful clinical 
improvement in these patients.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">David Shapiro, M.<wbr>D.<wbr>, Chief Medical Officer 
of Intercept noted that "POISE is Intercept's third successful international, 
placebo controlled trial of OCA in PBC patients conducted over the past seven 
years, setting the stage for our anticipated filing for approval of OCA in the 
U.<wbr>S.<wbr>, Europe and other countries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Primary Endpoint &amp; 
Clinical Outcomes <BR></STRONG><BR>In order to evaluate the clinical relevance 
of the POISE primary endpoint, Intercept sponsored an independent study 
conducted by the Global PBC Study Group (the 'PBC Supergroup'), consisting of 15 
leading PBC centers in eight countries that contributed to a clinical outcomes 
database of more than 6,000 PBC patients.<wbr> In this study, patients who did not 
achieve the POISE endpoint after one year were shown to have a greatly increased 
risk of liver transplant or death compared to those who achieved the endpoint 
(Hazard Ratio 2.<wbr>83, p=1x10-34).<wbr> The PBC Supergroup has also previously confirmed 
that higher ALP levels in patients correlate with increased risk of liver 
transplant and death.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Safety and Tolerability</STRONG> </div><div style="margin-bottom: 10px;">Pruritus, generally mild to moderate, was the most frequently reported 
adverse event associated with OCA treatment (placebo: 38%, OCA 10 mg: 68%, OCA 
5-10 mg titration: 56%).<wbr> Eight patients discontinued due to pruritus: none in 
the placebo group, seven (10%) of the patients in the 10 mg OCA group, and only 
one (1%) of the patients in the OCA 5-10 mg titration group.<wbr> Apart from 
pruritus, the incidence of adverse events was generally similar across both OCA 
and placebo groups (placebo: 90%, OCA 10 mg: 86%, OCA 5-10 mg: 89%).<wbr> Overall, 
serious adverse events (SAEs) occurred in 22 (10%) of the patients and, although 
there were more SAEs in the OCA treatment groups, none were considered 
drug-related and there were no apparent patterns in the SAEs.<wbr> PBC patients 
typically have significantly elevated HDL cholesterol levels and modest 
decreases in HDL were observed in both OCA dose groups, similar to those seen in 
the prior PBC clinical trials.<wbr> In addition, slight decreases in triglycerides 
but no change in LDL cholesterol were observed in the OCA dose groups.<wbr> </div><div>Source: <A href="http://www.intercept.com">www.<wbr>intercept.<wbr>com</A><BR> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10784">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-18T15:46:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-18T15:46:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ENETS Intelligence Part1- NET Competitor Intelligence & Novartis Symposium</title>
	<pubDate>2014-03-18T14:30:52+01:00</pubDate>
	<wp:post_id>5039</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; LINE-HEIGHT: 115%">Comment: 
A number of key points emerged about NET competitor development/<wbr>data timelines 
for Novartis’s fluid crystal technology, for the Lutathera &amp; LX1032 trials 
and for the RADIANT-4 &amp; COOPERATE II trials data release.<wbr> It was also noted 
that further development of BEZ-235 has been curtailed.<wbr> Importantly it was 
more evident during the Novartis Symposium the approach it intends to take to 
try and position tumour proliferation control seen with lanreotide as a class 
effect.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><B style="mso-bidi-font-weight: normal"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; LINE-HEIGHT: 115%">Soft 
Intelligence</SPAN></B> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; LINE-HEIGHT: 115%">Discussions 
with an MSL &amp; clinician on the Novartis stand reveaked that it is 
planning to start PhIII development with CAM2029 for acromegaly and NET in Q3 
2014 and March 2015 respectively.<wbr>  
Both trials will be non-inferiority studies vs.<wbr> Sandostatin LAR.<wbr> Internal 
assumptions about the potential design of such studies applied to these start 
dates imply approval for acromegaly in Q317 (US) and launch in EU Q318 and 
for NET approval for carcinoid syndrome in Q118 and for PFS one year later.<wbr> 
These dates will of course have to be validated once we have more information on 
the idividual trials.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; LINE-HEIGHT: 115%">We 
had already noted some delays with the BEZ-235 studies and finally it has been 
confirmed that development has stopped apparently for side-effect and 
pharmacokinetic reasons.<wbr> Its successor BLY-719, which has a different profile, 
is currently being evaluated in a dose escalation phI trial evaluating its 
safety in combination with everolimus in breast, renal cancer and pancreatic 
neuroendocrine tumour patients (<A href="http://clinicaltrials.gov/show/NCT02077933" title="Current version of study NCT02077933 on ClinicalTrials.gov"></A>)</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; LINE-HEIGHT: 115%">Thanks 
to Edda Gomez-Panzani, we have learnt </SPAN><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US">that 
Lexicon, has to date, only recruited 50% of their target number of patients 
in their pivotal phIII trial.<wbr> However, recruitment is still expected to complete 
by the year-end as Lexicon had a slow start due to the time it took to get 
sites up and running.<wbr> Moving forwards recruitment is expected to move 
faster.<wbr>  Lexicon plans to hire consultants and vendors to help with the 
submission as they don’t currently have any internal expertise.<wbr>  Even 
if recruitment is completed by Dec.<wbr> 2014, the data won’t be available until 
April 2014 and then it will take them a few months to clean the data to be 
able to submit.<wbr> Potentially, the earliest submission date appears to be Q315 
with a Q316 approval in the US.<wbr> A European entry strategy has still to be 
defined.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US">Edda 
also learnt that the lead person responsible for pasireotide at Novartis has 
been replaced and whilst there have been some rumors about resurrecting 
pasireotide for NET apparently this is still up in the air.<wbr> 
</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US">Professor 
Krenning (Erasmus) in his keynote lecture on PRRT, noted that the NETTER-1 study 
had now recruited 166 patients and hopes to have completed recruitment by the 
middle of this year.<wbr> Versus statements made at the EANM congress in October this 
suggests that the recruitment rate has slipped, as final enrollment of the 200 
patients required at that time was scheduled for March 2014.<wbr> A picture of the 
revised timeline is shown below.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_1_ScreenCapture1.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US">James 
Yao confirmed during the Ipsen Symposia and afterwards that the Co-operate II 
trial had completed accrual a while back and that data will be published this 
year.<wbr> Not at ASCO but definitely this year.<wbr> The Co-operate II is the first study 
to evaluate the combination of everolimus with pasreotide in pNET patients.<wbr> He 
also noted that the RADIANT-4 data was not likely to be first presented at ASCO 
but similarly later this year.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US">During 
his speech he also showed an interesting slide pointing towards analysis that 
 has been undertaken using the SEERS 
Medicare database highlighting the difference in survival probability in elderly 
stage IV patients with carcinoid syndrome treated with Octreotide LAR versus 
untreated patients.<wbr> We believe more of this data may be presented at ASCO this 
year.<wbr>  </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_2_ScreenCapture2.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><B style="mso-bidi-font-weight: normal"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US">Novartis 
Symposium – "NET Conversations Insights From The 
Experts"</SPAN></B> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US">Novartis’s 
Symposium didn’t highlight anything particularly new but the opportunity was 
taken to focus on tumour proliferation control as a “class effect” of the SSAs.<wbr> 
The approach of the symposia was to elicit information from the audience on 
their treatment choices for various types of NET patients and then ask the 
expert panel to comment upon those choices.<wbr>  Key parts of the commentary, which 
highlight the manner in which Novartis is drawing parallels between lanreotide 
and octreotide are highlighted below together with comments illustrating the 
importance of the CO-OPERATE II trial in terms of whether to continue SSA 
therapy during targeted treatment, higher dose treatment with the SSAs and 
finally the need for individualization of therapy based on the patient’s disease 
characteristics, particularly if patients have bulky 
disease.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US">The 
participants in the discussion included Simron Singh (Canada) Marianne Pavel 
(Germany) Rachel Riechelmann (Brazil) and Nick Pavlakis 
(Australia).<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US">Simon 
Singh chaired the meeting and Marianne Pavel started the discussion by reviewing 
the various treatment options available for NET patients (see below) whilst 
Rachel Riechelmann commented on the key factors to consider when selecting a 
treatment option for an individual patient e.<wbr>g.<wbr> site of origin, staging, 
prognostic algorithms, resectable or not, functional or not and lastly 
availability and patient preference.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_3_ScreenCapture4.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US">Simron 
Singh then introduced the first question for the audience</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; COLOR: #3c1957; LINE-HEIGHT: 115%; mso-ansi-language: EN-US"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_4_ScreenCapture5.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Simron noted that 
looking at the results Sandostatin LAR is widely used followed by lanreotide, 
whilst there is not too much usage of antidiarrhoeals.<wbr> The majority he concluded 
would use a SSA.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Simron’s 
next question was “Can one realistically expect a SSA to control tumour 
growth”</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_5_ScreenCapture6.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">He noted 
that the “Vast majority believe yes we can expect SSA to control tumour growth” 
He asked Nick Pavlakis to comment further.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Nick - “This 
demonstrates that people are well aware of the landmark studies that have been 
undertaken in this disease setting….<wbr>.<wbr> beginning with the Promid study in mid-gut 
NET; quite a small study in terms of sample size but one that showed significant 
reduction in tumour progression then the CLARINET study undertaken in a broader 
patient population that has demonstrated a similar degree of efficacy in mid-gut 
and now pancreatic NET.<wbr>”</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"> “What we have learnt” he continued, “is 
that these long-acting SSAs can produce symptomatic improvement but also have a 
disease modifying effect in terms of delaying tumour 
progression.<wbr>”</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Simron “It 
then comes down to a question of how to choose between octreotide and 
lanreotide, a difficult question? Marianne how do you approach this issue?” 
</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Marrianne “I 
think it is a drug a class effect.<wbr>  
We should consider both drugs equally effective with respect to symptom 
and tumour control.<wbr> Its rather a question of where the drug is available.<wbr> 
Lanreotide is not yet available for symptom control in the US.<wbr> Octreotide was 
introduced in the mid-80s lanreotide in the mid-90s starting in France and then 
accessible in other countries.<wbr> Otherwise when it comes to choice I would not 
consider any difference between the two drugs” </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Simron then 
changed the focus to pNET posing another question for the audience.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_6_ScreenCapture7.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Simron “So 
we have diverse opinion.<wbr> Many start with SSAs, although we do have a 
considerable no who would use everolimus and others liver-directed therapy and a 
smaller amount sunitinib or starting with PRRT.<wbr>  Everybody appears to be doing something 
different.<wbr> What does the panel think of these results? It seems like everybody 
is doing something different.<wbr>” </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">“Marianne 
are you surprised that so many would consider using SSAs 
first.<wbr>”</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Marianne – 
“If you consider our European NET Society guidelines, at least if it is 
progressive disease at onset or a patient has tumour progression systemic 
chemotherapy is recommended as first line therapy; so I am surprised a minority 
have chosen this option.<wbr> On the other hand, the Ki-67 is 5% and we have the 
CLARINET data, indeed now evidenced based level information, suggesting an SSA 
is effective in this type of patient so  why not start treatment with an SSA 
analogue and if patient is progressive within 3 months then switch to another 
treatment.<wbr> So I would consider both options but with a Ki-67 of 5% I feel 
absolutely comfortable to start with a SSA based on recent results from the 
CLARINET data.<wbr>”</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_7_ScreenCapture8.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Simron “So 
what this reflects especially with pNETs is we have a diverse no of options to 
choose from.<wbr> How best we choose Rachel would you like to review for us the 
different options available?”</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Rachel  “The variety of answers reflects how 
difficult it is to choose what to do.<wbr> We don’t know what the best sequence is.<wbr> 
There are many different options.<wbr> If a patient has predominantly liver disease 
loco-regional therapy can be something we start with particularly for well 
differentiated tumours.<wbr> Also surgery if a patient is resectable combined with 
RFA.<wbr> For patients who are not resectable closed RFA is an option.<wbr> If a patient 
has more bulky disease then embolization with or without chemotherapy is 
considered.<wbr> In some institutions where it is available radioembolisation is also 
an option.<wbr> Patients who progress after local regional therapy and have 
widespread disease you want to start with a systemic treatment and again you 
have many options going from the SS analogues for functioning and 
non-functioning disease to drugs like everolimus and sunitinib which are both 
approved for pNET.<wbr> Chemotherapy has been shown in phII studies in retrospective 
series to be consistently effective, with response rates ranging from  30-60%.<wbr> The mostly widely used 
chemotherapy schedules include streptozocin or capecitabine based regimens and 
PPRT is also something that can be considered in pNETS.<wbr> There are a very large 
no of options and it is very difficult to select the 
sequencing”.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Question 
from the audience about treating a patient with significant weight 
loss</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Nick 
Pavlakis “Weight loss probably suggests a higher burden disease.<wbr> You need to 
assess where is the burden of the disease and use this to guide therapy before 
you treat.<wbr> SSAs can be used to prevent progression but if you want tumour 
reduction you are going to have to consider chemotherapy or if the burden of the 
disease is in the liver then liver- directed therapy should be considered as an 
option”</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Question 
from the audience “Is the CLARINET data enough to treat pNET patients with SSA 
analogues” </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Nick 
Pavlakis “The CLARINET trial was an extremely well conducted trial, the largest 
of two trials undertaken with SSAs in GEPNET patients.<wbr> pNET patients represented 
a significant sub-population and the evidence stands for itself there was a 
demonstrated reduction in the risk of progression shown with treatment.<wbr> 
Therefore it is a reasonable therapy to choose from the perspective of delaying 
tumour progression.<wbr> The issue is if you want to do two things both delay tumour 
progression but also reduce bulky disease in a patient with significant burden 
of disease.<wbr> In this instance you may have to look at other 
options.<wbr>”</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Simron “So 
we talked a little about SSAs and pNET Marianne can you talk to us a little bit 
about everolimus and suntinib”</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Marianne “We 
have two large trials undertaken with these agents.<wbr> You rarely see tumour 
shrinkage but do see prolongation of PFS.<wbr> In the everolimus trial the difference 
in PFS was 6.<wbr>4 months, however some patients may not progress for years.<wbr> The 
sunitinib trial was smaller (n=170 pts) but similar results were seen again 6 
month prolongation of PFS.<wbr> If you look at both trials together you see that in a 
 sub-set of patients SSAs were 
concomitantly applied 30% sunitinib trial 40% everolimius trial.<wbr> In these 
studies you note that objective remission rate is low so this is also something 
I would consider if I have a patient with bulky disease I would downstage the 
disease with chemotherapy first.<wbr> If there is mild or moderate tumour burden then 
we are happy also with prolongation of survival.<wbr>  So sequencing of therapies may also 
translate to an improvement in overall survival in an individual patient.<wbr>  Based on the CLARINET study you would 
rather tend to continue SSA treatment.<wbr> Even in the NETTER study patients will 
continue on SSA treatment whilst on PRRT.<wbr> However, for cost reasons it is 
important to rule out the add-on value of SSAs.<wbr> For this purpose another study 
has been done.<wbr> The Co-operate II study.<wbr> Don’t have the results yet.<wbr> It is a 
comparative study evaluating everolimus plus pasireotide will look at the 
efficacy of combination vs.<wbr> monotherapy in pNET patients.<wbr> This will be only 
study that will provide evidence about the add-on value of SSA to a targeted 
drug in the management of pNET“</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_8_ScreenCapture9.jpg"> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_9_ScreenCapture10.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Simron “We 
definitely have a diverse opinion again about one third would choose dose 
escalation 5% switching to another SSA and a significant proportion of the 
audience choosing everolimus or PRRT a few.<wbr> Quite a few have chosen dose 
escalation.<wbr> Rachel is this something you would consider 
doing?”</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Rachel “Yes 
there is no prospective data on that but it is something we use.<wbr> A recent 
publication on 300 NET patients from the Moffitt Institution in the US looked at 
the benefit of dose escalation and there was a benefit in increasing the does in 
terms of both tumour and symptom control.<wbr> It is not Level 1 evidence but we do 
at least have some supportive data in the literature that it works and we see 
this in the clinic and I personally do this.<wbr>”</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'">Marianne 
“Yes we sometimes also do this shortening injection interval duration to 3 weeks 
for example…… We need to do a study looking at this.<wbr> The Netter study will help 
provide some data on PFS with high dose.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_10_ScreenCapture11.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_11_ScreenCapture12.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_12_ScreenCapture13.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_13_ScreenCapture14.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_14_ScreenCapture15.jpg"></SPAN> </div><div><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_15_ScreenCapture16.jpg"></SPAN> </div><!-- Comment details --><a name="endocrinology7617attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(136 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(49,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_3_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(61,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_4_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(42,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_5_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(39,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_6_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(51,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_7_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(54,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_8_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(77,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_9_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(49,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_10_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(55,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_11_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(69,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_12_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(48,2 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_13_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(48 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_14_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(59,3 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7617_15_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(67,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7617">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-18T14:30:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-18T14:30:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Head of Emerging Market Appointed at Takeda</title>
	<pubDate>2014-03-18T11:57:18+01:00</pubDate>
	<wp:post_id>5040</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Giles Platford has been appointed Head of Commercial Operation, Emerging Markets reporting to Ch.<wbr> Weber (COO).<wbr> Takeda recently reported it plans to increase its sales in emerging market to &gt;2,000 billion yen (27%) from 1,680 billion yen (19%) in 2013.<wbr> According to IMS, emerging markets are expected to contribute 70% of total global pharmaceutical market growth between 2013 and 2017<EM>.<wbr></EM> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Globalization is one of the core principles of Takeda's mid-range growth strategy.<wbr> </div><div style="margin-bottom: 10px;"><U>Product Portfolio Tailored to Local Needs</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10782_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In this role he will be responsible for leading the continued expansion of Takeda's commercial activities in this region, which comprises Russia-CIS, Latin America, Middle East/<wbr>Africa and South Asia.<wbr> </div><div style="margin-bottom: 10px;">A UK national, Platford has been with Takeda since 2009.<wbr> </div><div>Most recently, he served as Head of the Middle East, Turkey, Africa (META) region where he restructured the business, generating 60% of growth versus previous year in the first three quarters of the fiscal year.<wbr> Prior to this, Platford was General Manager of Takeda Brazil, where he led the successful acquisition of Multilab, a mid-sized company focused on branded generics and over-the-counter (OTC) products, positioning Takeda as one of the top 10 pharmaceutical groups in Brazil.<wbr> He previously spent eight years in the pharmaceutical industry in Asia Pacific, assuming various Business Development, Commercial and General Management roles.<wbr> </div><!-- Comment details --><a name="pharmaworld10782attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10782_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(98,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10782">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-18T11:57:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-18T11:57:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ferring Reinforces Committment in the Gastro Field</title>
	<pubDate>2014-03-18T11:21:51+01:00</pubDate>
	<wp:post_id>5041</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: TxCell SA, a French biotech developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, has granted Ferring an option to acquire an exclusive WW license for the development, manufacture and marketing of Ovasave<STRONG>®</STRONG> (Ph2 planned H2:14) for IBD, including Crohn's Disease(CD) and Ulcerative Colitis (UC).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">TxCell will receive EUR 3 million for the acquisition of the option by Ferring, of which EUR 1 million was paid upon signature of the agreement and the remainder will be paid depending on the progress of the Ovasave phase IIb trial planned to start in the second half of 2014.<wbr> </div><div style="margin-bottom: 10px;">TxCell will also be eligible in the future in the event of the exercise of the option to development, commercial and manufacturing milestones and payments up to a total of EUR 73 million.<wbr> </div><div style="margin-bottom: 10px;">TxCell will also receive tiered royalties up to double digits on future sales of Ovasave<STRONG>®</STRONG>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: justify">Ovasave<SUP>®</SUP> is classified as Advanced Therapy Medicinal Product (ATMP) by the EMA.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: justify">The first in man phase I/<wbr>IIa study, CATS 1, was an open label, 12 weeks multicenter clinical trial, assessing the tolerability and exploring the efficacy of escalating and multiple doses of Ovasave<STRONG>®</STRONG> in patients with active moderate to severe refractory Crohn's Disease.<wbr> Several eligible patients in CATS1 also received additional injections at the best responding dose.<wbr><BR><BR></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: justify">CATS1 study has been completed on Q3 2011 and final results have been presented at major international medical conferences, published in <EM>Gastroenterology</EM> and reviewed in <EM>Nature</EM>.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-ALIGN: justify"><SPAN style="TEXT-DECORATION: underline">The key findings are</SPAN>:</P> </div><div><UL><LI>Ovasave<SUP><SPAN style="FONT-WEIGHT: bold"><SPAN style="FONT-WEIGHT: bold">®</SPAN></SPAN></SUP> is well tolerated.<wbr></LI>
<LI>The positive effect of Ovasave<SUP><SPAN style="FONT-WEIGHT: bold"><SPAN style="FONT-WEIGHT: bold">®</SPAN></SPAN></SUP> was particularly relevant in the best dose group with 75% of patients responding and 38% remitting five weeks after treatment.<wbr></LI>
</UL> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2148c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">TxCell SA just announced the enrollment and dosing of the first patient in the Ph2b clinical study.<wbr><STRONG> </STRONG>Ovasave® (<SPAN style="COLOR: #000000">ovalbumin-specific autologous Treg cells)</SPAN><STRONG> </STRONG>is currently approved for study in 6 EU countries, with preliminary results expected by the end of 2016 to early 2017.<wbr> Previously completed studies on Ovasave® demonstrated a favorable tolerance profile and treatment response in 75% of patients, with 38% achieving remission after 5 weeks of treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About Ph2b study</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000">Lead investigator: Dr.<wbr> Severine Vermeire, Professor of Gastroenterology at the University Hospital Leuven</SPAN> </div><div style="margin-bottom: 10px;">Reference: CATS29 </div><div style="margin-bottom: 10px;">Location: 32 study sites across <SPAN style="COLOR: #000000">Austria, Belgium, France, Germany, Italy and the United Kingdom</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="COLOR: #000000">Recruitment: approx.<wbr> 160 patients with severe refractory Crohn’s disease.<wbr> </SPAN> </div><div style="margin-bottom: 10px;">Design: multicentre, randomised, double-blinded, placebo-controlled, multi-dose and multi-injection, 4 parallel groups study.<wbr> </div><div style="margin-bottom: 10px;">Objectives: to evaluate the efficacy and the safety of Ovasave (ovalbumin-specific autologous Treg cells (Ova-Treg)) in patients with active refractory Crohn’s disease.<wbr> <SPAN style="COLOR: #000000">CATS29 will be evaluating treatment response rate for one intravenous dose of 1.<wbr>10(6) cells of Ovasave, compared to a placebo 6 weeks following treatment.<wbr> Response rate will be measured according to a decrease of at least 100 points in the Crohn’s Disease Activity Index (CDAI).<wbr></SPAN> </div><div style="margin-bottom: 10px;">Dosing/<wbr>Regimen: Patients will receive, double-blinded, two intravenous (iv) injections 8 weeks apart of either 1.<wbr>10(4), 1.<wbr>10(6), or 1.<wbr>10(7) cells of Ovasave or placebo.<wbr> Patients will then receive either an open-label treatment with 2 additional iv injections of 1.<wbr>10(6) cells of Ovasave or a safety follow-up with no injection.<wbr> </div><div style="margin-bottom: 10px;">Finally, there will be an extended safety follow-up for all patients.<wbr> </div><div><EM>Source: TxCell PR</EM> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1943">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-18T11:21:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-18T11:21:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PC Data of Deciphera's Drugs Shows Potent Inhibition of Tumor Microenvironment Mechanisms</title>
	<pubDate>2014-03-18T11:09:03+01:00</pubDate>
	<wp:post_id>5042</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has presented PC data on 2 key drugs at AACR Conference (Feb.<wbr>26-March 1, 2014 in San Diego).<wbr> An oral presentation which disclosed PC data of rebastinib, a TIE2 kinase inhibitor currently in Ph1, potently inhibits tumor microenvironment mechanisms mediated by TIE2 kinase expressing macrophages.<wbr> In addition a poster was presented on DCC-3014, a highly selective inhibitor of FMS kinase, expressed in tumor-promoting macrophages in the cancer microenvironment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Rebastinib</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9545_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Preclinical Data</U> </div><div style="margin-bottom: 10px;">Rebastinib potently inhibited TIE2 kinase in cellular assays and blocked primary tumor growth by 75% as a single agent and by 90% in combination with the standard chemotherapeutic agent paclitaxel in the PyMT mouse breast cancer model.<wbr> Furthermore, rebastinib therapy significantly reduced the presence of tumor-promoting macrophages in tumor biopsies by 80%.<wbr> This blockade of tumor macrophages correlated with almost complete inhibition of breast cancer lung metastases.<wbr> In combination with the approved agent eribulin, rebastinib significantly prolonged survival in the PyMT breast cancer model (median survival &gt; 200 days) compared to single agent eribulin therapy (median survival 54 days).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>DCC-3014</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9545_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><U>Preclinical Data</U> </div><div><DIV class="section">
<DIV class="region region-content">
<DIV class="block block-system first last odd" id="block-system-main">
<DIV class="content">
<DIV class="node node-article view-mode-full clearfix" id="node-101">
<DIV class="content">
<DIV class="field field-name-body field-type-text-with-summary field-label-hidden">
<DIV class="field-items">
<DIV class="field-item even">
<P>In a broad screen of 300 kinases, DCC-3014 only potently inhibited FMS kinase, while not inhibiting even closely related kinases FLT-3, KIT, and PDGFR.<wbr> DCC-3014 exhibited profound inhibition of FMS in a pharmacodynamic model, effectively blocking FMS kinase in vivo for over 24 hours after a single dose.<wbr> In a prostate cancer model of bone invasion, treatment with DCC-3014 significantly reduced invasion of long bones by the tumor.<wbr> Such bone protection was shown mechanistically to correlate with inhibition of macrophages and bone-destroying osteoclasts in the bone tumor microenvironment.<wbr></P>
<P><EM>Source: Deciphera</EM></P></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV></DIV> </div><!-- Comment details --><a name="oncology9545attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9545_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9545_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(39,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9545">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-18T11:09:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-18T11:09:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Immunotherapy Still Considered As Challenging For Prostate Cancer</title>
	<pubDate>2014-03-18T08:46:45+01:00</pubDate>
	<wp:post_id>5043</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: At the recent Interdisciplinary Prostate Cancer Congress held last 
week in New York, Dr Robert Dreicer (Cleveland Clinic's Taussig Cancer 
Institute) delivered an interesting talk on Immunotherapies in prostate cancer 
suggesting that their use in this condition remains challenging.<wbr> </div><div style="margin-bottom: 10px;">Below is an extract from his talk:- </div><div style="margin-bottom: 10px;">Whilst approved immunotherapy sipuleucel-T (Provenge) improved overall 
survival (OS) for patients with prostate cancer in a phase III 
trial,<SUP>2</SUP> it is still finding its place in the arsenal of drugs used to 
treat the disease, and other immunotherapies tested in prostate cancer have been 
associated with some drawbacks, according to Dreicer.<wbr> </div><div style="margin-bottom: 10px;">“It gets to be a 
challenge to use a therapy that, from a mechanistic perspective, leaves you with 
less insight, and that has limited some of what we have done,” said Dreicer 
regarding combining sipuleucel-T with various targeted 
therapies.<wbr> </div><div style="margin-bottom: 10px;">Dreicer, chair of the Department of Solid Tumor Oncology at 
the Cleveland Clinic’s Taussig Cancer Institute and professor at the Lerner 
College of Medicine, presented an evolution of evidence for immunotherapies in 
prostate cancer, beginning with granuloctye macrophage colony-stimulating factor 
(GM-CSF), which is used in the development of sipuleucel-T and has been 
extensively studied in the disease.<wbr><SUP>3</SUP> </div><div style="margin-bottom: 10px;">In 2010, he said, the 
groundbreaking IMPACT trial<SUP>2</SUP> showed an increase in the probability of 
survival with sipuleucel-T, compared with placebo, in patients with metastatic 
CRPC who were asymptomatic or minimally symptomatic.<wbr> </div><div style="margin-bottom: 10px;">Dreicer reviewed 
data from a retrospective analysis of subsets within the IMPACT 
trial,<SUP>4</SUP> which showed that patients with PSA levels ≤22.<wbr>1 ng/<wbr>mL had a 
median OS of 41.<wbr>3 months compared with 28.<wbr>3 months for placebo.<wbr> In patients 
whose PSA was &gt;22.<wbr>1 to 50.<wbr>1 ng/<wbr>mL, OS was 27.<wbr>1 and 20.<wbr>1 months, respectively; 
in men with PSA levels &gt;50.<wbr>1 to 134.<wbr>1, OS was 20.<wbr>4 and 15 months, 
respectively; and in the subset of patients with PSAs &gt;134 ng/<wbr>mL, OS was 18.<wbr>4 
and 15.<wbr>6 months, respectively.<wbr> </div><div style="margin-bottom: 10px;">“What this basically tells us is that if 
you are going to use an immune-based therapy, using it very early in the 
clinical course—early meaning castrate, metastatic, asymptomatic, without a 
crescendo of disease that is about to explode—is the ultimate [setting for] a 
therapy like this,” he said.<wbr> </div><div style="margin-bottom: 10px;">While results from the IMPACT trial 
brought forth hope for these patients with what Dreicer deemed the 
“unprecedented development and integration of a novel therapy,” the findings did 
not come without challenges.<wbr> Despite its demonstrated impact on OS, sipuleucel-T 
is not a replacement for treatments designed to induce an objective anti-tumor 
response in real time, and it has not been shown to improve progression-free 
survival (PFS), according to Dreicer.<wbr> He added that access and cost continue to 
pose problems.<wbr> </div><div style="margin-bottom: 10px;">Dreicer mentioned that many of his patients with prostate 
cancer are also reluctant to put forth the time and effort for this treatment, 
which is infused in three doses at intervals of 2 weeks, each administered after 
cell collection (leukapheresis or apheresis).<wbr> “Men make treatment decisions much 
differently than women,” he said, mentioning that women are more likely to 
invest additional time in their own healthcare.<wbr> </div><div style="margin-bottom: 10px;">Due to all those factors, 
“It is not surprising that its uptake has been a little bit challenging,” 
Dreicer said of sipuleucel-T.<wbr>  But he stressed that the drug is part of a 
therapeutic paradigm in which multiple agents are used.<wbr> “You layer this therapy 
on; it’s not an end all and be all,” he said.<wbr> “Understanding that this therapy, 
when falling in the right place, may increase utility, is 
important.<wbr>” </div><div style="margin-bottom: 10px;">Fellow IPCC faculty member Daniel P.<wbr> Petrylak, MD, agreed 
that sipuleucel-T is an active agent for prostate cancer, especially when used 
early on.<wbr> He acknowledged that cost remains a challenge, but sees a future where 
this might change.<wbr> </div><div style="margin-bottom: 10px;">“I think that cost is certainly an issue, but also 
innovation helps to drop cost over time.<wbr> When you are looking at the overall 
costs, you have to think about what’s being returned: People are able to spend 
more time with their families; people are able to do other things, just 
surviving, that are hard to put a price tag on,” said Petrylak, professor of 
Medicine and Medical Oncology and director of Prostate and Genitourinary Medical 
Oncology at Yale Cancer Center in New Haven, Connecticut.<wbr> “So I think that, over 
time, some of these treatments, with competition, with further innovation, may 
find that production drops in price.<wbr> But I think one thing that we have to be 
careful of is not to throw the baby out with the bathwater, and make sure that 
we continue to innovate.<wbr>” </div><div style="margin-bottom: 10px;">Dreicer also discussed PROSTVAC, an 
immunotherapeutic vaccine in phase III trials.<wbr><SUP>3</SUP> “The NCI has been 
trying for a long time to figure out the optimal combination of stimulatory 
molecules and co-stimulatory molecules,” Dreicer said.<wbr> The phase III, three-arm 
PROSPECT trial is comparing PROSTVAC-VF combined with GM-CSF (n = 400) against 
PROSTVAC-VF (n = 400), and also against placebo (n = 400) in patients with 
asymptomatic or minimally symptomatic CRPC.<wbr> The trial includes a 5-month 
treatment phase, after which other therapies are left to the discretion of 
individual investigators.<wbr> This is an open and active ongoing multinational 
randomized trial with long-term follow-up every 6 months for 5 
years.<wbr> </div><div style="margin-bottom: 10px;">Dreicer expressed concern, however, about whether or not there 
ultimately will be a place for this therapy in practice.<wbr> </div><div style="margin-bottom: 10px;">“I am not sure 
the therapeutic paradigm 5 years from now would need another agent that might 
have similar activity to sipuleucel-T,” he said, mentioning that this is often a 
challenge for drugs that are in clinical trials for long periods of time.<wbr> </div><div style="margin-bottom: 10px;">Next-generation immunotherapeutics, such as checkpoint inhibitors 
that seem to be showing promise in other types of cancer, have faced problems 
with low efficacy and high toxicity when studied in patients with prostate 
cancer, according to Dreicer.<wbr> There is currently limited data for PD-1 and PD-L1 
in prostate cancer, and these inhibitors have shown limited activity in patients 
with prostate cancer to date.<wbr> </div><div style="margin-bottom: 10px;">Ipilimumab, approved for the treatment of 
melanoma, was studied in a randomized, double-blind, phase III trial<SUP>5</SUP> 
that compared the drug with placebo following radiotherapy in patients with CRPC 
who had received prior treatment with docetaxel.<wbr> In the intent-to-treat analysis 
(N = 799), the hazard ratio (HR) for OS, although not statistically significant, 
favored ipilimumab (HR = 0.<wbr>85; 95% CI = 0.<wbr>72-1.<wbr>00; <EM>P</EM> = .<wbr>053) and median 
OS for ipilimumab was 11.<wbr>2 months (95% CI = 9.<wbr>5-12.<wbr>7) compared with 10.<wbr>0 months 
(95% CI = 8.<wbr>3-11.<wbr>0) for placebo.<wbr> Median PFS also favored ipilimumab over placebo 
(HR = 0.<wbr>70; 95% CI = 0.<wbr>61-0.<wbr>82), as did PSA declines of ≥50% in evaluable 
patients (13.<wbr>1% vs 5.<wbr>3%, respectively).<wbr> </div><div style="margin-bottom: 10px;">Dreicer noted that ipilimumab has 
overt anti-tumor activity.<wbr> “You will see biochemical soft-tissue responses in 
some patients,” he said.<wbr> However, he cautioned that “Ipilimumab is a different 
type of immunomodulatory therapy than sipuleucel-T.<wbr> Ipilimumab has toxicity.<wbr> In 
many instances, it can actually be surprisingly toxic in some 
patients.<wbr>” </div><div style="margin-bottom: 10px;">Dreicer concluded by stating that low toxicity is important 
with immunotherapy because, in order for the treatment of CRPC to move forward, 
multiple targets will need to be hit at the same time with different agents, 
including immunotherapies.<wbr> Community oncologists already have several therapies 
on hand that can achieve that effect, he added.<wbr> </div><div style="margin-bottom: 10px;">“When you talk about this 
complex disease stratum that we have, one of the things that I would make people 
believe is that, in order to make progress in a disease in which resistance 
develops with many of its therapies, we need to hit multiple targets,” he 
said.<wbr> </div><div>Source: <A href="http://www.oncolive.com">www.<wbr>oncolive.<wbr>com</A><BR>- </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9544">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-18T08:46:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-18T08:46:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>CV9103's Efficacy Data in mCRPC Presented in ECCO-ImmunoTherapy of Cancer (ITOC) Conference</title>
	<pubDate>2014-03-17T18:00:33+01:00</pubDate>
	<wp:post_id>5044</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">First Results with a mRNA Vaccine in Patients with HRPC</span>&nbsp;<br><span style="font-size: 12px;">Comment: The results from a Ph1/<wbr>2a study suggest that CureVac's CV9103 is safe, well tolerated and biologically active.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=6783">...</a><br></div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;"><SPAN style="font-size: small;">Comment: CureVac has two leading RNA vaccines currently being investigated in Phase 1/<wbr>2 trials - CV9103 (Prostate Cancer) and CV9201 (NSCLC</SPAN>).<wbr> <SPAN style="font-size: small;">The data was presented in the plenary session (led by Jim Alison and Stephen Endres) by Karl-Josef Kallen (CureVac GmbH; Tubingen, Germany).<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: medium; font-family: times new roman,times;"><SPAN style="font-variant: normal; white-space: normal; word-spacing: 0px; text-transform: none; float: none; font-weight: normal; color: #000000; font-style: normal; display: inline !important; letter-spacing: normal; line-height: 32px; background-color: #ffffff; text-indent: 0px; -webkit-text-stroke-width: 0px;">CureVac developed a novel immunization technology, RNActive</SPAN><SUP style="vertical-align: baseline; white-space: normal; word-spacing: 0px; position: relative; text-transform: none; color: #000000; font: 14px/0 Georgia, 'Times New Roman', Times, serif; letter-spacing: normal; top: -0.5em; background-color: #ffffff; text-indent: 0px; -webkit-text-stroke-width: 0px;">&reg;</SUP><SPAN style="font-variant: normal; white-space: normal; word-spacing: 0px; text-transform: none; float: none; font-weight: normal; color: #000000; font-style: normal; display: inline !important; letter-spacing: normal; line-height: 32px; background-color: #ffffff; text-indent: 0px; -webkit-text-stroke-width: 0px;"> vaccines, that have two important characteristics: 1) mRNA based vaccine 2) activation of toll-like receptor (TLR) 7.<wbr> </SPAN></SPAN><SPAN style="font-size: medium; font-family: times new roman,times;"><SPAN style="font-variant: normal; white-space: normal; word-spacing: 0px; text-transform: none; float: none; font-weight: normal; color: #000000; font-style: normal; display: inline !important; letter-spacing: normal; line-height: 32px; background-color: #ffffff; text-indent: 0px; -webkit-text-stroke-width: 0px;">It was previously reported that it is safe and well tolerated (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=6783&brief=n&rsin=/link%20Oncology6783%20%27*%27" class="defaultlink">Oncology6783: First Results with a mRNA Vaccine in Patients with HRPC</a>).<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: medium; font-family: times new roman,times;"><SPAN style="font-variant: normal; white-space: normal; word-spacing: 0px; text-transform: none; float: none; font-weight: normal; color: #000000; font-style: normal; display: inline !important; letter-spacing: normal; line-height: 32px; background-color: #ffffff; text-indent: 0px; -webkit-text-stroke-width: 0px;">The preliminary survival data was reported in this year ITOC - an estimated of 31.<wbr>4 months median survival with metastatic CRPC.<wbr> Strong Immune responders are associated with longer survival outcome.<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: arial,helvetica,sans-serif;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_1_20140313%255f154636%255fresized.jpg"></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_6_20140313%255f155015%255fresized.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_9_20140313%255f155201%255fresized.jpg"> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: medium; font-family: times new roman,times;">Kallen acknowledged that no conclusion could be drawn from indirect comparison of survival benefit between different therapeutic vaccines from different trials.<wbr> The preliminary mOS data suggests favourable survival benefit from CV9103.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_8_20140313%255f155102%255fresized.jpg"> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: medium; font-family: times new roman,times;">Currently, there is an ongoing Phase IIb study with CV9104 for chemo na&iuml;ve mCRPC patients in 8 European countries</SPAN>.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_12_20140313%255f155323%255fresized.jpg"> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_13_20140313%255f155404%255fresized.jpg"> </div><!-- Comment details --><br><a name="oncology9539attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_1_20140313%255f154636%255fresized.jpg">20140313_154636_resized.jpg</a>&nbsp;&nbsp;(319 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_2_20140313%255f154824%255fresized.jpg">20140313_154824_resized.jpg</a>&nbsp;&nbsp;(306,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_3_20140313%255f154824%255fresized.jpg">20140313_154824_resized.jpg</a>&nbsp;&nbsp;(306,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_4_20140313%255f154931%255fresized.jpg">20140313_154931_resized.jpg</a>&nbsp;&nbsp;(304,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_5_20140313%255f154954%255fresized.jpg">20140313_154954_resized.jpg</a>&nbsp;&nbsp;(293,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_6_20140313%255f155015%255fresized.jpg">20140313_155015_resized.jpg</a>&nbsp;&nbsp;(288,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_7_20140313%255f155015%255fresized.jpg">20140313_155015_resized.jpg</a>&nbsp;&nbsp;(288,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_8_20140313%255f155102%255fresized.jpg">20140313_155102_resized.jpg</a>&nbsp;&nbsp;(302,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_9_20140313%255f155201%255fresized.jpg">20140313_155201_resized.jpg</a>&nbsp;&nbsp;(280,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_10_20140313%255f155233%255fresized.jpg">20140313_155233_resized.jpg</a>&nbsp;&nbsp;(267,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_11_20140313%255f155254%255fresized.jpg">20140313_155254_resized.jpg</a>&nbsp;&nbsp;(313,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_12_20140313%255f155323%255fresized.jpg">20140313_155323_resized.jpg</a>&nbsp;&nbsp;(317,4 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9539_13_20140313%255f155404%255fresized.jpg">20140313_155404_resized.jpg</a>&nbsp;&nbsp;(282 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9539">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology6783">View thread  Oncology6783: First Results with a mRNA Vaccine in Patients with HRPC</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-17T18:00:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-17T18:00:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BMS Inks Agreement to Discover Novel Immuno-Oncology Therapies</title>
	<pubDate>2014-03-17T17:42:36+01:00</pubDate>
	<wp:post_id>5045</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BMS have signed a collaboration agreement for the discovery, development and commercialization of immuno-oncology (IO) therapies directed toward targets identified in 2 undisclosed immune checkpoint pathways using Five Prime’s proprietary target discovery platform.<wbr> Drug candidates developed against these new and existing targets may be studied either as single agents or in combination with existing or potential Bristol-Myers Squibb IO therapies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">BMS will make an upfront payment of $20M, provide up to $9.<wbr>5M in research funding, and pay ~$21M to acquire 4.<wbr>9% of Five Prime’s common stock, a 30% premium.<wbr> </div><div style="margin-bottom: 10px;">Five Prime will also be eligible to receive up to $300M in milestone payments, and tiered mid-single digit rising to low-double-digit royalty payments on net sales of products commercialized by BMS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The agreement increases BMS's options in a segmented market, with different IO combinations probably showing activity in different tumor types and with anti-PD1s likely emerging as backbone therapy.<wbr> </div><div style="margin-bottom: 10px;">Moreover, given the potential size of the IO market, estimated at least $30 billion by 2023, the financials of the deal seem favorable for BMS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.fiveprime.com/">http:/<wbr>/<wbr>www.<wbr>fiveprime.<wbr>com/<wbr></A> </div><div style="margin-bottom: 10px;"><STRONG>Pipeline</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9535_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology9535attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9535_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(40,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9535">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-17T17:42:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-17T17:42:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Green Light Given to Repros for Starting Low Dose Trial of Proellex</title>
	<pubDate>2014-03-17T16:34:22+01:00</pubDate>
	<wp:post_id>5046</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Repros may proceed to conduct Ph1 and 2 studies of oral Proellex<SUP id="yui_3_9_1_1_1395070084006_1166">(R)</SUP> under 2 separate INDs for endometriosis and uterine fibroids (UF), while remaining on partial clinical hold.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The FDA guidance provides that the highest allowed dose will be 12 mg daily.<wbr> </div><div style="margin-bottom: 10px;">For the uterine fibroid Ph2 protocol, the FDA provided guidance as to the appropriate inclusion and exclusion criteria for study subjects as well as the preferred efficacy endpoint.<wbr> </div><div style="margin-bottom: 10px;">The FDA preferred efficacy endpoint is reduction in excessive menstrual bleeding associated with uterine fibroids.<wbr> </div><div style="margin-bottom: 10px;">The FDA also noted the preferred methodology to determine changes in bleeding.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Given the prior experience with Proellex at 6 and 12 mg daily dosages, Repros plans to enroll fewer than 75 women in a three arm, parallel design double blind trial.<wbr> The study is sized to provide greater than 90% power in demonstrating efficacy associated with reducing subject bleeding.<wbr> </div><div><EM>Source: Repros</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9533">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-17T16:34:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-17T16:34:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>CytRx to Develop Novel Albumin-binding Anti-cancer Pipeline</title>
	<pubDate>2014-03-17T14:05:52+01:00</pubDate>
	<wp:post_id>5047</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has appointed Dr F.<wbr> Kratz as VP of Drug Discovery and Dr A.<wbr> Warnecke as Senior Director of Drug Discovery to develop next generation therapeutics based on clinical results shown by aldoxorubicin, a tumor-targeted doxorubicin conjugate.<wbr> CytRx is currently conducting a Ph2 trial evaluating aldoxorubicin in patients with late-stage glioblastoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9531_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Potential Catalysts</STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Dr.<wbr> Kratz</STRONG>, one of the most highly regarded conjugation chemists in oncology, joins <ORG value="NASDAQ-SMALL:CYTR">CytRx</ORG> with 25 years of experience in drug discovery and research.<wbr> Dr.<wbr> Kratz’s research includes the development of novel, targeted molecules for cancer therapies, with a special emphasis on the use of albumin as a targeting agent.<wbr> His research in preclinical and early clinical development of these therapies has led to the creation of a number of new cancer-fighting agents that use albumin to concentrate chemotherapeutics inside cancers, including the invention of CytRx’s lead compound, aldoxorubicin.<wbr> Dr.<wbr> Kratz has been at the forefront of designing novel agents, using various linker chemistries to create a variety of protein-drug conjugates.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Dr.<wbr> Warnecke</STRONG> comes to <ORG value="NASDAQ-SMALL:CYTR">CytRx</ORG> with 16 years of experience in chemistry research, including the development of chemical architectures for innovative drug release mechanisms and albumin conjugates of anti-cancer agents.<wbr> </div><div><EM>Source: CytRx</EM> </div><!-- Comment details --><a name="oncology9531attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9531_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(124,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9531_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(87,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9531_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(102,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9531">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-17T14:05:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-17T14:05:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Soft Intelligence - Ferring Moves One Step Further with CV Benefits of Firmagon</title>
	<pubDate>2014-03-17T13:49:24+01:00</pubDate>
	<wp:post_id>5048</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Stefan Pfeifer (BU Director Urology in Germany) we have learnt that Ferring has planned to invite doctors to an advisory boards in Q:2.<wbr> According to a local source Ferring wants to have one urologist per practice - if more want to come they will accomodate them all as paid consultants.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">This 'CV benefits of Firmagon' message has already been conveyed by Ferring in Belux (where the company has a strong KOL involvement/<wbr>support), Ireland, Romania and the UK.<wbr> </div><div style="margin-bottom: 10px;">However, this German initiative is the first that we are aware of.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Intelligences Questions</STRONG> </div><div style="margin-bottom: 10px;">Is this initiative being conducted in your country ? </div><div style="margin-bottom: 10px;">How are competitors reacting ? Have they planned to counter Ferring's message ? </div><div>Any other information is very welcomed.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9529">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-17T13:49:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-17T13:49:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AVEO Has Reported Drug Strategy and Timelines for 2014 and Beyond</title>
	<pubDate>2014-03-17T11:05:16+01:00</pubDate>
	<wp:post_id>5049</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the financial results for 2013, the company indicated that it will regain rights to tivozanib from Astellas in Q3.<wbr> For 2014 and beyond, it will invest in the development of AV-380 (cancer cachexia), seek partners to advance the clinical development of AV-203, ficlatuzumab (nsclc), and tivozanib.<wbr> In parallel, management outlined it will continue to valuate additional strategic opportunities to access compounds with potential to further accelerate value creation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>AV-203</STRONG> </div><div style="margin-bottom: 10px;">Pursue external collaborations to advance clinical development, subject to our ability to regain certain rights from Biogen Idec.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Ficlatuzumab</STRONG> </div><div style="margin-bottom: 10px;">Evaluate external collaborations to advance clinical development.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Tivozanib</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Management believes this is 'an active VEGFR inhibitor, and look forward to getting a potential new partner to go through further clinical development'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>AV-380 (GDF-15 inhibitory Mab)</STRONG> </div><div style="margin-bottom: 10px;">Management estimates that 'In gastric and pancreatic cancer cachexia may be present in up to 80% of the patients".<wbr> </div><div style="margin-bottom: 10px;">According to Leerink analysts " .<wbr>.<wbr>.<wbr> There are a large number of agents (13 according to BioMedTracker) in Phase II or III clinical development for the treatment cachexia/<wbr>weight-loss, and with Phase I trials for AV-380 not starting until the 2H:15, AVEO could be a late-comer into the space, although its mechanism of action could be a differentiator".<wbr> </div><div style="margin-bottom: 10px;">2014 goals for the drug is: </div><div style="margin-bottom: 10px;"><UL><LI>to complete GMP manufacturing in Q3, </LI>
<LI>to conduct a pre-IND meeting to garner FDA feedback on POC dev plan in Q4, and</LI>
<LI>to file IND in H2:15</LI>
</UL> </div><div style="margin-bottom: 10px;">Partner is sought to explore potential indications beyonf cancer cachexia.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_5_ScreenCapture5.jpg"> </div><div>Source: AVEO </div><!-- Comment details --><a name="oncology9527attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(53,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(42,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(33,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(31,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(25,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9527_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(44,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9527">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-17T11:05:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-17T11:05:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Agios Reports Financial Results and Highlights Drug Progress</title>
	<pubDate>2014-03-14T15:31:24+01:00</pubDate>
	<wp:post_id>5050</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Agios has leveraged its core capabilities in cellular metabolism to build a product engine that is focused in the therapeutic areas of cancer and inborn errors of metabolism (IEMs).<wbr> The company scientists have discovered the altered metabolism associated with IDH1 mutations (found in 10-20% of cholangiocarcinoma), and have converted this discovery into potential drug candidates.<wbr> On March 6, alongside its financial results for 4Q:13 and FY13, management reported its intention to initiate Ph1 this year with AG-120, a potent IDH1 inhibitor.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7614_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7614_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7614_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Program</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="identifier">NCT02073994: <A href="http://clinicaltrials.gov/ct2/show/NCT02073994?term=cholangiocarcinoma&amp;recr=Open&amp;no_unk=Y&amp;phase=01234&amp;fund=2&amp;rank=6">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT02073994?term=cholangiocarcinoma&amp;recr=Open&amp;no_unk=Y&amp;phase=01234&amp;fund=2&amp;rank=6</A></DIV> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7614_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><B>Cash Position: </B>Cash, cash equivalents and marketable securities as of <CHRON>December 31, 2013</CHRON> were <MONEY>$193.<wbr>9 million</MONEY>, compared to <MONEY>$128.<wbr>0 million</MONEY> as of <CHRON>December 31, 2012</CHRON>.<wbr> The increase was primarily driven by net proceeds of <MONEY>$111.<wbr>0 million</MONEY> from Agios’ IPO and <MONEY>$12.<wbr>8 million</MONEY> from the concurrent private placement with <ORG>Celgene.<wbr></ORG> </div><div style="margin-bottom: 10px;"><B>R&amp;D Expenses:</B> Research and development expenses were <MONEY>$15.<wbr>3 million</MONEY> in the fourth quarter of 2013 and <MONEY>$54.<wbr>5 million</MONEY> for the year ended <CHRON>December 31, 2013</CHRON>, compared to <MONEY>$11.<wbr>2 million</MONEY> and <MONEY>$41.<wbr>0 million</MONEY> in the comparable periods in 2012.<wbr> The increase in R&amp;D expense was largely due to increased spending on clinical activities as AG-221 entered Phase 1 development in <CHRON>September 2013</CHRON>, and as the company prepares to begin clinical development of AG-120 in early 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>IDH1</STRONG>: 5 US pending patent applications for compositions of matter, methods of making and use for AG-120 • Related international and 4 pending PCT applications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- 2010 : Agios entered into a collaboration and license agreement with Celgene See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=6255" class="defaultlink">Oncology6255: Celgene Invests in Agios' Cancer Metabolism Platform</a>.<wbr> </div><div style="margin-bottom: 10px;">- October 2011, Celgene and Agios agreed, ahead of schedule, to extend the initial phase of Celgene's global strategic collaboration targeting cancer metabolism with Agios, extending its initial period of exclusivity of three years to four years.<wbr> According to the terms of this extension, Agios received a $20 million payment from Celgene.<wbr> The scope, purpose, and rights within the collaboration are otherwise unchanged.<wbr> </div><div><EM>Source: Agios; ThomsonOne</EM> </div><!-- Comment details --><a name="endocrinology7614attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7614_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(98 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7614_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(117,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7614_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(82 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7614_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(17,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7614_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(12,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7614_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(96,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7614">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-14T15:31:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-14T15:31:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Organization and Reporting Line Change at Takeda</title>
	<pubDate>2014-03-14T13:07:17+01:00</pubDate>
	<wp:post_id>5051</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Upon the arrival of Christophe Weber as COO organization will be changing.<wbr> All functions currently reporting to the CEO will now report directly to the COO, as well as the Takeda's commercial operations outside Japan and the Vaccine Business Division.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Office of the President &amp; CEO will be integrated into the Corporate Strategy Department in order to provide highly effective strategic and operational support to the President &amp; CEO as well as the COO.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>to create a truly global operating structure and achieve performance that meets the highest global standards</LI>
<LI>to strengthen global commercial operations</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10780_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10701" class="defaultlink">PharmaWorld10701: New COO at Takeda to Become Next CEO</a>.<wbr> </div><div><EM>Source: Takeda</EM> </div><!-- Comment details --><a name="pharmaworld10780attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10780_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(4,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10780">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-14T13:07:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-14T13:07:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Hikma Financial Results</title>
	<pubDate>2014-03-13T12:03:13+01:00</pubDate>
	<wp:post_id>5052</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the financial results for 2013, Hikma elaborated on its strategy to drive continued growth of its branded drugs in MENA and emerging markets.<wbr> Of note, the company did not mention any progress with Lutrate 1M, acquired through an agreement signed with GP Pharm.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management reported that: .<wbr>.<wbr>.<wbr> "Russia continues to be an exciting market, a market that has got a lot of potential for growth.<wbr> The Russian Minister of Health had warned the local manufacturing community that by 2014 they had to comply with GMPs.<wbr> Now they have given them another three years.<wbr> They've said now they've expanded to 2016.<wbr> </div><div style="margin-bottom: 10px;">So I think there is a place for a company like ours to enter that market, a company with very strong quality and EU and FDA quality.<wbr> I think there is a good case for a company like ours entering the market.<wbr> .<wbr>.<wbr>.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The Company operates in three business segments: Branded, Injectables, and Generics.<wbr> </div><div style="margin-bottom: 10px;">The majority of its operations are in the Middle East and North Africa region, the United States and Europe.<wbr> </div><div><EM>Source: Hikma</EM> </div><!-- Comment details --><a name="pharmaworld10779attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(86,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(89,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(78,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(95,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(76,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10779_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(34,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10779">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-13T12:03:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-13T12:03:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Has Started Global Observational Study to Describe Prostate Cancer Management</title>
	<pubDate>2014-03-12T16:36:50+01:00</pubDate>
	<wp:post_id>5053</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The purpose of this study is to describe patterns in disease management and to describe clinical outcomes, as well as to identify factors influencing physician treatment decisions including reason(s) for treatment choices and trigger(s) for treatment changes and to document healthcare resource utilization used to manage treatment-related complications.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx 2500 </div><div style="margin-bottom: 10px;">Subjects will be selected from the offices of either a medical oncologist, radiation oncologist, uro-oncologist, urologist, surgeon, or primary care physician.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Men Who Are at High Risk for Poor Clinical Outcomes After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-Resistant Prostate Cancer and Men With Metastatic Prostate Cancer at Initial Diagnosis.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><DIV align="center">
<TABLE border="1" cellpadding="5" cellspacing="0" class="data_table" width="100%"><TBODY><TR align="left" valign="top"><TD class="body3">Cohort 1 
<DIV class="indent2" style="MARGIN-TOP: 0.5ex">Subjects with biochemical failure experience after primary treatment and have high-risk disease</DIV></TD>
</TR>
<TR align="left" valign="top"><TD class="body3">Cohort 2 
<DIV class="indent2" style="MARGIN-TOP: 0.5ex">Subjects presenting with a medical diagnosis of castrations-resistant prostate cancer</DIV></TD>
</TR>
<TR align="left" valign="top"><TD class="body3">Cohort 3 
<DIV class="indent2" style="MARGIN-TOP: 0.5ex">Subjects with an initial diagnosis of metastatic prostate cancer</DIV></TD>
</TR>
</TBODY>
</TABLE></DIV> </div><div style="margin-bottom: 10px;"><U>Timelines</U> </div><div style="margin-bottom: 10px;">Start date: Jan 2014 /<wbr> Completion date: Nov 2019 </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02066961?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F12%2F2014&amp;rank=206">NCT02066961</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9524">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-12T16:36:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-12T16:36:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FDA Agrees on SPA for Ph3 Trial on Drug-Device Combination to Treat Cholangiocarcinoma</title>
	<pubDate>2014-03-12T16:16:30+01:00</pubDate>
	<wp:post_id>5054</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The clinical trial, expected to start next month, will study the efficacy and safety of photodynamic therapy (“<EM>PDT</EM>“) with PHOTOFRIN® (porfimer sodium) for injection as treatment for unresectable advanced perihilar cholangiocarcinoma (“<EM>CCA</EM>“) Bismuth type III/<wbr>IV.<wbr> PE will assess OS from the date of randomization until the date of death or the last date the subject was known to be alive.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Sponsor</U>: Concordia (focused on legacy pharmaceutical products, orphan drugs and medical devices for the diabetic population).<wbr> </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: Approx 200 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Males or females aged 18 or older</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Diagnosed with radiologically and biopsy or cytology confirmed inoperable perihilar cholangiocarcinoma Bismuth Tumor Stage III/<wbr>IV</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Non-menopausal or non-sterile female subjects of childbearing potential must have a negative serum beta-HCG and use a medically acceptable form of birth control.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Location</U>: US; EU </div><div style="margin-bottom: 10px;"><U>Timelines</U> </div><div style="margin-bottom: 10px;">Completion date: Dec 2018 </div><div style="margin-bottom: 10px;"><DIV class="identifier">Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02082522?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F12%2F2014&amp;rank=91">NCT02082522</A></DIV> </div><div style="margin-bottom: 10px;"><DIV class="identifier"><STRONG></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV class="identifier">- treatment of esophageal cancer, non-small-cell lung cancer and high-grade dysplasia in Barrett’s esophagus.<wbr> </DIV> </div><div><DIV class="identifier">- was granted orphan drug designation (ODD) by the FDA in 2004 for cholangiocarcinoma (CCA), and in December 2011, the FDA granted a second ODD for PHOTOFRIN® as adjuvant therapy to surgery for the treatment of malignant pleural mesothelioma.<wbr></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9523">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-12T16:16:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-12T16:16:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ireland's NCPE Disapproves J&J's Zytiga for Reimbursement</title>
	<pubDate>2014-03-12T15:15:50+01:00</pubDate>
	<wp:post_id>5055</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ireland's National Centre for Pharmacoeconomics (NCPE) has not recommended for reimbursement Zytiga (abiratone acetate) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.<wbr> </div><div style="margin-bottom: 10px;">The full guidance is available <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140431&edate=20140101&rs=/link%20Oncology9522%401" class="defaultlink">@1</a> or <A href="http://www.ncpe.ie/drugs/abiratone-acetate-zytiga-for-mcrpc-post-adt/">http:/<wbr>/<wbr>www.<wbr>ncpe.<wbr>ie/<wbr>drugs/<wbr>abiratone-acetate-zytiga-for-mcrpc-post-adt/<wbr></A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In the economic evaluation, the cost-effectiveness of Zytiga plus prednisolone was analysed in comparison with prednisolone plus placebo.<wbr> Data from a multinational, multicentre, double-blind, placebo-controlled study, COU-AA-302, was used to determine the time spent in each period of the model treatment pathway.<wbr> </div><div style="margin-bottom: 10px;">In the original submission by the company, the base-case incremental cost-effectiveness ratio (ICER) was estimated at EUR133,594 (USD185,412) per life year gained (LYG).<wbr> </div><div style="margin-bottom: 10px;">The NCPE has requested a revised base case, which would include the post-docetaxel treatment with cabazitaxel, in both arms, and the prophylactic use of G-CSF in 30% of patients, with no G-CSF to treat established febrile neutropaenia.<wbr> </div><div style="margin-bottom: 10px;">The ICER in the revised base case was EUR151,518 per LYG.<wbr> A probabilistic analysis was carried out on the original submission model, which showed that the probability that Zytiga plus prednisolone was cost-effective at a payor threshold of below EUR105,000/<wbr>QALY was 0%.<wbr> </div><div style="margin-bottom: 10px;">Zytiga was therefore not considered cost-effective at the submitted price.<wbr> </div><div><EM>Source: IHS Global Insight<BR></EM> </div><!-- Comment details --><a name="oncology9521attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9521_1_Abiraterone%2dZytiga%2dpre%2dchemotherapy%2dSummary3.pdf">Abiraterone-Zytiga-pre-chemotherapy-Summary3.pdf</a>&nbsp;&nbsp;(99,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9521">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-12T15:15:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-12T15:15:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda's GnRH Antagonist to Enter POC Trial for Prostate Cancer</title>
	<pubDate>2014-03-11T17:55:51+01:00</pubDate>
	<wp:post_id>5056</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Relugolix is expected to be next generation Lupron for Takeda.<wbr> This is a 3-arm, randomized, open-label, parallel group study of TAK-385 (Relugolix), together with a leuprorelin observational cohort, in patients with prostate cancer who require first-line ADT.<wbr> PE will measure the rate of effective castration defined as the estimated proportion of patients who have testosterone concentrations &lt; 50 ng/<wbr>dL at all scheduled visits.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx 125 </div><div style="margin-bottom: 10px;"><U>Timelines</U> </div><div style="margin-bottom: 10px;"><UL><LI>Start date: March 2014</LI>
<LI>Completion date: Jan 2016 /<wbr> March 2016</LI>
</UL> </div><div style="margin-bottom: 10px;">Location: USA </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02083185?phase=0123&amp;fund=2&amp;rcv_s=02%2F11%2F2014&amp;rank=257">NCT02083185<BR><BR></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9519">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-11T17:55:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-11T17:55:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi and UCB Partner to Identify New Therapies for Immune-mediated Diseases</title>
	<pubDate>2014-03-11T09:35:31+01:00</pubDate>
	<wp:post_id>5057</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Under the terms of the agreement, Sanofi and UCB will share costs and profits on a 50/<wbr>50 basis.<wbr> UCB will be entitled to initial upfront, preclinical and clinical development milestone payments from Sanofi, potentially exceeding €100M.<wbr> A dedicated team of scientists will be formed under the leadership of Sanofi and UCB, and will join forces in a discovery and development based collaboration to characterize and identify new potential therapies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale of the Deal</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>- </STRONG>both companies are very active in the field of immune-mediated diseases </div><div style="margin-bottom: 10px;"><UL><LI>UCB's product Cimzia, and epratuzumab for lupus </LI>
<LI>Sanofi's sarilumab for arthritis and Lemtrada for MS </LI>
</UL> </div><div style="margin-bottom: 10px;">- to identify novel small molecule therapies to address a wide range of immune-mediated diseases </div><div style="margin-bottom: 10px;"><UL><LI>currently immune-mediated conditions tend to be treated with biological agents such as monoclonal antibodies </LI>
<LI>small molecules could represent more durable treatments and could potentially be orally administered </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>About Immune-mediated Diseases</STRONG> </div><div style="margin-bottom: 10px;">There are hundreds of immune-mediated disorders that include joint diseases such as rheumatoid arthritis, inflammatory bowel diseases such as Ulcerative Colitis and Crohn’s Disease.<wbr> </div><div>Source: UCB; Sanofi; ThomsonOne </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1940">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-11T09:35:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-11T09:35:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Concert Pharm Recently Completed IPO</title>
	<pubDate>2014-03-10T19:04:18+01:00</pubDate>
	<wp:post_id>5058</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Concert Pharmaceuticals, co-founded  in 2006 by Richard Aldrich, Roger Tung and Christoph Westphal, is a clinical-stage biotech currently developing its 2 wholly-owned assets, CTP-354 (Ph2 expected to start H2:14 for spasticity associated with multiple sclerosis and spinal cord injury) and CTP-499 (for diabetic kidney disease).<wbr> The company completed its IPO by mid February and raised approx.<wbr> $93M beginning of March 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Upcoming Catalyst</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">In the second half of 2014, Concert will have read-outs from Ph1 multiple ascending dose trial with CTP-354 leading to the start of a Phase II study for treatment of spasticity in multiple sclerosis (MS) and spinal cord injury (SCI).<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI>
CTP-354 is currently subject to a partial clinical hold from the FDA that prevents the company from administering doses in excess of 6 mg per day.<wbr> It is possible it will need to complete additional pre-clinical studies in order to increase the dose past 6 mg per day in future clinical trials.<wbr>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Concert Model</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">- developing drugs more quickly and less expensively than before.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG>Technology Platform - Novel Drug Discovery Paradigm</STRONG> </div><div>The company applies its DCE Platform (deuterated chemical entity platform) to systematically identify approved drugs, advanced clinical candidates or previously studied compounds that we believe can be improved with deuterium substitution (see <A href="http://www.concertpharma.com/research/index.html">http:/<wbr>/<wbr>www.<wbr>concertpharma.<wbr>com/<wbr>research/<wbr>index.<wbr>html</A>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7451">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-10T19:04:18+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-10T19:04:18+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>First Hospital Exemption in Germany for a Non Marketed Drug</title>
	<pubDate>2014-03-10T14:47:44+01:00</pubDate>
	<wp:post_id>5059</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: German health regulators have granted Northwest Biotherapeutics Inc <NWBO.O>special permission to sell its experimental brain cancer drug, DCVax-L, in the country, even though the company has not yet completed its late-stage trial.<wbr> To be noted, DCVax-Prostate is awaiting partnering.<wbr></NWBO.O> </div><div style="margin-bottom: 10px;"><STRONG>Launch Timeline</STRONG> &gt; Northwest Biotherapeutics plans to begin selling its drug in the next few months in Germany, and to ramp up production at its manufacturing plant in Leipzig.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Indication</STRONG> &gt; 2nd-Line for Brain Cancer &gt; DCVax-L can be used after patients receive the standard care for brain cancer, which consists of surgery, radiation and treatment with Merck &amp; Co Inc's <MRK.N>Temodar chemotherapy.<wbr></MRK.N> </div><div style="margin-bottom: 10px;"><STRONG>Pricing</STRONG> &gt; DCVax-L initially could be priced higher than Temodar, which costs about $65,000 to $70,000 a year.<wbr> Powers said a premium price for DCVax-L was warranted because of signs of effectiveness seen in the informal early-stage trials.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">Northwest Biotherapeutics expects to report complete data from its formal late-stage trial of DCVax-L in 2015.<wbr> </div><div style="margin-bottom: 10px;">The Ph3 study, which began in 2008 and is being conducted in Europe and the United States, involves 312 patients who were newly diagnosed with GBM and received standard therapies.<wbr> </div><div style="margin-bottom: 10px;">Management indicated that "If we meet the goals of the trial, we would plan to apply for marketing approval in Europe and the United States simultaneously".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">DCVax® is a platform technology that uses activated dendritic cells (the master cells of the immune system), and is designed to reinvigorate and educate the immune system to attack cancers.<wbr> Unlike conventional cancer drugs, which use one active agent to hit one target on the cancer, DCVax uses many active agents to hit many targets on the cancer.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="oncology9515attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(62,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(62,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(14,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(4,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(79 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(73,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9515_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(27,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9515">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-10T14:47:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-10T14:47:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Survey Highlights Positive Reception from Huntington's Experts for Raptor's Drug</title>
	<pubDate>2014-03-07T15:02:28+01:00</pubDate>
	<wp:post_id>5060</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Analysts at JMP Securities asked 30 U.<wbr>S.<wbr> neurologists to respond 4 questions in an email survey.<wbr> Key messages are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Neurologists have reported as having knowledge of patients with HD and the Total Motor Score (TMS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Are the results compelling?</STRONG> </div><div style="margin-bottom: 10px;">- 98% of the respondents found the results and MoA of the Raptor's drug compelling.<wbr> Only 2 neurologists cited a lack of stastistical significance.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What constitutes a clinically meaningful change in TMS?</STRONG> </div><div style="margin-bottom: 10px;">- the median response from our experts was a difference of four points compared to placebo after 18 months of treatment (Figure 1), coinciding with results of monotherapy treatment with RP-103 </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7450_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Which patients will receive RP-103 if approved?</STRONG> </div><div style="margin-bottom: 10px;">- answers suggested that there is an opportunity to capture a significant percentage of the market.<wbr> As a follow-up, it was also asked which subgroups would be most likely to receive treatment and the most common response was patients relatively early in disease progression with significant motor function symptoms.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7450_2_ScreenCapture2.jpg"> </div><div><STRONG>Full report available on demand to Brigitte Deschamps</STRONG> </div><!-- Comment details --><a name="neurology7450attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7450_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(23,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7450_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(23,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7450">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-07T15:02:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-07T15:02:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Merck Serono Q4 and FY13 Results</title>
	<pubDate>2014-03-07T11:08:50+01:00</pubDate>
	<wp:post_id>5061</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The organic sales growth of the Serono division, which represents 56% share of group sales, increased by 4% (yoy).<wbr> The company has decided to move into the biosimilars market and expects to be one of the players in this upcoming market.<wbr> Management reported mature markets will continue to be affected from austerity measures in 2014.<wbr> The pipeline lists an emerging immuno-oncology pipeline which will be presented at ASCO2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10776_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Early 2012 Merck decided to set up the biosimilars unit to develop molecules for oncology and inflammatory disorders through in-house research &amp; development expertise in biologics as well as partnerships with other biosimilars players, such as Dr.<wbr> Reddy’s Laboratories.<wbr> </div><div style="margin-bottom: 10px;">The unit is located in Canton de Vaud, Switzerland, where it makes use of Merck’s state-of-the-art biologics manufacturing facilities of Aubonne and Corsier sur Vevey with support from other European sites of the company.<wbr> </div><div style="margin-bottom: 10px;">Management believes that biosimilars will become an interesting market after 2017/<wbr>2018.<wbr> The focus will be in oncology an immunology.<wbr> Simon Sturge, ex Boehringer Ingelheim, has been recently hired to run this business.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10776_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10776_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10776_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="pharmaworld10776attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10776_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(74,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10776_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(19,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10776_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(42,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10776_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(70,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10776_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(18,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10776">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-07T11:08:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-07T11:08:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sun Pharma Seeks to Enter Japan Generics Market</title>
	<pubDate>2014-03-06T20:32:14+01:00</pubDate>
	<wp:post_id>5062</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: To date, Lupin Ltd is the only Indian drugmaker that has so far made significant inroads in Japan.<wbr> </div><div>Management reported it could be a partnership or an acquisition.<wbr> Last month, during the Q3 2013-14 results, Dilip Shanghvi reported that the company 'would like to find a way to enter, but have not yet found'.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10775">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-06T20:32:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-06T20:32:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from GnRH 2014 International Symposium</title>
	<pubDate>2014-03-06T13:17:24+01:00</pubDate>
	<wp:post_id>5063</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The two-day event was hosted in Salzburg this year.<wbr> The topics of this triennial symposium covered new aspects in the neuroendocrine regulation of the gonadal axis and focused on future trends and challenges.<wbr> Approximately 170 basic scientics, clinicians and clinical researchers have highlighted their experiences to investigate new avenues.<wbr> A selection of key presentations is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Kinetic Characterization of Clinically used GnRH Agonist</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>I.<wbr> Nederpelt</STRONG> from Leiden University presented her work which shows: </div><div style="margin-bottom: 10px;">- high affinities for all agonists </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">- significant differences in residence time, ranging from 5mn (goserelin) to 130mn (buserelin) </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">She concluded that drug-target residence time should be taken into account as a new parameter in current treatment and future discovery.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Novel GnRH-Gemcitabine Conjugates</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>C.<wbr> Tamvakopoulos</STRONG> reported the opportunity to treat cancer by targeting the GnRH receptor beyond the pituitary directly on the tumor by using GnRH conjugates (GnRH analogue + linker + small molecule anticancer drug).<wbr> </div><div style="margin-bottom: 10px;">Gemcitabine was selected from a metabolic standpoint.<wbr> The molecule preserves the binding property of the GnRH.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;">The GnRH-gemcitabine conjugates were synthesized and evaluated against prostate cancer models.<wbr> </div><div style="margin-bottom: 10px;">The lead compound, GSG, shows a potent anticancer effect that appears to be associated with a dual mode of action: </div><div style="margin-bottom: 10px;"><UL><LI>targeted delivery to cancer celles over-espressing the GnRH-R</LI>
<LI>improved efficacy due to reduced meabolic inactivation of gemcitabine.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Future Plans</U> </div><div style="margin-bottom: 10px;"><UL><LI>Elaborate on the metabolism of gemcitabine</LI>
<LI>More work on receptor mediated endocytosis, gemcitabine intracellular levels (mass spec and confocal microscopy techniques).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Efficacy and Tolerability of Eligard</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>C.<wbr> Ohlmann</STRONG> presented pooled data from 2 prospective, non- interventional studies in patients with advanced prostate cancer, funded by Astellas.<wbr> The aims of the study was to investigate the efficacy/<wbr>safety of Eligard 3M-6M in routine urological practice.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><U>Main Reasons for Choosing Eligard</U> </div><div style="margin-bottom: 10px;"><UL><LI>for 77.<wbr>8% of physicians it is the long dosage interval</LI>
<LI>for 28.<wbr>8% the small injection volume</LI>
<LI>for 25.<wbr>6% the short needle</LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Final Assessment of Local Tolerability of Eligard Prefilled Syringe</U> </div><div style="margin-bottom: 10px;">Excellent for 44.<wbr>5% of physicians, Good for 46.<wbr>5% and Satisfactory 8.<wbr>1%.<wbr> </div><div style="margin-bottom: 10px;">In conclusion he outlined that: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Novel Potential Indication for Cetrorelix</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>A.<wbr> Kàss</STRONG> presented the AGRA study which aim was to assess short-term cetrorelix therapy in rheumatoid arthritis (RA) patients.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>n=99 patients with active, long-standing RA, </LI>
<LI>48 patients received subcutaneous cetrorelix (5 mg/<wbr>day on days 1 and 2; 3 mg/<wbr>day on days 3-5) and 51 received placebo.<wbr> </LI>
<LI>The PE was the change in the 28-joint Disease Activity Score based on C-reactive protein (DAS28-CRP) by day 5, when the greatest GnRH suppression was anticipated.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">His conclusion outlines the following: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">Results published in <EM>Scand J Rheumatol</EM>.<wbr> 2014;43(1):22-7. doi: 10.<wbr>3109/<wbr>03009742.<wbr>2013.<wbr>825007.<wbr> Epub 2013 Nov 1.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>GnRH Agonists and Antagonists Are Different in FSH Suppression</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>I Hutaniemi</STRONG> concluded his presentation outlining that: </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Role of Degarelix for Endometriosis Recurrence</STRONG> </div><div style="margin-bottom: 10px;">Speaker: F.<wbr> Scarpellini presented results from a controlled trial aimed at evaluating the role of a LA GnRH (degarelix) versus GnRH agonist in the treatment of endometriosis patients with recurrence of pain during treatment with progestins.<wbr> </div><div style="margin-bottom: 10px;">n=40 women with severe endometriosis, previously diagnosed by operative laparoscopy </div><div style="margin-bottom: 10px;">Selection timelines: from Sept 2011 through June 2012.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><U>Treatments</U> </div><div style="margin-bottom: 10px;"><UL><LI>Women of the study group were treated with only one sc injection the first day of menstrual cycle with degarelix 80mg</LI>
<LI>Women of the control group were treated for 3 mos with leuprolide acetate 3.<wbr>75mg monthly.<wbr></LI>
<LI>F-Up: the women of the two groups were followed up during the treatment and after the end of treatment for 6 mos.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">The conclusion shows that: </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_14_ScreenCapture14.jpg"> </div><!-- Comment details --><a name="oncology9512attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(76,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(85,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(65,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(29,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(39,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(57,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(64 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(71,1 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(55,5 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(99 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(63 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(28,8 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9512_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(81,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9512">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-06T13:17:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-06T13:17:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance At Cowen's H/C Conference - Key Takeaways</title>
	<pubDate>2014-03-05T16:55:07+01:00</pubDate>
	<wp:post_id>5064</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Following its recent IPO, Revance, yesterday gave its first detailed presentation on its ambition to build a global neurotoxin franchise, starting with three launches beginning 2017 and the 3 years beyond, the first with its topical toxin for crows feet.<wbr> Another notable announcement was that Angus Russel ex CEO of Shire Pharmaceuticals has joined the group as Chairman.<wbr> </div><div style="margin-bottom: 10px;">In terms of other indications for the topical formulation, hyperhydrosis is in phII development, migraine in phII and other indications phI.<wbr> Whilst for the injectable formulation RT-002, Glabeller lines will be the first indicaiton whilst therapeutic indications are being evaluated pre-clinically.<wbr> RT-002, it was claimed, will have a longer duration of action than existing toxin products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Safety Perspective of RT-001</STRONG> </div><div style="margin-bottom: 10px;">Management noted that RT-001 has now been evaluated in over 1000 patients and that there are:- </div><div style="margin-bottom: 10px;"><UL><LI>NO releated SAEs
</LI>
<LI>NO substantial discontinuations due to AEs
</LI>
<LI>NO significant observations or evidence of regional spread of toxin
</LI>
<LI>NO systemic safety concerns or evidence of any system exposure based on clinical lab results or ECG findings.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">Regarding the application of the product it was noted that it is dispensed directly in a physician's office never taken home.<wbr> That it is a viscous gel, is a pleasing consumer experience and very ease for the physician or nurse to apply.<wbr> It is left on for 30 minutes and then wiped off.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Development Plan For RT-0001</STRONG> </div><div style="margin-bottom: 10px;">Revance for the first time revealed detail regarding timelines and studies included in its development plan.<wbr> </div><div style="margin-bottom: 10px;">In the US it will conduct 2 pivotal phIII studies and one large safety study details of which are as follows:- </div><div style="margin-bottom: 10px;"><UL><LI>Pivotal trial 1 n=170 single dose PC.<wbr> Efficacy data will be available 2H2014
</LI>
<LI>Pivotal trial 2 n=170 single dose PC.<wbr> Efficacy data in 2015
</LI>
<LI>Safety study n=1800.<wbr> To start mid 2014.<wbr> Interim data 2018
</LI>
<LI>BLA filing will include data on &gt;2000 patients and will be filed at the end of 2016, with approval potentially 2017
</LI>
</UL> </div><div style="margin-bottom: 10px;">In Europe one trial will be undertaken:- </div><div style="margin-bottom: 10px;"><UL><LI>Pivotal trial n=200 single dose PC.<wbr> Efficacy data 2015
</LI>
<LI>MAA filing end 2016 approval 2017/<wbr>18
</LI>
</UL> </div><div style="margin-bottom: 10px;">There is a lot of additional data included in its presentation which we will circulate shortly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Therapeutic Indication Pursuit</STRONG> </div><div style="margin-bottom: 10px;">The only other key point to mention is its strategic intent from an indication perspective which is as follows:- </div><div style="margin-bottom: 10px;">For Superficial Targets with RT-001 </div><div style="margin-bottom: 10px;">Headache.<wbr> Post herpetic neuralgia, Stretch marks, Anal Fissure and osteotarthritis.<wbr> </div><div style="margin-bottom: 10px;">For Deeper Targets with RT-002 </div><div>TMJ Teeth grinding, Vocal cord dystonia, Back pain, OAB and BPH </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7448">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-05T16:55:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-05T16:55:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis CEO Predicts Few Players in the Oncology Space Within a Decade</title>
	<pubDate>2014-03-05T16:37:44+01:00</pubDate>
	<wp:post_id>5065</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:  </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="FONT-SIZE: 12pt"><SPAN style="FONT-SIZE: 12pt"><SPAN style="FONT-SIZE: 12pt">D</SPAN></SPAN></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 14pt 0px"><SPAN style="FONT-SIZE: 12pt"></SPAN>
<P><SPAN style="FONT-SIZE: 12pt"></SPAN><SPAN style="FONT-SIZE: 12pt"></SPAN></P></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 14pt 0px"><SPAN style="FONT-SIZE: 12pt"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9466" class="defaultlink">Oncology9466: Novartis Acquiers CoStim and Expands in Immunotherapy for Cancer</a></SPAN></DIV> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="FONT-SIZE: 12pt"></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 14pt 0px"><SPAN style="FONT-SIZE: 12pt"><STRONG>Novartis Strategy</STRONG></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 14pt 0px"><SPAN style="FONT-SIZE: 12pt"></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 14pt 0px"><SPAN style="FONT-SIZE: 12pt"></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 14pt 0px"><SPAN style="FONT-SIZE: 12pt"><STRONG>Conclusion Slide Presented at the Cowen Conference</STRONG></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 14pt 0px"><SPAN style="FONT-SIZE: 12pt"></SPAN></DIV> </div><div>Source: Scrip March 5 </div><!-- Comment details --><a name="oncology9508attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9508_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(82,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9508">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-05T16:37:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-05T16:37:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz North America Enhances Patient Access to Prescription Drugs</title>
	<pubDate>2014-03-05T11:04:24+01:00</pubDate>
	<wp:post_id>5066</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has announced the appointment of G.<wbr> B.<wbr> Bass as VP, Managed Markets.<wbr> Based in Greensboro, NC at Merz's North American headquarters, he will be responsible for market access and reimbursement strategy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Prior to joining Merz, Bass held the position of Senior Director, Managed Markets at J&amp;J Healthcare Systems.<wbr> Under his leadership, that team managed and grew a $6 billion portfolio of Immunology and Oncology products, including the most successfully launched pharmaceutical products across the industry in 2010 and 2011.<wbr> </div><div style="margin-bottom: 10px;">Bass has more than 17 years of experience in the pharmaceutical and biopharmaceutical industries and holds a Bachelor of Arts degree in Biology from Brandeis University in Waltham, MA.<wbr> </div><div><EM>Source: FirstWord; Merz</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7447">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-05T11:04:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-05T11:04:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Big Pharmas Have Scaled Back Payments to Physicians for Promo Talks</title>
	<pubDate>2014-03-05T10:48:23+01:00</pubDate>
	<wp:post_id>5067</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This fall, all drug and medical device companies will be required to publicly report payments to doctors.<wbr> As showed in a new ProPublica analysis, Lilly, Pfizer, GSK and Novartis have slashed payments to health professionals for promotional speeches amid heightened public scrutiny of such spending, others such as J&amp;J have increased speaker payments.<wbr> AstraZeneca’s payments stayed about flat in 2012 after a steep decline in 2011.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The fact that some companies are cutting back on speaking while preserving their spending on research and consulting depends on company's strategy (i;e loss of patent protection for key products).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Lilly’s payments to speakers dropped by 55%, from $47.<wbr>9 million in 2011 to $21.<wbr>6 million in 2012.<wbr> </div><div style="margin-bottom: 10px;">Pfizer’s speaking payments fell 62% over the same period, from nearly $22 million to $8.<wbr>3 million.<wbr> </div><div style="margin-bottom: 10px;">Novartis spent 40% less on speakers that year than it did between October 2010 and September 2011, reducing payments from $24.<wbr>8 million to $14.<wbr>8 million.<wbr> </div><div style="margin-bottom: 10px;">GSK speaking tab plummeted from $24 million in 2011 to $9.<wbr>3 million in 2012 (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10711" class="defaultlink">PharmaWorld10711: GSK Increases Stake in its Indian Business and Announces Measures on its Marketing Practices</a>).<wbr> </div><div style="margin-bottom: 10px;">J&amp;J increased speaker payments by 17% from 2011 to 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">ProPublica database for users to search for their doctors to see if they have received compensation.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10771_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Thanks to A Kornowski (for having forwarded this article.<wbr> </div><div><EM>Source:</EM> <A href="http://www.propublica.org/article/as-full-disclosure-nears-doctors-pay-for-drug-talks-plummets">http:/<wbr>/<wbr>www.<wbr>propublica.<wbr>org/<wbr>article/<wbr>as-full-disclosure-nears-doctors-pay-for-drug-talks-plummets</A> </div><!-- Comment details --><a name="pharmaworld10771attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10771_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(72,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10771">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-05T10:48:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-05T10:48:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AAA Expands Its Presence In The UK & Ireland & Receives ODS For Its Diagnostic Ga68- DOTATATE</title>
	<pubDate>2014-03-04T15:16:19+01:00</pubDate>
	<wp:post_id>5068</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AAA has announced today that it has received orphan drug designation for its radiopharmaceutical Gallium-68 DOTATATE for the diagnosis of GEP-NET tumours from the FDA and the EMA.<wbr> Alongside, it has also announced the acquisition of a privately held nuclear imaging company Imaging Equipement Ltd, representing its first entry into the UK and Irish nuclear medicine market.<wbr> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>What is Gallium-68 DOTATATE/<wbr> Benefits of Use?</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Gallium-68 DOTATATE is a radiopharmaceutical used in PET/<wbr>CT imaging of GEP-NETs.<wbr>The product will be prepared using AAA&rsquo;s patented kit, which is reconstituted in hospital radiopharmacies without the use of a radiochemistry module, thus making the product available to all hospitals, even those who do not have a fully equipped GMP production radiopharmacy unit.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Existing data show that the Gallium-68-labeled PET radiopharmaceutical should represent a major improvement compared to the current standard.<wbr> Available data indicates that Gallium-68 DOTATATE not only has greater sensitivity and specificity for tumor detection than the current standard, but it is also expected to significantly reduce radiation doses received by patients.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">This development will clearly help to reinforce AAA's position in NET not only from a diagnostic perspective but from a treatment perspective as well.<wbr> However, AAA is not the only company pursuiing such a development.<wbr> Octreopharm's SOMSCAN was also recently granted ODS status (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7583" class="defaultlink">Endocrinology7583: Diagnostic for Patients with GEP-NETS Granted ODD by EMA</a>).<wbr> Octreopharm has links with both Novartis and the large radiopharmaceutical company Eckert &amp; Zeigler.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Imaging Equipement Ltd Acquisition</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Deal Terms</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">AAA has entered into an agreement to acquire 100% of the shares of Imaging Equipment Ltd (&ldquo;IEL&rdquo;), in newly issued AAA shares.<wbr> As part of the transaction, IEL&rsquo;s founding shareholders and top management will become shareholders in AAA, The acquisition gives AAA its first direct presence in the UK and Ireland, expanding its existing services and expertise in nuclear medicine and providing it with an established sales and marketing platform.<wbr> AAA will also gain the rights in the UK and Ireland to IEL&rsquo;s licensed SPECT radiopharmaceutical diagnostic product, IELMAG3, which is used to image the kidneys and urinary tract.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">At end of December 2013, IEL generated sales of &pound;6.<wbr>77 million, up 58% on the previous year.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Commenting on the acquisition Stefano Buono, Chief Executive Officer of AAA, stated :" The acquisition of IEL is in line our strategy to further expand and strengthen our position in Europe.<wbr> The UK and Ireland are important markets for both our existing and future products.<wbr> IEL&rsquo;s specialist expertise and strong presence in these markets is a complementary fit with AAA&rsquo;s business and we look forward to working with their management team to drive the integration and growth in 2014.<wbr>&rdquo;</P> </div><div style="margin-bottom: 10px;"><P align="left">Founded in 2001, IEL is a specialist distributor of medical technologies in the UK and Ireland.<wbr> The company has particular expertise in molecular imaging and nuclear medicine diagnostics for preclinical and clinical imaging, and radionuclide therapy.<wbr> Its customers include a number of key international nuclear medicine companies.<wbr> In the UK, IEL is the exclusive distributor of AAA&rsquo;s myocardial perfusion PET imaging agent, Cardiogen and its oncology theragnostic product development, LuDOTATATE, which has seen real interest in the UK on a named patient basis.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">IEL has 18 employees and holds two licences from the MHRA, a Wholesalers Licence (WL 35903) and a Manufactures Specials Licence (MS 35903)</P> </div><div><P align="left">Source: <A href="http://www.aaa.com/">www.<wbr>aaa.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7609">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-04T15:16:19+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-04T15:16:19+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Heat Biologics Commences Dosing of First Patient in Phase 1/2 Study of HS-410 for The Treatment of Non Muscle Invasive Bladder Cancer</title>
	<pubDate>2014-03-04T14:01:40+01:00</pubDate>
	<wp:post_id>5069</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This is a multi-centre Phase 1/<wbr>2 study and 93 patients are expected to be enrolled into the study.<wbr> This study is designed to evaluate vaccination with HS-410 after transurethral resection of bladder tumour (TURBT) and bacillusCalmette-Guerin (BCG) extends the time to disease recurrence.<wbr> Safety is also being evaluated as primary end point.<wbr> No new approved drug for the treatment of non-muscle invasive bladder cancer by FDA for more than 25 years and HS-410 may represent a viable treatment option to address a significant unmet medical need.<wbr> </div><div style="margin-bottom: 10px;">About the Trial (ClinicalTrials.<wbr>gov Identifier:NCT02010203) </div><div style="margin-bottom: 10px;"><UL><LI>Title:A Phase 1/<wbr>2, Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With High-Risk Non-Muscle Invasive Bladder Cancer Who Have Undergone TURBT and Received Prior Treatment With Induction BCG
</LI>
<LI>Primary outcome measure:
<UL><LI>Phase 1: Immune response Up to 3 years - Immunologic response via intracellular cytokine staining (ICS) by flow cytometry and/<wbr>or enzyme-linked immunosorbent spot (ELISPOT) on CD8+ cells after receiving 6 vaccine doses.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Phase 2: Time to Recurrence Up to 3 years
</LI>
</UL>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Secondary outcome measure: PFS and OS up to 3 years
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Study start date: 30th Dec 2013
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Estimated patient enrolment = 93
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;">About HS-410</P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;">In Oct 2013, Heat Biologics submits IND application to FDA for HS-410.<wbr> In Jan 2014, Heat Biologics announced its PHASE1/<wbr>2 study of HS-410 was opened for patient enrolment.<wbr> HS-410 is a novel cancer immunotherapeutic product that is designed to activate a T-cell mediated pan-antigen immune response for bladder cancer.<wbr> Jeff Wolf, CEO of Heat stated "This is a significant milestone for the Company as we remain focused on advancing Heat's proprietary ImPACT therapy into late-stage clinical studies.<wbr>" Dr.<wbr> Mark P.<wbr> Schoenberg and Professor Bernard L.<wbr> Schwartz worked with the Company to design the Protocol of the Phase 1/<wbr>2 bladder cancer study.<wbr> The ImPACT technology platform reprograms live cancer cells from a single tumour source to continually secrete gp96 (a chaperone protein found in all human cells).<wbr> In turn, gp96 chaperones tumour antigens to T-cells to activate a robust, pan-antigen T-cell immune response and direct killer T-cells to attack the patient's cancer.<wbr> Heat's ImPACT technology holds promise for treating a wide variety of different cancers.<wbr> HS-410 consists of a bladder cancer cell line that has been genetically modified using ImPACT technology platform to secret a wide range of bladder cancer specific antigens and activate a T-cell mediated pan-antigen immune response against the patient's bladder cancer.<wbr></P> </div><div style="margin-bottom: 10px;">About Heat Biologics </div><div>The company focuses on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers.<wbr> Heat's ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells.<wbr> Heat's other leading compound, HS-110, will be entering Phase 2 trials against non-small cell lung cancer .<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9505">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-04T14:01:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-04T14:01:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New CMO at Canbex</title>
	<pubDate>2014-03-04T08:13:58+01:00</pubDate>
	<wp:post_id>5070</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dr Albert Lledó will lead Canbex's preparations for POC trials for VSN16R, an orally active small molecule intended for the treatment of spasticity in multiple sclerosis.<wbr> The company was established expressly to develop the VSN compound series.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Senior Consultant Neurologist at Clínica Creu Blanca, Barcelona </div><div style="margin-bottom: 10px;">Spent 16 years at Eli Lilly and Co in roles that included Global Senior Medical Advisor and CNS Clinical Research Physician for Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Canbex has successfully completed the Single Ascending Dose (SAD) stage of its Phase I study of VSN16R </div><div style="margin-bottom: 10px;">The Multiple Ascending Dose (MAD) part of the trial is due to start imminently.<wbr> The FIM study of VSN16R is enrolling a total of 72 healthy volunteers and is being carried out by Quintiles.<wbr> </div><div><EM>Source: Canbex</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7443">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-04T08:13:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-04T08:13:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Salix In-licenses 1st Encapsulated Bowel Cleanser</title>
	<pubDate>2014-03-03T18:59:35+01:00</pubDate>
	<wp:post_id>5071</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Salix Pharmaceuticals has entered into an exclusive agreement with 
RedHill Biopharma by which Salix has licensed the worldwide rights to 
RedHill's RHB-106 encapsulated formulation for bowel preparation which is in 
PhI/<wbr>II development.<wbr> Undisclosed rights to other purgative developments are 
also included in the deal.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Financial terms include an upfront payment of $7 million and $5 million in 
subsequent milestone payments to RedHill.<wbr> </div><div style="margin-bottom: 10px;">Salix also has agreed to pay RedHill tiered royalties on net sales, ranging 
from low single-digit up to low double-digits.<wbr> Under the worldwide license 
agreement, the parties also agreed on potential strategic collaboration with 
regard to certain other Salix products in specific territories.<wbr> </div><div style="margin-bottom: 10px;">Commenting on this agreement Carolyn Logan, President and Chief Executive 
Officer, Salix.<wbr>  “  “Salix is pleased to enter this strategic 
collaboration with RedHill and to secure what we believe could be the first 
prescription encapsulated bowel prep product,”  "Many patients" she claimed 
 "find the taste and palatability of current bowel prep products to be 
unacceptable.<wbr>  We believe the availability of a tasteless solid oral 
formulation bowel prep, if approved by the FDA, could potentially go a long way 
in helping to increase patient compliance and to ease patient burden associated 
with bowel cleansing prior to various medically important abdominal 
procedures.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG>About RHB-106</STRONG> </div><div style="margin-bottom: 10px;">RHB-106 is an encapsulated formulation intended for the preparation and 
cleansing of the gastrointestinal tract prior to the performance of abdominal 
procedures, including diagnostic tests, such as colonoscopy, barium enema or 
virtual colonoscopy, as well as surgical interventions, such as laparotomy.<wbr> The 
RHB-106 preparation is a tasteless solid oral dosage potentially allowing an 
unobstructed procedure with reduced side-effects and improved compliance.<wbr> It 
avoids patient exposure to the often unacceptable taste of current products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>RedHill Biopharma Ltd's Profile</STRONG> </div><div style="margin-bottom: 10px;">The company is an emerging Israeli biopharmaceutical company focused 
primarily on the development and acquisition of late clinical-stage, proprietary 
formulations and combinations of existing drugs for the treatment of 
inflammatory and gastrointestinal diseases, including cancers and related 
conditions.<wbr> The Company's current pipeline of proprietary products 
includes:  (i) <STRONG>RHB-104</STRONG> <STRONG>-</STRONG> an oral 
combination therapy for the treatment of Crohn's disease, with an ongoing Phase 
III study, (ii) <STRONG>RHB-105</STRONG> <STRONG>-</STRONG> an oral combination 
therapy for <EM>Helicobacter pylori</EM> infection, with an ongoing phase III 
study; (iii) <STRONG>RHB-106</STRONG> <STRONG>-</STRONG> an encapsulated 
formulation for bowel preparation licensed to Salix Pharmaceuticals Ltd.<wbr> (iv) 
<STRONG>RHB-103</STRONG> - an oral thin film formulation of rizatriptan for 
acute migraines with U.<wbr>S.<wbr> NDA under FDA review; (v) <STRONG>RHB-102</STRONG> 
<STRONG>-</STRONG> a once-daily oral pill formulation of ondansetron for the 
prevention of chemotherapy and radiotherapy induced nausea and vomiting and (vi) 
<STRONG>RHB-101-</STRONG> a once-daily formulation of carvedilol.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9501_1_ScreenCapture1.jpg"> </div><!-- Comment details --><a name="oncology9501attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9501_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(111,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9501">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-03T18:59:35+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-03T18:59:35+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Dendreon Reports Better Sales Momentum & Plans For European Launch Of PROVENGE</title>
	<pubDate>2014-03-03T18:43:17+01:00</pubDate>
	<wp:post_id>5072</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">as the first-and-only personalized immunotherapy approved for the treatment of mCRPC.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><UL><LI>
</LI>
<LI>
</LI>
</UL> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9499">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-03T18:43:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-03T18:43:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ASIS Device for Botox in ULS and in Chronic Migraine</title>
	<pubDate>2014-03-03T18:16:42+01:00</pubDate>
	<wp:post_id>5073</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; FONT-SIZE: small"><a href="http://www.asis-inc.com/product.html" class="defaultlink">Automatic Subdermal Injection System</a></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; FONT-SIZE: small"><STRONG></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; FONT-SIZE: small"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; FONT-SIZE: small"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; FONT-SIZE: small"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; FONT-SIZE: small"></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: small"><STRONG><SPAN style="FONT-FAMILY: arial, helvetica, sans-serif"><a href="http://clinicaltrials.gov/ct2/show/NCT02074150?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=02%2F03%2F2014&amp;rank=148" class="defaultlink">NCT02074150</a></SPAN></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline"><SPAN style="FONT-SIZE: small"><SPAN style="FONT-FAMILY: arial, helvetica, sans-serif"></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="li-content" style="FONT-SIZE: small"></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex"></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex"></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex"><SPAN class="li-content" style="FONT-SIZE: small"> less than 4, </SPAN> </LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline"><SPAN style="FONT-SIZE: small"><SPAN style="FONT-FAMILY: arial, helvetica, sans-serif"></SPAN></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: small"><SPAN style="FONT-FAMILY: arial, helvetica, sans-serif"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline">Recruitment</SPAN> </div><div style="margin-bottom: 10px;">n=60 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Must have history of chronic migraine (with or without aura) according to the criteria proposed by the Headache Classification Committee of the International Headache Society for at least 3 months prior to enrollment.<wbr> </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">If taking migraine preventive, must be on a stable dose of preventive medication for at least 3 months.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-DECORATION: underline">Timelines</SPAN> </div><div>Start date: June 2014 - Completion: June 2015 /<wbr> June 2016 </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7629c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">A new trial has been added for cervical dystonia (CD).<wbr> The purpose of the study is to assess the safety and efficacy of Botox (onabotulinumtoxinA) administered intramuscularly and subdermally </div><div style="margin-bottom: 10px;"><STRONG>Reference ASIS in CD</STRONG> <a href="http://www.clinicaltrials.gov/ct2/show/NCT02074293?term=NCT02074293&rank=1" class="defaultlink">NCT02074293</a> </div><div style="margin-bottom: 10px;">Over 6 months usage will demonstrate ASIS device's consistent performance on 60 adult subjects with cervical dystonia in which Gadolinium will be injected with ASIS subdermally in 30 subjects or conventional intramuscularly in other 30 subjects for these 7 muscle groups: Splenius, Scalene, Sterno-cleido-mastoid, Levator scapulae, Semispinalis, Trapezius, and Longissimus.<wbr> An MRI will be taken immediately after Gadolinium injection, as starting reference, to which subsequent MRI taken at 6 hrs, 12 hrs, and 24 hrs later will be compared for Persistent %.<wbr> </div><div style="margin-bottom: 10px;">Over 12 months usage of Botox, instead of Gadolinium, will demonstrate the advantages of ASIS device subdermally over intramuscularly, for the same 60 adult subjects with cervical dystonia, on these particular 7 muscle groups: Splenius, Scalene, Sterno-cleido-mastoid, Levator scapulae, Semispinalis, Trapezius, and Longissimus.<wbr> </div><div style="margin-bottom: 10px;">A total of 60 subjects are planned to be enrolled in the study </div><div>Timelines Start date June 2014 - Completion date June 2015 /<wbr> June 2016 </div></div><a name="neurology7440attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7440_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(49,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7440">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-03T18:16:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-03T18:16:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>US Market Access Strategy for Thrice-weekly Copaxone</title>
	<pubDate>2014-03-03T14:22:51+01:00</pubDate>
	<wp:post_id>5074</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The US FDA approved the thrice-weekly dose of Copaxone in January, which is now being marketed alongside the traditional once-daily dose (both forms of Copaxone are used in the treatment of multiple sclerosis).<wbr>Reports by Bloomberg suggest that Teva has begun reaching out to patients through an email marketing campaign targeting patients who are registered with its Copaxone patient support programme.<wbr> In addition to the marketing campaign, Teva is also reportedly offering patients a discount on the thrice-weekly dose, which is priced at USD60,500 annually, at a USD1,000 discount to the original formulation.<wbr> </div><div style="margin-bottom: 10px;">To date, 4.<wbr>6% of Copaxone patients have switched to the thrice-weekly dose.<wbr> Despite the enhanced patient experience from thrice-weekly doses, the reports suggest that insurers may be reluctant to reimburse this version once generic equivalents of the daily version become available.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Significance</STRONG> </div><div style="margin-bottom: 10px;">Key to the issue of insurance company reimbursement will be perception of the benefit over daily dosage.<wbr> Some insurance companies may take into account likely patient preference for a product with less frequent dosage while other insurance companies may require a clinical and/<wbr>or safety benefit before reimbursing.<wbr> </div><div style="margin-bottom: 10px;">The reports suggest that as clinical trials on thrice-weekly Copaxone compared it with placebo, Teva may face challenges should insurers demand this clinical/<wbr>safety benefit.<wbr> </div><div style="margin-bottom: 10px;">With Copaxone being a large component of Teva's total revenues and generic versions of daily Copaxone and newer MS products looming on the horizon, switching patients to thrice-weekly doses will be an essential strategy for Teva as it seeks out new business areas.<wbr> </div><div><EM>Source: IHS Global Insight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7439">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-03T14:22:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-03T14:22:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Novartis Has Been Discreetly Downsizing</title>
	<pubDate>2014-03-03T10:06:03+01:00</pubDate>
	<wp:post_id>5075</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Novartis Has Been Discreetly Downsizing</span>&nbsp;<br><span style="font-size: 12px;">Comment: When Novartis downsizes it tends to communicate locally where the ax is falling and rarely explains more.<wbr> Confronted by this silence, a Swiss Journalist has tallied up the job-cuts and is reporting in Tages-Anzeiger that the group has cut 3000 jobs around the world over the course of the last 4-months.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10762">...</a><br></div><div>I have recently heard that Novartis is downsizing its publications group (my source suggests by as much as a quarter).<wbr> One might speculate that this could have a noticeable impact on its publications activities.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10766">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10762">View thread  PharmaWorld10762: Novartis Has Been Discreetly Downsizing</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-03T10:06:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-03T10:06:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche's Potential Blockbuster Fails in Lung Cancer</title>
	<pubDate>2014-03-03T09:48:09+01:00</pubDate>
	<wp:post_id>5076</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: An independent committee has recommended Roche halt studies of development drug MetMab (onartuzumab), seen as potential blockbuster by analysts pending successful completion of trials.<wbr> The METLung study was stopped for lack of efficacy.<wbr> The drug is currently in 2 other Ph3 trials (NSCLC with EGFR activating mutations and in gastric cancer).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale for the Termination of the Study</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">METlung phase III <a href="http://clinicaltrials.gov/ct2/show/NCT01456325?term=METlung&rank=2" class="defaultlink">NCT01456325</a> - in patients with incurable non-small cell lung cancer identified to be Met diagnostic-positive</P> </div><div style="margin-bottom: 10px;"><P align="left">The committee had recommended the current study should be stopped because the drug wasn't shown to work in patients with non-small cell lung cancer when combined with Tarceva in late-stage studies.<wbr></P> </div><div><P align="left"><EM>Source: ThomsonOne; Roche</EM></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9496">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-03T09:48:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-03T09:48:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Australia's PBS Funds Botox for the Prevention of Migraine</title>
	<pubDate>2014-03-03T09:21:13+01:00</pubDate>
	<wp:post_id>5077</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Botox is also funded by the Pharmaceutical Benefits Scheme (PBS) for the treatment of cerebral palsy, urinary incontinence and hyperhidrosis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Patient Eligibility</STRONG> </div><div style="margin-bottom: 10px;">Patients must have unsuccessfully used at least three other preventive therapies to be eligible to receive Botox through the PBS.<wbr> </div><div><EM>Source: The Australian</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7438">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-03-03T09:21:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-03-03T09:21:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Endo Introduces the "New Endo"</title>
	<pubDate>2014-02-28T16:00:22+01:00</pubDate>
	<wp:post_id>5078</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the reporting of its financial results for Q4:13 and FY13, the company has announced "Endo International" combining a new strategic direction aimed at adapting to market realities and customer changes with a new operating model.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Perfomance</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Revenues by Segment</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">The company ended the year December 31, with about $500 million of cash on the balance sheet.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- continue to operate the business and those acquired with the lean and efficient operating structure.<wbr> </div><div style="margin-bottom: 10px;">- align International internal performance metrics with shareholder interests.<wbr> </div><div style="margin-bottom: 10px;">- continue to actively pursue M&amp;A as an important component of building the business longer-term.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>" .<wbr>.<wbr>.<wbr>With the creation of Endo International and the redomiciling of our business in Ireland, we believe M&amp;A coupled with a focus on organic growth will deliver superior performance".<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">- remain agnostic on therapeutic areas and focus on specialty arenas with a focused position and customer base.<wbr> </div><div style="margin-bottom: 10px;">- continue to invest in R&amp;D and lower risk with programs like Aveed and bema.<wbr> </div><div style="margin-bottom: 10px;">- operate in a streamlined manner with quick decision-making </div><div style="margin-bottom: 10px;">New Reporting Segments 2014 vs 2013 </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Branded Drugs</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Generic Drugs</STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_7_ScreenCapture7.jpg"> </div><!-- Comment details --><a name="pharmaworld10764attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(42,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(29,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(34,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(30,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(27,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(40,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10764_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(52,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10764">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-28T16:00:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-28T16:00:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer's New Drug Portfolio Registers Impressive Growth</title>
	<pubDate>2014-02-28T15:01:32+01:00</pubDate>
	<wp:post_id>5079</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Group fourth quarter earnings appear to have fallen short of analyst 
expectations, with forex &amp; portfolio adjustments the main factors for 
this.<wbr> Future guidance was also considered on the low side.<wbr> That said growth of 
the group's new pharmaceutical portfolio is impressive, with guidance for both 
the anticoagulant Xarelot and the eye drug aflibercept raised whilst peak sales 
projections of         &gt; €1bn for 
Xofigo remain unchanged.<wbr> </div><div style="margin-bottom: 10px;">Chief executive Marijn Dekkers at the group's annual press 
conference announced that its four new drugs, plus the pulmonary 
hypertension treatment Adempas (riociguat), will have peak sales of at least 7.<wbr>5 
billion euros.<wbr> Previously, the estimate was 5.<wbr>5 billion euros.<wbr> </div><div style="margin-bottom: 10px;">He added 
that Bayer currently ranks 14th in the pharmaceutical league table based on 
revenues but he expects it to reach 10th position in the next few 
years, without acquisitions.<wbr> The new products "should get us there or very close 
to it", Dr Dekkers claimed.<wbr><BR><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_6_ScreenCapture6.jpg"> </div><div>source: <A href="http://www.bayer.com">www.<wbr>bayer.<wbr>com</A> </div><!-- Comment details --><a name="oncology9495attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(53,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(58,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(50 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(40,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(83 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9495_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(84,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9495">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-28T15:01:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-28T15:01:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Has Been Discreetly Downsizing</title>
	<pubDate>2014-02-28T14:27:21+01:00</pubDate>
	<wp:post_id>5080</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: When Novartis downsizes it tends to communicate locally where the ax is falling and rarely explains more.<wbr> Confronted by this silence, a Swiss Journalist has tallied up the job-cuts and is reporting in Tages-Anzeiger that the group has cut 3000 jobs around the world over the course of the last 4-months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>European Situation</STRONG> </div><div style="margin-bottom: 10px;">Close to a thousand of those jobs are being axed in Europe; half in Basel.<wbr> There are an additional 400 or so confirmed layoffs in its Horsham, U.<wbr>K.<wbr>, R&amp;D site, not to mention some 170 consultants, </div><div style="margin-bottom: 10px;"><STRONG>US Situation More Sales Focused</STRONG> </div><div style="margin-bottom: 10px;">Additionally, there are 760 positions being eliminated in the U.<wbr>S.<wbr>, with the reductions largely focused on sales reps, largely due to Novartis' concentration on hospital specialist therapies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Manufacturing Optimisation</STRONG> </div><div style="margin-bottom: 10px;">On the manufacturing side, Novartis has either closed or reduced some 20 facilities since 2010, looking for maximum efficiency at all its production centers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>R&amp;D Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Apparently, there is moer to come with the concentration going forward on R&amp;D.<wbr> </div><div>source:-<a href="http://www.tagesanzeiger.ch/wirtschaft/unternehmen-und-konjunktur/Novartis-streicht-ganz-diskret-3000-Arbeitsplaetze/story/14323720" class="defaultlink" title="http://www.tagesanzeiger.ch/wirtschaft/unternehmen-und-konjunktur/Novartis-streicht-ganz-diskret-3000-Arbeitsplaetze/story/14323720">tagesanzeiger.ch/<wbr>&hellip;</a> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10766c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>I have recently heard that Novartis is downsizing its publications group (my source suggests by as much as a quarter).<wbr> One might speculate that this could have a noticeable impact on its publications activities.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10762">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-28T14:27:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-28T14:27:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AB Science Initiates A New Phase 3 Study To Evaluate Masitinib (AB1010) In Combination With Docetaxel In mCRPC</title>
	<pubDate>2014-02-28T13:04:53+01:00</pubDate>
	<wp:post_id>5081</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This is an international, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC).<wbr> Overall Survival is the primary end point.<wbr> The phase 3 study has been authorized by competent authorities and expects to enrol 550 patients in the trial.<wbr> </div><div style="margin-bottom: 10px;">Clinical Trial Details: </div><div style="margin-bottom: 10px;"><UL><LI>Multicentre, randomised, placebo controlled, double blind Phase 3 trial
</LI>
<LI>Patient Population: first line mCRPC patients (in combination with docetaxel)
</LI>
<LI>Start Date 20 Feb 2014
</LI>
<LI>Expected enrolment =550 patients
</LI>
</UL> </div><div style="margin-bottom: 10px;">The decision is based on encouraging results from an exploratory phase 2 study of 23 patients.<wbr> Phase 2 study demonstrated an acceptable safety profile in combination with docetaxel.<wbr> The patients in treatment arm have reached a median overall survival of 18.<wbr>4 months in second line setting (post docetaxel).<wbr> </div><div style="margin-bottom: 10px;">Masitinib's Mechanism of Action (MOA) </div><div style="margin-bottom: 10px;"><UL><LI>Oral tyrosine kinase inhibitor (TKI) that selectively binds to and inhibits both the wild type and mutated forms of the stem cell factor receptor (c-Kit; SCFR), PDGF-alpha, and LYN tyrosine kinase.<wbr>
</LI>
<LI>Stem cell factor (ligand of c-Kit receptor) is an important growth factor for mast cell and induces mast cells survival.<wbr> Mast cell comes from precursor in bone marrow expressing the CD34 molecule.<wbr>A mast cell contains granulocyte that is rich is histamine and heparin.<wbr> Upon binding to immunoglobulin E, a mast cell releases histamine, pro-inflammatory cytokines and chemokines.<wbr>
</LI>
<LI>Binding of Stem cell factor to c-Kit leads to activation of multiple pathways, including phosphatidyl-inositol-3 (PI3)-kinase, phospholipase C (PLC)-gamma, Src kinase, Janus kinase (JAK)/<wbr>Signal Transducers and Activators of Transcription (STAT) and mitogen activated protein (MAP) kinase pathways
</LI>
<LI>Due to its unique MOA, other development programmes include:
<TABLE border="0" cellpadding="5" cellspacing="1" id="TblNewsDeals" style="width: 100%; background-color: #d1d3d1;"><TBODY><TR class="row2"><TH scope="col">Therapy Area</TH>
<TH scope="col">Indications</TH>
<TH scope="col">Product Stage</TH>
<TH scope="col">Territory</TH>
</TR>
<TR class="row2"><TD>Oncology</TD>
<TD><A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=8316&amp;IndicationNames=Pancreatic%20Cancer" style="font-family: verdana;">Pancreatic Cancer</A>; <A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=8542&amp;IndicationNames=Gastrointestinal%20Stromal%20Tumor%20(GIST)" style="font-family: verdana;">Gastrointestinal Stromal Tumor (GIST)</A></TD>
<TD>Pre-Registration</TD>
<TD>EU</TD>
</TR>
<TR class="row2"><TD>Central Nervous System</TD>
<TD><A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=1198&amp;IndicationNames=Alzheimer's%20Disease" style="font-family: verdana;">Alzheimer's Disease</A></TD>
<TD>Phase III</TD>
<TD>Global</TD>
</TR>
<TR class="row2"><TD>Gastrointestinal</TD>
<TD>Systemic Mastocytosis</TD>
<TD>Phase III</TD>
<TD>Global</TD>
</TR>
<TR class="row2"><TD>Oncology</TD>
<TD><A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=7773&amp;IndicationNames=Multiple%20Myeloma%20(Kahler's%20Disease)" style="font-family: verdana;">Multiple Myeloma (Kahler's Disease)</A>; <A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=8542&amp;IndicationNames=Gastrointestinal%20Stromal%20Tumor%20(GIST)" style="font-family: verdana;">Gastrointestinal Stromal Tumor (GIST)</A>; <A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=8551&amp;IndicationNames=Metastatic%20Pancreatic%20Cancer" style="font-family: verdana;">Metastatic Pancreatic Cancer</A>; Metastatic Colorectal Cancer; Metastatic Melanoma</TD>
<TD>Phase III</TD>
<TD>Global</TD>
</TR>
<TR class="row2"><TD>Respiratory</TD>
<TD><A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=1262&amp;IndicationNames=Asthma" style="font-family: verdana;">Asthma</A></TD>
<TD>Phase III</TD>
<TD>Global</TD>
</TR>
<TR class="row2"><TD>Dermatology</TD>
<TD>Cutaneous Mastocytosis</TD>
<TD>Phase III</TD>
<TD>Global</TD>
</TR>
<TR class="row2"><TD rowspan="2">Central Nervous System</TD>
<TD><A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=8452&amp;IndicationNames=Amyotrophic%20Lateral%20Sclerosis" style="font-family: verdana;">Amyotrophic Lateral Sclerosis</A>; Primary Progressive Multiple Sclerosis (PPMS); Secondary Progressive Multiple Sclerosis (SPMS)</TD>
<TD>Phase II</TD>
<TD>Global</TD>
</TR>
<TR class="row2"><TD><A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=1223&amp;IndicationNames=Depression" style="font-family: verdana;">Depression</A>; Dysthymia</TD>
<TD>Phase II</TD>
<TD>Europe</TD>
</TR>
<TR class="row2"><TD rowspan="2">Immunology</TD>
<TD><A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=7760&amp;IndicationNames=Rheumatoid%20Arthritis" style="font-family: verdana;">Rheumatoid Arthritis</A></TD>
<TD>Phase II</TD>
<TD>Global</TD>
</TR>
<TR class="row2"><TD><A class="submenu1" href="http://www.pharmaetrack.com/DiseaseDetails.aspx?IndicationIDS=2539&amp;IndicationNames=Psoriasis" style="font-family: verdana;">Psoriasis</A></TD>
<TD>Inactive</TD>
<TD>Global</TD>
</TR>
</TBODY>
</TABLE>

</LI>
</UL> </div><div style="margin-bottom: 10px;">AB Science Company Profile </div><div>AB Science (ABS) focuses its research in developing tyrosine kinase inhibitors for cancer treatment, inflammatory diseases, and central nervous system diseases.<wbr> ABS&rsquo;s pipeline includes three Phase III clinical trials ongoing in pancreatic cancer, GIST, and mastocytosis and eight Phase II clinical trials completed.<wbr> The company&rsquo;s lead compounds include masitinib in oncology, mistinib in inflammatory diseases, masitibib in central nervous system and other compounds.<wbr> ABS is headquartered in Paris, France.<wbr> The company reported revenues of (Euro) EUR 1.<wbr>34 million during the fiscal year ended December 2012, an increase of 21.<wbr>38% over 2011.<wbr> The operating loss of the company was EUR 10.<wbr>61 million during the fiscal year 2012, as compared to an operating loss of EUR 9.<wbr>72 million during 2011.<wbr> The net loss of the company was EUR 10.<wbr>99 million during the fiscal year 2012, as compared to a net loss of EUR 9.<wbr>65 million during 2011.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9492">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-28T13:04:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-28T13:04:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Valeant Reporting of Q4 and FY2013 Financial Results</title>
	<pubDate>2014-02-28T12:02:28+01:00</pubDate>
	<wp:post_id>5082</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the financial results, management highlighted it remains very confident that it can execute at least one large deal in 2014, and that will probably be the biggest catalyst for the stock this year.<wbr> In the company's radar '50 targets opportunities .<wbr>.<wbr>.<wbr> a lot of private companies, and non-US companies", and 'a number of ongoing discussions in Asia and Latin America'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management reported it is '.<wbr>.<wbr>.<wbr> in multiple discussions as it always has been, and will continue to be.<wbr> .<wbr>.<wbr>.<wbr> If an opportunity comes, it will move on it, depending on the price'.<wbr> </div><div style="margin-bottom: 10px;">When asked on their thoughts on Forest, J.<wbr> M.<wbr> Pearson outlined that : ".<wbr>.<wbr>.<wbr> we don't bet on pipelines.<wbr> So, it was not the type of asset that we were particularly interested in".<wbr> </div><div style="margin-bottom: 10px;">"Good business to be in" is <U>animal health</U>: ".<wbr>.<wbr>.<wbr> relationships are durable, they are durable products, it is cash pay, it is growing.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Total revenue in the quarter was $2.<wbr>0 billion an increase of 116% over the fourth quarter of 2012.<wbr>
</LI>
<LI>Total revenue for FY2013 increased by 72% Y/<wbr>Y.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7436_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">The US business exhibited sales organic growth of 14%, driven by many of the dermatology prescription brands, the aesthetic consumer and oral health portfolios, and certain neurology products.<wbr> </div><div style="margin-bottom: 10px;">The RoW developed markets, which included Canada and Australia, delivered sales organic growth rate of 12% in the quarter.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7436_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Neurology</STRONG> and other business is now at a run rate of about $1 billion, with growth of more than 20%.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><U>aesthetic business</U>: the company is on its way to expanding the injectable SF of its aesthetic portfolio to approx 200 reps, and increasing the number of calls to physicians and groups.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Oral health</STRONG> is at $125 million run rate, and increased more than 20% in the quarter.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Canadian operations</STRONG> has a $400 million run rate and grew more than 10% year over year in the fourth quarter.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7436_3_ScreenCapture3.jpg"> </div><div><EM>Source: Valeant</EM> </div><!-- Comment details --><a name="neurology7436attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7436_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(15,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7436_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(27,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7436_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(30,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7436">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-28T12:02:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-28T12:02:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>FIM of Esanex' HSP90 Inhibitor and Everolimus for NETs</title>
	<pubDate>2014-02-27T18:41:14+01:00</pubDate>
	<wp:post_id>5083</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Esanex is a privately-held, stealth stage biotech with backing from Lilly Ventures.<wbr> The Ph1 is designed to determine the maximum tolerated dose (MTD) of SNX-5422 when given in combination with everolimus.<wbr> PE will assess frequency and severity of adverse events.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Heat shock protein 90 (Hsp90) plays a central role in the maturation and maintenance of numerous proteins, for example HER2 and mutated EGFR, that are critical for tumor cell viability and growth; </P>
<UL><LI>SNX-5422 is a pro-drug of SNX-2112, a potent, highly selective, small-molecule inhibitor of the molecular chaperone heat shock protein 90 (Hsp90).<wbr> Hsp90 has been found to be expressed in 95% of subjects with pancreatic neuroendocrine tumors.<wbr></LI>
</UL>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">This study will determine the MTD of SNX-5422 when given in combination with everolimus in patients with neuroendocrine tumors.<wbr></P>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><STRONG>Dosage</STRONG></P>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">The clinical starting dose of 50 mg/<wbr>m2 qod for SNX-5422 in combination with daily everolimus is 50% of the SNX-5422 qod mono-therapy MTD.<wbr> The choice to continue once every other day SNX-5422 dosing is based on the safety and efficacy profiles from prior studies, so that drug holidays are interspersed into weekly dosing.<wbr> The planned subsequent dose levels are 75% and 100% of the SNX-5422 qod mono-therapy MTD.<wbr></P>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><STRONG>Recruitment</STRONG>: approx 15 patients with pathologic evidence of locally advanced or metastatic neuroendocrine tumor of gastro-entero-pancreatic or pulmonary origin.<wbr></P>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><STRONG>Completion date</STRONG>: Feb 2015 /<wbr> April 2015</P>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Location: US (2 sites)</P>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Esanex <SPAN style="FONT-FAMILY: arial; COLOR: #424242; FONT-SIZE: 10pt">is a drug development company focused on advancing its highly selective, orally active Hsp90 inhibitors</SPAN>.<wbr></P>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02063958?term=PROSTATE+OR+BOTULINUM+OR+SPASTICITY+OR+ACROMEGALY+OR+NEUROENDOCRINE&amp;recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=01%2F27%2F2014&amp;rank=7">NCT02063958</A></P></DIV></DIV></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7607">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-27T18:41:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-27T18:41:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Real Life Impact of BOTOX® for UI in Belgium</title>
	<pubDate>2014-02-27T18:28:09+01:00</pubDate>
	<wp:post_id>5084</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The observational study will evaluate the impact of BOTOX® treatment on anticholinergic drug use in patients with urinary incontinence from NDO due to spinal injury or MS who are prescribed BOTOX® as standard of care in clinical practice.<wbr> PE will assess the reduction in anticholinergic drug use.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Participants: approx 100
 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients prescribed BOTOX® for urine incontinence from NDO due to spinal injury or MS as standard of care in clinical practice in Belgium</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Previous treatment with anticholinergic drugs ineffective</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Last BOTOX® treatment ≥18 months.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Start date: Jan 2014 </div><div style="margin-bottom: 10px;">Completion dates: Sept 2015 </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02072928?term=PROSTATE+OR+BOTULINUM+OR+SPASTICITY+OR+ACROMEGALY+OR+NEUROENDOCRINE&amp;recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=01%2F27%2F2014&amp;rank=6">NCT02072928</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7435">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-27T18:28:09+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-27T18:28:09+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer's Strategy is to Become N°1 OTC Company</title>
	<pubDate>2014-02-27T12:18:26+01:00</pubDate>
	<wp:post_id>5085</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bayer is to buy privately held Dihon Pharmaceutical Group Co, a maker of traditional herbal Chinese medicines (TCM).<wbr> Dihon has about 2,400 employees and generated sales of 123 million euros ($168 million) in 2013.<wbr> A spokeswoman closed to Bayer said it was too early to say whether Dihon's products would be exported to Germany or Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Timeline</STRONG> </div><div style="margin-bottom: 10px;">The Dihon deal is to close in the second half of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Dihon's products</STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.dihon.com/en/sub/our_company.php">http:/<wbr>/<wbr>www.<wbr>dihon.<wbr>com/<wbr>en/<wbr>sub/<wbr>our_company.<wbr>php</A> </div><div style="margin-bottom: 10px;">Dandruff treatments, antifungal creams and medicine against gynaecological conditions such as endometriosis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>OTC Market</STRONG> </div><div style="margin-bottom: 10px;">China's consumer health and wellness market is expect to hit almost $70 billion by 2020 as increasing numbers of consumers turn to health supplements and OTC health treatments, according to a recent report from Boston Consulting Group.<wbr> </div><div style="margin-bottom: 10px;">The OTC market alone was worth $18 billion and is estimated to grow at a rate of around 8 percent per year.<wbr> </div><div><EM>Source: ThomsonOne</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10828c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="background-color: #888888;"><SPAN style="background-color: #ffffff;"><SPAN style="background-color: #ffffff;">Bayer</SPAN> Healthcare China President Alok Kanti has stated that the acquisition of <SPAN style="background-color: #ffffff;">Kunming Dihon Pharmaceutical</SPAN> Group Co.<wbr>, Ltd.<wbr>, targets the OTC segment and Dihon's sales channels in small and medium-sized cities, but that its Traditional Chinese Medicine (TCM) and other businesses were not central to the transaction.<wbr> </SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #888888;"><SPAN style="background-color: #ffffff;">Kanti underlined that greater OTC strength will boost overall portfolio sales in grassroots markets.<wbr> </SPAN></SPAN> </div><div><SPAN style="background-color: #888888;"><SPAN style="background-color: #ffffff;">He noted that <SPAN style="background-color: #ffffff;">Bayer</SPAN> is also interested in Dihon's GMP-certified factory in mid-tier Kunming, whose municipal infrastructure is particularly compelling.<wbr></SPAN></SPAN> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10758">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-27T12:18:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-27T12:18:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Second POC Trial with Omeros' PDE10 Inhibitor for Huntington's Disease</title>
	<pubDate>2014-02-27T10:30:58+01:00</pubDate>
	<wp:post_id>5086</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Omeros has reported dosing of the first patient.<wbr> The Ph2 will evaluate OMS824 in patients with symptomatic HD.<wbr> Interim results are expected in H2:2014, with final data projected to be available in 2015.<wbr> The company previously announced results of Ph2 for schizophrenia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Design</STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx 120 (Patients will be randomized to receive placebo or one of three doses of OMS824).<wbr> </div><div style="margin-bottom: 10px;">Efficacy will be assessed across three functional domains that are affected by the disease: motor, cognitive, and behavior.<wbr> Patients in the trial are allowed to continue their usual medications based on the results of the earlier Phase 2 trial in which schizophrenia patients who took similar classes of drugs had no untoward interactions with OMS824.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Competitive Advantages</STRONG> </div><div style="margin-bottom: 10px;">OMS824 has the potential to improve the cognitive and psychiatric abnormalities as well as the movement disorders associated with the disease.<wbr> Omeros has been awarded Orphan Drug designation by the FDA to evaluate OMS824 in HD and recently received Fast Track designation from the FDA for the development of OMS824 to treat cognitive impairment in HD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>vs Pfizer's <a href="http://clinicaltrials.gov/ct2/show/NCT01806896?term=PFIZER+AND+HUNTINGTON&amp;rank=1" class="defaultlink">PF-0254920</a></STRONG> </div><div style="margin-bottom: 10px;">Management has outlined that " .<wbr>.<wbr>.<wbr> There is currently one other PDE10 inhibitor being evaluated in patients with HD.<wbr> Based on available information, OMS824 achieves greater PDE10 target occupancy without extrapyramidal symptoms (EPS) than does any other PDE10 inhibitor previously or currently in development".<wbr> </div><div><EM>Source: Omeros</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7434">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-27T10:30:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-27T10:30:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>IQWiG Decides Xtandi Deserves First Highest AMNOG Innovation Score After Re-assessment</title>
	<pubDate>2014-02-26T18:33:23+01:00</pubDate>
	<wp:post_id>5087</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) has amended its verdict on the additional benefit of the Astellas (Japan) drug Xtandi (enzalutamide) in the treatment of metastatic prostate cancer based on new evidence presented by the manufacturer.<wbr> It has now decided that the drug is worthy of the highest innovation score possible under the benefit assessment system: a major (erheblich) additional benefit.<wbr> </div><div style="margin-bottom: 10px;">Specifically, IQWiG has stated that in the case of patients with no metastases in internal organs, Xtandi demonstrates an indication of a major additional benefit, thanks to new data submitted that demonstrates the comparator therapy (best supportive care) was properly implemented.<wbr> </div><div style="margin-bottom: 10px;">Furthermore, IQWiG states that in the case of patients with visceral metastases, the drug shows an indication of a major additional benefit in this patient group, thanks to quantifiable information submitted on side effects.<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">The IQWiG amendment was posted on the same day (20 February) that the Federal Joint Committee (G-BA) published its final resolution on Xtandi's early benefit assessment, in which it decided that the drug demonstrated a hint of a significant additional benefit, which is the second-highest innovation score – somewhat reduced by the use of the word "hint" – owing to the reservations the G-BA had about the limitations of the study data submitted.<wbr> </div><div style="margin-bottom: 10px;">It can be expected that the G-BA will now update its resolution with the amendment from IQWiG in mind.<wbr> No drug that has passed through the benefit assessment process has been given the highest innovation score and, assuming the G-BA agrees with IQWiG's assessment, Xtandi will become the first one.<wbr> </div><div><EM>Source: IHS Global Insight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9491">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-26T18:33:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-26T18:33:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>BOTOX® to be Tested in a New Indication</title>
	<pubDate>2014-02-26T18:26:10+01:00</pubDate>
	<wp:post_id>5088</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph2 prospective double blind controlled randomized will be testing BOTOX® in patients diagnosed with Carpal Tunnel Syndrome (CTS).<wbr> PE will assess change from baseline Levine Scale function and symptom severity at week 6, week 12, and week 18.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> </div><div><DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Patients who meet inclusion criteria will be randomly distributed into two groups: a BOTOX® (onabotulinumtoxin A) injection group and a Normal Saline Injection (NS) (Placebo group).<wbr> Each group will consist of five randomly assigned individuals.<wbr></P>

<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><STRONG>Recruitment</STRONG></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">approx.<wbr> 10 (both genders).<wbr></P>

<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><STRONG>Timelines</STRONG></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Start date: April 2014.<wbr></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Completion date: July 2014 /<wbr> December 2014.<wbr></P>

<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Location: 1 site in the US (Phoenix, AZ).<wbr></P>

<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02070302?term=PROSTATE+OR+BOTULINUM+OR+SPASTICITY&amp;recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=01%2F26%2F2014&amp;rank=11">NCT02070302</A></P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7433">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-26T18:26:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-26T18:26:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J At Citigroup's H/C Conference - Key Takeaways</title>
	<pubDate>2014-02-26T18:24:41+01:00</pubDate>
	<wp:post_id>5089</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In a rare appearance, Joaquin Duato Worldwide Chairman of Pharmaceuticals at J&amp;J gave a more in-depth presentation on Pharmaceuticals than is usual for the group, highlighting the division's strength in terms of product innovation and market access.<wbr> This has resulted in it being the fastest growing top 10 global pharmaceutical company in the US, Europe &amp; Japan.<wbr> Registration submission for ARN-509 in nmCPRC was highlighted as being within the 2014-2017 timeframe.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="oncology9487attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(124 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(123,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(113,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(127,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(146,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(103,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(107,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(124,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9487_9_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(109 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9487">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-26T18:24:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-26T18:24:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UCB's CVN Drived Company Growth in 2013</title>
	<pubDate>2014-02-26T15:48:54+01:00</pubDate>
	<wp:post_id>5090</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: FY13 revenues grew 2% yoy at constant exchange rates.<wbr> Growth of the CVN drivers (Cimzia, Vimpat, Neupro) remains robust growing at &gt;30% yoy at constant currency, and new indications should accelerate growth and their opportunities.<wbr> In 2014, UCB expects the continued growth of CVN and emerging markets to drive company growth.<wbr> A selection of key data is reported below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10756_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10756_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10756_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The drug offers 2 solutions for the US market : lyophilized formulation and prefilled syringe.<wbr> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10756_1_ScreenCapture1.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10756">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-26T15:48:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-26T15:48:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New PhIII Study To Be Initiated In Primary Liver Cancer</title>
	<pubDate>2014-02-25T17:13:06+01:00</pubDate>
	<wp:post_id>5091</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <ORG value="NASDAQ-SMALL:CLSN">Celsion 
Corporation</ORG> has announced today that the <ORG>U.<wbr>S.<wbr> </ORG>FDA 
has provided clearance for the Company's planned pivotal, double-blind, 
placebo-controlled Phase III trial of ThermoDox®, its proprietary heat-activated 
liposomal encapsulation of doxorubicin in combination with radio frequency 
ablation (RFA) in  primary hepatocellular carcinoma (HCC).<wbr> </div><div style="margin-bottom: 10px;">The trial design is based on a comprehensive analysis of data from the 
Company's Phase III HEAT Study, which demonstrated that treatment with ThermoDox 
resulted in a 55% improvement in overall survival in a substantial number of HCC 
patients that received an optimized RFA treatment.<wbr>  <ORG value="NASDAQ-SMALL:CLSN">Celsion</ORG> expects to launch the 
study in the first half of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The new OPTIMA Study</STRONG> </div><div style="margin-bottom: 10px;">The Phase III trial, is expected to enroll 550 patients globally, with up to 
100 sites in <LOCATION value="LC/us">the United 
States</LOCATION>, <LOCATION value="LR/eur">Europe</LOCATION>, <LOCATION value="LC/cn">China</LOCATION> and <LOCATION value="LR/asp">Asia Pacific</LOCATION> and will evaluate ThermoDox in 
combination with RFA, which will be standardized to a minimum of 45 minutes 
across all investigators and sites for treating lesions 3 to 7 centimeters, 
versus standardized RFA alone.<wbr> The primary endpoint for the trial is overall 
survival (OS).<wbr>  The statistical plan calls for two interim efficacy 
analyses by an independent Data Monitoring Committee (iDMC).<wbr> </div><div style="margin-bottom: 10px;">Commenting on this development Nicholas Borys, MD, <ORG value="NASDAQ-SMALL:CLSN">Celsion's</ORG> Chief Medical 
Officer stated "ThermoDox appears to hold great promise as a 
first-line treatment when used in combination with  optimized RFA, for 
primary liver cancer, one of the most deadly and prevalent forms of cancer 
worldwide.<wbr> Consistency of the retrospective data emerging from the HEAT Study 
over the past year has been remarkable, and underscores the potential of 
ThermoDox to extend survival in primary liver cancer patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Data Supporting The Design Of The OPTIMA Study</STRONG> </div><div style="margin-bottom: 10px;"><CHRON></CHRON>Post-hoc data from the Company's  HEAT Study demonstrated 
that the patient subgroup in the ThermoDox arm whose RFA procedure lasted longer 
than 45 minutes (285 patients or 63% of single lesion patients), experienced a 
55% improvement in overall survival, with a Hazard Ratio of 0.<wbr>64 (95% CI 0.<wbr>41 - 
1.<wbr>00) and a P-value = 0.<wbr>0495.<wbr> Median overall survival for this subgroup has not 
yet been reached.<wbr> <ORG value="NASDAQ-SMALL:CLSN">Celsion</ORG> will continue to follow patients in the HEAT 
Study on a quarterly basis.<wbr> A presentation highlighting the results of the HEAT 
study is attached.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Global Expansion Plans</STRONG> </div><div style="margin-bottom: 10px;">In parallel with its efforts in <LOCATION value="LC/us">the United States</LOCATION>, Celsion is continuing to 
advance discussions with regulators in other important global markets, including 
a recent positive meeting with China FDA (CFDA) and near-term plans to meet with 
European regulatory authorities.<wbr> </div><div style="margin-bottom: 10px;">In support of the Company's global regulatory efforts, <ORG value="NASDAQ-SMALL:CLSN">Celsion</ORG> recently met with 
CFDA to discuss the Phase III trial, including minimum patient enrollment 
requirements supporting ThermoDox's registration in <LOCATION value="LC/cn">China</LOCATION>.<wbr> Based on those discussions, <ORG value="NASDAQ-SMALL:CLSN">Celsion</ORG> is submitting an 
application for accelerated approval of the study in <LOCATION value="LC/cn">China</LOCATION>.<wbr> <ORG value="NASDAQ-SMALL:CLSN">Celsion</ORG> also plans expand its clinical site footprint 
in <LOCATION value="LR/eur">Europe</LOCATION> and plans to 
meet with the <ORG value="ACORN:3106670068">European 
Medicines Agency</ORG> (EMA) in the first half of 2014.<wbr> </div><div>Source: <A href="http://www.celsion.com">www.<wbr>celsion.<wbr>com</A> </div><!-- Comment details --><a name="oncology9485attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9485_1_Celsion%255f%2d%255fPhase%255f3,%255fRandomized,%255fDouble%2dBlind,%255fDummy%2dControlled,%255fTrial%20(1).pdf">Celsion_-_Phase_3,_Randomized,_Double-Blind,_Dummy-Controlled,_Trial (1).pdf</a>&nbsp;&nbsp;(731,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9485">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-25T17:13:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-25T17:13:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Immuno-Oncology (IO) Highlighted at 2014 Leerink Global H/C Conference</title>
	<pubDate>2014-02-25T11:52:55+01:00</pubDate>
	<wp:post_id>5092</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Updates from several preeminent cancer immunology &amp; lung cancer key opinion leaders (KOLs) point to a transformation in cancer care across solid and liquid tumors.<wbr> For Leerink analyst, the IO market has the potential to exceed $29B in 2025.<wbr> KOLs expect new IO results at every major medical conference.<wbr> Selected data are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Enthusiasm for LAG3</STRONG> </div><div style="margin-bottom: 10px;">KOLs highlighted LAG3 as one of the most promising potential combinations with PD1 based on early animal data.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>BMS's plan to initiate combination testing with PD1 along with the start of a Ph I single-agent study of LAG3 is, in our opinion, a good initial sign for the drug's safety.<wbr> The initiation of four separate Ph II CHECKMATE studies of nivolumab monotherapy in liquid tumors (DLBCL, FL) and solid tumors (GBM, MSI-High CRC) point to the breadth of PD1's activity.<wbr> (NCT01968109; NCT02061761).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Furthermore, the start of nivolumab + Yervoy studies broadly in GBM and CRC suggests that the toxicity of the combination, while challenging, is manageable.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9478_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9478_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Combinations of LAG3 or TIM3 with PD1 or PDL1 antibodies</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Novartis' acquisition of CoStim (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9466" class="defaultlink">Oncology9466: Novartis Acquiers CoStim and Expands in Immunotherapy for Cancer</a> - likely includes preclinical antibodies to PD1/<wbr>PDL1, LAG3, TIM3) may provide it access to differentiated TIM3 IP and jumpstart the company's IO antibody efforts alongside its efforts with CART.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>AstraZeneca will present data from both (NCT02000947; NCT01454102) of its ongoing studies at ESMO in 2H14</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9478_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Interest in Cancer Vaccines, anti-KIR and IDO Inhibitors</STRONG> </div><div style="margin-bottom: 10px;">KOLs highlighted a potential "renaissance" for cancer vaccines as well as clear enthusiasm for targets that modulate the innate immune system, such as IPH's (OP) anti-KIR lirilumab as well as IDO inhibitors being pursued by Incyte Corp.<wbr> and New Link Genetic.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Both lirilumab and Incyte's INCB024360 are in combination trials with PD1 and CTLA4 agents.<wbr> (NCT01714739; NCT01750580).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Ongoing IO Trials</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9478_4_ScreenCapture4.jpg"> </div><div> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9478">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-25T11:52:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-25T11:52:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Takeaways from Allergan at 2014 Leerink Global H/C Conference</title>
	<pubDate>2014-02-25T11:18:28+01:00</pubDate>
	<wp:post_id>5093</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Jeffrey Edvards and David Pyott reported that BD implication is critical for extending Allergan's leadership in core areas such as aesthetics, medical dermatology, ophthalmolgy, neurology and urology.<wbr> When it comes to products, management was constructive on further opportunities for Botox (depression, osteoarthritis pain, and premature ejaculation), and and less constructive on Revance's topical botulinum toxin.<wbr> It was highlighted that the Medytox deal offers benefit to separate therapeutic from cosmetic for Average Sales Price (ASP) determination.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management highlighted at least 4 weakenesses : </div><div style="margin-bottom: 10px;"><UL><LI>(a) high FDA risk, </LI>
<LI>(b) lower perceived efficacy and duration of effect vs.<wbr> injectable botulinum toxins, </LI>
<LI>(c) prolonged 45 minutes in doctors office, and </LI>
<LI>(d) sole indication of crow’s feet at launch.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management cited its challenge of the current CMS ASP price determinations, which includes the Botox Cosmetic pricing and limits the company’s ability to separate therapeutic from cosmetic pricing – and limits the company’s ability to take price increases.<wbr> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> the recent deal with Medytox for the company’s liquid (vs.<wbr> the current lyophilized formulation that has to be reconstituted) botulinum toxin formulation offers not only a more convenient administration but the new formulation could be a way for Allergan to price and market Botox for therapeutic indications vs.<wbr> cosmetic indications separately and ultimately avoid the pricing limitations imposed by CMS*".<wbr> </div><div style="margin-bottom: 10px;"> </div><div><EM>Source: Leerink</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7431">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-25T11:18:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-25T11:18:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Re-aligns its Marketing System in Japan</title>
	<pubDate>2014-02-25T10:09:42+01:00</pubDate>
	<wp:post_id>5094</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Effective April 1st 2014, each Medical Representative (MR) will be responsible for one of three therapeutic areas; “Cardiovascular/<wbr>Metabolic Diseases”, “Gastrointestinal, Central Nervous System, Urological and Bone/<wbr>Rheumatic Diseases” and “Oncology”.<wbr> This transformation allows the MRs to better meet the evolving demands of delivering innovative medicines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Managers of sales offices and Team Leaders under the Managers will remain responsible for all Takeda products.<wbr> </div><div style="margin-bottom: 10px;">Managers and Team Leaders will also continue to engage in medical information distribution activities tailored to their region's unique characteristics and engage in promotional activities in cooperation with distributors, both of which contribute greatly to Takeda's competitive advantage in Japan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Expertise</STRONG> </div><div style="margin-bottom: 10px;">Each MR focuses more on one designated therapeutic area, to further improve their functional expertise.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Knowledge</STRONG> </div><div style="margin-bottom: 10px;">Takeda will continue internal MR training for all products so that MRs have the proper knowledge base to respond to inquiries from healthcare professionals regarding all Takeda products.<wbr> </div><div><EM>Source: Takeda</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10753">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-25T10:09:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-25T10:09:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Progress With New Prostate Cancer Tests</title>
	<pubDate>2014-02-24T18:33:52+01:00</pubDate>
	<wp:post_id>5095</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: New data from Myriad's Prolaris test  demonstrates that the test can predict the risk of cancer recccurence following radical prostatectomy.<wbr> Meanwhile, scientists at Cambridge Universtiy have demonstrated that a test assessing the level of a protein NAALADL2 can  correctly distinguish aggressive prostate tumours.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Myriad's Data</STRONG> </div><div style="margin-bottom: 10px;">Data from a US and German study in 582 biopsy specimens from men treated for prostate cancer by radical prostatectomy showed that CCP score as determined by Prolaris was significantly associated with biochemical recurrence in both univariable and multivariable analysis.<wbr> HR 1.<wbr>6 and 1.<wbr>47 respectively.<wbr> Additionally, CCP score was signficantly associated with metastatic disease in both univariable analysis and after adjusting for clinical variables.<wbr> </div><div style="margin-bottom: 10px;">The CCP score was found to be a stronger predictor of metastatic disease than either Gleason score or PSA.<wbr> </div><div style="margin-bottom: 10px;">Myriad markets Prolaris in the US, Europe and Canada to predict the risk of cancer recurrence following radical prostatectomy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Cambridge University Test</STRONG> </div><div style="margin-bottom: 10px;">Data published by Dr Haley Whitaker in Oncogene found that the protein NNAALAD12 can correctly distinguish aggressive tumours.<wbr> Clinical trials are expected to start this year.<wbr>.<wbr> </div><div style="margin-bottom: 10px;">The test has the ability to be run on technology already routinely used in the NHS and is likely to cost a couple of pounds maximum </div><div style="margin-bottom: 10px;">Professor Malcolm Mason from Cancer Research UK is quoted in the press as saying " I have been waiting years for a test that can define aggressive prostate disease.<wbr> I hope this research brings forward the day when I can say to patients, we know that your cancer doesn't need treatment".<wbr> </div><div>Source: <A href="http://www.myriad.com/">www.<wbr>myriad.<wbr>com</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9731c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Commmet: Myriad Genetics Inc presneted new data from a clinical validation study of Prolaris at the AUA 2014 in Orlando on 20th May 2014.<wbr> Tis study is the largest validation study to date of any gene based prognostic test in patients with prostate cancer who were diagnosed by needle biopsy.<wbr> Prolaris test can accurately differentiate newly diagnosed patients who were likely to die from prostate cancer within 10 years from thos with lower risk disease.<wbr> This is thought to be a much stronger indicator of clinical outcomes than Gleason score or PSA.<wbr> A quote from the study investigator " <EM>currently, with standard clinical tools like Gleason Score or PSA, we can't adequately define prognosis.<wbr> The Prolaris test provides useful new information and is highly prognostic or disease specific death among men being conservatively treated</EM>.<wbr>" </div><div>The objective of the study was to validate the test score in 761 conservatively managed prostate cancer pateints diagnosed by needle biopsy.<wbr> The primary end point was prostate cancer death and the median follow up time was 9.<wbr>5 years.<wbr> The resutls showed that for each one unit increase in the PRolaris score, patients had approximately double the risk of dying from prostate cancer.<wbr>In the second study featured in AUA, 230 men who had pathologic Gleason Scores of either 3+4 or 4+3 were examined.<wbr> The Prolaris test signifcanlty outperformed the current practice of upgrading to Gleaseon 3+4 or 43 in predicting which patients would experience biochemical recurrence after a radical prostatectomy.<wbr> This finding should lead to improved initial decisions on the most effective treatment for each patient based on the patient's own riskk of disease progression.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9476">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-24T18:33:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-24T18:33:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Merz' Xeomin 50U/100U Launched in Ireland</title>
	<pubDate>2014-02-24T16:40:27+01:00</pubDate>
	<wp:post_id>5096</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Emilie Chaudière (Neuro PM, Ireland) we have learnt that the Irish Medicine Board issued the licence on January 31 2014.<wbr> One sales rep has been recruited, part time (3 days a week).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Under investigation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><UL><LI>eyelid spasm (blepharospasm),</LI>
<LI>twisted neck (spasmodic torticollis),</LI>
<LI>increased muscle tension/<wbr>uncontrollable muscle stiffness in arms or hands after a stroke (post-stroke spasticity of the upper limb, going along with clinical pattern of fl exed wrist and clenched fist).<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7430">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-24T16:40:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-24T16:40:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Ex-Takeda to Join Acino as New CEO</title>
	<pubDate>2014-02-24T16:16:38+01:00</pubDate>
	<wp:post_id>5097</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Jostein Davidsen will join the Acino Group as its new CEO by mid-May 2014.<wbr> Currently Head of Emerging Markets at Takeda Pharmaceuticals, he is responsible for the EUR 1.<wbr>5 billion business in the emerging growth economies of the company.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company reaches out to customers across the world through its own brand “Acino Switzerland”.<wbr> </div><div style="margin-bottom: 10px;">Currently Acino offers its products over 80 countries in the Middle East, Africa, Asia and Latin America.<wbr> </div><div style="margin-bottom: 10px;">Geographically the company generates revenue from 21 different countries and regions.<wbr> </div><div>In 2012, Germany reported 29.<wbr>8% of the company's total revenue, followed by Rest of World with 12.<wbr>0%, Saudi Arabia (8.<wbr>4%), Switzerland (7.<wbr>4%), Iraq (7.<wbr>0%), West Africa (5.<wbr>8%), Rest of Europe (5.<wbr>7%), France (3.<wbr>4%), the UAE (3.<wbr>3%), Spain (2.<wbr>5%), Croatia (2.<wbr>2%), Ecuador (2.<wbr>0%), the Netherlands (1.<wbr>7%), Denmark (1.<wbr>4%), Kuwait (1.<wbr>3%), United Kingdom (1.<wbr>2%), Italy (1.<wbr>1%), Sweden (1.<wbr>1%), Poland (1.<wbr>0%), Portugal (0.<wbr>9%) and Belgium (0.<wbr>8%).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9474">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-24T16:16:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-24T16:16:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lilly's Ramucirumab Meets 2nd PhIII Endpoint This TIme in NSCLC</title>
	<pubDate>2014-02-24T15:41:25+01:00</pubDate>
	<wp:post_id>5098</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lilly's VEGFR-2 mAb suceeded in achieving another positive PhIII outcome last week , this time in NSCLC (previously in 2nd line gastric cancer).<wbr> Yet to be approved a decision is expected from the FDA in 2Q14 for the gastic cancer indication.<wbr> Meanwhile, other phIII trials ongoing include one to treat mCRC and another HCC.<wbr> Both of these are expected to produce top-line data this year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The REVEL study</STRONG> </div><div style="margin-bottom: 10px;">This PhIII study in &gt;1200 patients with disease progression after platinum-based chemotherapy for NSCLC, has demontrated an improvement in overall survival (primary endpoint) vs.<wbr> placebo plus docetaxel plus an improvement in PFS.<wbr> </div><div style="margin-bottom: 10px;">The most common Gr3/<wbr>4 side effects were neutropenia/<wbr>leukopenia, febrile neutropenia, fatigue/<wbr>asthenia and hypertension.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Lilly plans to submitt regulatory applications for NSCLC this year </div><div style="margin-bottom: 10px;">The product has Orphan Drug Designation in Europe for gastric cancer and HCC and fast track designation in the US for gastic cancer.<wbr> </div><div>Source: <A href="http://www.lilly.com/">www.<wbr>lilly.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9471">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-24T15:41:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-24T15:41:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novo Nordisk's Progress With LA-GH</title>
	<pubDate>2014-02-24T15:14:04+01:00</pubDate>
	<wp:post_id>5099</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Novo Nordisk disclosed this month in its 2013 earnings call that its open-lable phI trial with its long-acting growth hormone undertaken in patients with Adult GHD has demonstrated that the drug NN8640 is safe and well tolerated.<wbr> The company expects to decide whether to progress into phIII testing by mid-year.<wbr> </div><div style="margin-bottom: 10px;">The PhI 35 patients study evaluated 4 escalating doses of NN8640 or once daily subcutaneous Norditropin NordiFlex for 4 weeks.<wbr> A highly dose-dependent and very clear IGF-I response was observed.<wbr> In fact the potency was actually higher than had been anticipated suggesting that there are likely to be few problems in identifying a Phase III doses neither for adults but probably also not for kids.<wbr> </div><div>Source:www.<wbr>novonordisk.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7604">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-24T15:14:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-24T15:14:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Results from a Comparative Study of Liposomal BoNT-ONA for OAB</title>
	<pubDate>2014-02-24T11:04:46+01:00</pubDate>
	<wp:post_id>5100</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Findings of a Ph2 double-blind randomized parallel controlled pilot trial in OAB patients show the intravesical Lipotoxin instillation reduced frequency episodes 1 month after treatment without any increase in postvoid residual urine volume (PVR) or risk of urinary tract infection (UTI), adverse events commonly shown with injection.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=5107" class="defaultlink">Neurology5107: Liposome Encapsulated Botulinum Toxin A for Overactive Bladder Syndrome</a> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><H1></H1> </div><div style="margin-bottom: 10px;"><DIV class="content-columns cf">
<DIV class="content-main">
<DIV class="article-head">
<P class="author">Hann-Chorng Kuo <SUP><A href="http:///#aff0005" id="back-aff0005" name="back-aff0005">a </A></SUP><SUP><A href="http:///#cor0005" id="back-cor0005" name="back-cor0005"> </A></SUP><A href="mailto:hck@tzuchi.com.tw"></A>, Hsin-Tzu Liu <SUP><A href="http:///#aff0005" id="back-aff0005" name="back-aff0005">a </A></SUP><SUP><A href="http:///#aff0010" id="back-aff0010" name="back-aff0010">b </A></SUP>, Yao-Chi Chuang <SUP><A href="http:///#aff0015" id="back-aff0015" name="back-aff0015">c </A></SUP>, Lorie A.<wbr> Birder <SUP><A href="http:///#aff0020" id="back-aff0020" name="back-aff0020">d </A></SUP>and Michael B.<wbr> Chancellor <SUP><A href="http:///#aff0025" id="back-aff0025" name="back-aff0025">e </A></SUP></P></DIV></DIV></DIV> </div><div style="margin-bottom: 10px;"><SUP><A href="http:///#back-aff0005">a</A></SUP> Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan Department of Urology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan </div><div style="margin-bottom: 10px;"><SUP><A href="http:///#back-aff0010">b</A></SUP> Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan Institute of Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan </div><div style="margin-bottom: 10px;"><SUP><A href="http:///#back-aff0015">c</A></SUP> Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Kaohsiung, Taiwan Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Kaohsiung, Taiwan </div><div style="margin-bottom: 10px;"><SUP><A href="http:///#back-aff0020">d</A></SUP> Departments of Medicine and Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA Departments of Medicine and Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA </div><div style="margin-bottom: 10px;"><SUP><A href="http:///#back-aff0025">e</A></SUP> Oakland University, William Beaumont School of Medicine, Royal Oak, MI, USA Oakland University, William Beaumont School of Medicine, Royal Oak, MI, USA.<wbr> </div><div><EM>Source: Thanks to Alison Attard for having forwarded this paper.<wbr></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7429">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-24T11:04:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-24T11:04:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Prana Biotech Releases Positive PhII Huntington's Data</title>
	<pubDate>2014-02-21T18:53:57+01:00</pubDate>
	<wp:post_id>5101</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Prana Biotech was the second company today to release postivie phII results in patients with Parkinson's disease, this time demonstrating a postive effect of PBT2 on cognition.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Summary of Key Findings</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Safety</STRONG> - PBT2 was well tolerated and generally found to be safe over 26 weeks of therapy in patients with early to mid-stage Huntington's disease </div><div style="margin-bottom: 10px;"><STRONG>Efficacy</STRONG> - PBT2 250mg daily significantly improved cognition on a key measurement of executive function.<wbr> Trails Making Test B signficantly improved from baseline to week 26 in the PBT treatment group.<wbr> Such an improvement has never been previously demonstrated in a Huntington disease clinical trial.<wbr> Results are consistent with those seen in a prior phII study with PBT2 in Alzheimer's patients.<wbr> </div><div style="margin-bottom: 10px;">Cognitive improvements was also accompanied by a favourable signal in functional capacity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Imaging</STRONG> - A small sub-study suggested reduced brain atrophy among those exposed to active treatment.<wbr> </div><div style="margin-bottom: 10px;">Whilst such results look promising they do need to be confirmed in larger PhIII studies.<wbr> </div><div>source:- <A href="http://www.pranabio.com/">www.<wbr>pranabio.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7428">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-21T18:53:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-21T18:53:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Exelixis F/Y Results-Key Takeaways on MTC & CRPC</title>
	<pubDate>2014-02-21T18:17:51+01:00</pubDate>
	<wp:post_id>5102</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During its earnings call, Exelixis highlighted its progress with COMETRIQ in Medullary Thyroid Cancer (MTC).<wbr>both in the US where it has been commercially available for 1 year and in Europe where it is close to approval.<wbr>.<wbr> MTC is a small market opportunity where Cometriq within its first year, with 70-80% US penetration generated $15m in sales.<wbr> Additional information on Cometriq's combination studies in CRPC were also highlighted during the call.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Financials</STRONG> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Net revenue for the fourth quarter were $4.<wbr>3 million, which was entirely related to U.<wbr>S.<wbr> sales of COMETRIQ and $31.<wbr>3 million for the full year, of which $15 million was related to the sale of COMETRIQ.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">R&amp;D expenses for the quarter were $49.<wbr>6 million and $178.<wbr>8 million for the full year.<wbr> Year-over-year, R&amp;D expenses increased for both the fourth quarter as well as the full year, mainly as a result of substantially increased clinical trial expenses, predominantly driven by the ramp up of COMET-1 and METEOR, our Phase 3 pivotal studies in CRPC and RCC respectively, as well as the startup of CELESTIAL, our Phase 3 pivotal study in HCC.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">With a year-end cash balance of $416 million at the end of 2013, plus proceeds from a January equity offering of approximately $76 million, as well as with the amendment to the Deerfield financing arrangement announced in January, Exelixis is in a strong position to continue the broad development of cabozantinib and to work towards the potential build-out of its commercial infrastructure.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG>Comments of Interest on COMETRIQ's Performance, Safety Profile &amp; European Launch</STRONG> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">In the fourth quarter, Exelixis internalized its sales function for COMETRIQ such that it now has 15 sales reps calling on MTC customers.<wbr> The reps made over 2,300 calls on physicians in the fourth quarter, with an average frequency of 2.<wbr>1 calls.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Exelixis noted that brand awareness amongst target oncologists is now 90% and overall customer satisfaction remains high.<wbr> Market research it was claimed indicates that 90% of healthcare practitioners surveyed rated their impressions of COMETRIQ as either favorable or highly favorable and that close to 90% said the drug exceeded their expectations.<wbr> In addition, anecdotal feedback from prescribers, particularly those with experience using other VEGF TKIs, indicated that they are comfortable managing the side effects associated with COMETRIQ.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">With a positive CHMP opinion, Exelixis is continuing to work closely with Sobi its distribution partner, to get ready for a potential approval in the EU.<wbr> Reimbursement dossiers are nearing completion and several positive interactions have been had with national payers in some of the major countries in Europe.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr"><STRONG>Comments of relevance to COMETRIQ in CRPC</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Exelixis claimes to have made significant progress in its internal planning activities for a potential approval in CRPC.<wbr> it has completed a comprehensive CRPC launch plan for the U.<wbr>S.<wbr>, including market-sizing, resourcing and distribution network planning.<wbr> Interestingly, it also expects its first commercial hire in Europe to start in March and it has started work on a European launch plan.<wbr>.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">In addition to the COMET studies, the group has also been actively working on an evaluation of the the suitability of cabozantinib for use in the earlier line of treatment of CRPC patients prior to chemotherapy.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">The first study in this setting will evaluate the combination of cabozantinib with abiraterone.<wbr> This randomized Phase 2 study commenced in the fourth quarter of 2013.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">The study a randomized Phase 2 study,  is comparing full-dose abiraterone versus cabozantinib given at three different doses of 40-milligram daily, 20-milligram daily or 20 milligram every other day, combined with full-dose abiraterone.<wbr> The patient population is a pre-chemotherapy population of CRPC patients with bone metastases and the primary endpoint is radiographic progression-free survival.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">A second trial will evaluate the combination of cabozantinib with enzalutamide, and is expected to start later in 2014.<wbr> The objective for this Phase 1 combination study is to evaluate drug-drug interaction and resulting impact on pharmacokinetics as well as safety for different doses of cabozantinib given in combination with full-dose enzalutamide.<wbr></P> </div><div><P align="left" dir="ltr">Source: <A href="http://www.exelixis.com/">www.<wbr>exelixis.<wbr>com</A>.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7598">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-21T18:17:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-21T18:17:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on Botox iOAB Indication in Italy</title>
	<pubDate>2014-02-21T13:23:05+01:00</pubDate>
	<wp:post_id>5103</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Thanks to Patrizia Caglioni (PM, Italy) we have learnt that Allergan is developing a third line completely dedicated to urologists, and that it will defocus its activity on cervical dystonia and adult post stroke spasticity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Approved Indication</STRONG> </div><div style="margin-bottom: 10px;">Idiopathic overactive bladder with symptoms of urinary incontinence, urgency and frequency in adult patients who do not have an adequate response or were intolerant to anticholinergic drugs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The new indication is 100% reimbursed.<wbr><BR> </div><div style="margin-bottom: 10px;"><STRONG>Packaging </STRONG><STRONG>100U</STRONG> - 1 vial </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">Class of eligibility: Hospital </DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">Ex-factory price: € 142.<wbr>99 (before discounts) - € 129.<wbr>05 net -</DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">
<DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">The price for 100 units was unchanged but it was requested an additional mandatory discount in according to negotiation agreements.<wbr></DIV>
</DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px"><STRONG>Packaging 200U</STRONG> - 1, 2, 3 or 6 vials</DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">Not reimbursed</DIV> </div><div><DIV style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px">Class of elegibility: C</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7424">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-21T13:23:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-21T13:23:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Raptor Reports Top-Line Ph2/3 Results of its Huntington Drug</title>
	<pubDate>2014-02-21T11:51:36+01:00</pubDate>
	<wp:post_id>5104</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The trial was conducted at eight clinical sites throughout France under a collaboration agreement between Raptor and CHU d'Angers.<wbr> 18 month clinical results of an ongoing Ph2/<wbr>3 trial showed significantly slower progression of Total Motor Score (TMS) in RP103 treated patients without tetrabenazine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>96 patients with HD were randomized to treatment with RP103 or placebo.<wbr> </LI>
<LI>89 patients completed the initial 18 month phase.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">Analysis of all 96 patients enrolled in the trial showed a positive trend towards slower progression of Total Motor Score (TMS) in patients treated with RP103 vs.<wbr> those patients on placebo, the primary endpoint of the study.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>TMS progression was 32% slower in patients treated with RP103 vs.<wbr> those treated with placebo after 18 months treatment (4.<wbr>51 vs.<wbr> 6.<wbr>68 respectively, p=0.<wbr>19).<wbr> In 66 patients not taking concurrent tetrabenazine, RP103 treatment resulted in a statistically significant slower progression in TMS vs.<wbr> the placebo group (2.<wbr>84 points vs.<wbr> 6.<wbr>78 respectively, p=0.<wbr>03).<wbr></LI>
</UL> </div><div><UL><LI>RP103 was well tolerated with 48/<wbr>52 patients experiencing at least one adverse event (AE) during the 18 month study vs.<wbr> 38/<wbr>44 under placebo.<wbr> There were slightly more patients under RP103 than under placebo reporting at least one gastrointestinal AE (61.<wbr>5% RP103 vs.<wbr> 45.<wbr>5% placebo), mostly nausea, vomiting, abdominal pain, constipation and breath odor.<wbr> There were also slightly more headache AEs on RP103 than on placebo.<wbr> There were 5 patients treated with RP103 who experienced serious adverse events (SAEs) compared with 4 patients treated with placebo.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7423">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-21T11:51:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-21T11:51:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Jean-Christophe Tellier Named Next CEO at UCB</title>
	<pubDate>2014-02-21T10:25:52+01:00</pubDate>
	<wp:post_id>5105</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Roch Doliveux remains Chief Executive Officer of UCB until January 1, 2015.<wbr> Tellier joined UCB in 2011 as EVP, Biopharma Brands and Solutions.<wbr> He will be responsible for the company's next phase of evolution (the launch of late-stage projects in the areas of osteoporosis, lupus and epilepsy, the growth of Cimzia, Vimpat and Neupro, and the expansion in emerging markets and Japan).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10752_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10752_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10752_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>Doctor of Medicine (M.<wbr>D.<wbr>) – University of Reims Champagne-Ardenne, France </LI>
<LI>Post-graduate: Rheumatologist - University of Paris V, France</LI>
<LI>Executive business programs at Harvard and INSEAD</LI>
</UL> </div><div><EM>Source: UCB</EM> </div><!-- Comment details --><a name="pharmaworld10752attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10752_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10752_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(40,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10752_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(54 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10752">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-21T10:25:52+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-21T10:25:52+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Arno's Onapristone to Enter Ph1/2 in Patients With Advanced CRPC</title>
	<pubDate>2014-02-20T18:44:30+01:00</pubDate>
	<wp:post_id>5106</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This study will evaluate an extended-release (ER) formulation of onapristone in patients with prostate cancer in which Progesterone Receptor (PR) may be contributing to tumor progression.<wbr> The drug, a progesterone receptor antagonist, was originally developed by Schering AG.<wbr> Arno's strategy is to develop onapristone companion diagnostic for each indication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">A companion diagnostic to select patients whose prostate cancer expresses the activated form of the PR (APR) is under development and will be implemented in this study.<wbr></P>

<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Recruitment: approx.<wbr> 60</P>

<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><U>Timelines</U></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Start date: Feb 2014 - Completion dates: Feb 2015 /<wbr> Aug 2016</P>

<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Location: UK</P>

<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02049190?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=01%2F20%2F2014&amp;rank=312">NCT02049190</A></P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9470">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-20T18:44:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-20T18:44:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>SOTIO to Start Ph3 with its Therapeutic Cancer Vaccine for Prostate Cancer</title>
	<pubDate>2014-02-20T16:10:26+01:00</pubDate>
	<wp:post_id>5107</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: SOTIO, a biotechnology company based in Prague, is developing DCVAC/<wbr>PCa, which consists of dentritic cells pulsed with dead PCa cells.<wbr> Key opinion leaders in prostate cancer from the US and EU reviewed the Ph3 study protocol and contributed to the final design.<wbr> The company introduced itself for the first time to the WW oncology community at ASCO 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The acronym VIABLE is derived from the description of the trial: acti<B>V</B>e <B>I</B>mmunother<B>A</B>py using dendritic cell-<B>B</B>ased treatment for <B>L</B>ate stage prostat<B>E</B> cancer.<wbr> </div><div style="margin-bottom: 10px;"><U>ID</U>: Eudra <A href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-002814-38/HU">CT: 2012-002814-38</A>; IND: 015255.<wbr> </div><div style="margin-bottom: 10px;"><U>Design</U>: add-on therapy to 1st-line standard of care chemotherapy in men with mCRPC.<wbr> </div><div style="margin-bottom: 10px;"><U>Primary Endpoint</U>: to show superiority of treatment with DCVAC/<wbr>PCa in addition to Standard of Care Chemotherapy over placebo in addition to Standard of Care Chemotherapy in men with mCRPC as measured by OS.<wbr> </div><div style="margin-bottom: 10px;"><U>Timelines</U>: first patients expected in March 2014.<wbr> </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: approx.<wbr> 1,170 prostate cancer patients.<wbr> </div><div style="margin-bottom: 10px;"><U>Location</U>: US, Belgium, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, the Netherlands, Portugal, Spain, Sweden, the UK, Croatia, Poland, Romania, Slovakia, Russia, Serbia, and Turkey.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.sotio.com/news/sotio-at-asco-annual-meeting-2013">http:/<wbr>/<wbr>www.<wbr>sotio.<wbr>com/<wbr>news/<wbr>sotio-at-asco-annual-meeting-2013</A> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9468_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><U>Research - Active Cellular Immunotherapy</U> </div><div style="margin-bottom: 10px;"><A href="http://www.sotio.com/research/active-cellular-immunotherapy">http:/<wbr>/<wbr>www.<wbr>sotio.<wbr>com/<wbr>research/<wbr>active-cellular-immunotherapy</A> </div><div style="margin-bottom: 10px;"><EM>Management</EM> </div><div><A href="http://www.sotio.com/about-us/people">http:/<wbr>/<wbr>www.<wbr>sotio.<wbr>com/<wbr>about-us/<wbr>people</A> </div><!-- Comment details --><a name="oncology9468attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9468_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(57 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9468">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-20T16:10:26+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-20T16:10:26+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Versartis Secured $55M in Series E Financing</title>
	<pubDate>2014-02-20T11:48:03+01:00</pubDate>
	<wp:post_id>5108</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The proceeds from this financing will primarily be used to prepare for an international Ph3 pediatric GHD trial of VRS-317, the company's once-monthly dosing rhGH.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Five undisclosed new investors have joined existing investors Sofinnova Ventures, Aisling Capital, New Leaf Venture Partners and Advent Life Sciences in this round.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">VRS-317 is currently being studied in pediatric GHD patients in a Phase 2a clinical trial to evaluate the 6-month efficacy and safety.<wbr> </div><div><EM>Source: Versartis</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7596">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-20T11:48:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-20T11:48:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ISS to Test New Indication with Botox</title>
	<pubDate>2014-02-18T18:34:46+01:00</pubDate>
	<wp:post_id>5109</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The purpose of this ph2 research study is to determine if Botox injections will provide relief from chronic testicular pain.<wbr> </div><div style="margin-bottom: 10px;">In the study, the spermatic cord of particpants will be injected with either Botox or a placebo of saline.<wbr> </div><div style="margin-bottom: 10px;">Botox is currently used to treat other urological conditions like overactive bladder and lower urinary tract problems.<wbr> For these conditions, Botox works by relaxing muscles in the affected areas.<wbr> The investigators believe that Botox will act similarly in the treatment chronic testicular pain.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx 50<BR> </div><div style="margin-bottom: 10px;">Timelines </div><div style="margin-bottom: 10px;">from March 2014 to March 2015 </div><div>Source: NCT02058836 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7422">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-18T18:34:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-18T18:34:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AZD2014 (TOR kinase inhibitor) to Enter FIM for Prostate Cancer</title>
	<pubDate>2014-02-18T18:28:46+01:00</pubDate>
	<wp:post_id>5110</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The purpose of this study is to investigate the molecular pharmacology of AZD2014 treatment given to patients with prostate cancer prior to radical prostatectomy.<wbr> The feasibility, safety and tolerability of a short course of AZD2014 will also be assessed.<wbr> </div><div style="margin-bottom: 10px;"><P style="margin-top: 0ex; margin-bottom: 1ex;">Recruitment: approx 20</P> </div><div style="margin-bottom: 10px;"><P style="margin-top: 0ex; margin-bottom: 1ex;">Timelines: tne Ph1 study is to start in June 2014 and is expected to complete June /<wbr>Sept 2015</P> </div><div><P style="margin-top: 0ex; margin-bottom: 1ex;">Source: NCT02064608</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9467">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-18T18:28:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-18T18:28:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Acquiers CoStim and Expands in Immunotherapy for Cancer</title>
	<pubDate>2014-02-18T18:00:24+01:00</pubDate>
	<wp:post_id>5111</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The acquisition gives Novartis a number of late discovery stage immunotherapy programmes directed to several targets, including PD-1.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Analyst Forecasts</STRONG> </div><div style="margin-bottom: 10px;">Citigroup analyst Andrew Baum predicts that the market for immunotherapies may eventually reach $35 billion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Competition</STRONG> </div><div>Other companies developing PD-1 inhibitors include Bristol-Myers Squibb with nivolumab and Merck &amp; Co.<wbr> via MK-3475.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9466">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-18T18:00:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-18T18:00:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Prana' Huntington Drug Poised to Enter Registration Trial</title>
	<pubDate>2014-02-18T17:51:40+01:00</pubDate>
	<wp:post_id>5112</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The ph2 REACH2HD clinical trial investigating PBT2 as a treatment for Huntington disease met its primary safety endpoint and achieved statistically significant improvement in a measure of executive function (cognition), which comprised part of the study's main efficacy outcome.<wbr> Prana plans to advance PBT2 into a confirmatory Phase 3 clinical trial that could allow PBT2 to be approved for the treatment of Huntington disease.<wbr> </div><div style="margin-bottom: 10px;">Reach2HD is a double-blind, placebo-controlled study was conducted by the Huntington Study Group at research sites in the United States and Australia.<wbr> The study enrolled 109 individuals with Huntington disease who were randomly assigned to receive daily doses of either PBT2 250mg, PBT2 100mg, or placebo for 26 weeks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Findings</STRONG> </div><div style="margin-bottom: 10px;">The primary endpoint of the study was met.<wbr> In this study, PBT2 was safe and well tolerated.<wbr> Ninety-five percent (104 of 109) of participants completed the study on their assigned dose.<wbr> There were no substantial differences in adverse events across the two PBT2 dose groups and the placebo group.<wbr> Only one of the ten reported serious adverse events was deemed by the clinical site investigator to be related to drug treatment.<wbr> </div><div style="margin-bottom: 10px;">An independent Data Safety Monitoring Board met on five occasions over the course of the trial and on each occasion recommended that the trial continue as per the original protocol.<wbr> </div><div style="margin-bottom: 10px;">The effects of PBT2 were tested on cognition, motor performance, behaviour and functional capacity, of which cognition was pre-specified as the main efficacy outcome.<wbr> </div><div style="margin-bottom: 10px;">There was a statistically significant improvement in performance on the Trail Making Test Part B, in the PBT2 250mg group compared to placebo.<wbr> </div><div>Source: Prana </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7421">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-18T17:51:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-18T17:51:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Management of Pasireotide-induced Hyperglycemia in Cushing's Disease or Acromegaly</title>
	<pubDate>2014-02-17T18:31:54+01:00</pubDate>
	<wp:post_id>5113</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The Ph4 study aims to demonstrate that pasireotide-induced hyperglycemia can be effectively and safely managed in majority of patients, including those with diabetes at start of pasireotide treatment.<wbr> PE will assess the change in HbA1c from randomization to approximately 16 weeks.<wbr> </div><div style="margin-bottom: 10px;">Eligible patients will start pasireotide subcutaneously (s.<wbr>c.<wbr>) for Cushing's disease and pasireotide LAR (long-acting release) for acromegaly.<wbr> </div><div style="margin-bottom: 10px;">Patients currently treated at screening visit with pasireotide s.<wbr>c.<wbr> or LAR are eligible as long as they meet protocol criteria during the screening period.<wbr> If previously normo-glycemic patients experience increases in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they will start anti-diabetic treatment using metformin.<wbr> If they continue to have elevated blood sugars above target on metformin within the first 16 weeks, they will be randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks </div><div><DIV class="identifier">Source: NCT02060383</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7595">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-17T18:31:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-17T18:31:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novel Topical Soft Anticholingeric for Hyperhidrosis</title>
	<pubDate>2014-02-17T18:02:38+01:00</pubDate>
	<wp:post_id>5114</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new randomized, vehicle controlled, double blind study in subjects with axillary hyperhidrosis designed to assess the safety, tolerability and the effect on sweat production of topically applied Brickell Biotech's BBI-4000 for 14 days.<wbr> PE will evaluate the percent change in the gravimetrically measured sweat production from baseline.<wbr> </div><div style="margin-bottom: 10px;">Brickell Biotech, Inc.<wbr>is a clinical-stage pharmaceutical company focused on the acquisition, development and commercialization of innovative drug therapies for the treatment of skin diseases.<wbr> </div><div style="margin-bottom: 10px;">The company was founded in November 2009 by a team of experienced pharmaceutical executives committed to efficiently developing a portfolio of novel and viable treatment alternatives to address rapidly growing skin indications where new therapies will be welcomed in the marketplace.<wbr> </div><div><DIV class="identifier">Source: <a href="http://www.clinicaltrials.gov/ct2/show/NCT02058264?recr=Open&no_unk=Y&fund=2&rcv_s=01%2F17%2F2014&rank=191" class="defaultlink">NCT02058264</a></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7420">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-17T18:02:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-17T18:02:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AAA's Fund Raising Should Help To Accelerate Development & Expansion Plans</title>
	<pubDate>2014-02-17T11:54:43+01:00</pubDate>
	<wp:post_id>5115</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: AAA has successfully completed a capital raising of &euro;41m to help fund its US expansion plans and finance its portfolio of diagnostic and therapeutic radiopharmaceuticals, most notably Lutathera  and the NETTER-1 trial but possibly sooner than anticiapted a trial in pancreatic-NET.<wbr> </div><div style="margin-bottom: 10px;"><P align="left">The fundraising came from existing and new shareholders, including private investors and funds such as a company of the Tamburi Investment Partners Group and the specialist biotech and pharma investment company HBM Healthcare Investments Ltd who led the investment with &euro;20m.<wbr></P> </div><div style="margin-bottom: 10px;">Commenting on the fund raising Stefano Buono, Chief Executive Officer of AAA stated: <EM><EM></EM></EM>The support we continue to receive is testament to the confidence of our shareholders in the continued growth and positive achievements of the Company and its solid business model.<wbr> The money raised will help us accelerate our international growth, which includes the expansion of our activities in the US, and finance the development of our promising product pipeline.<wbr> We welcome HBM Healthcare Investments Ltd as a shareholder and believe their experience in backing biotech and pharma will be of great use to guide our strategic directions.<wbr>&rdquo; </div><div style="margin-bottom: 10px;"><P align="left">Andreas Wicki, Chief Executive Officer of HBM Healthcare Investments added:-</P> </div><div style="margin-bottom: 10px;"><P align="left">"We are elighted to add AAA to our portfolio of promising healthcare companies.<wbr> We believe that AAA&rsquo;s approach to targeted therapy is very promising and will further advance innovation and product development in Molecular Nuclear Medicine, a niche which has been poorly exploited until now.<wbr> AAA is a fast growing company that we are excited to support and to accompany on the way to further success.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Timeline For Completion Of The NETTER-1 Trial</STRONG></P> </div><div><P align="left">AAA announced in October that it had reached the 100 patient milestone in its NETTER-1 study.<wbr> Completioni of the study is scheduled for Q32015 woth market authorisation in Europe anticipated in 1H2017.<wbr> The fund raising increases the possibility that a study in pancreatic -NET may be started sooner than might have been anticipated.<wbr>.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7594">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-17T11:54:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-17T11:54:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New Degarelix Data Demonstrates CV Benefit</title>
	<pubDate>2014-02-17T09:36:13+01:00</pubDate>
	<wp:post_id>5116</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New Degarelix Data Demonstrates CV Benefit</span>&nbsp;<br><span style="font-size: 12px;">Comment: A new paper published in European Urology indicates a 50% reduction in cardiac events for prostate cancer patietns with pre-existing cardiovascular disease when treated with Firmagon compared to LHRH agonists.<wbr> The data at this stage is considered hypothesis generating and needs validation.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9462">...</a><br></div><div style="margin-bottom: 10px;">Following the evaluation of some extracts from NICE 2014, Patrick Cabri notes that the manufacturer only applied the risk of having a cardiovascular event to those patients who had a cardiovascular event at baseline (30.<wbr>7% of patients) because the pooled trial data only indicated a statistically significant difference between degarelix and leuprorelin for these patients.<wbr> </div><div style="margin-bottom: 10px;">The ERG obtained advice from clinical specialists who highlighted that most patients in the UK who receive treatment with LHRH agonists will receive anti-androgen flare protection with bicalutamide and the proportion of patients who received anti-androgen flare protection in the data sample was low.<wbr> The ERG noted that the manufacturer used several pooled analyses to present the data for advers events and PSA progression from the 6 included open label randomised controlled trials.<wbr> If considered this to be inappropriate becuase such polling ignores the characteristics of the individual studies and relies on the assumption that there is no difference between individual trials.<wbr> Therefore the ERG considered that the results presented in pooled analysis in the manufacturer's submission were inappropriate and should be interpreted with caution.<wbr> </div><div>In summary, as written in the paper, the findings should be interpreted only as hypothesis generating and still further studies are required to validate this observation.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9463">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9462">View thread  Oncology9462: New Degarelix Data Demonstrates CV Benefit</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-17T09:36:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-17T09:36:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Degarelix Data Demonstrates CV Benefit</title>
	<pubDate>2014-02-14T17:39:08+01:00</pubDate>
	<wp:post_id>5117</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: A new paper published in European Urology indicates a 50% reduction in cardiac events for prostate cancer patietns with pre-existing cardiovascular disease when treated with Firmagon compared to LHRH agonists.<wbr> The data at this stage is considered hypothesis generating and needs validation.<wbr> </div><div style="margin-bottom: 10px;">The paper was published in the 5th February edition of European Urology </div><div style="margin-bottom: 10px;">The report is based on a pooled analysis of 2,328 men with prostate cancer from six prospective, randomised trials.<wbr> The data was in fact first presented at EAU &amp; ESMO last year (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9201" class="defaultlink">Oncology9201: ESMO Intelligence Part 1- New Hormonal Prostate Cancer Therapy Data</a>).<wbr> </div><div style="margin-bottom: 10px;">The paper's authors note that this post-hoc analysis of prospective randomised trials should be interpreted as hypothesis generating and highlights the need for additional studies.<wbr> </div><div style="margin-bottom: 10px;">Study co-author Jan Nilsson MD, Department of Clinical Sciences, Lund University, Sweden, said, </div><div style="margin-bottom: 10px;">&ldquo;<EM>One recent study suggests that cardiovascular disease is among the most common causes of early mortality in men with advanced prostate cancer, not the cancer itself<SUP>2</SUP>.<wbr> As a cardiologist I want urologists to be aware of this and to consider CV risk when selecting treatment options for their patients and analyses such as this are a positive step towards helping them to do just that.<wbr></EM>&rdquo; </div><div style="margin-bottom: 10px;"><STRONG>The Rerported Data</STRONG> </div><div style="margin-bottom: 10px;">The paper entitled &ldquo;Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist,&rdquo; reported that for men with pre-existing CVD at baseline there were &lsquo;significantly fewer cardiac events or deaths&rsquo; experienced by patients receiving degarelix (6.<wbr>5%) compared with patients receiving LHRH agonists (14.<wbr>7%).<wbr> A Cox proportional hazard model showed a 56% lower risk of a cardiac event or death during the initial year of treatment for men receiving degarelix compared with men receiving LHRH agonists (CI 0.<wbr>26-0.<wbr>74, p=0.<wbr>002).<wbr> The absolute risk reduction during the first year was 8.<wbr>2% which yields a number needed to treat of 12.<wbr> </div><div style="margin-bottom: 10px;">Among the men who had no pre-existing cardiovascular disease at baseline there was no difference in the incidence of either death from any cause or the incidence of cardiac events.<wbr> Moderate alcohol consumption and a low baseline serum testosterone level were the only other predictors of a lower risk of a cardiac event or death.<wbr> </div><div style="margin-bottom: 10px;">In the six prospective randomised trials included in the analysis, cancer patients were randomised to receive androgen deprivation therapy (ADT) in the form of GnRH antagonist degarelix (1,491) or an existing LHRH agonist (458 received goserelin and 379 received leuprolide).<wbr> Most patients (72%) received treatment for one year, while the remaining patients were treated for three to seven months.<wbr> Both treatment groups were well balanced for baseline characteristics e.<wbr>g.<wbr> statin medication, elevated blood pressure, diabetes, cholesterol and history of CV disease.<wbr> The CV event analysis was based on death from any cause or a serious CV event defined as arterial, embolic /<wbr> thrombotic; haemorrhagic /<wbr> ischemic cerebrovascular; myocardial infarction or other ischemic heart disease.<wbr> </div><div>Laurence Klotz MD, Division of Urology, University of Toronto, Ontario, Canada is quoted as saying &ldquo;<EM>Androgen deprivation therapies play an important role in the treatment of men with prostate cancer.<wbr> As these therapies become more widely used and for longer periods of time, we are understanding more about what needs to be done to help patients beyond management of the cancer itself.<wbr> I believe this analysis provides insights which have the potential to help physicians better manage the cardiovascular health of their androgen deprivation therapy patients - particularly those with pre-existing cardiovascular disease</EM>&rdquo;.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9463c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Following the evaluation of some extracts from NICE 2014, Patrick Cabri notes that the manufacturer only applied the risk of having a cardiovascular event to those patients who had a cardiovascular event at baseline (30.<wbr>7% of patients) because the pooled trial data only indicated a statistically significant difference between degarelix and leuprorelin for these patients.<wbr> </div><div style="margin-bottom: 10px;">The ERG obtained advice from clinical specialists who highlighted that most patients in the UK who receive treatment with LHRH agonists will receive anti-androgen flare protection with bicalutamide and the proportion of patients who received anti-androgen flare protection in the data sample was low.<wbr> The ERG noted that the manufacturer used several pooled analyses to present the data for advers events and PSA progression from the 6 included open label randomised controlled trials.<wbr> If considered this to be inappropriate becuase such polling ignores the characteristics of the individual studies and relies on the assumption that there is no difference between individual trials.<wbr> Therefore the ERG considered that the results presented in pooled analysis in the manufacturer's submission were inappropriate and should be interpreted with caution.<wbr> </div><div>In summary, as written in the paper, the findings should be interpreted only as hypothesis generating and still further studies are required to validate this observation.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9462">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-14T17:39:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-14T17:39:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Aveo's TKI Inhibitor Tivozanib Hits A Major Roadblock</title>
	<pubDate>2014-02-14T14:16:36+01:00</pubDate>
	<wp:post_id>5118</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Aveo and Astellas have ended their pact to develop the cancer drug 
tivozanib, a tyrosine kinase inhibitor that has been in development for 
multiple cancer indications including, breast, CRC and HCC, </div><div style="margin-bottom: 10px;">The two companies signed a W/<wbr>W development &amp; commercialisation 
agreement in 2011.<wbr> </div><div style="margin-bottom: 10px;">Tivozanib was rejected by the US Health regulators in June 2013 for use in 
kidney cancer, citing inconsitent results.<wbr> </div><div style="margin-bottom: 10px;">A breast camcer study was stopped last month due to insufficient enrollment 
and in December Aveo announced that the drug was not likely to succeed in 
CRC.<wbr> </div><div style="margin-bottom: 10px;">The termination of the collaboration will be effective August 11 with the 
product returned to Aveo.<wbr> </div><div>Source:www.<wbr>aveo.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9461">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-14T14:16:36+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-14T14:16:36+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UK Issues New Guidelines on Aesthetic Practices</title>
	<pubDate>2014-02-13T11:59:15+01:00</pubDate>
	<wp:post_id>5119</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The UK has issued new guidelines on the injection of dermal fillers and botulinum toxin and plastic surgery for breast implants, following warnings of "cowboy practices" and a "crisis waiting to happen".<wbr> However, the guidelines come nowhere close to what had been called for by the Association of Aesthetic Plastic Surgeons (BAAPS).<wbr> </div><div style="margin-bottom: 10px;">A review last year by the Department of Health in England said there was considerable concern that regulations had failed to keep pace - leaving patients vulnerable.<wbr> One aspect that had been called for was legislation to classify fillers as prescription only drugs.<wbr> This has not happened.<wbr> </div><div style="margin-bottom: 10px;">Rajiv Grover, a consultant plastic surgeon and president of the British Association of Aesthetic Plastic Surgeons (BAAPS), told the BBC: "Frankly, we are no less than appalled at the lack of action taken.<wbr>" </div><div style="margin-bottom: 10px;">Ministers believe that the action taken including a review of training by Health Education England for both dermal fillers and Botox injections will help with legislation will be introduced to make it illegal to offer such procedures without training.<wbr> Anyone offering fillers will have to do so under a named doctor or nurse, whose reputation will be on the line.<wbr> </div><div style="margin-bottom: 10px;">The government said it was working at an EU level to as part of a review of medical devices to change the rules on fillers.<wbr> </div><div style="margin-bottom: 10px;">Ministers say other measures being announced will improve the whole industry including:- </div><div style="margin-bottom: 10px;"><UL><LI>A registry of breast implants to prevent a repeat of PIP </LI>
<LI>A review into a system of redress if things go wrong with treatment </LI>
<LI>More rigorous consent process to let patients have time to fully consider their decision to have surgery.<wbr> </LI>
<LI>A clamp down on irresponsible advertising with the help of the Advertising Standards Authority.<wbr> </LI>
<LI>The Royal College of Surgeons should set standards for the training and practice of cosmetic surgery </LI>
</UL> </div><div><A href="http://www.bbc.com/">www.<wbr>bbc.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7414">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-13T11:59:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-13T11:59:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Daewoong's Nabota Slated for Roll-Out in Argentina</title>
	<pubDate>2014-02-13T11:03:39+01:00</pubDate>
	<wp:post_id>5120</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Daewoong has selected Argentina-based Bago company to distribute Nabota, and will supply the product for 7 years from 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">This contract paves the way for NABOTA to make inroads into the fourth region of Latin America, which Daewoong targets after it signed contracts last year to make entry into : </div><div style="margin-bottom: 10px;">- the US, EU (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7191" class="defaultlink">Neurology7191: Evolus to Sell Daewoong's Botulinum Toxin (Nabota) in the US and EU Markets</a>), </div><div style="margin-bottom: 10px;">- Latin America (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7296" class="defaultlink">Neurology7296: Daewoong's Botulinum Toxin NABOTA Gains Ground in Latin America</a>), </div><div style="margin-bottom: 10px;">- Iran (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7356" class="defaultlink">Neurology7356: Daewoong Inked Contract with TKJ to Supply NABOTA in Iran</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to the Daewoong PR : </div><div style="margin-bottom: 10px;">- The pharmaceutical market of Argentina is worth $5 billion (as of 2011), accounting for approx.<wbr> 10% of entire pharmaceutical market of Central and Latin America.<wbr> </div><div style="margin-bottom: 10px;">- Argentina’s botulinum toxin formulation market, currently worth $16 million, has steadily expanded, growing at an annual average rate of 5%(average of the 5 preceding years).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Website: <A href="http://www.bago.com.ar/">http:/<wbr>/<wbr>www.<wbr>bago.<wbr>com.<wbr>ar</A> </div><div style="margin-bottom: 10px;">- Founded: 1934 </div><div style="margin-bottom: 10px;">- Products in &gt;47 countries, 11 pharmaceutical production facilities worldwide, 85 patents developed in 15 countries under own research and over 479 products comprising 40 therapeutic lines </div><div><EM>Source: Daewoong</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7410">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-13T11:03:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-13T11:03:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Beyond Enzalutamide & Abiraterone: What's Next In Androgen Therapy</title>
	<pubDate>2014-02-12T15:41:42+01:00</pubDate>
	<wp:post_id>5121</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Andrew Armstrong gave an interesting presentation at the recent ASCO 
GU meeting highlighting possible new therapeutic approachs to modulation of 
the androgen axis when clinical resistance to enzalutamide and 
abiraterone emerges.<wbr> These approaches in the main represent very early 
clinical or pre-clinical development therapeutics, with the exceptioni of 
reference to ARN-509, ODM-201 &amp; TOK-001.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">HSP90 mixed response so far </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_7_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_8_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_9_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_10_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">Viable option to overcome AR mutants </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_11_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_12_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">loosing Ligand Dependence </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_13_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_14_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_15_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;">AR variants confer resistance to bicalutamide and enzalutamide </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_16_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_17_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;">None of the above have enetered phI studies currently.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_18_ScreenCapture20.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_19_ScreenCapture21.jpg"> </div><div style="margin-bottom: 10px;">Inhibiting GR is going to be a challenge<img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_20_ScreenCapture22.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_21_ScreenCapture23.jpg"> </div><div style="margin-bottom: 10px;">The above illustrative patient case illustrates how emergence of resistance 
to both abiraterone and enzalutamide is associated with changes in the genomic 
profile of the patient over time.<wbr> They point towards the emergence of a 
neuroendocrine pheynotype.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_22_ScreenCapture24.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_23_ScreenCapture25.jpg"> </div><!-- Comment details --><a name="oncology9460attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(97,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(99,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(100,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(98,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(108,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(74,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_7_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(109,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_8_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(79,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_9_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(107,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_10_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(73,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_11_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(60 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_12_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(114,5 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_13_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(71,5 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_14_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(103,3 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_15_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(96,4 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_16_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(121,5 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_17_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(141,3 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_18_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(87,7 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_19_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(95,5 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_20_ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(69 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_21_ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(105,8 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_22_ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(94 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9460_23_ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(119,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9460">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-12T15:41:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-12T15:41:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>OncoGenex Completes PhIII mCPRC Trial</title>
	<pubDate>2014-02-12T14:44:22+01:00</pubDate>
	<wp:post_id>5122</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: OncoGenex has announced that the pre-specified number of events required for final analysis of its PhIII SYNERGY trial with Custirsen has now been reached The primary efficacy endpoint of the trial is OS looking at the benefit of custrisen in combination with docetaxel in men with metastic CRPC.<wbr> </div><div style="margin-bottom: 10px;">  Overall survival results will remain blinded until all study data has been thoroughly reviewed.<wbr> </div><div style="margin-bottom: 10px;"><TABLE style="width: 100%;"><TBODY><TR align="left"><TD>
<DIV class="article_body">OncoGenex notes that "The conclusion of the SYNERGY trial represents a critical milestone for the company and for the custirsen development programm.<wbr></DIV>

<DIV class="article_body"><STRONG>Scope Of The Trial</STRONG></DIV>
<DIV class="article_body">Altogether 1,022 men have been enrolled in the trial at 148 cancer centres throughout North America, Europe, Israel and South Korea.<wbr></DIV>
<DIV class="article_body">Trial enrollment was completed in 2012 and final survival results are expected to be announced by mid-2014.<wbr></DIV>
<DIV class="article_body">During the trial custirsen was administered as a weekly infusion oc 640mg following three loading doses in combination with docetaxel given in 3-week cycles.<wbr> In the comparative arm</DIV>
<DIV class="article_body">patients received docetaxel &amp; prednisone without custirsen.<wbr></DIV>
<DIV class="article_body">In both arms patients were treatment until disease progressions, unacceptable toxicity or completion of up to 10 cycles.<wbr></DIV>

<DIV class="article_body"><STRONG>Partnership &amp; FDA Status</STRONG></DIV>
<DIV class="article_body">OncoGenex has been working in partnership with Teva which has development and commercialisation rights.<wbr> The drug has received Fast Track designation from the FDA for this combination approach in mCRPC and the protocl design of the SYNERGY trial was agreed under an SPA.<wbr>.<wbr> <BR><BR>Source: <A href="http://www.oncogenex.com">www.<wbr>oncogenex.<wbr>com</A></DIV>
</TD>
</TR>
</TBODY>
</TABLE> </div><div><TABLE style="width: 100%;"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9457">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-12T14:44:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-12T14:44:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on Degarelix 3M</title>
	<pubDate>2014-02-12T11:21:55+01:00</pubDate>
	<wp:post_id>5123</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Soft intelligence gathered at the GnRH international symposium (Feb.<wbr> 9-11 in Salzburg) indicates that the 3M formulation tested in the Ph3 trials will not reach the market (additional details are provided below).<wbr> Ferring had a sympo on controlled ovarian stimulation, and several sessions with degarelix pool analysis results.<wbr> The company supported all the 'basic science session' and the event with a grant of 100 000 euros.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV style="margin-top: 0px; margin-bottom: 0px;"></DIV> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><DIV style="margin-top: 0px; margin-bottom: 0px;"></DIV> </div><div style="margin-bottom: 10px;"><UL><LI>
</LI>
<LI>
</LI>
</UL> </div><div><DIV style="margin-top: 0px; margin-bottom: 0px;"></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9454">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-12T11:21:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-12T11:21:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Pharma Strategic Review Underway at Reckitt Benckiser</title>
	<pubDate>2014-02-12T10:24:20+01:00</pubDate>
	<wp:post_id>5124</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has reported it is considering all options for the business, which could include selling it, spinning it off, or keeping it.<wbr> An update will be provided in the course of this year.<wbr> </div><div style="margin-bottom: 10px;"><P align="justify"><STRONG>Pharmaceuticals ("RBP")</STRONG></P> </div><div style="margin-bottom: 10px;">FY 2013 net revenue was &pound;777m, a decrease of 8%.<wbr> </div><div style="margin-bottom: 10px;">The non US business was impacted by government imposed price reductions in a number of European markets.<wbr> </div><div>" .<wbr>.<wbr>.<wbr> RBP is a strong, sustainable business with good long term prospects.<wbr> It has a market leading, physician and patient preferred product in the US, with strong patent protection up until 2030.<wbr> The business outside of the US has much potential in what are currently under-treated markets.<wbr> We also have a strong pipeline, as we look to deliver to patients the next generation products for opioid addiction.<wbr>" </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1939">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-12T10:24:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-12T10:24:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Analyst Discussion with D. Pyott</title>
	<pubDate>2014-02-11T14:31:27+01:00</pubDate>
	<wp:post_id>5125</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The discussion focused on DARPin vs Lucentis, Levadex and recently launched Voluma.<wbr> </div><div style="margin-bottom: 10px;"><P align="left">Management is still hopeful that <STRONG>DARPin</STRONG> may offer greater durability (fewer injections per year) than Lucentis and potentially Eylea (and still yield similar efficacy).<wbr> The key point is that the 2nd stage of Ph II that reported last year did NOT include dosing intervals to assess the duration of DARPin vs.<wbr> Lucentis.<wbr> But the 3rd stage, which will be reported in 2H:14, will evaluate duration of efficacy.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Levadex</STRONG> (acute migraine) should be approved in 2Q, but initial sales ramp likely modest.<wbr> Management outlined that it will take time to ramp up the supply chain after approval.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Voluma</STRONG> (facial filler) priced at a 30% premium to Allergan's Juvedermis justified because Voluma is labeled for "up to two years' duration" vs.<wbr> Juvederm's "one year duration.<wbr>" Voluma is priced at $392 per 1 ml syringe vs.<wbr> Juvederm's $274 per 1 ml syringe.<wbr> Voluma offers compelling efficacy and should enable Allergan to grow the market and take share from competitors.<wbr> Although it will cannibalize Juvederm to some degree, Management expects cannibalization to be modest.<wbr></P> </div><div><P align="left"><EM>Source: Morgan Stanley</EM></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7409">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-11T14:31:27+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-11T14:31:27+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nestle Buys Galderma For €3.1bn</title>
	<pubDate>2014-02-11T13:09:17+01:00</pubDate>
	<wp:post_id>5126</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Nestl&eacute; and L'Or&eacute;al have approved by unanimous decision a strategic transaction for both companies under which L'Or&eacute;al will buy 48.<wbr>5 million of its own shares (8% of its share capital) from Nestl&eacute;.<wbr> The buyback will be partly financed through the disposal by L'Or&eacute;al to Nestl&eacute; of its 50% stake in Swiss dermatology pharmaceuticals company Galderma for an enterprise value of 3.<wbr>1 billion euros (2.<wbr>6 billion euros of equity value), paid by Nestl&eacute; in L'Or&eacute;al shares (21.<wbr>2 million shares) </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">For the remainder of the transaction, corresponding to 27.<wbr>3 million L'Or&eacute;al shares held by Nestl&eacute;, payment will be in cash for an amount of 3.<wbr>4 billion euros </div><div style="margin-bottom: 10px;">Following the transaction, Nestl&eacute;'s stake in L'Or&eacute;al will be reduced from 29.<wbr>4% to 23.<wbr>29% of the share capital and the Bettencourt Meyers family's stake in L'Or&eacute;al will increase from 30.<wbr>6% to 33.<wbr>31%.<wbr> </div><div style="margin-bottom: 10px;">The transaction will be accretive by more than 5% on L'Or&eacute;al's recurring earnings per share on a full year basis.<wbr> The buyback will be exclusively financed with L'Or&eacute;al's available cash and through the issuance of commercial paper.<wbr> It will not require the disposal of Sanofi shares held by L'Or&eacute;al.<wbr> </div><div style="margin-bottom: 10px;">The transaction is subject to customary conditions, including the prior consultation of Galderma's and L'Or&eacute;al's works councils and the clearance of relevant antitrust authorities.<wbr> It is expected to close before the end of the first semester of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Implications For Galderma</STRONG> </div><div style="margin-bottom: 10px;">Commenting on the transcation Mr.<wbr> Peter Brabeck-Lemathe, Chairman of Nestl&eacute;, said: </div><div style="margin-bottom: 10px;">"With this proposed acquisition of 50% of Galderma, Nestl&eacute; will pursue its strategic development in Nutrition, Health, and Wellness, by expanding its activities to medical skin treatments.<wbr> </div><div style="margin-bottom: 10px;">In this respect, Nestl&eacute; will create a new centre of activities in this area, through a new entity: Nestl&eacute; Skin Health SA.<wbr> Galderma will be the foundation of this entity which will be run by Galderma's management.<wbr> </div><div>As a wholly owned subsidiary of Nestl&eacute;, Galderma will have all the required means for its development which will benefit to the company, its employees as well as all other stakeholders.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7405">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-11T13:09:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-11T13:09:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Alternative To Recent PhIII HCC Failures - What Does The Future Hold - ASCO GU Presentation</title>
	<pubDate>2014-02-11T12:40:43+01:00</pubDate>
	<wp:post_id>5127</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: As HCC continues to evade best efforts to improve the overall 
treatment paradigm Andrew Zhu delivered at ASCO GU an  impressive 
overview of ongoing developments in this therapy area.<wbr> </div><div style="margin-bottom: 10px;">There are essentially two trials with Bayer's sorafenib that have set 
the standard from a the perspective of future clinical trial development in 
HCC, the SHARP trial and the Asia-Pacific study (see below).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Follwing sorafenib's success, there has been renewed focus on drug 
development in HCC but there have also been a number of 
high-profile phIII failures.<wbr> None have demonstrated improved survival or 
non-inferiority to sorafenib </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;">Dr Zhu noted that EGFR inhibitors are not effective in this disease and 
whilst there is continuinig development of old targets such as VEGF 
VEGFr inhbitors, increasingly other agents are being evaluated that 
target intracellular mechanisms.<wbr> The success of these agents will rely on 
the precise molecular signature of the tumours and also if these signatures 
predict the oncogene addiction of these tumours to the agent.<wbr> The redudancy of 
the pathway has the potential to limit single agent efficacy in many 
instances.<wbr> </div><div style="margin-bottom: 10px;">Most patients with underlying cirrhosis have signifcant 
inflammation and there are ongoing efforts to target this inflammation.<wbr> 
Additionally.<wbr> stromal and cancer metabolism may represent 
alternative viable strategies.<wbr> </div><div style="margin-bottom: 10px;">Ongoing efforts with antianangiogenic agents in HCC are shown below.<wbr> PhIII 
evaluation of Lilly's ramucirumab is currently ongoing, whilst a phIII study 
with Esai's levantinib has just been initiated.<wbr> Levantinib demonstrated good 
phII single arm efficacy.<wbr> Combination therapies are also being explored.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;">.<wbr><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;">Earely signs of efficacy have been shown with CC-223 but 
additional clinical data is needed to validate its profile </div><div style="margin-bottom: 10px;">Dr Zhu noted that immune based therapy has gained recent success in 
melanoma and that there is a need to critically re assess the 
importance of various molecules andd cell populations in HCC  Most 
excitement at the moment is centred on inhibitors targeting the checkpoint 
pathway with early clinical trials entering the field.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;">The first reported study with tremilimumab has demonstrated some early 
signs of efficacy registering a  modest response rate of 17% and 
PFS of approx of 6 months.<wbr> Of interest was that the drug was also shown to 
modulated viral load.<wbr> PDL-1 inhibitors are also entering clinical trials 
for HCC </div><div style="margin-bottom: 10px;">A concept increasingly recognised within the field is 
that targeted therapy &amp; chemo are unlikely to erradicated the cancer 
stem cell population.<wbr> Agents targeting this filed are now under development with 
two clinical trials now under development employing this strategy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_12_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;">Dr Zhu stated that technology is now available for genomic guided therapy to 
be increasingly integrated into treatment regimens.<wbr> He cited other 
tumour types where we have actually achieved succesful examples 
of targeting the oncogene acddiction and noted that the list is getting 
longer and longer and highlighted several such approaches that are underway.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_16_ScreenCapture16.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_17_ScreenCapture17.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_18_ScreenCapture18.jpg"> </div><div style="margin-bottom: 10px;">A recently concluded trial of tivantinib in 2nd line HCC and in an enriched 
population demonstrated a median survival of 7.<wbr>2mnths vs 3.<wbr>8 mnths in the 
placebo population.<wbr> The unanswered question is whether the benefit was 
derived from  from c-met inhibition or through cytotoxicity.<wbr> </div><div style="margin-bottom: 10px;">Lastly he focused on where do we stand right now in terms of the status of 
phIII HCC trials.<wbr> Dr Zhu noted that the Y90 radioembolisation (trial 
ongoing in Signapore) approach is very appealing recognising the 
aggressivce of HCC invasion.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_19_ScreenCapture20.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_20_ScreenCapture21.jpg"> </div><!-- Comment details --><a name="oncology9453attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(65,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(72,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(63,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(92,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(63,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(121 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(88,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(73,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(114,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(107,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(82 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(93,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(53,5 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(90,9 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(79,4 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_16_ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(89,6 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_17_ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(80 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_18_ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(73,2 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_19_ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(78,8 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9453_20_ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(73 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9453">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-11T12:40:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-11T12:40:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Eisai Thyroid Cancer Drug Meets PhIII Endpoint</title>
	<pubDate>2014-02-10T19:48:23+01:00</pubDate>
	<wp:post_id>5128</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Eisai recently announced that its Phase III SELECT trial (Study 303) of lenvatinib, an investigational selective tyrosine kinase inhibitor (TKI) showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).<wbr> A global PhIII in HCC is also underway </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">The SELECT Study of (E7080) LEnvatinib in differentiated Cancer of the Thyroid) study was a multicenter, randomized, double-blind, placebo-controlled Phase III study to compare the PFS of patients with RR-DTC and radiographic evidence of disease progression within the prior 12 months, treated with once-daily, oral lenvatinib (24 mg) versus placebo.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Secondary endpoints of the study included overall response rate (ORR), overall survival (OS) and safety.<wbr> The study enrolled 392 patients at over 100 sites in Europe, North and South America and Asia and was conducted by Eisai in collaboration with the SFJ Pharmaceuticals Group.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">The preliminary safety analysis showed that the five most common adverse reactions were hypertension, diarrhea, decreased appetite, decreased weight and nausea.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Next Steps</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Based on these clinical results, Eisai will submit marketing authorization applications for lenvatinib to health authorities in Japan, the United States and Europe.<wbr> If approved, lenvatinib will be the first molecular-targeted small molecule agent developed by a Japanese pharmaceutical company.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Thyroid Cancer Incidence/<wbr>Unmet Need</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Thyroid cancer is the most common endocrine malignancy and global figures show that its incidence has significantly increased over the last 50 years.<wbr> RR-DTC, a life-threatening form of the disease, has a significant unmet treatment need.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Other Development Programmes for lenvatinib</STRONG></P> </div><div><P align="left">Eisai has also initiated a global Phase III trial of lenvatinib in hepatocellular carcinoma (HCC) and is conducting Phase II studies of lenvatinib in several other tumor types.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7592">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-10T19:48:23+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-10T19:48:23+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Targacept Completes Enrolment in Ph2b iOAB Study</title>
	<pubDate>2014-02-10T19:21:00+01:00</pubDate>
	<wp:post_id>5129</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:- Targacept, Inc, a clinical-stage biopharmaceutical company developing novel NNR Therapeutics today announced it has completed recruitment of patients in its Phase 2b clinical study of TC-5214 as a treatment for overactive bladder (OAB).<wbr> The company expects to report top-line results from the study in mid-2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>TC5214's MOA</STRONG> </div><div style="margin-bottom: 10px;">TC-5214 acts potently on alpha3beta4 and other neuronal nicotinic receptors (NNRs) located in or around the bladder that are believed to play a key role in bladder contraction and signaling of the urge to urinate </div><div style="margin-bottom: 10px;"><STRONG>Nature of the study</STRONG> </div><div style="margin-bottom: 10px;">The ongoing Phase 2b study is a double blind, placebo controlled, randomized, parallel group study being conducted at sites in the United States.<wbr> The study's co-primary endpoints are change in micturition frequency per 24 hours and change in urinary incontinence episodes per 24 hours, in each case from baseline to 12 weeks.<wbr> </div><div style="margin-bottom: 10px;">The study is designed to randomize approximately 750 patients and includes a 3- or 5-week screening period followed by a 12-week treatment period during which patients receive either one of three doses of TC-5214 (0.<wbr>5mg, 1mg or 2mg) or placebo twice daily, randomized in a ratio of 2:1:1:1 (placebo, low dose, mid dose, high dose), with a 2-week follow-up period.<wbr> </div><div>Source: <A href="http://www.targacept.com/">www.<wbr>targacept.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7403">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-10T19:21:00+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-10T19:21:00+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ZYTIGA® Reimbursed in Quebec for Pre-Chemo Setting</title>
	<pubDate>2014-02-07T10:27:43+01:00</pubDate>
	<wp:post_id>5130</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Effective February 3, 2014, the province has added ZYTIGA<SUP>®</SUP> (abiraterone acetate) to the public drug formulary for the treatment of mCRPC in men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT).<wbr> Quebec joins British Columbia as the second province to add ZYTIGA<SUP>®</SUP> to its public formulary.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">July 2011 - ZYTIGA<SUP>® </SUP>was approved by Health Canada for the treatment of men with mCRPC who had received prior chemotherapy containing docetaxel after failure of ADT.<wbr> </div><div style="margin-bottom: 10px;">May 2013 - Health Canada approved ZYTIGA<SUP>® </SUP>for the treatment of men with mCRPC who are asymptomatic or mildly symptomatic after failure of ADT.<wbr> </div><div>Source: <A href="http://www.ramq.gouv.qc.ca/en/publications/citizens/legal-publications/Pages/list-medications.aspx">http:/<wbr>/<wbr>www.<wbr>ramq.<wbr>gouv.<wbr>qc.<wbr>ca/<wbr>en/<wbr>publications/<wbr>citizens/<wbr>legal-publications/<wbr>Pages/<wbr>list-medications.<wbr>aspx</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9452">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-07T10:27:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-07T10:27:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from AstraZeneca Q4 and FY 2013 Results</title>
	<pubDate>2014-02-06T15:03:44+01:00</pubDate>
	<wp:post_id>5131</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: FY13 revenue was $m25,711 (-6% at CER vs FY12).<wbr> Revenue from key growth platforms were more than offset by the impact of patent expiries.<wbr> Management reported that 2014 will be a challenging year for AstraZeneca, with generic competition emerging for Nexium.<wbr> On the product side, Zoladex sales were $m247 (-9% vs Q4:12), and $m996 (-9% vs FY12).<wbr> An update of the restructuring progam started last year is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In March 2013 the Company described how transforming the way it works is crucial to delivering its strategy.<wbr> The Company committed to dramatically simplifying its organisation and processes, while creating an innovative environment, including through co-location on a more focused footprint.<wbr> </div><div style="margin-bottom: 10px;">This restructuring with a previously announced programme will create a combined Phase 4 programme that entails an estimated global headcount reduction of about 5,050 over the 2013-2016 period.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9449_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Those initiatives have been expanded in order to create further headroom to invest behind the pipeline and key growth platforms.<wbr> Additional activities include the exit of R&amp;D activities in Bangalore, India, and the exit from branded generics in certain Emerging Markets to further reduce costs and increase flexibility.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- to keep investing in diabetes, where its presence has been bolstered by a recent $4 billion deal to take full control of an alliance with Bristol-Myers Squibb.<wbr> </div><div style="margin-bottom: 10px;">- to throw resources behind Brilinta, which has got off to a slow start.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9449_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9449_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Multiple ongoing trials wth innovative immuno-oncology portfolio.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9449_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9449_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="oncology9449attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9449_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9449_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(24 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9449_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(37,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9449_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(53,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9449_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(71,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9449_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(70,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9449">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-06T15:03:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-06T15:03:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Hanmi and MSD Establish a Novel Co-Promotion Model Contract in Korea</title>
	<pubDate>2014-02-06T11:55:49+01:00</pubDate>
	<wp:post_id>5132</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: <SPAN lang="EN-US" style="FONT-FAMILY: '바탕체','serif'; FONT-SIZE: 11pt"></SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Selected products of each company are being co-promoted in parallel.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div><SPAN style="FONT-FAMILY: '바탕체','serif'; FONT-SIZE: 11pt; mso-font-kerning: 0pt"></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10745">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-06T11:55:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-06T11:55:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Strategy of Takeda's TAK-700 (pre-chemo) Under Evaluation</title>
	<pubDate>2014-02-06T11:26:13+01:00</pubDate>
	<wp:post_id>5133</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Alongside the financial results and updates related to R&amp;D activities, management outlined that the Ph3 pre-chemo study of TAK-700 may end "earlier than planned, around summer 2014".<wbr> With both results in hands (pre and post-chemo), the company will then decide of the strategy and announce the timeline.<wbr> It was added that there is "no back-up project" in the same series of TAK-700.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9448_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Momentums in emerging markets</U>: Management reported a significant slowdown in the growth of the company between Q2 (+28%) to Q3 (approx.<wbr> 15%), and outlined that there is a 'possibility even that this growth will slow down even further in Q4.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9448_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Sales of top 10 products</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9448_2_ScreenCapture2.jpg"> </div><div><EM>Source: Takeda</EM> </div><!-- Comment details --><a name="oncology9448attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9448_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(44,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9448_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(55,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9448_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(101,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9448">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-06T11:26:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-06T11:26:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AbbVie Invests in Singapore Manufacturing</title>
	<pubDate>2014-02-06T10:34:13+01:00</pubDate>
	<wp:post_id>5134</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The $320M facility will be dedicated to produce new drugs for cancer and immunology.<wbr> This is the company's first manufacturing presence in Asia (research facilities already present in Tokyo and Shanghai).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9447_1_ScreenCapture1.jpg"></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9447_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9447_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">The plant is expected to become fully operational in 2019, and will create about 250 jobs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">12 sites across the US, EU and Puerto Rico, as well as strategic partnerships with third-party manufacturers.<wbr> </div><div><EM>Source: AbbVie</EM> </div><!-- Comment details --><a name="oncology9447attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9447_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(11,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9447_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(32 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9447_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(13,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9447">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-06T10:34:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-06T10:34:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Q4 Figures Demonstrate Strong Momentum</title>
	<pubDate>2014-02-06T09:48:50+01:00</pubDate>
	<wp:post_id>5135</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: With fourth quarter sales growth above Q3 up 15.<wbr>6% in local currencies and 14.<wbr>6% in US dollar, Allergan met its long-term goal of growing sales in double digit figures with full year sales up 11.<wbr>7% to $6.<wbr>2bn.<wbr> Strong growth momentum continues to be seen across all businesses.<wbr> A new BOTOX X programme, highlighted but not disclosed (possible new serotype) has one early candidate scheduled to enter clinical development at the end of this year.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>BOTOX sales</STRONG> </div><div style="margin-bottom: 10px;">Increased in Q4 by 12.<wbr>1% in local currencies and by 10.<wbr>7% in dollars.<wbr> With full-year performance at 13.<wbr>2% in local currencies and 12.<wbr>2% in dollars.<wbr> </div><div style="margin-bottom: 10px;">In terms of the split of therapeutic and esthetic sales for 2013, therapeutic indications accounted for 54% of the total and grew 16% in local currencies and 17% in dollars.<wbr> Whilst aesthetic indications constituting 46% grew 10% in local currencies and 8% in dollars and experienced some minor share loss, For crow's feet it now has national licenses in 21 countries across the European region with only Italy outstanding amongst the major markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Regulatory Approvals</STRONG> </div><div style="margin-bottom: 10px;">Regarding BOTOX for overactive bladder recent approvals have been obtaine in Canada, the U.<wbr>K, the Netherlands, Switzerland, Slovakia, Egypt, Saudi Arabia, Israel, Hong Kong and reimbursement by the Australian government.<wbr> In the U.<wbr>K.<wbr> it also received the additional indication of lower limb spasticity as announced yesterday.<wbr><BR><BR><STRONG>Pricing</STRONG> </div><div style="margin-bottom: 10px;">In the U.<wbr>S.<wbr> a small price increase on Jan 2 was announced for both BOTOX therapeutic and BOTOX cosmetic and it was sone in such a way to avoid any pull-forward sales into December.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Urology Performance</STRONG> </div><div style="margin-bottom: 10px;">Regarding urology Pyott noted that in the US Allergan has been able to secure coverage in December for 81% of commercial lines, for 82% of Medicare lines, and good levels of approvals for prior authorizations.<wbr> About 4,500 urologists and uro gynecologists are regular uses of BOTOX of a universe of about 13,000 physicians many of whom do not treat incontinence at all.<wbr> </div><div style="margin-bottom: 10px;">In Europe Allergan has invested heavily in medical education and training for chronic migraine, urogenic and overactive bladder but only in those countries where it has secured reimbursement.<wbr><BR><BR><STRONG>Aesthetics</STRONG> </div><div style="margin-bottom: 10px;">Allergan suggests its surveys reveal that BOTOX cosmetics' share remains high at 79% in December versus 84% in December of 2012.<wbr> With DYSPORT at 14% share versus 15 a year ago, with XEOMIN at 6 1/<wbr>2% versus 1% a year ago as this was when the product was being reintroduced into the market after the lifting of the injunction.<wbr> A significant amount of XEOMIN's current share it was suggested stems from free samples.<wbr> </div><div style="margin-bottom: 10px;">In western Europe Allergan estimates the market is growing mid single digits with Vistabel or BOTOX growing slightly in excess of market despite strong competition from Merck.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Investment Behind Botox</STRONG> </div><div style="margin-bottom: 10px;">The group continues to invest heavily in DTC advertising to support this growth particularly on Restasis and Botox for chronic migraine and has plans to further leverage its SG&amp;A expenses in 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botox Development Pipeline</STRONG> </div><div style="margin-bottom: 10px;">On the BOTOX side, Pyott claimed to be "pretty excited" just with new indications for BOTOX.<wbr> Key points emphasised were:- </div><div style="margin-bottom: 10px;"><UL><LI>PhIIB for osteoarthritis pain - initial data probably later this year but an intention to move forward with the program.<wbr>
</LI>
<LI>Starting phII for depression &amp; phII for premature ejaculation underway.<wbr>
</LI>
<LI>BOTOX X programs not previously disclosed for competitive reasons but one is likely to enter the clinic at the end of this year.<wbr> Given the reference to the TSI programme below, this potentially could be a new serotype.<wbr>
</LI>
<LI>Collaboration with Medytox, "so they have a liquid formulation, we've been meeting with them, the collaboration's going very well and I'm sure David or myself or Jeff will update you on the development plan as soon as we finalize those plans, but a lot of resources are going there.<wbr>"
</LI>
<LI>Program that target exocytosis for pain.<wbr> In ph2 for higher dose, if that works that's an exciting program, not quite BOTOX, it's really a novel platform but potentially in the neuropathic pain platform we're excited about that, it's a larger need.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>M&amp;A Strategy</STRONG> </div><div style="margin-bottom: 10px;">When questione about this Pyott responded:- </div><div style="margin-bottom: 10px;">"In addition to internally derived programs, we'll be grafting in new technology.<wbr> On top of that, of course, we're always looking to see are there other products or companies that would fit our business model, but also fulfill the very rigorous criteria of providing growth.<wbr> Because clearly with our strong internal growth, we would have no interest in buying and I'll exaggerate, a product or a company that we're only growing 2 or 3% because all we'd do would be diluting our already really strong internal performance so I hope that gives you a good framework about how we think about these targets" </div><div style="margin-bottom: 10px;">"In summary, we're always looking to see if we can add other neurology or urology products to our product range where we can leverage the relationships we've created and also leverage the fixed cost of our sales and marketing organizations.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>2014 Full Year Guidance</STRONG> </div><div style="margin-bottom: 10px;">Total product net sales between $6,650 million and $6,950 million, excluding any anticipated revenue from the transition service agreements related to the sale of the obesity intervention business.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Total specialty pharmaceuticals net sales between $5,720 million and $5,960 million.<wbr>
</LI>
<LI>Total core medical devices net sales between $930 million and $990 million.<wbr>
</LI>
<LI>ALPHAGAN<SUP>&Acirc;&reg;</SUP> franchise product net sales between $460 million and $490 million.<wbr>
</LI>
<LI>LUMIGAN<SUP>&Acirc;&reg;</SUP> franchise product net sales between $590 million and $620 million.<wbr>
</LI>
<LI>RESTASIS<SUP>&Acirc;&reg;</SUP> product net sales between $1,030 million and $1,070 million.<wbr>
</LI>
<LI>BOTOX<SUP>&Acirc;&reg;</SUP> product net sales between $2,180 million and $2,280 million.<wbr>
</LI>
<LI>LATISSE<SUP>&Acirc;&reg;</SUP> product net sales between $100 million and $110 million.<wbr>
</LI>
<LI>Breast aesthetics product net sales between $390 million and $420 million.<wbr>
</LI>
<LI>Facial aesthetics product net sales between $540 million and $570 million.<wbr>
</LI>
<LI>Non-GAAP cost of sales to product net sales ratio at approximately 13%.<wbr>.<wbr>
</LI>
<LI>Non-GAAP selling, general and administrative expenses to product net sales ratio between 37% and 38%.<wbr>
</LI>
<LI>Non-GAAP research and development expenses to product net sales ratio at approximately 16.<wbr>5%.<wbr>
</LI>
</UL> </div><div>source: <A href="http://www.allergan.com/">www.<wbr>allergan.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7398">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-06T09:48:50+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-06T09:48:50+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Kyowa Hakko Kirin Commences PhIII Development of ARQ197 for HCC</title>
	<pubDate>2014-02-05T13:22:15+01:00</pubDate>
	<wp:post_id>5136</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: KHK has announced today the start of a phIII trial in Japan in patients with c-MET diagnositc high inoperable hepatocellular carcinoma treated with one prior sorafenib therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design - NCT02029157</STRONG> </div><div style="margin-bottom: 10px;">Double-blind placebo controlled study to compare PFS of ARQ197 vs.<wbr> placebo.<wbr> 160 patients will be enrolled.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Licensing Status</STRONG> </div><div style="margin-bottom: 10px;">ARQ197 an oral agent whose molecular target is c-MET was discovered by ArQule Inc.<wbr> KHK in-licensed development and commercialisation rights to ARQ197 in Japan and some parts of Asia (China, Korea and Taiwan) in April 2007.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Satus of ArQule's Development Programme </STRONG> </div><div style="margin-bottom: 10px;">ArQule, Inc.<wbr> recently (January 16th) provided clinical updates on its ongoing pivotal Phase 3 METIV-HCC trial in hepatocellular carcinoma conducted by the Company and its partner, Daiichi Sankyo Co.<wbr>, Ltd.<wbr>, </div><div style="margin-bottom: 10px;"><STRONG>METIV-HCC Trial</STRONG> </div><div style="margin-bottom: 10px;">The Data Monitoring Committee (DMC) of the METIV-HCC trial recommended continuation of the ongoing pivotal Phase 3 METIV-HCC trial of tivantinib as a single agent in hepatocellular carcinoma with a lower dose of tivantinib, 120 milligrams (mg) tablets administered twice daily (BID).<wbr> This decision followed the DMC's review of data analyses from a predefined number of patients who received this lower dose.<wbr> </div><div style="margin-bottom: 10px;">A recently completed safety analyses among patients treated with 120 mg BID tivantinib tablets showed that the incidence of neutropenia was reduced with this lower dose.<wbr> In addition, pharmacokinetic analyses from this patient cohort, reviewed by the DMC, demonstrated that the plasma exposure of the 120 mg BID tablets dose was comparable to the exposure achieved with the 240 mg BID capsules dose employed in the Phase 2 trial, with similar medians and overlapping ranges.<wbr> </div><div style="margin-bottom: 10px;">A dose reduction from 240 mg BID tablets to 120 mg tablets BID was implemented in September, 2013 following the observation of a higher incidence of neutropenia in the initial phase of the METIV-HCC trial than was observed in the Phase 2 trial in the same patient population where a 240 mg BID capsule dose was administered.<wbr> Certain enhanced patient monitoring procedures had been temporarily instituted to confirm the safety profile of the lower dose.<wbr> </div><div style="margin-bottom: 10px;">The METIV-HCC trial is a pivotal randomized, double-blind study of tivantinib as single agent therapy in previously treated patients with MET diagnostic-high, inoperable HCC.<wbr> The primary endpoint is overall survival in the intent-to-treat population, and the secondary endpoint is progression free survival in the same population.<wbr> METIV-HCC is being conducted under a Special Protocol Assessment (SPA) </div><div>source: <A href="http://www.arqule.com/">www.<wbr>arqule.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9444">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-05T13:22:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-05T13:22:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>GW Pharma Q1 Figures - Key Takeaways</title>
	<pubDate>2014-02-05T12:10:24+01:00</pubDate>
	<wp:post_id>5137</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Total revenues for the three months ended Dec 31st were &pound;7.<wbr>5m compared to &pound;5.<wbr>2m in the corresponding period last year.<wbr> Net loss was &pound;2.<wbr>8m compared to a profit of &pound;2.<wbr>1m in 2013.<wbr> A successful follow-on offering of American Depositary Shares on NASDAQ in January 2014 raising total gross proceeds of $101.<wbr>1 million has put the group in a strong position both to pursue the Epidiolex<SUP>&reg;</SUP> development program for childhood epilepsy, a product which GW is very enthusiastic about but also to develop its earlier cannabinoid programme including a phIb/<wbr>2a programme for the treatment of recurrent Glioblastoma.<wbr> </div><div style="margin-bottom: 10px;">The 44% increase in revenues vs Q1 13 will have been largely derived from increased uptake of Sativex for spasticity, but at this juncture we do not have a picture of in-market sales through the group's licensees.<wbr> However, in terms of life cycle management and geographic expansion GW continues to make good progress as it highlighted below: </div><div style="margin-bottom: 10px;"><UL><LI>Phase 3 cancer pain trials in recruitment - top-line data due towards the end of 2014.<wbr> Data intended to lead to a New Drug Application (NDA) filing with the FDA in the U.<wbr>S.<wbr>
</LI>
<LI>Phase 3 IND opened with the FDA for Sativex as a treatment for Multiple Sclerosis (MS) spasticity; request for Special Protocol Assessment (SPA) submitted to the FDA
</LI>
<LI>Recent regulatory approvals in France and Switzerland as a treatment for MS spasticity; Sativex now approved for use in 25 countries
</LI>
<LI>Agreement with Ipsen to promote and distribute Sativex in Latin America
</LI>
</UL> </div><div style="margin-bottom: 10px;">There is also significant additional on-going clinical trial activity for cannabinoid pipeline product candidates </div><div><BLOCKQUOTE>
<UL><LI>Phase 2a trial data of GWP42003 for the treatment of ulcerative colitis ongoing - data expected in mid-2014
</LI>
<LI>Phase 2b dose ranging trial of GWP42004 in type-2 diabetes expected to commence in H1 2014
</LI>
<LI>Phase 2a trial of GWP42003 for the treatment of schizophrenia expected to commence in H1 2014
</LI>
<LI>Phase 1b/<wbr>2a clinical trial underway of GWP42002:GWP42003 for the treatment of Recurrent Glioblastoma Multiforme (GBM), with safety cohort data expected in 2014.<wbr> Patent Notice of Allowance issued for the use of cannabinoids in treating GBM
</LI>
</UL>
</BLOCKQUOTE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7396">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-05T12:10:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-05T12:10:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Reorganizes Global Management Structure</title>
	<pubDate>2014-02-05T11:45:04+01:00</pubDate>
	<wp:post_id>5138</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The responsibilities of the Chief Medical Officer (CMO) will be reinforced.<wbr> From the beginning of Q2:14, Global Development Head, Global Regulatory Affairs Head, Global Clinical &amp; Research Quality Assurance Head and Global Quality Assurance will report to CMO.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The position of QA and RA Head of Astellas Pharma Inc.<wbr> will be dissolved.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The company reported that the objectives of this restructuration is to enhance global product compliance and the overall synergy with Global Development.<wbr> </div><div><EM>Source: Astellas</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9443">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-05T11:45:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-05T11:45:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Galderma Divests Osteoarthritis Assets to Bioventus</title>
	<pubDate>2014-02-05T10:28:21+01:00</pubDate>
	<wp:post_id>5139</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Bioventus which previously had exclusive distribution rights in EU, Canada and Australia will now controls all future plans and distribution outside of the US.<wbr> Galderma will continue to manufacture DUROLANE, a joint-fluid treatment containing non-animal stabilized hyaluronic acid (NASHA).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Osteoarthritis is no more a core indication for Galderma.<wbr> </div><div style="margin-bottom: 10px;">The company has been focused on 2 segments: Medical solutions for the skin, and Aesthetic &amp; Corrective.<wbr> </div><div style="margin-bottom: 10px;">However it has kept the manufacturing of its patented NASHA technology.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7394_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">The acquisition is a very good fit with Bioventus activities.<wbr> DUROLANE has been treating patients for 12 years.<wbr> </div><div style="margin-bottom: 10px;">The company is a global leader in active orthopaedic healing.<wbr> Product portfolio lists: </div><div><UL><LI>
Exogen (US waves to activate cells near the site of the fractured bones</LI>
<LI>
SUPARTZ and DUROLANE (joint injection therapies for OA)</LI>
<LI>
Muskuloskeletal diagnostic equipment partnered with Esaote North America.<wbr></LI>
</UL> </div><!-- Comment details --><a name="neurology7394attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7394_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(37,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7394">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-05T10:28:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-05T10:28:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Approval of BOTOX® for Adult LLS in the UK</title>
	<pubDate>2014-02-04T17:46:38+01:00</pubDate>
	<wp:post_id>5140</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: BOTOX® has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of ankle disability due to lower limb spasticity associated with stroke in adults.<wbr> The toxin becomes the first and only neuromodulator to be approved specifically for both upper and lower limb spasticity in adults who had a stroke.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">152,000 new cases each year (Stroke Association, Stoke Statistics available at <A class="c4" href="http://www.stroke.org.uk/resource-sheet/stroke-statistics" rel="nofollow">http:/<wbr>/<wbr>www.<wbr>stroke.<wbr>org.<wbr>uk/<wbr>resource-sheet/<wbr>stroke-statistics</A> Last accessed January 2014).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">This new indication is based on an multi-centre, randomized, double-blind, placebo-controlled study, assessing its efficacy in patients with post-stroke lower limb spasticity affecting the ankle.<wbr> </div><div style="margin-bottom: 10px;">A total of 120 patients were randomized to a single treatment of Allergan's Botulinum toxin type A (300 units) or placebo.<wbr> Patients who were enrolled in this study had had their stroke on average approximately 6 years earlier.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Patients treated with Botulinum toxin type A achieved a significant improvement in muscle tone compared to those treated with placebo, using the Modified Ashworth Scale (MAS) ankle score and measuring baseline to week 12 results </div><div style="margin-bottom: 10px;">Significant improvements compared to placebo were also observed at the individual post-treatment visits at weeks 4, 6 and 8 </div><div>Botulinum toxin type A treatment was associated with a significant improvement in the investigator's clinical global impression (CGI) of functional disability compared to placebo.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7393">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-04T17:46:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-04T17:46:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Cheaper Version of Merz' Radiesse Showcased at IMCAS 2014</title>
	<pubDate>2014-02-04T16:59:29+01:00</pubDate>
	<wp:post_id>5141</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Luminera, an R&amp;D company and manufacturer of injectable medical devices in the aesthetic field, presented its Crystalys dermal filler (a calcium hydroxyapatite based filler), as a "generic" of Merz' Radiesse, the sole dermal filler in this category.<wbr> The substance produces a very natural result, doesn't migrate, and side effects are rare.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9442_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Crystalys has been marketed in Israel since September 2011 for soft tissue augmentation.<wbr> </div><div style="margin-bottom: 10px;">The company recently conducted a PMS among 173 patients to assess its safety and efficacy.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>"Post marketing study of safety and efficacy of Crystalys, a calcium hydroxyapatite based filler for facial soft tissue augmentation - Tsvi Segal, MD; Ana Schwartz, MD; Konstantin Konfino, MD, PhD.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div>Panaxia is an R&amp;D and a manufacturer of medical devices and cosmeceuticals, <EM>luminera</EM> is the injectable aesthetic line.<wbr> </div><!-- Comment details --><a name="oncology9442attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9442_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(136,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9442">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-04T16:59:29+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-04T16:59:29+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Astellas Q3 2013 Figures - Key Takeaways Including PREVAIL Data</title>
	<pubDate>2014-02-04T15:35:24+01:00</pubDate>
	<wp:post_id>5142</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Astellas's third quarter figures illustrate how the success of  
the prostate cancer drug XTANDI and the OAB drug Mirabegron are contributing to 
the group's overall strong growth.<wbr> XTANDI's annualised sales are likely to 
exceed $400m this year a figure ahead of internal expectations.<wbr> Some of the 
key highlights of the recently disclosed PREVAIL data were also 
presented during the group's earning presentation (see below), with a 
few interesting answers prompted by analyst questions.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;">Overall XTANDI has been launched in 19 countries.<wbr> Early 2014 is the target 
date for an NDA filing of the PREVAIL data.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_10_ScreenCapture10.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">In the Q/<wbr>A that followed one analyst questioned whether the delay to 
chemotherapy was going to be one of the more influential properties of the 
drug from a urologist perspective and also on the comparative level of 
fatigue seen vs.<wbr> Zytiga (where of course steroid use helps to alleviate 
fatigue).<wbr> </div><div style="margin-bottom: 10px;">Yazushi Miyazawa from Astellas acknolwedged the attractiveness of the time to 
initiate chemo data but also that this data has to be reviewed by the 
authorities so it is too early to gauge what kind of impact can be expected.<wbr> 
However, he did suggest it was the correct way to think about the 
data.<wbr> </div><div style="margin-bottom: 10px;">He also noted that fatigue has been previously reported with XTANDI but 
compartively with regard to Zytiga further analysis is required before 
further comments will be made, other than it is not considered 
worrisome.<wbr> </div><div>Whilst a lot of data on enzalutamide was presented at ASCO GI, nothing was 
disclosed on the effect of XTANDI on bone metastases.<wbr> That data does exist and 
will it seems be presented on another as yet to be disclosed 
occaision.<wbr> </div><!-- Comment details --><a name="oncology9439attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(163,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(132,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(138,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(118,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(190,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(160,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(133,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(150,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(156,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(116,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9439_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(146,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9439">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-04T15:35:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-04T15:35:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Furiex Provides Update on its IBS-d Drug</title>
	<pubDate>2014-02-04T14:41:31+01:00</pubDate>
	<wp:post_id>5143</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Furiex' eluxadoline (oral locally-acting mu opioid receptor agonist and delta opioid receptor antagonist) met the main goal of two arge Ph3 trials by significantly alleviating diarrhea and abdominal pain.<wbr> In the US, the company plans to apply by mid-year for approval of the drug, and expects to seek EU approval in early 2015.<wbr> Management reported it is still considering the alternatives to partner the product.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1938_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1938_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Eluxadoline was tested at 2 doses against a placebo over the course of 12 weeks to meet requirements by the US FDA, and for 26 weeks for European health regulators, in Ph3 studies involving 2,428 patients.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1938_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><DIV class="identifier"><A href="http://clinicaltrials.gov/ct2/show/NCT01553591">NCT01553591</A></DIV> </div><div><DIV class="identifier">
<DIV class="identifier"><A href="http://clinicaltrials.gov/ct2/show/NCT01553747">NCT01553747</A></DIV>

<DIV class="identifier"><STRONG></STRONG></DIV>

<DIV class="identifier">In 2011, Furiex acquired full exclusive license rights from Janssen to develop and commercialize eluxadoline.<wbr>
<P><STRONG></STRONG>
</P><P><A href="http://www.furiex.com/about-us/background/">http:/<wbr>/<wbr>www.<wbr>furiex.<wbr>com/<wbr>about-us/<wbr>background/<wbr></A></P></DIV></DIV> </div><!-- Comment details --><a name="gastroenterology1938attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1938_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(45,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1938_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(62,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1938_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(15,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1938">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-04T14:41:31+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-04T14:41:31+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Daewoong to Supply Products to Azerbaijan and Georgia</title>
	<pubDate>2014-02-04T11:58:57+01:00</pubDate>
	<wp:post_id>5144</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Daewoong has entered into contracts with Azerbaijan’s Sanimed and Georgia’s Eczamed to supply a range of products worth $15M over the next 5 years.<wbr> Daewoong expects to use these contracts to open up additional distribution channels into CIS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Before those contracts Daewoong was used to sign the export contracts wth Russia and CIS every year.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Neovist, the CT contrast agent, signed in 2011</LI>
<LI>Easyef (external solution/<wbr> ointment), the diabetic foot ulcer treatment drug, signed in 2012</LI>
<LI><STRONG>Luphere</STRONG> <STRONG>Depot</STRONG>, the prostate cancer treatment drug, inked in 2013</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Azerbaijan’s <STRONG>Sanimed </STRONG>specializes in the pharmaceutical import and distribution and has made steady strides with the annual sales growth exceeding 45%.<wbr> </div><div style="margin-bottom: 10px;">Georgia’s <STRONG>Eczamed</STRONG> distributes pharmaceutical products to the neighboring CIS such as Turkey and Kazakhstan.<wbr> </div><div>Source: Daewoong </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10742">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-04T11:58:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-04T11:58:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Botox / Myobloc Comparison Stuy to Assess Muscular Atrophy in Spastic Patients</title>
	<pubDate>2014-02-04T11:15:15+01:00</pubDate>
	<wp:post_id>5145</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Although the benefits of botulinum therapy is indisputable, muscle atrophy is one of the main adverse effect noticed.<wbr> A new small pilot study will evaluate if there is a statistically significant difference in the degree of muscle atrophy using BTX-A vs BTX-B.<wbr> PE will measure the volume and cross-sectional area of the muscle.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Sponsor</STRONG>: Georgetown U.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Collaborator</STRONG>: Solstice Neurosciences </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG>: approx 10 men and women aged 18 or older with spasticity secondary to either a disorder or trauma, such as a spinal cord injury (SCI), a brain injury, a tumor, a stroke, multiple sclerosis (MS), or a peripheral nerve injury.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG>: study planned to start last month (Jan 2014) - completion date: Jan 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Dosage</STRONG>: Botox 100U /<wbr> Myobloc 5000U </div><div style="margin-bottom: 10px;"><STRONG>PI</STRONG>: Fernando Pagan, MD </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02052024?term=myobloc&amp;rank=2&amp;submit_fld_opt=">NCT02052024</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7388">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-04T11:15:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-04T11:15:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant To Buy PreCision Dermatology For Up To $500m</title>
	<pubDate>2014-02-04T09:24:42+01:00</pubDate>
	<wp:post_id>5146</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Valeant had been expected to make another acquisition in the dermatology space and whilst this is smaller than might have been anticipated (2014 forecast sales of $130m) it fits well alongside its existing medical dermatology portfolio.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Acquisition Rational</STRONG> </div><div style="margin-bottom: 10px;">Commenting on the deal Valeant's Chairman and CEO Michael Pearson noted that "PreCision Dermatology has a wide range of medical dermatology products, treating a number of topical disease states such as acne and atopic dermatitis, and should bring tremendous value to Valeant's medical dermatology portfolio Furthermore, PreCision's diversified portfolio of products enjoys high physician loyalty, premium product quality and lifecycle management opportunities that will enhance our future growth strategies.<wbr> We believe this acquisition will strengthen Valeant's product portfolio and solidify our position as a leader in dermatology.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>PreCision Business Profile</STRONG> </div><div style="margin-bottom: 10px;">PreCision operates in two key segments: Onset Dermatologics, which focuses on prescription therapies, and PrecisionMD&reg;, which focuses on physician dispensed products.<wbr> The Company is based in Cumberland, Rhode Island and has approximately 175 employees.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Analysts View On The Acquisition</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>BMO Capilal Markets: "</STRONG>At ~3.<wbr>8x sales, it may appear that Valeant might be over-paying for this company; however, PreCision is a growing company with several assets in dermatology that treat a number topical disease states such asacne and atopic dermatitis.<wbr> This is a growing and mostly cash-pay market that Valeant is very familiar with, given itsexisting dermatology product portfolio.<wbr> Valeant should clearly be able to leverage its existing dermatologyinfrastructure to market PerCision's products, and as such we have little doubt that the deal would indeed be immediately accretive.<wbr>" </div><div style="margin-bottom: 10px;">It sees this deal is yet another example that there are plenty of small-mid sized acquisition opportunities available for Valeant.<wbr> </div><div><STRONG>Cannacord Genuity - MA strategy as a growth driver</STRONG> - "We view PreCision as a smaller acquisition for Valeant, which is in line with our expectqations for small to mid-sized deals in the near-term.<wbr> However, we note that Valeant continues to pursue a "merger of equals" that could de-lever the balance sheet.<wbr> " </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7385">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-04T09:24:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-04T09:24:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AbbVie's Q4 13 Revenues Led by Humira</title>
	<pubDate>2014-02-03T17:29:44+01:00</pubDate>
	<wp:post_id>5147</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management highlighted that initial data from the first of two pivotal studies of elagolix for endometriosis are expected H2:14.<wbr> Fourth-quarter sales were led by the continued strength of HUMIRA (Global HUMIRA sales increased 13.<wbr>4% to $3.<wbr>01 bln; U.<wbr>S.<wbr> HUMIRA sales grew 18.<wbr>1% to $1.<wbr>67 bln).<wbr> The Humira patent does not expire until 2016, however "possible successors are already being studied".<wbr> Detailed sales of Lupron are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Lupron continues to hold a leadership position and maintains significant share of the market.<wbr> Management expects Lupron sales to be down "modestly from 2013".<wbr> </div><div style="margin-bottom: 10px;"><U>Quarter ended Dec 31 2013</U> </div><div style="margin-bottom: 10px;"><UL><LI>US: 156</LI>
<LI>Int'l: 53</LI>
<LI><STRONG>Total:</STRONG> 209 (down 5% versus PY)</LI>
</UL> </div><div style="margin-bottom: 10px;"><U>FY 2013</U> </div><div><UL><LI>US: 566</LI>
<LI>Int'l: 219</LI>
<LI><STRONG>Total</STRONG>: 785</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9437">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-03T17:29:44+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-03T17:29:44+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Hyperhidrosis Update at IMCAS 2014</title>
	<pubDate>2014-02-03T15:17:04+01:00</pubDate>
	<wp:post_id>5148</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The one-hour session was chaired by Davi de Lacerda (dermatologist, Brazil) and David Goldberg (dermatologist, USA).<wbr> A review of the management of the condition provided recent data on botulinum toxins A (but not on the topical toxin), on a new dedicated ultra-sound system having just received European marking approval, and a new RF technology developed by Alma Lasers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">David Golberg (US dermatologist) introduced the session highlighting that: </div><div style="margin-bottom: 10px;">&gt;30M people have the condition &gt;&gt; 1 in 5 Americans (18-49 years) experiences excessive sweat.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7378_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- New findings from a comparative double-blinded dtudy show that Onabotulinum toxin A (Botox) and Incobotulinumtoxin A (Xeomin) seem to be comparable in terms of anhidrotic effect (short-term results), duration of benefits (long-term efficacy), muscle strength reduction (safety), pain related to injections (tolerability), and treatment satisfaction expressed by patients.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- On January 6th 2014 Miramar Labs®'s miraDry<B>®</B> System received Conformite European (CE) Mark approval for the treatment of primary axillary hyperhidrosis.<wbr> </div><div style="margin-bottom: 10px;">The miraDry procedure uses microwave energy to provide a non-invasive, lasting solution to axillary hyperhidrosis.<wbr> </div><div style="margin-bottom: 10px;">Delivers energy non-invasively to the area under the arm where the sweat glands reside, creating localized heat to destroy and eliminate the glands, which are not necessary to cool the body.<wbr> Since sweat glands do not regenerate, results are lasting.<wbr> </div><div style="margin-bottom: 10px;">Each miraDry procedure takes approximately one hour in the doctor's office.<wbr> The full treatment plan requires two procedures to maximize results.<wbr> The procedure is safe and the results can be seen almost immediately.<wbr> Since the procedure is non-invasive, there is little to no downtime, so patients can go about their normal routine after treatment.<wbr> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"> </div><div> </div><!-- Comment details --><a name="neurology7378attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7378_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7378_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(78,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7378_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(74,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7378">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-03T15:17:04+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-03T15:17:04+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>IMCAS 2014 - Key Takeaways From The Industry Tribune</title>
	<pubDate>2014-02-03T11:59:06+01:00</pubDate>
	<wp:post_id>5149</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Two of the more interesting session at this year's Industry Tribune event at IMCAS were a presentation by New York based Michel Dyens &amp; Co covering M&amp;A transactional trends within the aesthetic market and then individual company presentations given by Galderma, Allergan &amp; Merz during a session on the "Big Players".<wbr> Additionally, in the "Breaking News" session it was noted that TEOXANE is to collaborate with US newcomer Alphaeon (Strathspey Crown) and become the European aesthetic distributor for Daewoong's new toxin DWP450.<wbr>.<wbr> </div><div style="margin-bottom: 10px;">A selection of some of the key slides plus comments are highlighted below.<wbr> Apologies for the quality of the photos.<wbr> It was a difficult forum in which to capture data.<wbr> </div><div style="margin-bottom: 10px;">Jean-Yves Coste from Michel Dyens noted that a robust continuation of the momentum observed in the last few years is expected.<wbr> Although a flattening in numbers was seen in 2013 there are a few factors pointing to an increase in M&amp;A in 2014 The US and developed countries maintain their lead both in terms of number of transactions and valuations across all sub-sectors.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_1_ScreenCapture1.jpg">H </div><div style="margin-bottom: 10px;">Highlighted were the three key trends that are underpinning the M&amp;A trends but uppermost is the desire by patients for technological sophistication which is prompting companies to continue to seek technological innovation.<wbr> Acquisition multiples are in general expanding with the entry ticket multiple now around 3.<wbr>8x EV.<wbr> However, there are differrences seen between the different sectors wwith medical aesthetic multiples tending to decrease, dermal filler multiples stable, contouring and electric device expanding and dermacosmetic witnessing a growth in multiples.<wbr> The latter because it is now recognised that cosmoceuticals are the first-line of treatment before patients undergo more invasive facial treatments </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_11_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_4_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_3_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_2_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_5_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_6_ScreenCapture9.jpg"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_7_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_8_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_9_ScreenCapture12.jpg"> </div><div style="margin-bottom: 10px;">Galderma Humberio Antunes </div><div style="margin-bottom: 10px;">Humberio addressed the question "How patients expectations &amp; awareness will influence the aesthetic market".<wbr> </div><div style="margin-bottom: 10px;">He made a couple of points in terms of introductory remarks.<wbr> </div><div style="margin-bottom: 10px;">1) The vast majority of patients want to look better but in the main they do not want injections on their face.<wbr> </div><div style="margin-bottom: 10px;">2) Changing demographics come with growing skin health needs.<wbr> </div><div style="margin-bottom: 10px;">3) The aging demographic presents a major opportunity for aesthetic companies.<wbr> Consumer types are broadening and they are better educated.<wbr> </div><div style="margin-bottom: 10px;">He also highlighted the results of a survey Galderma has undertaken called the IMPACT study, which notes that </div><div style="margin-bottom: 10px;">a) 43% of patients will definitely continue with the same practitioner.<wbr> however, </div><div style="margin-bottom: 10px;">b) 52% have changed practitioner since their first treatment as the customer service was not satisfying enough </div><div style="margin-bottom: 10px;">In terms of choice of brands 40 KOLS interviewed as part of the survey noted the following criteria as influential in terms of their choice </div><div style="margin-bottom: 10px;"><UL><LI>Quality of the products
</LI>
<LI>Innovation
</LI>
<LI>Customer centricity and support
</LI>
</UL> </div><div style="margin-bottom: 10px;">From an innovative perspective he then followed with a description of the company's new Rosacea product which also has application for melisma and noted that the company has a new BoNT in PhII development for the US &amp; Canada.<wbr> He stated it will be super pure and created from the group's own proprietary product.<wbr> We are aware that this is an injectable liquid formulation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Merz Philip Burchard CEO</STRONG> </div><div style="margin-bottom: 10px;">Merz was asked to address the question "How to operated as a W/<wbr>W challenger? </div><div style="margin-bottom: 10px;">Mr Buchard noted that the group was pursuing and increased focus on aesthetics and that the company would soon achieve &euro;1bn in sales.<wbr> He remarked that growth in profitability was being derived from the aesthetic business.<wbr> </div><div style="margin-bottom: 10px;">He commented on the 5 reasons why the market is attractive </div><div style="margin-bottom: 10px;"><OL><LI>Double digit growth rate
</LI>
<LI>Scope for innovation
</LI>
<LI>Growing acceptance of procedures
</LI>
<LI>New growth markets offer continued acceleration
</LI>
<LI>The fragmented nature of the market
</LI>
</OL> </div><div style="margin-bottom: 10px;">He claimed that Merz is aiming to take market share from competitors and that a presence in the US market is crucial.<wbr> Also crucial is innovation, the pursuit of new indications, new treatment regimens, new technology and new NMEs.<wbr> He emphasised that a mid-sized aspiring player still needs to focus on innovation.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the fragmented nature of the market, he noted that there are &lt;10 companies with &lt;$200m sales, so he expects consolidation to continue.<wbr> There are a large number of mid-sized companies that may need re-financing and where there is an opportunity to collaborate </div><div style="margin-bottom: 10px;">Overall Mr Buchard sees 5 potential success factors for Merz's aesthetic business:- </div><div style="margin-bottom: 10px;"><UL><LI>Gain share through strong execution
</LI>
<LI>Drive innovation
</LI>
<LI>Win new patients
</LI>
<LI>Enter new markets; and.<wbr>
</LI>
<LI>Participate in the M&amp;A market
</LI>
</UL> </div><div style="margin-bottom: 10px;">Allergan Paul Navarre President of Allergan EMEA </div><div style="margin-bottom: 10px;">Mr Navarre was asked to address "How to maintain leadership in a more competitive market?" </div><div style="margin-bottom: 10px;">He acknowledge that all aesthetic markets are becoming more competitive than they were, with 9 toxins in the market now compared to two 15 years ago and filler and breast implant markets also becoming increasingly competitive.<wbr> </div><div style="margin-bottom: 10px;">He emphasised that he believes competition is a good thing as it stimulates the market to be innovative and to perform.<wbr> It allows you he suggested to show who you are and what you stand for.<wbr> </div><div style="margin-bottom: 10px;">He stated that Allergan always asks itself the question about whether it is bringing value to both the physician and the patient and that one company it tries to emulate is Apple.<wbr> David Pyott apparently is quoted as saying he admires Apple because of its ability to innovate </div><div style="margin-bottom: 10px;">It recognised that Apple's 4 pillars that have helped the company to reinforce its position and create leadership are </div><div style="margin-bottom: 10px;"><UL><LI>Innovation- it has changed the way we live through innovative product design and advertising
</LI>
<LI>Shaped the market by always trying to build out the market
</LI>
<LI>Focused on customer centricity e.<wbr>g specialised Apple stores which offer fantastic customer service
</LI>
<LI>Simplicity - regardless of innovation it has kept its products simple
</LI>
</UL> </div><div style="margin-bottom: 10px;">The manner in which Allergan is trying to mimmick Apple was illustrated:- </div><div style="margin-bottom: 10px;"><UL><LI>Innovation - introduced two new products in the aesthetic market in the last 12 months e.<wbr>g.<wbr> new Juvederm range and new indication for Vistabel
</LI>
<LI>Shaping the market - focus is on broad DTC advertising and now moving to digital media
</LI>
<LI>Customer centricity - developed a consulting programme for physicians and educated over 4,700 clinicians on its new toxin innovation over the last few months.<wbr> It also never compromises on quality
</LI>
<LI>Simplicity - Allergan believes the highest level of sophistication is simplicity
</LI>
</UL> </div><div style="margin-bottom: 10px;">Finally he posed the question as to whether Allergan has succeeded, claiming that it has as </div><div style="margin-bottom: 10px;">Vistable revenues have grown 53% over the last 4 years.<wbr> Its fillers have gown by 57% over the same period and its breast implants by 17%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Teoxane Distributorship News</STRONG> </div><div style="margin-bottom: 10px;">Valerie Taupin Teoxane's CEO highlighted the success of her company which she founded 10 years ago.<wbr> To date it has sold over 5 million syringes of its filler and has consistently registerd double-digit growth.<wbr> Its products are available in 80 countries through 65 distributorships and in late 2013 its signed a license agreement with Alphaeon, (Strathspey Crown) for US distribution of its fillers, a company it met at IMCAS the previous year.<wbr> </div><div style="margin-bottom: 10px;">Valerie noted that the main reasons why she had chosen to partner with this company were threefold:- the very high level of experience of the team (ex-Allergan), its focus on the cash-pay market and the KOL network around which the company is formed (it is operating with a new business model) (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7257" class="defaultlink">Neurology7257: Daewoong Still Awaits Toxin Approval In Korea But Analysts Are Impressed With The Export Deal It Has Negotiated</a>).<wbr> </div><div style="margin-bottom: 10px;">Finally, she was pleased to announce the extension of the partnership with Alphaeon regarding the distribution of its in-licensed toxin from Daewoong across Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Alphaeon</STRONG> </div><div style="margin-bottom: 10px;">Robert Grant from Strrathspey Crown also spoke briefly about his company, highlighting how its uses a crowd intelligence platform called SHOUT MD to derive great data from its KOL network, data that is very valuable to the industry in terms of highlighting upcoming trends, even to the point that it asks its clinicians what products to bring into the company portfolio such as our new toxin.<wbr> He noted that Strathspey has a global license to the Daewoong product both for aesthetic and therapeutic indicaitons but that it doesn't plan to commercialise the therapeutic line as its focus is on non-reimbursed products </div><div>Source Industry Tribune IMCAS 2014 </div><!-- Comment details --><a name="neurology7367attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(69,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_2_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(81,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_3_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(82,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_4_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(97,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_5_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(77,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_6_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(648 B)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_7_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(85,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_8_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(103 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_9_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(82,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_10_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(48,2 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7367_11_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(67,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7367">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-03T11:59:06+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-03T11:59:06+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>IMCAS 2014 - Update of Toxins and Dermal Fillers in Asia</title>
	<pubDate>2014-02-03T11:48:17+01:00</pubDate>
	<wp:post_id>5150</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: For this year congress, a series of IMCAS sessions were dedicated to the differences between Caucasian and Asian faces and the criteria of preference to focus on when it comes to botulinum toxin and dermal fillers injections.<wbr> Patient trends, market drivers/<wbr>limiters and prospectives were discussed by a panel of speakers in the aesthetic, medicine and dermatologic fields.<wbr> Key messages are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Key findings from 5 surveys undertaken from 20112 (see sources below) were reported.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_11_ScreenCapture11.jpg"> </div><div style="margin-bottom: 10px;">The Asian market is growing rapidly in numbers, both procedures and physicians.<wbr> </div><div style="margin-bottom: 10px;">The Asia Pacific region will experience the most growth in facial injectable procedures globally.<wbr> Of note, the decrease of the US market.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>The Global Facial Injectables Market to Grow at a CAGR of 7% </STRONG><STRONG>to reach $2.<wbr>8 bln by 2018</STRONG> </div><div style="margin-bottom: 10px;">The N.<wbr> American, European, Asia Pacfific and Latin American facial aesthetics markets are expected to grow at CAGRs of approx.<wbr> 7%, 3%, 10% and 9% respectively.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_13_ScreenCapture13.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Top Indications with Toxins</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_14_ScreenCapture14.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Market Landscape</STRONG> </div><div style="margin-bottom: 10px;"><U>Botulinum toxin procedure share by brand and % of respondents</U> </div><div style="margin-bottom: 10px;">In the botulinum toxin segment, local competitors are also leading competitors in the market.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><U>Dermal filler procedure share by brand, and % of respondents</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_15_ScreenCapture15.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_10_ScreenCapture10.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Botox, Botulax and Neuronox are the top 3 brands.<wbr> Top indications include masseter, (age&lt;34); crow's feet (age 35 to &gt;45).<wbr> </LI>
<LI>When it comes to filler Restylane, Anteis and Juvederm are the most popular.<wbr> Top indications include nose (age &lt;34), nasal folds (age 35-44).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">China is becoming the fast growing country when it comes to non invasive procedures.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Neuromodulators</STRONG> still dominate the market segment with 50% Botox and 50% 'others'.<wbr> </LI>
<LI><STRONG>Dermal fillers</STRONG> are limited in the public hospitals.<wbr> Only 3 are allowed: Artecoll, Restylane and collagen fillers (20% of the Chinese market).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Peter HUANG (plastic surgeon in Taiwan) highlighted that product safety is a major concern in China; approx.<wbr> 90% of products are counterfeited, cost probably being the main reason.<wbr> He listed the 11 injectables products appoved by the Chinese FDA (9  and 2 ).<wbr> </div><div><UL><LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
<LI></LI>
</UL> </div><!-- Comment details --><a name="neurology7365attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(81,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(53,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(58 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(121,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(73,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(61,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(56,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(58,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(105 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(49,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_11_ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(75,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_12_ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(82,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_13_ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(77 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_14_ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(41,5 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7365_15_ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(64,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7365">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-02-03T11:48:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-02-03T11:48:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Korlym's Cushing Syndrome Sales Start To Gain Momentum</title>
	<pubDate>2014-01-31T14:11:34+01:00</pubDate>
	<wp:post_id>5151</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Corcept reported net revenue for the fourth quarter of $4.<wbr>1m and 
$10.<wbr>4m for the full year with the expectation 
that group/<wbr>Korlym revenue will grow to $24m in 2014.<wbr> Cash at the 
year end was $54.<wbr>9m </div><div style="margin-bottom: 10px;"><STRONG>2014 Guidance</STRONG> </div><div style="margin-bottom: 10px;">The company estimates 2014 net revenue based on Korlym sales will be between 
$24m and $28m.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Korlym's Performance</STRONG> </div><div style="margin-bottom: 10px;">Korlym for Cushing's disease reported a 56% increased in the fourth quarter 
compared to the prior quarter, a momentum that is expected to continue into 
2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other Key Developments</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Enrollment in  a PhI study of mifepristone in triple negative breast 
  cancer to commence in the next few days.<wbr></LI>
<LI>PhIII interim results from the group's trial with Korlym in psychotic 
  depression expected in Q214,</LI>
<LI>Advance two its next-generation selective GR antagonists into the clinic 
  in 2H14</LI>
</UL> </div><div style="margin-bottom: 10px;"><TABLE width="100%"><TBODY><TR align="left"><TD valign="top">
      <DIV class="article_body">Successful commercialisation of Korlym for 
      Cushing;s syndrome remains a key strategic priority for 
      2014.<wbr><BR><BR><BR>Source: <A href="http://www.corcept.com">www.<wbr>corcept.<wbr>com</A><BR><BR></DIV></TD>
</TR>
</TBODY>
</TABLE> </div><div><TABLE width="100%"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7591">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-31T14:11:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-31T14:11:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan's Presentation At JP Morgan</title>
	<pubDate>2014-01-31T12:04:53+01:00</pubDate>
	<wp:post_id>5152</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Verdana','sans-serif'">Comment: 
Thanks to the team at this year's JP Morgan H/<wbr>C conference, we have slides 
from Allergan's presentation to share with you.<wbr> It is interesting to 
note 2017 growth projections for both the therapeutic and aesthetic 
neuromodulator markets valued at $2.<wbr>6bn and just short of $2bn 
respectively.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: 'Verdana','sans-serif'">Whilst we 
don't have access to the presentation transcript their dosen't appear to be 
anything exceptionally new in the content other than the manner in 
which Alelrgan is redefining facial aesthetics, its growth projections 
and its perspective that with new therapeutic neuromodulator markets 
it takes an estimated 5-7 years to reack peak sales in the US and a further 2 
years in overseas markets because of prising and reimbursement 
issues.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_9_ScreenCapture9.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_10_ScreenCapture10.jpg"> </div><!-- Comment details --><a name="neurology7364attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(120,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(124,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(118 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(118,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(112,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(116 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(131,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(122,5 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(131,8 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7364_10_ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(133,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7364">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-31T12:04:53+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-31T12:04:53+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Roche Q4 Figures - Key Takeaways</title>
	<pubDate>2014-01-31T10:37:59+01:00</pubDate>
	<wp:post_id>5153</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Roche reported strong growth with group revenues up 6% in line with guidance and EPS up 10%.<wbr> Pharmaceutical revenue growth +3% (c.<wbr>c.<wbr> +7%) with operating profit similarly up 7% at CER.<wbr> We now have confirmation that Roche will not make regulatory submissions for its oral octreotide until 2015.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">With regard to oral octreotide, partnered with Chiasma, Daniel O'Day COO made the following comment:- </div><div style="margin-bottom: 10px;">"We'll be getting results from that this year with the potential to file next year depending on those results in acromegaly.<wbr> Just so you know this is an oral medication and the current standard of care is infusion by rather large bore needle.<wbr> So, it could be a significant advance for patients.<wbr>" </div><div style="margin-bottom: 10px;">A filing in 2015 is also validated by a recent Roche job posting for a  Senior Product Manager for oral octreotide posted by Roche in the US which mentions an FDA submission in Q1 2015 with an anticipated launch in Q1 2016.<wbr> Thanks to Jean-Pierre Covilard for alerting us to this.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_7_ScreenCapture7.jpg"> </div><!-- Comment details --><a name="endocrinology7589attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(101,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(75,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(111,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(84 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(67,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(152,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(117,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7589_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(99,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7589">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-31T10:37:59+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-31T10:37:59+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Key Messages from Novartis FY2013 Results</title>
	<pubDate>2014-01-30T09:18:08+01:00</pubDate>
	<wp:post_id>5154</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Key Messages from Novartis FY2013 Results</span>&nbsp;<br><span style="font-size: 12px;">Comment: David Epstein reported net sales in 2013 increased to $57.<wbr>9 billion (+2%, +4%cc), and pharmaceutical division grew to $32.<wbr>2 billion (+3% cc vs previous year).<wbr> Emerging markets, which are listed as one of the company's strategic priorities for 2014, grew +9% vs.<wbr> 2012 in cc, lead by Russia and China.<wbr> FDA action and CHMP opinion for Signifor LAR in acromegaly are expected during H2:14.<wbr> Key slides are provided below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7582">...</a><br></div><div style="margin-bottom: 10px;">In its full length press release, Novartis elaborates on its Signifor filing.<wbr> This occurred in the fourth quarter both in the US &amp; EU with the regulatory submission made for the treatment of patients with acromegaly for whom medical therapy is appropriate (a fairly broad label).<wbr> similar to the approach it took regarding the submission for Signifor in Cushing's disease.<wbr> </div><div>Signifor currently approved for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.<wbr> Whether such a broad label will be granted for acromegaly remains to be seen, especially in light of the high incidence of hyperglycaemia observed with the drug, which suggests in practice usage could well be limited to octreotide and lanreotide failures.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7587">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7582">View thread  Endocrinology7582: Key Messages from Novartis FY2013 Results</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-30T09:18:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-30T09:18:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Diagnostic for Patients with GEP-NETS Granted ODD by EMA</title>
	<pubDate>2014-01-29T16:12:51+01:00</pubDate>
	<wp:post_id>5155</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: OctreoPharm's OPS202 (future trade name SOMscan) is a new <SUP>68</SUP>Gallium-labeled radiopharmaceutical in clinical development for positron emission tomography (PET, PET/<wbr>CT) with the potential to detect even smallest lesions of NETs.<wbr> Depending on the labeled radionuclide OPS202 can be used for diagnosis (<SUP>68</SUP>Ga) as well as for therapy (<SUP>90</SUP>Y).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Company claims that the whole diagnostic procedure can be completed in 1 hour and provides quantification capability that might be improved compared to other radio-labeled compounds.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">In Oct 2011, OctreoPharm Sciences GmbH received the WW exclusive license for the development and commercialization of SOMscan, from Novartis Pharma AG.<wbr> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Novartis is to receive an upfront payment and milestone payments upon regulatory approvals, as well as royalties.<wbr> </div><div style="margin-bottom: 10px;">Novartis has the right to re-acquire the rights to SOMscan on pre-agreed financial terms.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About OctreoPharm Sciences GmbH</STRONG> </div><div style="margin-bottom: 10px;">OctreoPharm Sciences GmbH, located in Berlin (Germany) is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control of tumors.<wbr> </div><div style="margin-bottom: 10px;">Current shareholder of OctreoPharm Sciences GmbH are: </div><div>- Eckert &amp; Ziegler AG, VC Funds Technology managed by IBB Berlin GmbH, KfW Mittelstandsbank, Eckert Life Science Accelerator GmbH, OctreoPharm (Holding) GmbH and the Chinese investor Shaanxi Xinyida Investment Co.<wbr> Ltd.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7825c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><span style="font-weight: bold;">re: Diagnostic for patients with GEP-NETS Granted ODD by EMA</span> </div><div style="margin-bottom: 10px;">OctreoPharm's OPS202 has received US FDA ODD for the management of neuroendocrine tumors.<wbr> </div><div style="margin-bottom: 10px;">Status: Ph1/<wbr>2 </div><div>MOA: has the potential to improve the Imaging of NET patients </div></div><a name="Endocrinology7831c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div><STRONG>Please note that Novartis does not have an option or any other rights for OctreoPharm&rsquo;s OPS202 diagnostic (SomScan).<wbr> </STRONG>Novartis had an option for another product (a Pasireotide based diagnostic) that OctreoPharm is not developing anymore.<wbr> The confusion comes from the fact that at the time they had used the name Som Scan for that product as well.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7583">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-29T16:12:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-29T16:12:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Novartis FY2013 Results</title>
	<pubDate>2014-01-29T15:57:07+01:00</pubDate>
	<wp:post_id>5156</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: David Epstein reported net sales in 2013 increased to $57.<wbr>9 billion (+2%, +4%cc), and pharmaceutical division grew to $32.<wbr>2 billion (+3% cc vs previous year).<wbr> Emerging markets, which are listed as one of the company's strategic priorities for 2014, grew +9% vs.<wbr> 2012 in cc, lead by Russia and China.<wbr> FDA action and CHMP opinion for Signifor LAR in acromegaly are expected during H2:14.<wbr> Key slides are provided below.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Arial','sans-serif'; background: white; color: black; font-size: 11pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Arial','sans-serif'; background: white; color: black; font-size: 11pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"></SPAN><SPAN style="line-height: 115%; font-family: 'Arial','sans-serif'; background: white; color: black; font-size: 11pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"> </SPAN> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7582_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Pharmaceuticals delivered net sales of USD 32.<wbr>2 billion (0%, +3% cc) for the full year, driven by strong volume growth (+9 percentage points) and pricing (+1 percentage point), which more than offset the impact of generic competition (USD 2.<wbr>2 billion, -7 percentage points).<wbr> Growth products grew 25% in constant currencies and contributed USD 12.<wbr>3 billion or 38% of division net sales in 2013, compared to 31% in 2012.<wbr> </div><div style="margin-bottom: 10px;">Novartis is still awaiting some cheaper, copycat competition for Diovan, since Ranbaxy Laboratories &lt;RANB.<wbr>NS&gt;has faced regulatory delays for its generic version.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7582_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7582_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7582_4_ScreenCapture4.jpg"> </div><div><STRONG></STRONG> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7587c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">In its full length press release, Novartis elaborates on its Signifor filing.<wbr> This occurred in the fourth quarter both in the US &amp; EU with the regulatory submission made for the treatment of patients with acromegaly for whom medical therapy is appropriate (a fairly broad label).<wbr> similar to the approach it took regarding the submission for Signifor in Cushing's disease.<wbr> </div><div>Signifor currently approved for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.<wbr> Whether such a broad label will be granted for acromegaly remains to be seen, especially in light of the high incidence of hyperglycaemia observed with the drug, which suggests in practice usage could well be limited to octreotide and lanreotide failures.<wbr> </div></div><a name="endocrinology7582attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7582_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(31,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7582_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(35,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7582_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(53,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7582_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(55,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7582_5_NVS%255fq4%2d2013%2dinvestor%2dpresentation.pdf">NVS_q4-2013-investor-presentation.pdf</a>&nbsp;&nbsp;(1,2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7582">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-29T15:57:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-29T15:57:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New NET Therapy Area Landscape</title>
	<pubDate>2014-01-29T11:51:10+01:00</pubDate>
	<wp:post_id>5157</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Meanwhile, in what is expected to be an active year for newsflow, please keep us updated with any information of relvance to this document, so together we can build a tool that is useful for us all.<wbr></span>&nbsp;<br></div><div>Extremely valuable piece of work Jacquie.<wbr> Will catch up with you on this when you are next in Slough.<wbr> Thanks Nigel </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7581">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7578">View thread  Endocrinology7578: New NET Therapy Area Landscape</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-29T11:51:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-29T11:51:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>XTANDI® PREVAIL Final Results in Pre-Chemo Met Endpoints</title>
	<pubDate>2014-01-29T09:17:49+01:00</pubDate>
	<wp:post_id>5158</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Preliminary final rsults demonstrate a statistically significant reduction both in the risk of death and a delay in cancer progression in men with metastatic prostate cancer who have a rising PSA and few, if any, symptoms.<wbr> Astellas plans to submit regulatory applications to the FDA and EMA early this year.<wbr> In Japan, a review by regulators is set for Feb 3.<wbr> It could be approved in Japan without any pre-chemo/<wbr>post-chemo restrictions.<wbr> Further medical details from the ASCO GU presentation will be published tomorrow.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- XTANDI® reduced the risk of death by 29% and progression free survival by 81% compared with a placebo.<wbr> </div><div style="margin-bottom: 10px;">- Men taking XTANDI® on average went 17 months longer than those in the placebo group before requiring chemotherapy - 28 months versus 10.<wbr>8 months.<wbr> </div><div style="margin-bottom: 10px;">- Nearly 4 out of 5 patients in the XTANDI® group experienced a PSA decline of 50% or more, compared to less than 4% in the placebo group (78% vs.<wbr> 3.<wbr>5%; p &lt; 0.<wbr>0001).<wbr> </div><div style="margin-bottom: 10px;">- Safety: XTANDI® did raise blood pressure in more than 13% of patients versus about 4% on placebo, but that was easily controlled by common hypertension medicines.<wbr> Serious heart issues were observed in 2.<wbr>8% of XTANDI® patients compared with 2.<wbr>1% in the placebo group.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Investor at Barclays reported : " .<wbr>.<wbr>.<wbr> Based on our comparison of this data to that of the Zytiga Phase III COU-AA-302 study (see table below), we believe the results between Zytiga plus prednisone and Xtandi are largely comparable.<wbr> However, when looking at the overall survival curves, we do see a noticeable difference in the initial months between the two curves – there is an early separation between the two arms of the study in the PREVAIL study and a later separation in the COU-AA-302 study.<wbr> Overall, we believe this is explained by the fact that the comparator arm in the PREVAIL study was placebo, while in the COU-AA-302 study it was prednisone (an active drug in prostate cancer).<wbr> Also 12% of PREVAIL patients had visceral metastases at baseline.<wbr> While the treatment duration for Xtandi in the PREVAIL study is slightly longer relative to Zytiga plus prednisone in the COU-AA-302 study (16.<wbr>6 months vs.<wbr> 13.<wbr>8 months), we note that the average duration is always shorter in real life than in a clinical trial.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- approved by the FDA on August 31, 2012 and is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel.<wbr> </div><div><STRONG>PREVAIL Design</STRONG> : <A href="http://www.clinicaltrials.gov/ct2/show/NCT01212991?term=prevail+AND+ENZALUTAMIDE&amp;rank=1">http:/<wbr>/<wbr>www.<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT01212991?term=prevail+AND+ENZALUTAMIDE&amp;rank=1</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9433">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-29T09:17:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-29T09:17:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Medigene Acquisition of Trianta Boosts Immunotherapy Pipeline</title>
	<pubDate>2014-01-28T19:16:43+01:00</pubDate>
	<wp:post_id>5159</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Medigene has acquired 100% of the Munich-based company, Trianta Immunotherapies GmbH for approx.<wbr> &euro;4M.<wbr> Trianta is developing 3 T-cell cancer vaccines, with programs in clinical development to treat various tumour types (i;e AML and prostate).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financial Terms</STRONG> </div><div style="margin-bottom: 10px;">The acquisition is milestone-based with &euro;4M upfront (corresponds to 1,017,811 newly issued shares) and milestone payments of up &euro;5.<wbr>9M in shares or cash.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trianta Platforms</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>next generation antigen-tailored dendritic cell (DC) vaccines (being evaluated in 2 ongoing, externally funded investigator-initiated trials: a clinical Ph1/<wbr>2 trial (NCT01734304)  in acute myeloid leukemia (AML), and a clinical Ph2 trial in prostate cancer (NCT01197625) .<wbr> Both trials are scheduled to complete 2016/<wbr>2017.<wbr>
</LI>
<LI>T cell receptor (TCR)-based adoptive cell therapy
</LI>
<LI>T cell-targeted antibodies (TABs)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Competitive Advantages of the DC Platform</STRONG> </div><div style="margin-bottom: 10px;">Trianta&rsquo;s DC vaccine is patient-derived (autologous) and an example of a third-generation candidate, which has been developed to display two key advantages: &lsquo;fast&rsquo; and &lsquo;polarised&rsquo;.<wbr> Whereas standard procedures to produce mDCs take seven days, Trianta scientists developed a protocol that delivers young mDCs in just three days, so-called &lsquo;fast DCs&rsquo;.<wbr> These cells have been shown to be as effective as seven-day mDCs in processing and presentation of tumour-associated antigen, while also being more robust in withstanding the stress of electroporation required for efficient antigen loading and freezing for later use.<wbr> This clearly provides significant manufacturing efficiencies over current practice, allows for 10 doses to be prepared in one go, and for these doses to be frozen (current shelf life more than two years).<wbr> </div><div style="margin-bottom: 10px;">As well as being &lsquo;fast&rsquo;, Trianta&rsquo;s DCs have been developed to &lsquo;polarise&rsquo; the T-cell response, to optimise the activation of natural killer cells.<wbr> This is achieved primarily by the addition of toll-like receptor (TLR) agonists to the maturation mixture.<wbr> TLR agonists can stimulate the mDCs to produce cytokines, with IL-12 seen to be the most important in terms of helping to polarise/<wbr>optimise the immune response.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trianta Mini Profile</STRONG> </div><div style="margin-bottom: 10px;">Trianta was founded in late 2013 as a spin-off from the Helmholtz Zentrum, Munich and is the culmination of 15 years of extensive research in the field of immunotherapy.<wbr> </div><div style="margin-bottom: 10px;">Professor Dolores Schendel, the managing director of Trianta and director of the Institute for Molecular Immunology at the Helmholtz Zentrum, will become Medigene&rsquo;s chief scientific officer and will be accompanied by her team of 15 immunotherapy specialists from the Helmholtz Zentrum.<wbr> </div><div><EM>Source: Medigene</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9432">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-28T19:16:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-28T19:16:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>UK NICE Issued Second Draft Guidance on Xtandi</title>
	<pubDate>2014-01-28T17:18:58+01:00</pubDate>
	<wp:post_id>5160</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In addition to the previously-issued guidance in which Xtandi was recommended for patients who progressed during or after one docetaxel-containing chemotherapy regimen, the new draft guidance excludes the treatment of patients which have previously been treated with JNJ’s Zytiga.<wbr> Since Zytiga is approved both in the pre- and post-chemotherapy settings, this new draft guidance would restrict the number of eligible patients for Xtandi.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">If formally adopted, new draft guidance will negatively affect the growth trajectory of Xtandi in UK.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: verdana, arial, sans-serif; COLOR: #585858; FONT-SIZE: 9pt"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: verdana, arial, sans-serif; COLOR: #585858; FONT-SIZE: 9pt"></SPAN> </div><div><SPAN style="FONT-FAMILY: verdana, arial, sans-serif; COLOR: #585858; FONT-SIZE: 9pt"><EM>Source: ThomsonOne; <A href="http://www.nice.org.uk/newsroom/pressreleases/NICEConsultsAgainDecisionRecommendNewProstateCancerDrug.jsp">NICE</A>; Barclay</EM></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9430">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-28T17:18:58+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-28T17:18:58+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Revance To Proceed With IPO & Further Development Of Its Toxin Portfolio</title>
	<pubDate>2014-01-28T14:43:20+01:00</pubDate>
	<wp:post_id>5161</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Revance yesterday announced the initial public offering of its common stock to raise minimum gross proceeds of $70m to further fund the development of its topical toxin RT-001 for the treatment of crows feet lines.<wbr> Meanwhile, plans for a phII study with the injectable formulation RT002 are underway for the treatment of glabellar lines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>IPO Terms</STRONG> </div><div style="margin-bottom: 10px;">The company will issue 5 million shares at a price range between US$14 and US$16 per share.<wbr> The company granted underwriters a 30-day option to purchase up to 750,000 additional shares to cover over-allotments, if any.<wbr> The company intends to list its common stock on The NASDAQ Global Market, under the symbol 'RVNC'.<wbr> </div><div style="margin-bottom: 10px;">Cowen and Company, LLC and Piper Jaffray &amp; Co.<wbr> are acting as joint book-running managers; whereas BMO Capital Markets Corp.<wbr> is acting as underwriter; while Cooley LLP is acting as legal advisor to the company for the offering.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Use Of Funds<BR></STRONG><BR>The company intends to use the proceeds for the following purposes:- </div><div style="margin-bottom: 10px;"><UL><LI>To fund R&amp;D expenses associated with RT001 and RT002 manufacturing, quality and regulatory efforts;
</LI>
<LI>To complete one Phase III clinical pivotal trial in the US, to continue a long term safety clinical trial and other associated programs relating to RT001 for the treatment of crow&rsquo;s feet lines.<wbr> Interestingly, there has been some soft intelligence regarding RT001 running into problems with skin allergies.<wbr>:
</LI>
<LI>To initiate first US Phase II clinical trial and associated programs relating to RT002 for the treatment of glabellar lines;
</LI>
<LI>To make payments through 2014 under September 2011 term loan agreement with Hercules Technology Growth Capital, Inc.<wbr>, which bears interest at a rate equal to the greater of 9.<wbr>85% or the prime rate plus 6.<wbr>60%, and requires the principal balance to be repaid in thirty-three equal monthly installments beginning in July 2012;
</LI>
<LI>Make payments under settlement agreement with Medicis Pharmaceutical Corporation (acquired by Valeant Pharmaceuticals International, Inc.<wbr>); and.<wbr>
</LI>
<LI>With the remaining balance of the proceeds, if any, for the development of RT001 for the treatment of hyperhidrosis and other indications, as well as for working capital and other general corporate purposes.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>RT-002's Profile</STRONG> </div><div><UL><LI>RT002 will employ Revance&rsquo;s TransMTS<SUP>&reg;</SUP> peptide technology and will be a freeze-dried (not HSA free) injectable formulation requiring reconstituion and serial dilution.<wbr>
</LI>
<LI>The main feature of RT002 is claimed to be &ldquo;less-diffusion&rdquo; when compared to Botox making it possible to apply higher doses; 158 vs.<wbr> 108 U with Botox
</LI>
<LI>Preclinical studies have apparently demonstrated an extended duration of drug effect as compared to Botox
</LI>
<LI>A RT002 Phase I/<wbr>II trial was initiated in Q2 2013 post a $33 Million E Series financing round in May 2013
<UL><LI>This is due to conclude on or before Q2 2014
</LI>
</UL>
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7359">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-28T14:43:20+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-28T14:43:20+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New NET Therapy Area Landscape</title>
	<pubDate>2014-01-28T12:59:10+01:00</pubDate>
	<wp:post_id>5162</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New NET Therapy Area Landscape</span>&nbsp;<br><span style="font-size: 12px;">Comment: You will find attached an updated version of the Neuroendocrine Tumour competitive landscape thanks to the collaborative efforts of the CI/<wbr>SI departments and the Endocrinology Franchise.<wbr> It incorporates, key developments over the last 3 months post ESMO &amp; ASCO GI and a revised list of Key Intelligence Topics we hope you will try to address.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7578">...</a><br></div><div>Thanks Jacquie.<wbr>  This is extremely useful.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7580">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7578">View thread  Endocrinology7578: New NET Therapy Area Landscape</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-28T12:59:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-28T12:59:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>MS Drug's Rejection By The EMA Bad News For Active Biotech</title>
	<pubDate>2014-01-27T19:29:25+01:00</pubDate>
	<wp:post_id>5163</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:: Friday's news that the multiple sclerosis drug NERVENTRA would not be approved by the EMA, seemingly because of safety concerns, was bad news for Teva but even worse news for its partner &amp; licensor Active Biotech, whose shares fell by 46%.<wbr> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Considering Teva&rsquo;s boardroom shakeup and the imminent genericisation of its blockbuster Copaxone, the group and its investors probably have bigger problems to worry about than last week&rsquo;s EU rejection of the multiple sclerosis project.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="hugin">The CHMP has concluded that the risk-benefit profile of NERVENTRA is not favorable at this time.<wbr> In accordance with European regulations, Teva and Active Biotech intend to request a re-examination of the CHMP opinion.<wbr> Teva and Active Biotech are focusing on evaluating the CHMP's review and will continue to liaise closely with the EMA in working to make NERVENTRA available as a new treatment option for patients with RRMS in Europe.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="hugin">The issue appears to centre around concerns about animal studies showing a higher occurrence of cancers after long-term exposuire to the medicine that can not be excluded in humans,</P> </div><div><P class="hugin">Source: <A href="http://www.teva.com/">www.<wbr>teva.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7358">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-27T19:29:25+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-27T19:29:25+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Trial Evaluates Patient Preference Between Cabazitaxel and Docetaxel in mCRPC</title>
	<pubDate>2014-01-27T19:17:55+01:00</pubDate>
	<wp:post_id>5164</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The randomized Ph3 is currently comparing the efficacy of Taxotere and Jevtana in 1st-line setting with OS as a primary end-point.<wbr> Assessing patient preference between Jevtana and Taxotere would contribute to further identify differences between these two taxanes and clarify which one of these two taxanes should be used for second-line chemotherapy and perhaps for first-line chemotherapy in the future.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details - CABA-DOC</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Study Chair</SPAN>: Karim Fizazi MD, PhD </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Sponsor:</SPAN> Gustave Roussy, Cancer Campus, in collaboration with Sanofi.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Recruitment</SPAN>: approx.<wbr> 174 </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Timelines</SPAN> </div><div style="margin-bottom: 10px;">Start date: January 2014 - Completion date: January 2016 /<wbr> February 2016 </div><div>Source: <a href="http://www.clinicaltrials.gov/ct2/show/NCT02044354?recr=Open&fund=2&rcv_s=12%2F27%2F2013&rank=323" class="defaultlink">NCT02044354</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9429">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-27T19:17:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-27T19:17:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer to Start Comparison Ph3 of Radium-223 and Abiraterone</title>
	<pubDate>2014-01-23T17:45:03+01:00</pubDate>
	<wp:post_id>5165</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This study, conducted at approx.<wbr> 150 centers (&gt;50 locations) in approx.<wbr> 800 subjects, will determine if the addition of radium-223 dichloride to standard treatment is able to prolong life and to delay events specific for prostate cancer which has spread to the bone, such as painful fractures or bone pain which needs to be treated with an X-ray machine.<wbr> PE will measure symptomatic skeletal event free survival (SSE-FS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: Feb 2014 </div><div style="margin-bottom: 10px;">Completion dates: July 2020 /<wbr> July 2017 </div><div style="margin-bottom: 10px;"><STRONG>Design</STRONG> </div><div style="margin-bottom: 10px;">Randomization allocation ratio of 1:1 (radium-223 dichloride plus abiraterone acetate plus prednisone/<wbr>prednisolone: placebo plus abiraterone acetate plus prednisone/<wbr>prednisolone).<wbr> </div><div style="margin-bottom: 10px;">The study period will consist of screening/<wbr>randomization, treatment, active follow-up with clinic visits, active follow-up without clinic visits, and long-term follow-up phases.<wbr> </div><div style="margin-bottom: 10px;">In this study, subjects will receive study treatment (radium-223 dichloride or placebo in addition to abiraterone acetate plus prednisone/<wbr>prednisolone for the first 6 cycles followed by abiraterone acetate plus prednisone/<wbr>prednisolone thereafter) until an on-study symptomatic skeletal event (SSE) occurs (or other withdrawal criteria are met).<wbr> </div><div style="margin-bottom: 10px;">Follow-up will continue for up to 7 years or until the subject dies, is lost to followup, or withdraws informed consent and actively objects to collection of further data.<wbr> </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02043678?recr=Open&amp;fund=2&amp;rcv_s=12%2F23%2F2013&amp;rank=11&amp;submit_fld_opt=">NCT02043678</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9427">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-23T17:45:03+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-23T17:45:03+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Daewoong Inked Contract with TKJ to Supply NABOTA in Iran</title>
	<pubDate>2014-01-23T16:40:07+01:00</pubDate>
	<wp:post_id>5166</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: TKJ, Iran’s leading pharmaceutical company, is the major shareholder of the second largest pharmaceutical distribution company of Iran, and has the advantage in the distribution network straddling the entire parts of Iran.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Financial: $15M </div><div style="margin-bottom: 10px;">Duration: Daewoong will supply the products to the Iranian market for 5 years from 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Profile</U>: Tadbir Kalaye Jam Trading Company (TKJ) was established in 1997 as a private import-export company.<wbr> </div><div style="margin-bottom: 10px;"><U>Group organization</U> <A href="http://www.tadbirkala.com/en/TKJ_Group.asp">http:/<wbr>/<wbr>www.<wbr>tadbirkala.<wbr>com/<wbr>en/<wbr>TKJ_Group.<wbr>asp</A> </div><div style="margin-bottom: 10px;"><U>Business Partners</U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7356_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">According to Daewoong PR, Iran's Pharma market is worth approx.<wbr> $3.<wbr>1 billion(as of 2011), among which the botulinum toxin formulation segment garners $10 million.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Daewoong Pharmaceutical signed a contract valued at approximately KRW 300 billion in September last year with the U.<wbr>S.<wbr>-based Evolus to supply NABOTA which is slated to roll out nationwide in March next year (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7257" class="defaultlink">Neurology7257: Daewoong Still Awaits Toxin Approval In Korea But Analysts Are Impressed With The Export Deal It Has Negotiated</a>) </div><div style="margin-bottom: 10px;">The company entered into a sales contract worth KRW 100 billion on January 2 with Pharmavital to export NABOTA to 15 countries of Latin America (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7296" class="defaultlink">Neurology7296: Daewoong's Botulinum Toxin NABOTA Gains Ground in Latin America</a>).<wbr> </div><div><EM>Source: Daewoong</EM> </div><!-- Comment details --><a name="neurology7356attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7356_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(53,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7356">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-23T16:40:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-23T16:40:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New NET Therapy Area Landscape</title>
	<pubDate>2014-01-23T15:57:22+01:00</pubDate>
	<wp:post_id>5167</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: You will find attached an updated version of the Neuroendocrine Tumour competitive landscape thanks to the collaborative efforts of the CI/<wbr>SI departments and the Endocrinology Franchise.<wbr> It incorporates, key developments over the last 3 months post ESMO &amp; ASCO GI and a revised list of Key Intelligence Topics we hope you will try to address.<wbr> </div><div style="margin-bottom: 10px;">Additionally.<wbr> there is: </div><div style="margin-bottom: 10px;"><UL><LI>an updated picture of the current and future pharmacological treatment options for NET:
</LI>
<LI>an expanded comment on the strategic importance of Novartis's NET portfolio; and,
</LI>
<LI>updated ID cards on the key therapeutic drugs, extended now to include Roche's bevacizumab.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">Reference at this stage to Octreolin (Roche) and CAM2029 (Novartis) is fairly minimal, as we await futher clarity regarding progress wtih any NET development programmes.<wbr> </div><div>Meanwhile, in what is expected to be an active year for newsflow, please keep us updated with any information of relvance to this document, so together we can build a tool that is useful for us all.<wbr> <a name="Endocrinology7581c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Extremely valuable piece of work Jacquie.<wbr> Will catch up with you on this when you are next in Slough.<wbr> Thanks Nigel </div></div></div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7580c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Thanks Jacquie.<wbr>  This is extremely useful.<wbr> </div></div><a name="endocrinology7578attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7578_1_NET%20Therapeutic%20Landscape%20%2d%2023%20January%20%202014.ppt">NET Therapeutic Landscape - 23 January 2014.ppt</a>&nbsp;&nbsp;(3,5 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7578">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-23T15:57:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-23T15:57:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Launches Developing-World Business Unit</title>
	<pubDate>2014-01-23T12:29:39+01:00</pubDate>
	<wp:post_id>5168</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The formation of the business unit is likely to allow J&amp;J to focus on devising strategies to meet the marketing conditions in many developing markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">An important new group unifying Janssen’s commitment to research, develop, and deliver transformational medicines to address the world’s greatest unmet public health needs.<wbr> </div><div style="margin-bottom: 10px;">Janssen GPH will align the company’s groundbreaking science and innovative access models under a single entity to drive better health outcomes, improve quality of life for patients, and sustainably advance health for people all over the world.<wbr> </div><div style="margin-bottom: 10px;">Many pharmaceutical companies are realising that developing countries offer substantial market potential, especially in the future.<wbr> Other companies such as GSK have begun actively engaging in this area with low–price, high-volume models targeting a number of key products.<wbr> </div><div style="margin-bottom: 10px;">Over time, as these regions become more affluent, these business models will likely change to target growing middle classes and non-communicable diseases.<wbr> </div><div><EM>Source: J&amp;J</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10739">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-23T12:29:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-23T12:29:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Daewoong New Strategy for 2014 Presented at Kick-Off Meeting with Employees</title>
	<pubDate>2014-01-23T11:34:57+01:00</pubDate>
	<wp:post_id>5169</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: President Lee Jong-wook unveiled the vision statement that would transform its "business to the next advanced level.<wbr>” He outlined that the company is already on track to proceed with the export of its mainstay products, among which NABOTA (botulinum toxin).<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- cement leadership in Korea </div><div style="margin-bottom: 10px;">- push forward R&amp;D and new drug development </div><div style="margin-bottom: 10px;">- expand to international market </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Management stressed the need to sharpen the manufacturing competitiveness with the production system onforming to current GMP.<wbr> </div><div><EM>Source: Daewoong</EM> </div><!-- Comment details --><a name="neurology7352attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7352_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(26,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7352">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-23T11:34:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-23T11:34:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis Will Create New Roles to Support New Product Launches</title>
	<pubDate>2014-01-22T11:14:32+01:00</pubDate>
	<wp:post_id>5170</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The yesterday reported cutting of 500 jobs in the pharma division follows Novartis' plans to close sites in England and Austria announced last quarter of 2013.<wbr> The new measures will free resources to support the launches of new products (such as branded and generic respiratory drugs and treatments for heart disease, lung cancer and skin disease).<wbr> The company has put big hopes on the approval this year for its heart failure drug serelaxin and secukinumab, a treatment for moderate to severe plaque psoriasis </div><div style="margin-bottom: 10px;"><STRONG>Staff Reorganization</STRONG> </div><div style="margin-bottom: 10px;">Mangement reported that the reorganisation would not affect the active clinical trial programmes in Switzerland.<wbr> </div><div style="margin-bottom: 10px;">Most of the job cuts will be in support functions at its headquarters as well as operational roles in development.<wbr><BR><BR>In parallel, several hundred positions will be added in areas such as oncology development, OTC manufacturing and supply chain management at its generics unit Sandoz.<wbr> </div><div><EM>Source: ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10736">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-22T11:14:32+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-22T11:14:32+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>J&J Q4 Results - Key Takeaways</title>
	<pubDate>2014-01-21T18:48:16+01:00</pubDate>
	<wp:post_id>5171</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment:J&amp;J continues to register very strong worldwide pharmaceutical revenue growth with sales in the fourth quarter up 11.<wbr>8% (+13.<wbr>1% l.<wbr>c.<wbr>) vs.<wbr> the same period last year, with Remicade, Prezista and Zytiga all important growth drivers, </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">By any measure, the performance of the pharmaceutical group is regarded by management as exceptional.<wbr> J&amp;J claims to be the fastest-growing of the 10 pharmaceutical companies in the United States, in Europe and in Japan having recorded 15 consecutive quarters of operational sales growth.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr"><STRONG>What is behind this success?</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">It claims its success is driven by several important factors.<wbr> It starts with great science, which has consistently delivered meaningful advancements for patients with 13 new products launched since 2009 and three major medicines launched in 2013 including INVOKANA for the treatment of type-2 diabetes, IMBUVICA for mantle cell lymphoma and OLYSIO for hepatitis C.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Next, and very importantly, it is claimed is its strong clinical development programs to optimally characterize these therapies.<wbr> Managment cites as an example the extensive number of patients enrolled in the registration trials for XARELTO and the direct comparative claims in the label of INVOKANA and multiple indications we&rsquo;ve obtained for XARELTO and ZYTIGA.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Thirdly it emphasises its solid commercial excellence programs and launch execution processes with all recently launched products having done extremely well in terms of launch uptake.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">And finally, increased access through strong reimbursement and contracting abilities.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr"><STRONG>In terms of example:-</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Sales of oncology products increased 37.<wbr>4% on an operational basis in the fourth quarter primarily due to the strong results for ZYTIGA which grew by 45% with similar results within and outside the US.<wbr> In the US it now holds a 34% share of the combined metastatic resistant prostate cancer market, a market currently growing at 18%.<wbr><BR><BR>Additional country rollouts plus an expansion of the label to chemo na&iuml;ve patients drove strong results outside the US with.<wbr> ZYTIGA now approved in more than 80 countries.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">With J&amp;J's focuses on the here and now, little is given away in terms of its development strategy, with no information provided on its development activities with ARN-509.<wbr> However, with multiple indications being cited as an important part of the strong clinical development programme for Zytiga one can only assume that J&amp;J has equivalent plans for ARN-509 that it has yet to disclose.<wbr></P> </div><div><P align="left" dir="ltr">Source: <A href="http://www.jnj.com/">www.<wbr>jnj.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9425">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-21T18:48:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-21T18:48:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EU Drugmakers to Report Growth and Earnings in 2014</title>
	<pubDate>2014-01-21T09:31:15+01:00</pubDate>
	<wp:post_id>5172</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to Credit Suisse, EU drugmakers will report 4% sales growth and 6% earnings growth this year, as reported Monday in London South East.<wbr> Bayer and Novartis will outperform the market, with Roche also doing well, although AstraZeneca and GlaxoSmithKline are likely to underperform.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Drug Categories in Focus</STRONG> </div><div style="margin-bottom: 10px;">Credit Suisse suggested that drug categories such as cancer, respiratory, diabetes, cholesterol and haemophilia are likely to be in focus during 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Emerging Markets</STRONG> </div><div style="margin-bottom: 10px;">Following a tough year in emerging markets, Credit Suisse expects companies should benefit from a recovery in China and bounce back from company-specific shocks.<wbr> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10735">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-21T09:31:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-21T09:31:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Auspex To IPO & Raise Up To $66m To Fund Huntington's Disease Development</title>
	<pubDate>2014-01-20T15:25:40+01:00</pubDate>
	<wp:post_id>5173</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Auspex is aiming to IPO with a view to raising around $66m to fund the ongoing phIII development of its SD-809 a deuterated form of tetrabenazine for the treatment of involuntary movements associated with Huntington's disease.<wbr> </div><div style="margin-bottom: 10px;">SD-809 has pharmacokinetic properties that allow for more consistent blood levels and less frequent dosing (twice vs three times daily) compared to the marketed form of tetrabenazine, properties that may faciliated better compliance and outcomes.<wbr> </div><div style="margin-bottom: 10px;">Auspex started its phIII trial in July 2013 , a randomised double-blind placeob-controlled study in 90 patients who have not previously taken tetrabenazine.<wbr> The study is being undertaken in combination with the Huntington Study Group, an international network of experienced clinical trial investiagators at leading academic centres that care for HD patients and their families.<wbr> </div><div style="margin-bottom: 10px;">Money raised from the new financing will also be used to fund a phII/<wbr>III development of the drug in tardive dyskinesia and a phI study in Tourette's syndrome.<wbr> </div><div>Source: <A href="http://www.auspexpharma.com/">www.<wbr>auspexpharma.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7351">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-20T15:25:40+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-20T15:25:40+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New NET Data to Emerge From ASCO GI 2014</title>
	<pubDate>2014-01-20T11:32:28+01:00</pubDate>
	<wp:post_id>5174</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Two interesting trials were presented this weekend, one demonstrating the potential effectiveness of temozolomide/<wbr>capecitabine in carcinoid patients progressive on Sandostatin LAR, the other highlighting the benefits of dose intensification of octreotide LAR to 40-60mg for symptom control in refractory NET patients.<wbr> Additional to this was also an interesting overview of the NET treatment paradigm presented by Diane Lauren Reddy in a "Meet the Professor" Session, where it was acknowledged that RADIANT-4 is now complete and should report this year and that some interesting VEGF data is on the horizon.<wbr> </div><div style="margin-bottom: 10px;">Copies of both posters highlighted below are attached.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>CAPTEM Data</STRONG> </div><div style="margin-bottom: 10px;">Fine et al (Columbia University Medical Centre New York) have conducted a prospective single arm phII study in patients with progressive metastatic well differentiated NETs who had shown progression on 60mg Sandostatin LAR.<wbr> These patients were treated with a 28 day cycle CAPTEM regimen (capecitabine/<wbr>temzolomide).<wbr> 28 patients have been treated so far including 12 with carcinoid tumours ( a group previously not recognised as responding to CAPTEM).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>The primary objective was response rate based on RECIST &amp; secondary objectives PFS, OS &amp; toxicity.<wbr>
</LI>
<LI>The overall RR reported was 43% (11%CR &amp; 32% PR).<wbr>SD was 54% giving an overal CBR of 97%.<wbr>
</LI>
<LI>Interestingly, the ORR in the carcinoid gourp (typical and atypical patients) was 41% (8%CR &amp; 33%PR).<wbr> SD was 58% giving an overall CBR of 99%.<wbr>
</LI>
<LI>Ongoing PFS is &gt;22mnths for all subtypes with ongoing OS &gt;29.<wbr>1mnths from the initiation of chemotherapy to death.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">The authors make the point that CAPTEM appears to be an effective regiment for patients with metastatic NETS progressing on higher doses of Sandostatin.<wbr> In comparison the phIII trials with everolimus and Sutent had a mPFS or 11 months and 11,4 months respectively and both had RR of &lt;10%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Higher Dose Octreotide Data</STRONG> </div><div style="margin-bottom: 10px;">Efraija et al with the approval of the British Columbia Cancer Agency Ethics Committee retrospectively evaluated data for all patients receiving 60mg Octreotide LAR between 2005 and 2011, grading symptoms prior to and post any incremental dosage increase (DI).<wbr> Pre and post ChGA and 5HIAA levels were also evaluated.<wbr> </div><div style="margin-bottom: 10px;">A total of 37 patients received DI therapy with 40mg (36), 50mg (3), 60mg (16) for a total of 55 DI events.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Tumour locality was small bowel (49%), pancreas (19%) and other (32%)
</LI>
<LI>Post ChGA and 5HIAA levels decreased respectively in 31% and 23% of patients respectively
</LI>
<LI>Symptom improvement post DI was 62% in patients with diarrhoea (13/<wbr>21), 76% in patients with flushing (13/<wbr>17) and 53% in those with abdominal pain (8/<wbr>15).<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Meet The Professor Session</STRONG> </div><div style="margin-bottom: 10px;">The suprise findings in carcinoid patients was acknowledged by Diane Lauren Reddy in her "Meet The Professor" session on Neuroendocrine tumours.<wbr> She commented on the small no of carcinoid patients evaluated and questioned the location of these tumours (details of which are unclear) and concluded that it remains to be seen the role of cytotocis chemotherapy for carcinoids.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the higher dose SSA data, she suggested that there is an indication that incremental dosing may help to control symptoms but that currently no prospective data exists to support this.<wbr> </div><div style="margin-bottom: 10px;">Much of Diane Reddy's review focused on what is already known.<wbr> However, she did acknowledge that the RADIANT-4 study is now complete and that the data this year should give us a more conclusive answer than RADIANT-2 on whether everolimus is effective for the treatment of mid-gut carcnoids.<wbr> </div><div style="margin-bottom: 10px;">Focusing in brief on "What is on the horizon" Reddy highlighted the following:- </div><div style="margin-bottom: 10px;"><UL><LI>the Lutathera trial;
</LI>
<LI>a phII study that will be evaluating the role of everolimus as an adjuvant therapy in resected pNET which will be started very soon;
</LI>
<LI>some potentially "exciting" data to emerge from some VEGF studies.<wbr> PhII combination bevacizumab/<wbr>temsirolimus data was referenced which at ASCO 2013 was shown to demonstrate a 37% ORR &amp; a 6-month PFS of 80%, well in excess of single targeted agnets in pNET.<wbr> The bevacizumab single-agent arm in this trial is currently accruing (NCT01010126).<wbr> Secondly, Mathew Kulke's phII study evaluating everolimus &amp; octreotide with or without bevacizumab in patients with locally advanced metastatic pNET has just completed (NCT01229943)
</LI>
</UL> </div><div><EM>Source: ASCO GI 2014</EM> </div><!-- Comment details --><a name="endocrinology7571attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7571_1_Fine%20CAPTEM%20Poster%20ASCO%20GI%202014.jpg">Fine CAPTEM Poster ASCO GI 2014.jpg</a>&nbsp;&nbsp;(4,5 MB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7571_2_Efraij%20Poster%20ASCO%20GI%202014.jpg">Efraij Poster ASCO GI 2014.jpg</a>&nbsp;&nbsp;(3 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7571">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-20T11:32:28+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-20T11:32:28+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Actavis Plans to Divest its EU Commercial Operations to Aurobindo</title>
	<pubDate>2014-01-20T11:20:34+01:00</pubDate>
	<wp:post_id>5175</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Actavis announced that it intends to enter into an agreement to divest its generics commercial operations in France, Italy, Belgium (new territories for Aurobindo), Spain, Portugal, Germany and the Netherlands for approx &euro;30M.<wbr> Aurobindo reported that the deal would provide a "ready-made hospital sales infrastructure" for it to introduce its own injectable and specialty portfolio across Western Europe (The hospitals portfolio includes a number of injectables including oncology, pain management and anti infective therapies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- Aurobindo to acquire Actavis' pharmaceutical commercial infrastructure in the 7 markets, including products, marketing authorisations and dossier license rights.<wbr> </div><div style="margin-bottom: 10px;">- The companies would also enter into a long-term strategic supply arrangement.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10733_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">The acquisition will expand Aurobindo's front-end operations with about 1200 products (with more than 450 INNs) and 200 more in the works.<wbr> </div><div style="margin-bottom: 10px;">The company estimates the businesses acquired would record net sales of 320 million euros ($433 million) for 2013, growing at 10% YoY, and it expects the operations to turn profitable in combination with its vertically integrated platform.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10733_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10733_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Mix Business</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10733_2_ScreenCapture2.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10733_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="pharmaworld10733attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10733_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(127,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10733_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(61,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10733_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(130,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10733_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(159,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10733_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(135 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10733">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-20T11:20:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-20T11:20:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novel Three-Step Approach for a More Youthful Face</title>
	<pubDate>2014-01-17T15:50:49+01:00</pubDate>
	<wp:post_id>5176</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In line with the desire of patients to achieve an overall youthful facial appearance, the authors report for the first time three cases where patients have been successfully treated across the whole face with a novel, three-step approach, layering Merz' Xeomin (incobotulinumtoxinA) and two dermal fillers (Radiesse/<wbr>calcium hydroxylapatite and Belotero/<wbr>a monophasic hyaluronic acid filler with CPM Technology) injected at three separate treatment visits.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Findings</STRONG> </div><div style="margin-bottom: 10px;">The results suggest that this layering approach based on an understanding of the underlying causes of facial aging, where different products are used in combination to treat the entire face, can enable patients to achieve the desired outcome of a return to the characteristics of a more youthful face.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Reference</STRONG> </div><div style="margin-bottom: 10px;"><H2><STRONG>A novel, multistep, combination facial rejuvenation procedure for treatment of the whole face with incobotulinumtoxinA, and two dermal fillers- calcium hydroxylapatite and a monophasic, polydensified hyaluronic acid filler.<wbr></STRONG></H2> </div><div>2013: Tatjana Pavicic; Julius W Few; Jurgen Huber-Vorl&auml;nder - Journal of drugs in dermatology : JDD 2013;12(9):978-84. </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7350">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-17T15:50:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-17T15:50:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Actavis Plans to Quit the China Market</title>
	<pubDate>2014-01-17T11:18:22+01:00</pubDate>
	<wp:post_id>5177</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: In an interview with Bloomberg News, CEO has cited an 'unfavorable business climate'.<wbr> Management has reportedly sold one operation in China and is in talks to sell another.<wbr> Eight months previously it announced it felt confident about prospects in China, with product launches in the country.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Actavis China</STRONG> </div><div style="margin-bottom: 10px;">Actavis Foshan is an important manufacturing site in Asia.<wbr> The Guangdong plant produces antibiotics and other products for use in the treatment of the digestive and cardiovascular system.<wbr> Dosage forms include tablet, soft gel capsule, hard capsule, oral solution, dry suspension, ointments and liniments.<wbr> <BR><BR>The Actavis (Foshan) Pharmaceutical Co.<wbr>, Ltd.<wbr> is a joint venture between the Actavis Group and Foshan Chanbende Development Co.<wbr>, Ltd.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Major Shift for the Company</STRONG> </div><div style="margin-bottom: 10px;">In May 2013, Actavis China President Gao Ren stated that the company was feeling confident about prospects in China, and that it would launch two new products annually, with the goal of launching 5-10 products annually by 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sales and Revenues Picture</STRONG> </div><div style="margin-bottom: 10px;">The company generates annual profits in China of approx.<wbr> USD 41.<wbr>5 million.<wbr> </div><div><EM>Source: GBI</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10731">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-17T11:18:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-17T11:18:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Shares Rise As Patent-Cliff Worries Subside</title>
	<pubDate>2014-01-16T16:04:07+01:00</pubDate>
	<wp:post_id>5178</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan has received two pieces of good-news in one week.<wbr> A Judge has upheld US patents covering the group's glaucoma treatment Lumigan and coincidentally the US Patent Office has issued Allergan with new protection for its lead opthalmic product Restasis.<wbr> Morgan Stanley analysts have raised 2015-2020 EPS estimates by 15-20% as a result.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Court Decision On Lumigan</STRONG> </div><div style="margin-bottom: 10px;">Whilst generics are likely to appeal the appelate court decision is probably about 1-2 years ways.<wbr> The U.<wbr>S.<wbr> District Court for the Eastern District of Texas effectively affirmed all 5 patents covering Lumigan through 2027.<wbr> </div><div style="margin-bottom: 10px;">Allergan had sued several drugmakers looking to launch copies of the glaucoma drug's 0.<wbr>1% formulation.<wbr> That version in 2010 replaced a stronger solution that had caused temporary eye redness in some patients.<wbr> </div><div style="margin-bottom: 10px;"><P style="text-align: left; background-color: #ffffff; color: #000000; overflow: hidden; text-decoration: none;">Allergan can keep its lock on the Lumigan market as long as at least one of the patents stays in place and that means keeping Lumigan's revenues, which totaled $622.<wbr>6 million in 2012.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="text-align: left; background-color: #ffffff; color: #000000; overflow: hidden; text-decoration: none;"><STRONG>Restasis Patent</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left" style="text-align: left; background-color: #ffffff; color: #000000; overflow: hidden; text-decoration: none;">Alongside this verdict AGN announced its new patent on U.<wbr>S.<wbr> Restasis that expires in Aug.<wbr> 2024 plus plans to submit a Citizen Petition in response to FDA&rsquo;s draft guidance on generic Restasis.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" style="text-align: left; background-color: #ffffff; color: #000000; overflow: hidden; text-decoration: none;"></P> </div><div style="margin-bottom: 10px;"><P align="left" style="text-align: left; background-color: #ffffff; color: #000000; overflow: hidden; text-decoration: none;"></P> </div><div style="margin-bottom: 10px;"><P align="left" style="text-align: left; background-color: #ffffff; color: #000000; overflow: hidden; text-decoration: none;"></P> </div><div style="margin-bottom: 10px;"><P align="left" style="text-align: left; background-color: #ffffff; color: #000000; overflow: hidden; text-decoration: none;"></P> </div><div style="margin-bottom: 10px;">Sources: <A href="http://www.allergan.com">www.<wbr>allergan.<wbr>com</A> </div><div style="margin-bottom: 10px;">Morgan Stanley report 15th January </div><div>Leerink &amp; Swann report 14th January </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7348">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-16T16:04:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-16T16:04:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Bayer's Radium-223 Dichloride + Abiraterone or Enzalutamide in CRPC Patient with Bone Mets</title>
	<pubDate>2014-01-16T15:53:08+01:00</pubDate>
	<wp:post_id>5179</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This newly reported Ph2a trial in clinicaltrials.<wbr>gov is to assess safety and efficacy of the combination evaluated by rPFS (as a PE).<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 66 </div><div style="margin-bottom: 10px;">Timelines </div><div style="margin-bottom: 10px;"><UL><LI>Start date: January 2014</LI>
<LI>Comletion dates: Jan 2016 /<wbr> Jan 2022</LI>
</UL> </div><div style="margin-bottom: 10px;">Trial Design </div><div style="margin-bottom: 10px;">All patients involved in the study will be randomized into one of three arms: </div><div style="margin-bottom: 10px;"><UL><LI>radium-223 dichloride 50 kBq/<wbr>kg administered every 4 weeks; </LI>
<LI>radium-223 dichloride 50 kBq/<wbr>kg administered every 4 weeks together with abiraterone acetate 1000 mg orally daily plus prednisone 5 mg orally twice daily; </LI>
<LI>radium-223 dichloride 50 kBq/<wbr>kg administered every 4 weeks together with enzalutamide 160 mg orally daily.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Location: USA </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02034552?term=NCT02034552&amp;rank=1">NCT02034552</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9424">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-16T15:53:08+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-16T15:53:08+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Results from Ph3 Pasireotide LAR vs Octreotide LAR in Medically Naïve Acromegalic Patients Just Published</title>
	<pubDate>2014-01-16T15:23:57+01:00</pubDate>
	<wp:post_id>5180</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Comment: Data from the first of two PhIII with pasireotide in acromegaly has just been published in JCEM.<wbr> The results highlight, as known, that a significantly better proportion of patients in the pasireotide LAR group achieved biochemical control (both GH and IGF1 criteria) compared with the octreotide LAR group (Primary Endpoint met).<wbr> More details are provided below.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Pasireotide LAR demonstrates superiority over octreotide LAR in a prospective double-blind randomized 12-month study conducted in 358 medically na&iuml;ve acromegalic patients.<wbr> </SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><STRONG>Patients</STRONG>: They either had prior pituitary surgery but no medical treatment or were de novo.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><STRONG>Treatment</STRONG>: 176 patients received pasireotide LAR 40mg every 28 days and 182 patients received octreotide LAR 20mg every 28 days.<wbr> Titration was permitted.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;"><STRONG>Main outcome measure</STRONG>: </SPAN>Proportion of patients in each treatment arm with biochemical control (GH &lt; 2.<wbr>5 microg /<wbr> liter and normal IGF-1) at month 12.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Results:</STRONG> Biochemical control was achieved by significantly more pasireotide LAR patients than octreotide LAR patients (31.<wbr>3% versus 19.<wbr>2%; <EM>p=</EM>0.<wbr>007; In pasireotide LAR and octreotide LAR patients, respectively, 38.<wbr>6% and 23.<wbr>6% ( p<EM>=</EM>0.<wbr>002) achieved normal IGF-1, and 48.<wbr>3% and 51.<wbr>6% achieved GH &lt; 2.<wbr>5 microg /<wbr> liter.<wbr>  In terms of tumour control, from baseline to month 12, mean tumour volume decreased by 40% and 38% respectively (p=0.<wbr>838) </div><div style="margin-bottom: 10px;"><STRONG>Safety:</STRONG> Hyperglycemia related adverse events were more common with pasireotide LAR (57.<wbr>3% versus 21.<wbr>7%).<wbr> </div><div><UL><LI>Trial details <a href="http://clinicaltrials.gov/show/NCT00600886" class="defaultlink">http://clinicaltrials.gov/show/NCT00600886</a>
</LI>
<LI>Publication Reference <a href="http://press.endocrine.org/doi/pdf/10.1210/jc.2013-2480" class="defaultlink">http://press.endocrine.org/doi/pdf/10.1210/jc.2013-2480</a>
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7568">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-16T15:23:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-16T15:23:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: New Deal To Focus On Increased Awareness & Adoption Of Intrathecal Therapies For Pain & Spasticity</title>
	<pubDate>2014-01-16T11:48:41+01:00</pubDate>
	<wp:post_id>5181</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New Deal To Focus On Increased Awareness & Adoption Of Intrathecal Therapies For Pain & Spasticity</span>&nbsp;<br><span style="font-size: 12px;">Comment: Medtronic and Mallinckrodt have entered into a multi-year agreement to advance the availability within the US of intrathecal therapeutics for the treatment of chronic pain and severe spasticity.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7343">...</a><br></div><div style="margin-bottom: 10px;">Comment: Mallinckrodt's presentation late yesterday at the JP Morgan H/<wbr>C conference, didn't focus particularly on the Medtronix deal but did note how Gablofen, a pre-filled syringe preparation for intrathecal administration for spasticity is now its no 2 lead product and how intrathecal product development will be part of its growth strategy.<wbr> Gablofen was acquired through the purchase of CNS Therapeutics in September 2012.<wbr> </div><div style="margin-bottom: 10px;">Mark Trudeau CEO focused on his intention to grow the specialty part of the group's business and how the group's pipeline would support this growth.<wbr> Mid-term this is focused on Xartemis XR a combination opioid product.<wbr> Longer-term, the focus move to the potential within the intrathecal space.<wbr> Whilst not specfied we have identified a CNS Therapeutics patent covering  a new and improved versions of baclofen WO-2010090765-A2 which offers improved stability a lower concentrations of degredation products.<wbr> </div><div>Longer-term coporate growth he suggested will also focus on BD&amp;L opportunities in CNS in adjacent channels and therapeutics including neurology and orthopaedics.<wbr> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7347">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7343">View thread  Neurology7343: New Deal To Focus On Increased Awareness & Adoption Of Intrathecal Therapies For Pain & Spasticity</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-16T11:48:41+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-16T11:48:41+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Update on Dendreon's Provenge and Q4:13 Results</title>
	<pubDate>2014-01-16T11:38:39+01:00</pubDate>
	<wp:post_id>5182</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company's levers to improve commercial effectiveness of Provenge have been based on the development of multiple stakeholder champions at 3 levels (clinical, operational and administrative).<wbr> Management reported strategic investments to accelerate path for profitability as a top priority.<wbr> Slides presented at JP Morgan H/<wbr>C conference outlined that additional data on the sequencing study with Zytiga will be reported H2:14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9423_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9423_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Strategy to Improve COGS and Gross Margin </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9423_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;">Cost Position Improving </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9423_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="oncology9423attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9423_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(78,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9423_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(65,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9423_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(96,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9423_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(81 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9423">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-16T11:38:39+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-16T11:38:39+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>2014 Expected to be a Pivotal Year for Exelixis</title>
	<pubDate>2014-01-16T11:07:10+01:00</pubDate>
	<wp:post_id>5183</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Management oultined mission and vision to build a global oncology franchise with cabozantinib and maximize the opportunity the drug provides.<wbr> It also reported to have 4 pivotal trials readout throughout the course of 2014, as well as lots of catalysts<STRONG> </STRONG>and news flow.<wbr> Key slides from the presentation at JP Morgan H/<wbr>C are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9421_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><U>5 ongoing pivotal trials</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9421_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9421_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9421_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9421_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="oncology9421attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9421_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(77 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9421_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(63,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9421_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(102,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9421_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(76,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9421_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(76,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9421_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(74,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9421">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-16T11:07:10+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-16T11:07:10+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Novartis' PI3K Inhibitor + Cabazitaxel for 2nd-Line mCRPC</title>
	<pubDate>2014-01-15T17:27:11+01:00</pubDate>
	<wp:post_id>5184</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: This is the second trial assessing Novartis' BKM120 for prostate cancer.<wbr> This Ph2 study will be conducted in two parts.<wbr> The ultimate purpose is to determine PFS, response rate, disease control rate and OS of patients treated with the combination regimen and compare outcomes to historical results with single-agent cabazitaxel.<wbr> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><STRONG></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><U>Sponsor</U>: SCRI Development Innovations, LLC.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">In a lead-in cohort, the feasibility and safety of administering BKM120 with a standard dose of cabazitaxel will be assessed.<wbr> If safety is confirmed, a subsequent Phase II portion will assess the activity of the combination in patients with mCRPC previously treated with docetaxel.<wbr> The treatment will consist of 3-week (21-day) cycles.<wbr></P> </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: approx; 49 </div><div style="margin-bottom: 10px;"><U>Timelines</U> /<wbr> Start date: March 2014 /<wbr> Completion date: March 2016 /<wbr> January 2017.<wbr> </div><div style="margin-bottom: 10px;"><U>Location</U>: Tennessee Oncology PLLC (USA) </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02035124?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=12%2F15%2F2013&amp;rank=279">NCT02035124</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9418">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-15T17:27:11+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-15T17:27:11+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>re: Xofigo® Approved in the EU</title>
	<pubDate>2014-01-15T17:19:22+01:00</pubDate>
	<wp:post_id>5185</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Xofigo® Approved in the EU</span>&nbsp;<br><span style="font-size: 12px;">Comment: Xofigo® 1000 kBq/<wbr>ml, solution for injection has been granted MA less than 2 months after it gained a positive opinion from the EMA CHMP.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9320">...</a><br></div><div style="margin-bottom: 10px;">Following EMA approval, Bayer HealthCare annouced UK launch of Xofigo® (radium-223 dichloride) solution for injection on 13th January 2014.<wbr> Joe Hemphill (BU Head Speciality medicine, Bayer) stated " The launch and availability of Xofigo in the UK should be welcomed news for physicians and patients, who have been looking for new treatment options".<wbr> </div><div style="margin-bottom: 10px;">The technology appraisal has been sumbitted to NICE and first committee took place on 25 Sept 2013, however, outcome of the commitee could not be released as the marketing authorisation had not been granted at the time.<wbr> </div><div style="margin-bottom: 10px;">The expected date of issue is Feburary 2014.<wbr> </div><div><EM>Source: nice.<wbr>org.<wbr>uk, FirstWorld, PBR</EM> </div><!-- Comment details --><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9417">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9320">View thread  Oncology9320: Xofigo® Approved in the EU</a>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-15T17:19:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-15T17:19:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New Deal To Focus On Increased Awareness & Adoption Of Intrathecal Therapies For Pain & Spasticity</title>
	<pubDate>2014-01-15T17:04:33+01:00</pubDate>
	<wp:post_id>5186</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Medtronic and Mallinckrodt have entered into a multi-year agreement to advance the availability within the US of intrathecal therapeutics for the treatment of chronic pain and severe spasticity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nature of the Deal</STRONG> </div><div style="margin-bottom: 10px;">Under the agreement, the two companies will focus on the development and testing of Mallinckrodt's future intrathecal products for use in Medtronic's SynchroMed Programmable Infusion System.<wbr> As of today both companies manufacture and market intrathecal baclofen.<wbr> Thus the nature of the future products that Mallinckrodt refers to has not been made clear.<wbr> </div><div style="margin-bottom: 10px;">The companies will also develop a joint marketing and sales programm to increase awareness and adoption of these drug delivery therapies.<wbr> Intrathecal therapeutics use an implanted pump to deliver very small quantities of medication directly to a patient's spinal fluid.<wbr> </div><div style="margin-bottom: 10px;">The collaboration is intended to accelerate innovation and expand clinician and patient education regarding targeted delivery of drugs for the management of chronic disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on the deal Mark Trudeau, President &amp; CEO of Mallinckrodt stated:-</STRONG> </div><div style="margin-bottom: 10px;">"This agreement enables Mallinckrodt and Medtronic to focus on further pre-clinical, clinical and commercial aspects of intrathecal therapeutics, allowing each organisation to leverage their respective strengths, Mallinckrodt in specialty pharmaceuticals and Medtronic in terms of implantable drug delivery technology.<wbr> Together, we will focus on advancing the development and delivery of therapeutic agents to serve patients suffereing from chronic pain and severe spasticity.<wbr> We are excited about the future of our intrathecal product line and this agreement will enable us to deliver meaningful solutions to this market".<wbr> </div><div style="margin-bottom: 10px;">Source: <A href="http://www.malinckrodt.com/">www.<wbr>malinckrodt.<wbr>com</A> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" style="width: 100%;"><TBODY><TR><TD>
<TABLE style="width: 100%;"><TBODY><TR align="left"><TD valign="top">
<DIV class="article_body bp">.<wbr></DIV>
</TD>
</TR>
</TBODY>
</TABLE>
</TD>
</TR>
<TR><TD>&nbsp;</TD>
</TR>
<TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7347c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: Mallinckrodt's presentation late yesterday at the JP Morgan H/<wbr>C conference, didn't focus particularly on the Medtronix deal but did note how Gablofen, a pre-filled syringe preparation for intrathecal administration for spasticity is now its no 2 lead product and how intrathecal product development will be part of its growth strategy.<wbr> Gablofen was acquired through the purchase of CNS Therapeutics in September 2012.<wbr> </div><div style="margin-bottom: 10px;">Mark Trudeau CEO focused on his intention to grow the specialty part of the group's business and how the group's pipeline would support this growth.<wbr> Mid-term this is focused on Xartemis XR a combination opioid product.<wbr> Longer-term, the focus move to the potential within the intrathecal space.<wbr> Whilst not specfied we have identified a CNS Therapeutics patent covering  a new and improved versions of baclofen WO-2010090765-A2 which offers improved stability a lower concentrations of degredation products.<wbr> </div><div>Longer-term coporate growth he suggested will also focus on BD&amp;L opportunities in CNS in adjacent channels and therapeutics including neurology and orthopaedics.<wbr> </div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7343">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-15T17:04:33+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-15T17:04:33+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sales in China Getting Better for GSK</title>
	<pubDate>2014-01-15T16:45:57+01:00</pubDate>
	<wp:post_id>5187</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Chief Financial Officer Simon Dingemans said in an interview in San Francisco at JPMorgan H/<wbr>C Conference that sales in China have improved since the third quarter of 2013 when drug revenu plunged as 61% vs a year earlier.<wbr> </div><div style="margin-bottom: 10px;">“The trend is definitely looking a bit more positive” since the quarter ended Sept.<wbr> 30 .<wbr>.<wbr>.<wbr>" </div><div style="margin-bottom: 10px;">“We can see the future opportunities to rebuild the business as and when we get to the other side of the inquiry.<wbr> We’ll be working hard in 2014 to deliver that.<wbr>” </div><div style="margin-bottom: 10px;">.<wbr>.<wbr>.<wbr> We have seen some stabilization, as I said, in the third quarter.<wbr> In the back half of that quarter, it got a little bit better.<wbr> Not dramatically better, but a bit better.<wbr> And I don't want to comment on the fourth quarter yet other than to say that trend probably continued".<wbr> </div><div><EM>Source: Bloomberg</EM>; <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10661" class="defaultlink">PharmaWorld10661: GSK's Chinese Sales Slump</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10729">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-15T16:45:57+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-15T16:45:57+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>AstraZeneca Presents Strategic Ambitions at JP Morgan H/C Conference</title>
	<pubDate>2014-01-15T09:09:37+01:00</pubDate>
	<wp:post_id>5188</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Slides presented by Pascal Soriot (CEO) have highlighted a faster return to growth, with five key internal platforms (CV, diabetes (boosted by a recent $4.<wbr>3 deal with BMS), emerging markets, respirator and Japan).<wbr> In China where AZ is the 2nd largest company, 2013 sales registered strong growth relative to peers.<wbr> The company will give a more detailed update on its progress in full-year results on Feb.<wbr> 6.<wbr> A selection of key slides is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9414_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9414_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9414_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9414_1_ScreenCapture1.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9414">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-15T09:09:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-15T09:09:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Preps Market For Multibillion Dollar Spending Spree</title>
	<pubDate>2014-01-14T18:06:46+01:00</pubDate>
	<wp:post_id>5189</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: According to feedback from the JP Morgan H/<wbr>C Conference, a confident Pyott was telling FierceBiotech that he's ready to pay billions to cover the cost of a new acquisition in a move aimed at expanding the company's core research focus.<wbr> </div><div style="margin-bottom: 10px;">He reportedly said "We can afford to pay more than anyone else when it comes to adding new programs to the company's top fields and that reputation has earned us a first look at just about everything on the market.<wbr> </div><div style="margin-bottom: 10px;">The company has been carving out new fields in medical dermatology, neurology and urologics, all areas where it is reportedly willing to go out and take the extra steps needed to hunt down new programs of interest whether through a buyout,a licensing deal or partnership.<wbr> </div><div><BR>Source: <A href="http://www.fiercebiotech.com/">www.<wbr>fiercebiotech.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7339">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-14T18:06:46+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-14T18:06:46+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Stem Cell Trial In Post-Stroke Patients Initiated In China</title>
	<pubDate>2014-01-14T14:53:49+01:00</pubDate>
	<wp:post_id>5190</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Neuralstem Inc has announced that the first patients has been 
treated in a phI/<wbr>II tiral with its stem cell product NSI-566 to treat motor 
deficits from ischaemic stroke.<wbr> The study is being undertaken in China.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The nature of the treatment</STRONG> </div><div style="margin-bottom: 10px;"><TABLE width="100%"><TBODY><TR align="left"><TD>
      <DIV class="article_body">The stroke motor deficit trial is the first in 
      which Neuralstem's spinal-cord derived stem cells are being transplanted 
      directly into the patient's brain.<wbr> They are placed near the stroke lesion, 
      where it is hoped they will rebuild damaged neural circuitry and promote 
      repair and recovery.<wbr> </DIV>
      
      <DIV class="article_body"><STRONG>About the Trial <BR><BR></STRONG>The 
      Neuralstem China Phase I/<wbr>II ischemic stroke trial will enroll up to 118 
      patients who have suffered an ischemic stroke and have chronic residual 
      motor disorders, between four and 24 months after they have their strokes.<wbr> 
      The treatment will consist of one-time intracerebral injections of 
      Neuralstem's NSI-566 stem cells into the stroke area using well-accepted 
      stereotactic injection procedures.<wbr></DIV>
      
      <DIV class="article_body">Phase I will enroll up to 18 patients in three 
      cohorts, each receiving an increasing dose, to determine the maximum 
      safely-tolerated dose.<wbr> Phase II, a multi-site, randomized and blinded 
      study with a control group, will enroll up to 100 post-stroke patients.<wbr> 
      Half of the patients will receive a one-time treatment with the cells and 
      physical therapy.<wbr> The other half will receive only the physical therapy 
      with no surgery.<wbr> Measurements of outcome during the follow-up period will 
      be blinded.<wbr>The trial is expected to last two years.<wbr>
      <TABLE width="100%"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE></DIV>
      <DIV class="article_body"><STRONG>Key comments concerning the 
      trial<BR><BR></STRONG>"We are excited to begin the first trial where the 
      route of administration for our cells is injection into the brain," said 
      Karl Johe, PhD, Neuralstem Chairman and Chief Scientific Officer.<wbr> "We 
      would like to thank our colleagues at BaYi, who are making this possible, 
      and the patients who have volunteered for this ground-breaking trial.<wbr> It 
      is a crucial step forward for the company and the field at large, since 
      optimizing cell therapy treatment for CNS indications will require 
      delivering cells to the brain, as well as to the spinal cord.<wbr>" <BR><BR>"We 
      are glad to be part of this world-leading clinical research project," said 
      Professor Ruxiang Xu, Chief Physician, BaYi Brain Hospital.<wbr> "BaYi Brain is 
      a leading neurological medical institution in China with a 
      state-of-the-art facility and advanced medical research and care staff.<wbr> 
      Through international collaborations, such as the clinical trial of neural 
      stem cells for the treatment of ischemic stroke, we hope to be at the 
      forefront of this new medical paradigm, treating multiple neurological 
      diseases/<wbr>disorders, such as ischemic stroke, spinal cord injury, ALS, and 
      others, using the most advanced neural stem cells, developed by our U.<wbr>S.<wbr> 
      partner, Neuralstem.<wbr>" <BR><BR><BR>Source: <A href="http://www.neuralstem.com">www.<wbr>neuralstem.<wbr>com</A> <BR></DIV></TD>
</TR>
</TBODY>
</TABLE> </div><div><TABLE width="100%"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7338">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-14T14:53:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-14T14:53:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Nymox Close To Reporting PhII Results For NX-1207 In Low-Risk Prostate Cancer</title>
	<pubDate>2014-01-14T14:38:42+01:00</pubDate>
	<wp:post_id>5191</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Nymox Pharmaceuticals announced that recruitment is being closed for 
the company's phII study of NX-1207 for low-risk localised, prostate cancer.<wbr> 
Initial top line study results are expected to be available in around 6-8 
weeks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;"><TABLE width="100%"><TBODY><TR align="left"><TD>
      <DIV class="article_body">The NX03-0040 study involves approximately 150 
      patients with low grade localized prostate cancer who are randomized to 
      low or high single dose NX-1207 or to control (active surveillance with no 
      drug or surgical or radiation treatment).<wbr> Patients undergoing active 
      surveillance in the trial also have the opportunity to receive NX-1207 
      after completion of their active surveillance portion of the trial.<wbr> 
      <BR><BR>The NX03-0040 study assesses the safety and efficacy of a single 
      injection of NX-1207 in eradicating or shrinking low grade localized 
      prostate cancer tumors by multiple clinical and laboratory measurements 
      and blinded prostate biopsies at 6 weeks after treatment.<wbr> Initial top-line 
      results from trial NX03-0040 will be available soon after completion of 
      the post-treatment biopsy assessment of the last patient randomized to 
      drug.<wbr> <BR><BR>Safety assessments of patients treated to date have been 
      positive with no serious or unexpected adverse effects related to the 
      drug, based on ongoing monitoring and safety committee reviews.<wbr> In the 
      study, NX-1207 is administered directly into the area of the prostate 
      where the cancer was detected.<wbr> The drug treatment is performed by a 
      urologist in an office setting, and does not require anaesthesia, 
      sedation, or catheterization.<wbr> Treatment takes only a few minutes and 
      involves minimal discomfort to the 
      patient.<wbr> <BR><BR><STRONG>Developments Other Than Prostate 
      Cancer <BR><BR></STRONG>NX-1207 is also in late stage Phase 3 
      development in the U.<wbr>S.<wbr> for the treatment of benign prostatic hyperplasia 
      (BPH), In Europe a similar programme is being sponsored by Recordati 
      S.<wbr>p.<wbr>A.<wbr>, the company's European licensing partner for the NX-1207 BPH 
      indication.<wbr></DIV></TD>
</TR>
</TBODY>
</TABLE> </div><div>Source: <a href="http://www.nymox.com" class="defaultlink" title="www.nymox.com">nymox.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9412">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-14T14:38:42+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-14T14:38:42+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Acorda At The JP Morgan H/C Conference. - Key Takeaways</title>
	<pubDate>2014-01-14T14:12:56+01:00</pubDate>
	<wp:post_id>5192</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Acorda provided more details of its POC study with AMPYRA in 
post-stroke patients with walking deficits, confirmed positive discussions with 
the FDA and noted its intention to start a phIII study in Q214.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Commenting on the stroke opportunity 
with AMPURA, Ronald Cohen President &amp; CEO stated "We had a successful proof-of-concept Phase 
II study that we announced in 2013.<wbr> Just to give you the highlights on the outcome of major focus was walking in a timed walk, much as it was in MS.<wbr> And you could see here even in this relatively small study with 80 total participants, a statistically significant improvement 
in walking speed in the dalfampridine group was seen.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">And if you look at this as a responder analysis, which is also found in the label for AMPYRA in MS, where you – in this case, you look very simply at what percent of the people on drug versus placebo had certain threshold improvements in their walking speed greater than 10%, greater than 20%, 30%, 40% and 50%.<wbr> And what you see here for both sides of this crossover study – by crossover, for those who are unfamiliar, we mean in the beginning some patients got drug, some got placebo and then they switched and we looked at them again in the second period.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">So, regardless of which period you looked at, the patients on drug on average had more responders at every single threshold all the way to 50% and greater improvement.<wbr> And this, again, is highly reminiscent of what we've seen in the MS story.<wbr> We had said that we were going to meet with the FDA by the end of last year.<wbr> Indeed, we did in December.<wbr> We believe the meeting was highly constructive and the FDA made some recommendations to the design, which we're now integrating into the Phase III protocol.<wbr> We'll be sending that back to them to get agreement and we plan to start the Phase III in the second quarter of this year.<wbr> </P> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_7_ScreenCapture7.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_8_ScreenCapture8.jpg"> </div><!-- Comment details --><a name="neurology7337attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(76,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(69,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(41,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(55,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(66,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(62,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(55,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7337_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(54,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7337">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-14T14:12:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-14T14:12:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Takeda Recaps Strategy by Country</title>
	<pubDate>2014-01-14T13:12:01+01:00</pubDate>
	<wp:post_id>5193</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Takeda  has a well diversified global footprint, and expects to mainly accelerate growth in emerging markets.<wbr> Its marketing strategy has been to maintain n°1 position in Japan, and penetrate each market with a diverse product portfolio tailored to local needs.<wbr> Models for Japan, the US, EU and emerging markets are provided below.<wbr> Of note, in China the company is to maximize sales of existing products among which leuprorelin.<wbr> Key slides from the presentation @JP Morgan H/<wbr>C Conference (Jan.<wbr>13th) are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9411_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9411_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9411_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9411_4_ScreenCapture4.jpg"> </div><!-- Comment details --><a name="oncology9411attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9411_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(91,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9411_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(99,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9411_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(84,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9411_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(64,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9411">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-14T13:12:01+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-14T13:12:01+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Key Messages from Novartis Presentation at JP Morgan H/C Conference</title>
	<pubDate>2014-01-14T11:42:30+01:00</pubDate>
	<wp:post_id>5194</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Ahead of the 2013 year-end-results planned on Jan.<wbr> 29th, Joe Jimenez (CEO) reported on Novartis' performance for 9Mo2013, and on the three main objectives and priorities for 2014: extend lead in innovation, accelerate growth and drive productivity.<wbr> He ended his presentation with a 'couple of thoughts on why everybody should own a piece of the company'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>16 approvals across US, EU and Japan</LI>
<LI>4% net sales growth</LI>
<LI>good progress in productivity ($2 bln)</LI>
<LI>good performance in emerging markets (+10%), lead by Russia and China.<wbr> Management reported a 'little bit of slowdown in China, based on what is happening in the country'</LI>
<LI>good progress in pipeline development (AIN457, secukinumab shows superiority in  over Enbrel with a very strong safety profile.<wbr> Filing in the US and EU in Q4:13.<wbr> " .<wbr>.<wbr>.<wbr> So we could be expecting approval this current fiscal year".<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7562_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Jimenez outlined three key elements of the plan: </div><div style="margin-bottom: 10px;"><U><STRONG>Managing Portfolio Actively</STRONG></U> </div><div style="margin-bottom: 10px;">Last summer, the company started a review of all its businesses with market attractiveness, competitive position and synergistic fit with the rest of portfolio as main selection criteria.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7562_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><U><STRONG>Delivering Synergy Between Division</STRONG></U> </div><div style="margin-bottom: 10px;"><STRONG>R&amp;D synergy</STRONG> - Collaboration between Sandoz and the Oncology Pharma Division was highlighted : ' .<wbr>.<wbr>.<wbr> the oncology development group is running some of the biosimilars trials for the Sandoz division and it is more collaboration like this that is going to untap value and give Novartis competitive advantage particularly in the area of R&amp;D'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Revenue synergies</STRONG> - with a program called'Customers First', being 'go to market as one company, one face to the trade'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Cost synergies across divisions</STRONG> - management said ' .<wbr>.<wbr>.<wbr> We have organized our procurement group globally so no matter what division you are in at Novartis you have a central procurement group that is group wide'.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7562_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><U><STRONG>Greater Comittment to Shareholder Return</STRONG></U> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7562_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_endocrinology_7562_5_ScreenCapture5.jpg"> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7562">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-14T11:42:30+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-14T11:42:30+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sanofi Acquires 12% of Alnylam</title>
	<pubDate>2014-01-13T14:42:38+01:00</pubDate>
	<wp:post_id>5195</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sanofi will buy a 12% stake in Alnylam for 
$700m deepening its already existing partnership with the company.<wbr> It will pay 
$80 per share representing a 27% premium over the past 30-days share price.<wbr> The 
siRNA &amp; drug delivery technology Alnylam has deployed for its 
products was in-licensed from Tekmira, a company now developing its lead 
product for NET &amp; adrenal cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;">Sanofi's earlier partnership with Alnylam started in 
2012.<wbr> Attracted by its RNAi interfernce technology, the two companies agreed to 
work together to develop Alnylam's lead product patisiran, which is currently in 
late-stage development of transthyretin (TTR)-familial amyloid 
polyneuropathy.<wbr> </div><div style="margin-bottom: 10px;">Sanofi originally had rights to this product in Japan 
and the broader Asia-Pacific region.<wbr> These rights have now been extended to all 
markets outside of the US &amp; Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Additional Opportunities To Which Sanofi Now Has 
Rights</STRONG> </div><div style="margin-bottom: 10px;">Additionally it has gained right to three other products 
in the Alnylam portfolio including one drug for familiail cardiomyopathy and 
another for the treatment of hemophilia.<wbr> The former will be co-developed and 
co-marketed in North America and Europe/<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Implications For Other Companies</STRONG> </div><div style="margin-bottom: 10px;">The expanded relationship adds credibility to Alnylam's 
technology, a technology it partnered from another small biotechnology company 
Tekmira.<wbr> The latter is developing a polo-like kinase drug to treat 
neuroendocrine tumours and adrenal cancer (see slides below).<wbr> </div><div style="margin-bottom: 10px;">Source: <A href="http://www.sanofi.com">www.<wbr>sanofi.<wbr>com</A> &amp; <A href="http://www.tekmira.com">www.<wbr>tekmira.<wbr>com</A> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10724_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;">Source: <A href="http://www.sanofi.com">www.<wbr>sanofi.<wbr>com</A><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10724_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10724_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10724_4_ScreenCapture4.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10724_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="pharmaworld10724attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10724_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(86,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10724_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(137,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10724_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(101,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10724_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(118,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_pharmaworld_10724_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(128,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10724">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-13T14:42:38+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-13T14:42:38+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Lexicon Restructures As CEO Steps Down</title>
	<pubDate>2014-01-13T14:02:49+01:00</pubDate>
	<wp:post_id>5196</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lexicon has announced the departure of its CEO Arthur Sands and a 45% reduction in its workforce as it moves its focus away from drug discovery to development of its late-stage products.<wbr> </div><div style="margin-bottom: 10px;">115 positions will be cut in R&amp;D to reduce costs by $14m in 2014 net of severance costs and some other charges and by $20m annually thereafter.<wbr> </div><div style="margin-bottom: 10px;">Arthur Sands intends to develop a succession plan with the boaord to identify a new CEO and will step down once his successor is appointed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">The company intends to focus on the late stage development of its diabetes drug and LX1032 for carcinoid syndrome, to more effectively advance these late stage programms and to prepare for commercialisation.<wbr> </div><div>Source: <A href="http://www.lexicon/">www.<wbr>lexicon</A> .<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7560">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-13T14:02:49+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-13T14:02:49+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>President of Novartis Oncology Leaves the Company</title>
	<pubDate>2014-01-13T10:21:24+01:00</pubDate>
	<wp:post_id>5197</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9410_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9410_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9410_1_ScreenCapture1.jpg"> </div><div> </div><!-- Comment details --><a name="oncology9410attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9410_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(63,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9410_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(99 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9410_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(138,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9410">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-13T10:21:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-13T10:21:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Sinclair IS Pharma Buys Perfectha™ Dermal Fillers Through the Acquisition of ObvieLine Lab. SA</title>
	<pubDate>2014-01-10T18:39:17+01:00</pubDate>
	<wp:post_id>5198</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The company has entered into agreements to acquire the global rights to Perfectha&trade; dermal fillers through the acquisition of Obvieline Laboratories SA, and has also entered into agreements to acquire distribution rights principally in Brazil and Russia from Pharmavital SA (Obvieline's parent company) for a total of up to &euro;32.<wbr>2 million in cash with an initial payment of &euro;10.<wbr>0 million.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale for Sinclair</STRONG> </div><div style="margin-bottom: 10px;">Perfectha&trade; acquisition gives Sinclair a global facial aesthetics presence </div><div style="margin-bottom: 10px;"><P class="bh">&middot;     Strong sales in Asia, Russia and Brazil</P> </div><div style="margin-bottom: 10px;"><P class="bh">&middot;     Opportunity to leverage Sinclair EU5 sales forces</P> </div><div style="margin-bottom: 10px;"><P class="bh">&middot;     Significant earnings accretion expected from 2014/<wbr>15</P> </div><div style="margin-bottom: 10px;"><STRONG>Perfectha&trade; brand </STRONG> </div><div style="margin-bottom: 10px;">5 gel products which reduce folds, lines and wrinkles in different facial areas.<wbr> </div><div style="margin-bottom: 10px;">It is expected that the Perfectha&trade; range will be extended to include a pre-mixed lidocaine (anaesthetic) product in late 2014.<wbr> </div><div style="margin-bottom: 10px;">Perfectha's E-brid technology requires lower injected volumes and is easy for clinicians to inject.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Perfectha&trade; Revenues</STRONG> </div><div style="margin-bottom: 10px;">&euro;5.<wbr>2 million and profit before tax and exceptional items of &euro;0.<wbr>4 million in the year ended 31 December 2012 and over 60% revenue growth to approximately &euro;8.<wbr>4 million (unaudited) in its financial year to 31 December 2013, which included approximately &euro;3.<wbr>6 million from Asia.<wbr> </div><div style="margin-bottom: 10px;">Around 90% of Perfectha&trade; 2013 revenues came from emerging markets with the balance from Western Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sinclair Pharma SnapShot</STRONG> </div><div style="margin-bottom: 10px;">Sinclair IS Pharma is an international speciality pharma company, with corporate headquarters in London, UK and operations headquarters in Paris, France.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Focus on Dermatology
</LI>
<LI>Drive operating leverage in the business through volume growth using European infrastructure
</LI>
<LI>Create strong organic sales growth from fast growing Emerging Markets
</LI>
</UL> </div><div style="margin-bottom: 10px;">Aesthetic Products <A href="http://www.sinclairispharma.com/our-products/aesthetic.aspx">http:/<wbr>/<wbr>www.<wbr>sinclairispharma.<wbr>com/<wbr>our-products/<wbr>aesthetic.<wbr>aspx</A> </div><div style="margin-bottom: 10px;"><STRONG>ObvieLine Laboratories SA</STRONG> </div><div style="margin-bottom: 10px;">Engages in research, development, manufacturing, and distribution of Hyaluronic Acid (HA) derma fillers.<wbr> </div><div>The company was founded in 2005 and is based in Dardilly, France.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7335">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-10T18:39:17+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-10T18:39:17+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>ESS Has Started to Evaluate Safety/Efficacy of Degarelix with Ipilimumab for Castration-sensitive Oligometastatic PCa</title>
	<pubDate>2014-01-10T17:37:05+01:00</pubDate>
	<wp:post_id>5199</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sponsored by the Memorial Sloan-Kettering Cancer Center and in collaboration with Ferring, the objective of the Ph2 is to find out what effects taking ipilimumab with degarelix before surgery (radical prostatactomy) followed by more degarelix and ipilimumab after RP, will have on the condition.<wbr> PE will measure undetectable PSA.<wbr> </div><div style="margin-bottom: 10px;">* oligometastatic = (&le;5 lesions).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Details</STRONG> <a href="http://www.clinicaltrials.gov/ct2/show/NCT02020070?recr=Open&no_unk=Y&fund=2&rcv_s=12%2F10%2F2013&rank=296" class="defaultlink">NCT02020070</a> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Timelines</SPAN> </div><div style="margin-bottom: 10px;">Completion date: Dec 2018 </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Recruitment</SPAN> </div><div style="margin-bottom: 10px;">Approx 53 men with castration-sensitive oligometastatic prostate cancer who have not received primary local therapy (radiation or surgery), and no more than 2 months of prior ADT.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Location</SPAN> </div><div>MSK Cancer Center (PI: Howard Scher, MD) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9407">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-10T17:37:05+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-10T17:37:05+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>France OKs Use of Sativex for MS Spasticity</title>
	<pubDate>2014-01-10T09:16:34+01:00</pubDate>
	<wp:post_id>5200</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Sativex, a cannabis-based mouth spray, is indicated for spasticity associated with multiple sclerosis (MS).<wbr> Alongside its Q3:13 financial results, management reported that " .<wbr>.<wbr>.<wbr>Germany is the largest market for Sativex, and we've now been able to successfully renegotiate an acceptable price in Germany.<wbr><A class="link" href="SyncMedia('00:19:24')" id="L132" name="1164" style="color: black;"> And the underlying volume growth is proceeding well, up nearly one-third year on year".<wbr></A> </div><div style="margin-bottom: 10px;"><STRONG>Background in France</STRONG> </div><div style="margin-bottom: 10px;">October 2013 - Successful closing of Mutual Recognition Procedure for Sativex in Franc<EM>e.<wbr></EM> </div><div style="margin-bottom: 10px;"><STRONG>US Situation</STRONG> </div><div style="margin-bottom: 10px;">August 2013: GW opened a Ph3 IND application with the FDA to conduct a pivotal efficacy and safety clinical program to evaluate Sativex&reg; for the treatment of MS spasticity.<wbr> GW expects the U.<wbr>S.<wbr> Phase 3 trial to commence in 2014 </div><div style="margin-bottom: 10px;"><STRONG>Cancer Pain Indication</STRONG> </div><div style="margin-bottom: 10px;">Currently in Phase 3 clinical trials as a treatment for cancer pain.<wbr> This represents the lead target indication for the product in the U.<wbr>S.<wbr> </div><div><EM>Source: GW Pharm.<wbr>; ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7333">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-10T09:16:34+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-10T09:16:34+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Tokai to Initiate Ph3 of Galeterone for CRPC</title>
	<pubDate>2014-01-09T17:51:24+01:00</pubDate>
	<wp:post_id>5201</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Tokai has reported that the results from the ongoing ARMOR2 Ph2 trial will be used to define the Phase 3 trials planned for initiation in the second half of 2014.<wbr> New data from this Ph2 trial will be presented by the co-investigator at the 2014 ASCO GU in San Francisco.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Poster</U> </div><div style="margin-bottom: 10px;">Date &amp; Time: Thursday, January 30, 2014 from 11:30 a.<wbr>m.<wbr> to 1:00 p.<wbr>m.<wbr> and 5:15 p.<wbr>m.<wbr> to 6:45 p.<wbr>m.<wbr> (PT) </div><div style="margin-bottom: 10px;">Title: ARMOR2: Galeterone in progressive CRPC patients who have failed oral therapy </div><div style="margin-bottom: 10px;">Abstract: #71 Poster Board: E6 Session: General Poster Session A – Prostate Cancer </div><div style="margin-bottom: 10px;">Location: Golden Gate Hall </div><div style="margin-bottom: 10px;">Presenter: Mary-Ellen Taplin, M.<wbr>D.<wbr>, associate professor of medicine, director of genitourinary clinical research, Dana-Farber Cancer Institute, Harvard Medical School, and co-principal investigator of ARMOR2 </div><div><STRONG>ARMOR Ph2 Details</STRONG> - <A href="http://clinicaltrials.gov/ct2/show/NCT01709734?term=galeterone&amp;rank=1">NCT01709734</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9406">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-09T17:51:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-09T17:51:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New CEO at Galderma North America</title>
	<pubDate>2014-01-09T09:46:51+01:00</pubDate>
	<wp:post_id>5202</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Stuart Raetzman is appointed Chief Executive Officer of Galderma Laboratories, L.<wbr>P.<wbr> and Vice President North America, effective March 1, 2014.<wbr> He previously worked for Allergan, Chiron Vision and for over 20 years with Alcon lab.<wbr>, a division of Novartis.<wbr> North America represents roughly 50% of the company total sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7332_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Business</STRONG> </div><div style="margin-bottom: 10px;">Has led: </div><div style="margin-bottom: 10px;"><UL><LI>teams in the U.<wbr>S.<wbr> and on international assignment in Europe, the Middle East and Africa (EURMEA).<wbr> </LI>
<LI>small, multi‐functional executive level teams to develop Board of Director level strategic plans.<wbr> These teams included the heads of R&amp;D, manufacturing and finance.<wbr> He has also led large commercial organizations.<wbr> </LI>
<LI>the Alcon U.<wbr>S.<wbr> organization with 2,500 associates and in his latest role, he led a team of more than 4,000 associates across EURMEA.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Education</STRONG> </div><div style="margin-bottom: 10px;">Holds a bachelor’s degree from the McCombs School of Business at the University of Texas and attended the Advanced Management Program at Harvard.<wbr> </div><div><EM>Source: Galderma</EM> </div><!-- Comment details --><a name="neurology7332attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7332_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(6,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7332">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-09T09:46:51+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-09T09:46:51+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>PARP Inhibitors Are Bouncing Back in Oncology</title>
	<pubDate>2014-01-08T18:34:07+01:00</pubDate>
	<wp:post_id>5203</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: PARP inhibitors, once the most promising class of anti-cancer agents, experienced a few disappointing set backs in 2011 and are now possibly staging a comeback.<wbr> The field is fizzling and rejuvated with four companies including AstraZeneca, Tesaro, BioMarin, and Clovis, in the process of launching pivotal trials.<wbr> </div><div style="margin-bottom: 10px;">Beginning in the 1990s, companies began developing PARP inhibitors as chemopotentiators because many chemotherapy drugs cause DNA damage that is repaired by PARP mediated DNA repair.<wbr> Despite of its promising anti-tumour activity, they are highly toxic.<wbr> In 2005, two breakthrough Nature papers published promising results of PARP inhibitors in cancer cells with pre-existing DNA repair defects &ndash; mutation in <EM>BRCA1 </EM>and<EM> BRCA2 </EM>genes.<wbr> Positive Phase II results of iniparib in triple negative breast cancer patients (TNBC) generated enormous excitement as it featured an oral plenary presentation at 45<SUP>th</SUP> ASCO meeting (2009) &ndash; combination of iniparib with chemotherapy doubled PFS without inducing myelosuppression.<wbr> In 2009, Sanofi-aventis agreed to pay up to $500 million for BiPar Sciences, Inc.<wbr> in order to gain development right for iniparib.<wbr> At the time of the BiPar acquisition, iniparib was viewed as the most advanced PARP inhibitor in the field.<wbr> The elation was short-lived as Sanofi reported disappointing negative phase III results of iniparib in 2011.<wbr> In December 2011, AstraZeneca discontinued development of their PARP inhibitor &ndash; olaparib - for ovarian cancer.<wbr> This has led many observers to give up and the excitement around PARP inhibitors &ldquo;came to a screeching halt&rdquo;.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><EM>&ldquo;I think we've made that turnaround.<wbr> A lot has been going on to get us excited again in this field&rdquo; Dr.<wbr> Susan Domchek (an oncologist and breast cancer researcher at the University of Pennsylvania</EM></STRONG> </div><div style="margin-bottom: 10px;">Independent investigators confirmed that iniparib and its metabolite were not functional PARP inhibitors.<wbr> Sanofi also acknowledged the recent research demonstrating iniparib can&rsquo;t inhibit PARP at pharmacological concentration.<wbr> AstraZeneca then re-examined the olaparib from trial 19 and discovered an emerging trend towards improved overall survival in <EM>BRCA</EM> mutant patient group &ndash; specifically patients with germline or somatic tumour BRCA mutations (median PFS of 11.<wbr>2 months compared to 4.<wbr>3 months for placebo).<wbr> </div><div style="margin-bottom: 10px;"><EM><STRONG>&ldquo;Stopping olaparib development was just a big mistake.<wbr> It allowed competitors to move forward quite quickly.<wbr>&rdquo; Dr.<wbr> Jonathan Ledermann (leading investigator and oncologist in UCL Cancer Institute)</STRONG></EM> </div><div style="margin-bottom: 10px;"><STRONG>Table</STRONG> below outlined the five active PARP inhibitors currently under clinical development.<wbr> Three companies &ndash; AZstraZeneca, Tesaro and Clovis &ndash; are testing their candidates as a single agent for maintenance therapy with the goal of delaying or preventing disease relapse following chemotherapy treatment in ovarian cancer.<wbr> So far the pharmacological properties suggest little differentiation amongst these candidates, they do have somewhat different specificity profile - while they all target PARP1 and PARP 2, they do target other PARP family members, of which have unknown functions.<wbr> As tolerability is key in the maintenance setting, off-target toxicity may vary enough to make a difference.<wbr> In addition, the success will also be dependent on their target patient population as three companies differ in their strategy for target patient population.<wbr> AstraZeneca targets the narrowest but least risky population with serous ovarian cancers that harbour <EM>BRCA</EM> mutations only.<wbr> Tesaro targets a wider patient pool including all relapsed patients with high grade serous ovarian cancer regardless of BRCA status.<wbr> Clovis targets the same patient population as Tesaro but with additional effort to identify the subpopulation most likely to benefit from rucaparib via collaboration with cancer genomics company.<wbr> </div><div style="margin-bottom: 10px;">.<wbr> <img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9400_3_table%201.jpg"> </div><div style="margin-bottom: 10px;">A recent <A href="http://cancerdiscovery.aacrjournals.org/content/early/2012/09/19/2159-8290.CD-12-0120.full.pdf+html">preclinical study published</A> in Cancer Discovery suggests a newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients - functions of PARP-1 were found not only include DNA damage repair but also androgen receptor (AR) regulation in advanced prostate cancer growth and progression.<wbr> Researchers believe that the dual functions of PARP-1&mdash;as both a regulator of AR as well as critical for DNA damage repair&mdash;could be leveraged for therapeutic benefit.<wbr> Using various <EM>in vitro</EM> and <EM>in vivo</EM> model systems, the researchers found that PARP-1 activity is required for AR function and is increased in castrate-resistant prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><EM><STRONG>&ldquo;These findings introduce a paradigm shift with regard to PARP-1 in prostate cancer, and provide the basis for new therapies that could help a whole population of cancer patients who have little options.<wbr>&rdquo; Dr.<wbr> Knudsen</STRONG></EM> </div><div style="margin-bottom: 10px;">Other rationale for clinical development of PARP inhibitors includes combination with radiotherapy.<wbr> Dr.<wbr> Anthony Chalmers discussed the scientific rationale behind the combination strategy of PARP inhibitors with radiation therapy in one of the scientific symposiums during ESMO 2013.<wbr> A variety of <EM>in vitro</EM> models demonstrated PARP inhibitors increased radiosensitivity (~30-50%) and similarly <EM>in vivo</EM>.<wbr> Up to date, olaparib, veliparib, and niraparib are being explored in early clinical development in combination with radiotheraoy (Phase I-II).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Scientific Background</STRONG> </div><div style="margin-bottom: 10px;">Poly(ADP-ribose) polymerase 1 (PARP-1) is a DNA-binding enzyme that is activated by DNA breaks, converting them into an intracellular signal to facilitate the access of base excision/<wbr>single strand break repair proteins and activating these repair enzymes.<wbr> PARP inhibitors have been developed to investigate the role of PARP-1 in cell biology and to overcome DNA repair-mediated resistance of cancer cells to cytotoxic therapy.<wbr> Since the early benzamide inhibitors of the 1980s PARP inhibitors, developed through structure-activity relationships and crystal structure-based drug design, that are 1,000x more potent have been identified.<wbr> These novel PARP inhibitors have been shown to enhance the antitumour activity of temozolomide (a DNA-methylating agent), topoisomerase poisons and ionising radiation in advanced pre-clinical studies and are now under clinical evaluation.<wbr> PARP inhibitors can also selectively kill cells and tumours with homozygous defects in the hereditary breast cancer genes, <EM>BRCA1</EM> and <EM>BRCA2</EM>.<wbr> The one common dose-limiting disadvantage is myelosuppression, and a more potent compound could mean a lower does can be effective.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Challenges</STRONG> </div><div style="margin-bottom: 10px;">Several PARP inhibitors are under investigation and it is anticipated that this novel class of compounds will ultimately receive regulatory approval in subsets of cancers.<wbr> AstraZeneca, Tesaro and Clovis are focusing their effort to the maintenance strategy as the fast route to FDA/<wbr>EMA approval.<wbr> Companion test of this agents need to be validated and lack of predictive biomarkers remain the key to the success for PARP inhibitors in the future.<wbr> </div><div style="margin-bottom: 10px;">References: </div><div><OL><LI>PARP inhibitors bounce back.<wbr> Ken Garber Nature Reviews Drug Discovery Vol 12 Oct 2013
</LI>
<LI>PARP inhibitors for BRCA 1/<wbr>2 mutation-associated and BRCA-like malignancies.<wbr> J-m, Lee, J.<wbr>L.<wbr> Ledermann &amp; E.<wbr>C.<wbr> Kohn Annals of Oncology Vol 25 2014
</LI>
<LI><SPAN style="color: #000000;"><A href="http://www.ncbi.nlm.nih.gov/pubmed/20832020"><SPAN style="color: #000000;">Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.<wbr></SPAN></A> </SPAN>Chalmers AJ, Lakshman M, Chan N, Bristow RG.<wbr> Semin Radiat Oncol.<wbr> 2010 Oct;20(4):274-81.
</LI>
<LI>ESMO 2013 Scietific Symposium: Exploiting defective DNA damage response pathways in tumours
</LI>
</OL> </div><!-- Comment details --><a name="oncology9400attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9400_1_table%201.jpg">table 1.jpg</a>&nbsp;&nbsp;(33,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9400_2_table%201.jpg">table 1.jpg</a>&nbsp;&nbsp;(100,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9400_3_table%201.jpg">table 1.jpg</a>&nbsp;&nbsp;(102,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9400">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-08T18:34:07+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-08T18:34:07+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Forest Acquires Aptalis for $2.9bln</title>
	<pubDate>2014-01-08T10:58:22+01:00</pubDate>
	<wp:post_id>5204</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Forest lab has acquired Aptalis, a privately held U.<wbr>S.<wbr> based specialty Gastrointestinal and Cystic Fibrosis company, for $2.<wbr>9bln.<wbr> The transaction is expected to close in H1:14.<wbr> Key slides from the Forest Investor Webcast are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_9_ScreenCapture9.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">- deal immediately accretive to non-GAAP EPS </div><div style="margin-bottom: 10px;">- synergy </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_7_ScreenCapture7.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_8_ScreenCapture8.jpg"> </div><div style="margin-bottom: 10px;">- ideal fit for Forest because of Aptalis strong product offerings in two therapeutic franchises that are complementary to Forest - GI in the US.<wbr> and Canada and Cystic Fibrosis in EU.<wbr><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_3_ScreenCapture3.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_5_ScreenCapture5.jpg"> </div><div style="margin-bottom: 10px;">- to offset the loss of Lexapro and Namenda patents, its top profit drivers (respectively 69% and 84% of current product revenues).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Sales</STRONG>: $687.<wbr>9 million for the fiscal year ended September 30, 2013.<wbr> </div><div style="margin-bottom: 10px;">Aptalis has a number of drugs that treat cystic fibrosis and gastrointestinal disorders, and sells its products primarily in Canada, US and EU.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>
Sales of the top three products in the U.<wbr>S.<wbr> - <STRONG>Canasa, Carafate, </STRONG>and<STRONG> Zenpep</STRONG> - accounted for more than 60% of company sales in FY2013</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_6_ScreenCapture6.jpg"> </div><div style="margin-bottom: 10px;"><UL><LI>
International sales accounted for approximately 15% of revenues.<wbr> </LI>
<LI>
Aptalis Pharmaceutical Technologies, a third party delivery technology provider and drug manufacturer, accounted for approximately 15% of revenues.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Products Portfolio</STRONG> @ <A href="http://www.aptalispharma.com/featured-products">http:/<wbr>/<wbr>www.<wbr>aptalispharma.<wbr>com/<wbr>featured-products</A><BR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="SectionArea Align1" value="BusinessDescription">Main products include:</DIV> </div><div style="margin-bottom: 10px;"><DIV class="dojoMinMaxContent" value="BusinessDescription">
<UL><LI><STRONG>Namenda</STRONG>, a N-methyl-D-aspartate (NMDA) antagonist for the treatment of moderate to severe dementia of the Alzheimer's type; </LI>
<LI><STRONG>Bystolic</STRONG>, a beta-blocker for the treatment of hypertension; </LI>
<LI><STRONG>Linzess</STRONG>, a guanylate cyclase type-C receptor agonist for the once-daily treatment for men and women suffering from IBS-C or CIC; </LI>
<LI><STRONG>Tudorza</STRONG>, a long-acting antimuscarinic agent for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema;</LI>
<LI><STRONG>Viibryd</STRONG>, a SSRI and a 5-HT1A receptor partial agonist for the treatment of adults with depressive disorder (MDD).<wbr> </LI>
</UL></DIV> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">TPG has been exploring the sale of Aptalis since August last year (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1906" class="defaultlink">GastroEnterology1906: TPG Is Exploring The Sale of Specialty Drugmaker Aptalis</a>).<wbr> </div><div style="margin-bottom: 10px;">In October, Aptalis appointed underwriters for an initial IPO after efforts to sell the compnay failed (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1926" class="defaultlink">GastroEnterology1926: Aptalis Hires Banks for an IPO</a>).<wbr> </div><div><EM>Source: ThomsonOne; Forest Lab.<wbr>; Aptalis</EM> </div><!-- Comment details --><a name="gastroenterology1934attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(50,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(48,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(51,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_6_ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(62,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_7_ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(22,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_8_ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(35,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_gastroenterology_1934_9_ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(39,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140431&edate=20140101&rec=1934">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-08T10:58:22+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-08T10:58:22+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category gastroenterology > <![CDATA[gastroenterology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Allergan Secures Agreement With Medytox</title>
	<pubDate>2014-01-07T16:46:13+01:00</pubDate>
	<wp:post_id>5205</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Allergan today announced that it has closed the license 
agreement which was previously announced on September 25, 2013 with Medytox.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Allergan will pay Medytox an upfront cash 
payment of U.<wbr>S.<wbr> $65 million within seven business days of closing and Medytox 
has granted Allergan exclusive rights, worldwide outside of Korea, to develop 
and, if approved, commercialize certain neurotoxin product candidates currently 
in development, including a potential liquid-injectable product.<wbr> </div><div style="margin-bottom: 10px;">Pursuant to the agreement, Allergan has also agreed to make additional 
contingent payments, including up to an aggregate of U.<wbr>S.<wbr> $116.<wbr>5 million upon 
achieving certain development milestones, up to an aggregate of U.<wbr>S.<wbr> $180.<wbr>5 
million upon achieving certain commercialization milestones, and royalties on 
product sales.<wbr> </div><div>Source: <a href="http://www.allergan.com" class="defaultlink" title="www.allergan.com">allergan.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7331">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-07T16:46:13+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-07T16:46:13+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>The ADT Competitive Area Landscape (2)</title>
	<pubDate>2014-01-07T16:40:54+01:00</pubDate>
	<wp:post_id>5206</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: You will find attached an update version of Decapeptyl competitive landscape.<wbr><WBR> We encourage you to contribute to our internal knowledge by evaluating some of the "Key Intelligence Questions" included in the document.<wbr></WBR> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="ii" id="pharmaworld10508.02ii">
<DIV class="i" id="oncology9052.04i">
<DIV class="ii" id="oncology9052.04ii">No matter what competitive information /<wbr><WBR></WBR><WBR> soft intelligence you have, please do keep us informed on any key developments in your countries.<wbr></WBR></DIV>

<DIV class="ii">We hope that you will find it a useful tool.<wbr></DIV></DIV></DIV> </div><div>Access to the slides by clicking <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140431&edate=20140101&rs=/link%20Oncology9399%401" class="defaultlink">@1</a> </div><!-- Comment details --><a name="oncology9396attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9396_1_DKP%255fTAL%255fFinal%20Version%255fJan2014.pptx">DKP_TAL_Final Version_Jan2014.pptx</a>&nbsp;&nbsp;(948,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9396">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-07T16:40:54+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-07T16:40:54+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Valeant's Aspiration To Rank Amongst The Top 5</title>
	<pubDate>2014-01-07T16:37:14+01:00</pubDate>
	<wp:post_id>5207</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: During today's call, Michael Pearson Valeant's CEO stated his ambition for Valeant to be ranked amongst the world's top five pharmaceutical companies by market capitalisation by the end of 2016, largely through acquisitions, so called merger of equals as well as smaller deals.<wbr> Possibly given the number of positive references to aesthetics and size relative to Allergan, we might expect further deals within this market segment.<wbr> </div><div style="margin-bottom: 10px;">Commenting on its business prospects Pearson made the following key comments:- </div><div style="margin-bottom: 10px;">"We are extremely excited about the opportunities that we believe lie ahead for Valeant in 2014 and we thought it&rsquo;d be helpful to outline our priorities for the year.<wbr> Firstly we expect to continue our strong organic growth performance and plan to drive growth in all of our businesses.<wbr> All of our businesses are expected to grow in 2014 and most of our businesses are expected to grow double digit including our aesthetics, contact lens, consumer, neurology, and oral health in the U.<wbr>S.<wbr> and all of our emerging market businesses.<wbr> In 2014, we see additional opportunity to grow U.<wbr>S.<wbr> aesthetics and oral health businesses by significantly expanding the sales force".<wbr> </div><div style="margin-bottom: 10px;">"In 2013, the Medicis aesthetic portfolio achieved record sales.<wbr> By expanding the sales force to approximately 200, we hope to build long-term partnerships with a larger group of doctors and with the acquisition of Solta and our continued relationship with Mentor, we will have the broadest and most attractive portfolio of products in the market.<wbr> Since we acquired OraPharma in Q2 of 2012, the business is growing each quarter greater than 10% even though we call on a very small percentage of dentists.<wbr> By increasing the number of reps by approximately 50%, we will be able to reach a greater number of dentists and significantly increase revenue.<wbr>" </div><div style="margin-bottom: 10px;">During the Q/<wbr>A he stated:- </div><div style="margin-bottom: 10px;">"We&rsquo;re very pleased with our aesthetics business.<wbr> As I mentioned there are injectables Restylane, Perlane, Sculptra, Dysport, overall grew over 30% year-on-year.<wbr> In terms of the economics, we&rsquo;re selling on average about $2.<wbr>5 million per sales rep.<wbr> So that leads to very attractive economics for us.<wbr> But we were very undersized relative to Allergan.<wbr> We had a roughly 90 reps.<wbr> They&rsquo;re closer to 200, that&rsquo;s why we&rsquo;re increasing our field force for injectibles up to similar amount as Allergan because we think with the product line that we now have especially with the addition of Solta, we have the products and portfolio.<wbr> And a lot of doctors encourage us to get into the medical devices area and are quite pleased on that, that will now be adding this set of products to our current products.<wbr> So, aesthetics continues to be better than we&rsquo;ve even hoped when we purchased Medicis.<wbr>" </div><div>Source: <A href="http://www.valeant.com">www.<wbr>valeant.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7327">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-07T16:37:14+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-07T16:37:14+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Richter Expands into Four More Countries in Latin America</title>
	<pubDate>2014-01-07T09:59:21+01:00</pubDate>
	<wp:post_id>5208</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Richter aims to tap into fast-growing markets for its gynea portfolio (which represents a third of its total sales).<wbr> The company declined to name the countries involved.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">CEO Erik Bogsch, in charge at Richter since 1992, told Reuters that ".<wbr>.<wbr>.<wbr> this will probably also take the form of joint ventures (and) we are in talks about this .<wbr>.<wbr>.<wbr> " </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9379" class="defaultlink">Oncology9379: Richter to Establish Strategic Position in Brazil for its Female HC Business</a>.<wbr> </div><div><EM>Source: ThomsonOne</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9395">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-07T09:59:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-07T09:59:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Neurocrine to Finalize Ph3 Draft Protocol with FDA for its Tardive Dyskinesia Drug</title>
	<pubDate>2014-01-07T09:42:45+01:00</pubDate>
	<wp:post_id>5209</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NBI-98854, a small molecule VMAT2 inhibitor, showed a statistically significant and clinically meaningful reduction in tardive dyskinesia symptoms in the Ph2b Kinect 2 study.<wbr> The company now anticipates filing the Ph3 protocol with the FDA in the first half of 2014.<wbr> Management reported to be in 'contact with numerous interested partners'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;">Chris O'Brien, CMO, announced during a January 6th webcast that : " .<wbr>.<wbr>.<wbr> The Kinect 3 study will be a Phase 3 study.<wbr> So all the work that we've been -- we've actually been working diligently in the background, planning for all the work that goes into education and recruitment efforts because it's a big project ramping up for the next study.<wbr> </div><div style="margin-bottom: 10px;">The Kinect 3 study was designed to be a 12-week study, was designed to be either a fixed-dose or a titration study depending on the Kinect 2 results.<wbr> It was designed to pool schizophrenic, schizoaffective, bipolar, and depression patients.<wbr> It was designed to look at probably a 50-milligram and a 75-milligram dose.<wbr> So in fact, there's not really a lot has changed.<wbr> </div><div style="margin-bottom: 10px;">The only difference is to be worked out with the FDA, is it one study or is it two studies for Phase 3? Is it 6 weeks of placebo or is it 12 weeks of placebo? It's going to be a 12-week study no matter what, and we only need to finish -- we need to finish our PK/<wbr>PD work to decide what the final dose is for the titration design.<wbr> So it's actually not a big leap.<wbr> The biggest leap is -- has got to be video AIMS scored by movement disorder neurologists with this consensus adjudication process".<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7326_1_ScreenCapture1.jpg"> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7326_2_ScreenCapture2.jpg"> </div><div style="margin-bottom: 10px;"><STRONG>Primary Endpoint: AIMS</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7326_4_ScreenCapture4.jpg"> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7326_5_ScreenCapture5.jpg"> </div><!-- Comment details --><a name="neurology7326attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7326_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(86,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7326_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(43,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7326_3_ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(61,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7326_4_ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(59 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_neurology_7326_5_ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(67 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7326">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-07T09:42:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-07T09:42:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Brazil's National Supplementary Health Agency Orders Health Plans to Cover 37 Oral Oncology Drugs</title>
	<pubDate>2014-01-06T13:03:45+01:00</pubDate>
	<wp:post_id>5210</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The 37 oral oncology drugs are those for treating some of the most common cancers, including those affecting the stomach, liver, intestine, kidney, testes, uterus, ovary, and breast.<wbr> Specific products that are on the list include among others Johnson &amp; Johnson 's Zytiga (abiraterone), which costs BRL11,000 per pack.<wbr> </div><div style="margin-bottom: 10px;">The National Supplementary Health Agency's new list of obligatory medicines, tests and procedures means that coverage will be available even earlier than had previously been stipulated under a new law that had been approved in October 2013, but which is not due to take effect until May this year.<wbr> </div><div style="margin-bottom: 10px;">The scope of the new law provides for the obligatory inclusion not only of the 37 oral drugs specified by the ANS, but also other types of drugs.<wbr> </div><div style="margin-bottom: 10px;">The provision of oral cancer medicines has long been demanded by users of health plans and by doctors, but up until now patients have had to go to court to obtain treatment with these drugs.<wbr> Unlike traditional forms of chemotherapy, oral cancer drugs have a comparatively low side-effect profile and can be administered at home, avoiding the need for hospital treatment.<wbr> </div><div style="margin-bottom: 10px;">However, although the inclusion of the 37 oral drugs in the new ANS list has been widely welcomed, the ANS has received criticism over the fact that the use of genetic tests can only be requested by specialist geneticist doctors.<wbr> The fact that there are only around 200 such doctors throughout Brazil will severely limit the use of these tests.<wbr> </div><div><EM>Source: IHS GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9393">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-06T13:03:45+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-06T13:03:45+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>New CSO at Aeterna Zentaris</title>
	<pubDate>2014-01-06T11:02:24+01:00</pubDate>
	<wp:post_id>5211</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Dr Richard Sachse will be responsible for all areas of the global R&amp;D activities.<wbr> Before joining Aeterna Zentaris, he was Vice President, Head of Global Translational Medicine at Boehringer Ingelheim.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><U>Education</U> </div><div style="margin-bottom: 10px;">Dr.<wbr> Sachse holds a degree in medicine from the Friedrich-Alexander-University Erlangen, in Germany, and a board certification in Clinical Pharmacology.<wbr> With more than 20 years experience as a physician and scientist, he has extensive expertise in a variety of different therapeutic areas including endocrinology and oncology.<wbr> In addition to registration studies, he is especially experienced in the design and implementation of translational programs to bridge research programs to the clinic, as well as in the design and implementation of clinical pharmacology programs, including all required profiling studies and activities, enabling successful registration of products at the international level.<wbr> </div><div style="margin-bottom: 10px;"><U>Professional Activities</U> </div><div style="margin-bottom: 10px;">In 2007, after a merger, he became Senior Director, Head of Experimental Medicine, at UCB in Belgium, where he managed the implementation of novel biomarkers in clinical development to provide data supporting identification of appropriate target indication and target population.<wbr> </div><div style="margin-bottom: 10px;">In 2010, Dr.<wbr> Sachse became Vice President, Head of Global Translational Medicine at Boehringer Ingelheim.<wbr> </div><div style="margin-bottom: 10px;"><STRONG></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9392_1_ScreenCapture1.jpg"> </div><div><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9392_2_ScreenCapture2.jpg"> </div><!-- Comment details --><a name="oncology9392attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9392_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(76,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9392_2_ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(39,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9392">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-06T11:02:24+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-06T11:02:24+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Global Reach Of Indian Pharmaceutical Companies</title>
	<pubDate>2014-01-06T10:51:55+01:00</pubDate>
	<wp:post_id>5212</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Yesterday's FT highlights the growing influence of Asia in 
the global pharmaceutical market, noting how India is now producing as many 
medicines for the UK as those manufactured within the UK itself.<wbr> Indian 
factories are producing the finished form of 3,685 drugs compared with 
3,815 made within the UK </div><div style="margin-bottom: 10px;">This statistics from the UK MHA, places Indian manufactureres ahead of 
all other foreign producers including companies located in Germany, Ireland and 
France.<wbr> </div><div style="margin-bottom: 10px;"><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<P>The British statistics mirrors high and rising penetration rates by Indian 
producers in other industrialised countries around the world and has raised some 
concerns over quality as manufacturing shifts beyond national boundaries.<wbr> 
However, whilst there were concerns with 9-10 manufactureres over the last 2 
years as a proportion of the total no undertaken this is similar to that 
observed in other parts of the world.<wbr></P></DIV> </div><div>Meanwhile, a separate report by a legal IP consultancy notes an increase in 
annual patent filings by Indian companies over the past decade from 160 to 450 
per year.<wbr> Most are focused on manufacturing procedures for drugs, new 
formulations and crystalline forms of existing drugs rather than 
NCEs.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10720">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-06T10:51:55+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-06T10:51:55+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Natpara (rhPTH) Granted Orphan Drug Status In Europe</title>
	<pubDate>2014-01-06T10:33:15+01:00</pubDate>
	<wp:post_id>5213</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: NPS Pharmaceuticals announced on Friday that the European Commission 
has granted ODS status to its recombinant parathyroid hormone Natpara for the 
treatment of hypoparathyroidism.<wbr> </div><div>Commenting on this development Francois Nader MD, President and CEO of NPS 
Pharmaceuticals stated "We are very pleased that Natpara has received orphan 
drug status in the EU.<wbr> As a global rare disease biopharmaceutical company, this 
aligns with our commitment to deliver innovative therapies that transform the 
lives of patients around the world.<wbr> Hypoparathyroidism patients face a 
significant burden of disease given the multitude of physical, cognitive, and 
emotional symptoms associated with this disorder.<wbr> Natpara could be the first PTH 
replacement therapy to treat this condition.<wbr>" </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7559">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-06T10:33:15+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-06T10:33:15+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Israel Adds Janssen's Zytiga to Healthcare Basket</title>
	<pubDate>2014-01-03T16:19:43+01:00</pubDate>
	<wp:post_id>5214</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Zytiga is part of a list of 83 drugs and technologies to be proposed for reimbursement approval by the Public Committee for the Update of the Basket.<wbr> These recommendations require the approval of the National Health Council and the Israeli cabinet.<wbr> </div><div style="margin-bottom: 10px;">The list cover a diverse range of indications, including allergies, cardiovascular, dermatology, endocrinology, food supplements, gastroenterology, metabolic diseases, neurology, oncology, respiratory, rheumatology, transplants, and urology.<wbr> Estimates put forward by Minister of Health Yael German suggest that these medicines could benefit approximately two million Israelis.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9391_1_ScreenCapture1.jpg"> </div><div><EM>Source: IHS GlobalInsight</EM> </div><!-- Comment details --><a name="oncology9391attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://wave-eu-west-1.s3-eu-west-1.amazonaws.com/websites/CINEWSBACK-PROD/wp-content/uploads/2016/02/attachments_oncology_9391_1_ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(139,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140431&edate=20140101&rec=9391">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-03T16:19:43+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-03T16:19:43+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category uro-oncology > <![CDATA[Uro-oncology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>China to Introduce Corruption "Blacklist" of Drugmakers and Device Manufacturers</title>
	<pubDate>2014-01-03T15:33:37+01:00</pubDate>
	<wp:post_id>5215</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Lists of offending manufacturers, agents and individuals will be published online from the beginning of March 2014.<wbr> </div><div style="margin-bottom: 10px;">The companies named on the list once will be banned for 2 years from selling within the region where they were implicated, while those appearing on the list twice in 5 years will be banned nationally, also for 2 years.<wbr> </div><div style="margin-bottom: 10px;">In addition, any medical practitioners who receive bribes will be punished.<wbr> </div><div><EM>Source: FirstWord</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140431&edate=20140101&rec=10718">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-03T15:33:37+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-03T15:33:37+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category pharma-news > <![CDATA[Pharma News]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Long-term Extension Study of Lexicon's Telotristat Etiprate for Carcinoid Syndrome</title>
	<pubDate>2014-01-02T19:09:56+01:00</pubDate>
	<wp:post_id>5216</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: The objective of the Ph3 TELEPATH trial is to evaluate the long-term safety and tolerability of the drug (dose: 250mg/<wbr>500mg).<wbr> PE will measure incidente of treatment-emergent AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">Recruitment: n=160 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="margin-top: 0.7ex;">Ongoing participation in a Phase 2 (LX1606.<wbr>1-202-CS, LX1606.<wbr>1-203-CS) or Phase 3 (LX1606.<wbr>1-301-CS, LX1606.<wbr>1-303-CS) study
</LI>
</UL> </div><div style="margin-bottom: 10px;">Location: one site in Germany </div><div style="margin-bottom: 10px;">Completion date is planned for Dec 2014.<wbr> </div><div>Source: <a href="http://www.clinicaltrials.gov/ct2/show/NCT02026063?recr=Open&no_unk=Y&fund=2&rcv_s=12%2F02%2F2013&rank=180" class="defaultlink">NCT02026063</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7558">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-02T19:09:56+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-02T19:09:56+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>Focused Cold Therapy Tested for Upper Limb Spasticity (ULS) and Occipital Neuralgia</title>
	<pubDate>2014-01-02T18:23:21+01:00</pubDate>
	<wp:post_id>5217</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: Myoscience is currently conducting two small POC studies to evaluate its Cryo-Touch III Device.<wbr> In the ULS trial, PE will measure improvement of hypertonia of the upper arm.<wbr> In the other study, PE will measure the reduction in either pain frequency or severity associated with the condition.<wbr> Focused Cold Therapy is currently approved in EU and Canada for temporary wrinkle reduction, temporary pain reduction and treatment of dermatologic conditions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Upper Limb Spasticity Trial</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Recruitment:</SPAN> n=20 male or female, 18 years of age and older.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>
Trial participants must have a confirmed diagnosis that results in spasticity involving muscle innervated by the musculocutaneous nerve (MCN).<wbr>

</LI>
<LI>
Any medications must be maintained on a stable schedule for at least two weeks prior to treatment.<wbr> No washout period is allowed.<wbr>

</LI>
<LI>
Must have an average score on the Modified Ashworth Scale for Spasticity of &ge; 2 over the last 30 days in the elbow


</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;"><SPAN style="text-decoration: underline;">Location</SPAN>: 2 sites in the US</P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;">Source: <a href="http://clinicaltrials.gov/ct2/show/NCT01863901?term=Cryo-Touch+III&rank=4" class="defaultlink">NCT01863901</a></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;"><STRONG>Occipital Neuralgia Study</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;"><SPAN style="text-decoration: underline;">Recruitment</SPAN>: n=30 male or female, 18 years of age and older.<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="margin-top: 0.7ex;">A confirmed diagnosis of occipital neuralgia (unilateral or bilateral) .<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Any medication must be maintained on a stable schedule for at least two weeks prior to treatment.<wbr> No washout period is allowed.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Must have an average score for pain of &ge; 4/<wbr>10 Visual Analog Scale (VAS) over the last 7 days
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Location</SPAN>: 3 sites in the US </div><div>Source: <a href="http://clinicaltrials.gov/ct2/show/NCT01753765?term=Cryo-Touch+III&rank=5" class="defaultlink">NCT01753765</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140431&edate=20140101&rec=7324">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-02T18:23:21+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-02T18:23:21+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category neurology > <![CDATA[Neurology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	
			<item>

	<title>EMA Accepts Otsuka's MAA for Polycystic Kidney Disease Drug</title>
	<pubDate>2014-01-02T15:31:16+01:00</pubDate>
	<wp:post_id>5218</wp:post_id>
	<dc:creator><![CDATA[spoon]]></dc:creator>
	<description></description>
	<content:encoded><![CDATA[<div style="margin-bottom: 10px;">Comment: If approved by the Agency, tolvaptan would become the 1st pharmaceutical therapy in Europe for patients with autosomal dominant polycystic kidney disease (ADPKD).<wbr> In August 2013, the EMA&rsquo;s Committee for Orphan Medicinal Products (COMP) granted tolvaptan orphan drug designation for the treatment of ADPKD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is ADPKD</STRONG> </div><div style="margin-bottom: 10px;">ADPKD is an inherited genetic disease that causes cyst growth in the kidneys, which gradually impairs their functioning.<wbr> There is no current pharmaceutical treatment option.<wbr> </div><div style="margin-bottom: 10px;">The condition is estimated to affect approximately 200,000 people in Europe </div><div style="margin-bottom: 10px;"><STRONG>Drug Mini Profile</STRONG> </div><div style="margin-bottom: 10px;">MoA: Tolvaptan is a selective V<SUB>2</SUB> vasopressin receptor antagonist.<wbr> </div><div style="margin-bottom: 10px;">Status: In Japan, the application for ADPKD is currently under review.<wbr> In the US, Otsuka and FDA have been working together to determine the most appropriate path forward to allow tolvaptan to be available for patients suffering from ADPKD.<wbr> </div><div><EM>Source: Otsuka</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140431&edate=20140101&rec=7557">Add a Comment on this Article</a><br>]]></content:encoded>
	
	<wp:post_date><![CDATA[2014-01-02T15:31:16+01:00]]></wp:post_date>
	<wp:post_date_gmt><![CDATA[2014-01-02T15:31:16+01:00]]></wp:post_date_gmt>
	<wp:comment_status><![CDATA[open]]></wp:comment_status>
	<wp:ping_status><![CDATA[open]]></wp:ping_status>
		
		<wp:status><![CDATA[publish]]></wp:status>
		<wp:post_parent>0</wp:post_parent>
		<wp:menu_order>0</wp:menu_order>
		<wp:post_type><![CDATA[post]]></wp:post_type>
		
				<category endocrinology > <![CDATA[Endocrinology]]> </category>
		
		<wp:postmeta>
			<wp:meta_key><![CDATA[_thumbnail_id]]></wp:meta_key>
			<wp:meta_value><![CDATA[531]]></wp:meta_value>
		</wp:postmeta>
		
	</item>
	

</channel>
</rss>
